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ABSTRACT 
Calcium (Ca2+) functions as a primary and secondary messenger regulating crucial cellular 
processes. We study two central membrane proteins, extracellular calcium-sensing receptor 
(CaSR) and connexin26 (Cx26) gap junction (GJ) channel, that are regulated by Ca2+ and play 
critical roles in regulating Ca2+ homeostasis and communication between the intra- and extra- 
cellular milieu. Mutations in CaSR are associated with abnormal Ca2+ homeostasis, 
hypoparathyroidism, myocardial infarction and cancers. Similarly, mutations in Cx26 are 
implicated in many hereditary deafness and dermatological disorders. The role of Ca2+ in CaSR 
biosynthesis, CaSR mediated intracellular Ca2+ signaling, Cx26 regulation and tuning of their 
regulators in biological and pathological is reported, however, the knowledge of exact molecular 
mechanism is obscure due to challenges associated with membrane proteins.  
 
 
In this dissertation, we first report the discovery of 98 novel putative CaSR interactors 
using co-immunoprecipitation, mass-spectrometry and confocal imaging. Our findings suggest 
that extracellular Ca2+ dependent CaSR mediated intracellular signaling facilitates ER quality 
control and trafficking by upregulating the interaction with proteins affiliated with ubiquitination, 
chaperoning and glycosylation. Next, the cooperative activation of CaSR by Ca2+, Mg2+ and 
aromatic amino acids is validated in wild type CaSR in HEK293 cells. CaSR mutations at 
conserved metal binding sites reduce Ca2+/Mg2+ evoked intracellular Ca2+ mobilization and Ca2+ 
oscillation. This work further uses single cell imaging, immunoassay and sequencing to report 
tissue specific expression and differential capabilities of cations and drugs to tune CaSR mediated 
signaling in prostate (PCa) and thyroid cancer cells. We report a presence of wild type CaSR in 
PCa cell using RT-PCR. Additionally, proteomics and gene ontology show differential 
proteostasis between prostate cancer and HEK293 cells. Finally, this study endeavored at 
expressing and purifying a challenging protein, Cx26, and established binding affinity for Tb3+ 
and Ca2+ as 1.8 µM and 37 mM, respectively. The N-terminal lobe of CaM was found to bind Ca2+ 
tighter by 2.5-folds greater than C-lobe in the presence of Cx26p1-21. Our study on role of Ca
2+ on 
regulation of CaSR and Cx26 allows for greater understanding of their function and provides 
avenue for potential therapeutic targets. 
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1. CHAPTER I: INTRODUCTION` 
1.1 Calcium  
1.1.1 Calcium distribution 
Calcium (Ca2+) is an integral part of life and impacts almost every aspect of life. It exists 
as the fifth most abundant element in the human body [17] and plays a crucial role in skeletal 
mineralization and Ca2+ signaling. ~ 99 % of the Ca2+ is primarily present as calcium-phosphate 
complexes, mostly as hydroxyapatite, in bones [19]. The rest of the 1 % of total body calcium (~ 
10 g in an adult) [17] is used for a broad range of functions, including extra- and intracellular 
signaling, nerve impulse transmission, and muscle contraction [20, 21]. The existence of various 
forms of Ca2+ are as follows: free ions (~ 51%), protein-bound complexes (~ 40%), and ionic 
complexes (~ 9%) [22]. The physiologic range of serum ionized calcium is tightly maintained 
within a concentration of 1.10 to 1.35 mM [17] (Figure 1.3) in the form of calcium- phosphates, 
carbonates, and oxalates. There are many Ca2+ pools and Ca2+ buffer proteins in the cells that allow 
for the rapid and constant exchange of Ca2+ (Figure 1.3). 
1.1.2 Physical properties of Ca2+ 
Evolution of cells is accompanied by complexity but is refined the spatial and temporal 
compartmentalization of specific mineral such as Ca2+. Ca2+ is able to modulate protein in two 
ways, namely, by binding to a protein and changing its conformation and/or charge [23]. To carry 
out a defined function, Ca2+ is compartmentalized in specialized pools, sequestered by buffers 
proteins or extruded by channels (Figure 1.3). Furthermore, the binding affinity of Ca2+ for various 
proteins is broad, ranging from nM to mM [23]. This property is established due to its special 
physical properties. Ca2+ ions can bind 4-12 oxygen atoms in their primary coordination sphere 
2 
(Figure 1.1). Proteins bind to Ca2+ using their oxygen atoms of carboxyl and carbonyl groups (and 
sometimes water). The usual coordination geometry that Ca2+ attains is pentagonal bipyramid with 












Ca2+ ions have special physical properties where Ca2+can bind 4-12 oxygen atoms in its 
primary coordination sphere with a coordination geometry of  pentagonal bipyramid with 6-
7 oxygen atoms binding Ca2+ at ~2.5Å. Mg2+, on the other hand, favors six-fold, octahedral 
coordination with six ligands. Proteins bind to cation using their oxygen atoms of carboxyl 
and carbonyl groups (and sometimes water).  
Figure 1.1 Coordination properties of Ca2+ and Mg2+ 
 
Properties Ca2+ Mg2+
Ionic radius A 0.99 0.65
Ligands O O
Coordinating residues Asp, Glu Asp, Glu
Metal-Oxygen distance 2.3-2.6 2.00−2.15
H2O molcule/per metal site 1.5 2.2
Molecular geometry Pentagonal bipyramidal Octahedral
Coordination number 6-8 6
Interaction electrostatic electrostatic
Intracellular concentration 0.1-1uM 0.25-1mM
Table 1.1 Physical properties of Ca2+ and Mg2+ 
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1.1.3 Comparison of Ca2+ with Magnesium (Mg2+) cations  
Mg2+ is the fourth most abundant ion in the body and second most abundant intracellularly 
[25]. Mg2+ acts as a competitive ion to Ca2+, either inhibiting or modifying the function. Both Mg2+ 
and Ca2+ are small, closed-shell, spherical cations that prefer the formation of ionic bonds as 
compared to covalent bonds (Figure 1.1). Mg2+ favors six-fold, octahedral coordination, whereas 
Ca2+ prefers seven to eight ligands [26]. Both are hard ions and prefers hard ligands with low 
polarizability like oxygen [27]. The Mg2+ ligands to primarily to Asp/Gln carboxylic side chains, 
followed by Asn/Gln side chains or peptide backbone of carbonyl groups [28]. Rest of the 
coordination is complemented by water ligand. The bond distance between Ca2+ and the ligand is 
usually 2.3-2.6 Å [26]. On the other hand, Mg2+ and ligand bond distance is usually 2.0-2.1 Å. 
Mg2+ has 1000-fold lower desolvation rate than Ca2+ [29]. 
1.2 Background on CaSR  
The calcium-sensing receptor (CaSR) belongs to one of the largest cell surface receptor 
family, the C family, G-protein-coupled receptor (cGPCR). Other members of the cGPCR 
comprise of the two heterodimeric-aminobutyric acid B (GABAB) receptors, eight metabotropic 
glutamate (mGlu1-8) receptors, three taste (T1R) receptors, one L-amino acid receptor (GPRC6A), 
and five orphan receptors [8]. CaSR was first cloned by Dr. Edward M. Brown in 1993 from the 
bovine parathyroid gland [30]. This receptor is present in a wide range of tissues and organs for 
systemic Ca2+ homeostasis such as parathyroid, thyroid, gastrointestinal tract, kidney and bone 
(osteoclasts, osteoblasts, and osteocytes) (Figure 1.2). In addition, CaSR is also expressed in renal 
tubule, liver, lung, breast, placenta, vasculature, chondrocytes, lens epithelial cells, pancreas, 
neurons and glia in the CNS, exocrine cells in the pituitary, peripheral perivascular sensory nerves, 
keratinocytes and prostate [31]. Furthermore, the detection of CaSR in multiple cardiovascular 
4 
cells and tissue types, such as vascular smooth muscle cells (VSMCs), human aortic smooth 
muscle cells (HAoSMC), cardiac myocytes, myocardial microvasculature, cardiac fibroblasts, the 
atria and ventricle of the rat heart, human aortic endothelial cells (HAECs), etc implicates the 
importance of CaSR function in cardiovascular system [32]. In addition to the diverse expression 
of CaSR in many tissues and organs, CaSR activation and mechanism is also complicated with 
Figure 1.2 Systemic regulation of calcium homeostasis by CaSR [1] 
The systemic balance is an integrated regulation by serum ionized calcium and the 
calcium-sensing receptor (CaSR), parathyroid hormone (PTH) and the PTH receptor 
(PTHR) and 1,25-dihydroxyvitamin D [1,25(OH)2D] and the vitamin D receptor (VDR. 
CaSR regulates parathyroid hormone (PTH) secretion from parathyroid glands and 
calcitonin secretion from thyroidal C-cells upon sensing the alteration of the Ca2+o 
concentration. A decrease in serum calcium inactivates the CaSR in the parathyroid glands 
to increase PTH secretion, which acts on the PTHR in the kidney to increase tubular 
calcium reabsorption, and in the bone to increase net bone resorption[17]. The increased 
PTH also stimulates the kidney to increase secretion of 1,25(OH)2D, which activates the 
VDR in gut to increase calcium absorption, in the parathyroid glands to decrease PTH 
secretion, and in bone to increase resorption. The decrease in serum calcium probably also 
inactivates the CaSR in the kidney to increase calcium reabsorption and potentiate the 
effect of PTH. This integrated hormonal response restores serum calcium and closes the 
negative feedback loop. 
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numerous types of agonists and co-agonists that can cooperatively mediate CaSR signaling. 
Furthermore, the sensitivity of CaSR to extracellular [Ca2+] can vary in different cells and tissues. 
For example, in bone, the local extracellular [Ca2+] can reach 40 mM but in skin, the extracellular 
[Ca2+] range from 0.03 mM to > 0.5 mM [33]. Moreover, numerous mutations related to CaSR 
diseases and CaSR associated cancer along with diversified expressions of CaSR with altered 
signaling is prevalent. It is vital to explore the varied tissue- and species-specific genetic 
information of CaSR and its disease related mutations in order to understand the versatile function 
of CaSR in broad microenvironments at genetic and molecular levels. 
1.2.1 Calcium Homeostasis 
Calcium (Ca2+) homeostasis is an indispensable process where a 10,000 fold 
electrochemical gradient is maintained between the extracellular (1.10~1.35 mM) and intracellular 
(10−7 to 10−8 M) of the cell [20] (Figure 1.3). Ca2+ controls crucial processes such as apoptosis, 
fertilization, exocytosis, contraction, proliferation, transcription, and metabolism. Ca2+ was the 
first intracellular signal messenger discovered [34] and was established as an extracellular first 
messenger in 1993 by Brown et al. [30]. Calcium metabolism is regulated by three main 
mechanisms: intestinal absorption, renal reabsorption, and bone turnover [17] (Figure 1.2). This 
systemic balance is an integrated regulation by serum ionized calcium and the calcium-sensing 
receptor (CaSR), parathyroid hormone (PTH) and the PTH receptor (PTHR) [35] and 1,25-
dihydroxyvitamin D [1,25(OH)2D] and the vitamin D receptor (VDR) [36]. CaSR regulates 
parathyroid hormone (PTH) secretion from parathyroid glands and calcitonin secretion from 
thyroidal C-cells upon sensing the alteration of the Ca2+o concentration [8]. A decrease in serum 
calcium inactivates the CaSR in the parathyroid glands to increase PTH secretion, which acts on 
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the PTHR in the kidney to increase tubular calcium reabsorption, and in the bone to increase net 
bone resorption [17] (Figure 1.2). The up regulation in PTH further stimulates the increase in the 
Figure 1.3  Divalent Cation 
Metabolism for Calcium and 
Magnesium (Adapted from 











































A. The physiologic range of serum ionized calcium is tightly maintained within a concentration 
of 1.10 to 2.2 mM and cytosolic Ca2+at about 10,000-fold lower gradient. Apart from GPCR 
such as CaSR, many Ca2+ and Na+ channels, ORAI, TRPC and gap junctions allows for Ca2+ 
sensing and influx/efflux on plasma membrane. The intracellular compartmental channels like 
Ryanodine receptor (RyR), inositol-triphosphate receptor (IP3R) and sarco/endoplasmic 
reticulum Ca2+ ATPase (SERCA) in the ER and uniporters in mitochondria allows for 
cytoplasmic Ca2+ control as ER and mitochondria act as Ca2+ stores.B. Mg2+ functions as a 
versatile cofactor to more than 300 enzymes, regulator in replication, protein synthesis,  
glycolysis GPCR signaling, muscle contraction, potassium transport, calcium channels, and 
neuronal conduction. 
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secretion of 1,25(OH)2D in the kidney. These results in the increase in calcium absorption in the 
gut, decrease in PTH secretion in the parathyroid glands and an increase in resorption in the bone 
by activating the VDR. The decrease in serum calcium may inactivate the CaSR in the kidney to 
increase calcium reabsorption and potentiate the effect of PTH. This integrated hormonal response 
restores serum calcium and closes the negative feedback loop. With a rise in serum calcium, these 
actions are reversed, and the integrated hormonal response reduces serum calcium. Together, these 
negative feedback mechanisms help to maintain total serum calcium levels in healthy individuals 
within a relatively narrow physiologic range of ~ 10 % [17].  
1.2.2 Comparison of Ca2+ with Mg2+ in cellular function 
Both Ca2+ and Mg2+ are ubiquitously present cations that are essential for cellular 
function and shares parathyroid hormone (PTH) and vitamin D during their regulatory roles. 
Mg2+ functions as a versatile cofactor to more than 300 enzymes for the enzyme by not only 
complexing with ATP but also acting as an allosteric activator [25]. Mg2+ functions as a regulator 
in oxidative phosphorylation, replication, protein synthesis, and glycolysis [25] (Figure 1.3). It 
also is essential for GPCR signaling, muscle contraction, potassium transport, calcium channels, 
and neuronal conduction. Therefore, Mg2+ has both catalytic and structural roles. Out of the total 
Mg2+, 0.5-5.0% are free. The serum contains 0.66-1.07 mM Mg2+ [25]. Disorders in Mg2+ lead to 
hypo- or hypermagnesemia.  
1.2.3 Activation and regulation of CaSR 
The architecture of CaSR consists of an extracellular domain (ECD) with the first 612 
amino-acids, the seven transmembrane domains (TMDs) which comprise residues 613 to 862, and 
the intracellular domain (ICD), which comprises residues 863 to 1068 [8] (Figure 1.4). The ECD 
domain is important for the dynamic co-translational processing, receptor dimerization, binding 
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ligands, and transmitting activation signals. The principal agonist of CaSR is known to be the 
extracellular Ca2+ (Ca2+o) that binds to the CaSR is a highly cooperative process (the hill coefficient 
of ~3) [37]. CaSR can distinguish small (~200 μM) fluctuations in the extracellular [Ca2+] [38]. 
The functional diversity of CaSR results from its ability to activate multiple downstream signaling 
pathways through Gq/11, Gi/o, G12/13 and Gs proteins when a ligand binds to the CaSR ECD [39] 
(Figure 1.5). In addition to Ca2+, CaSR is also regulated through several orthosteric agonists such 
as cations, polyamines, cationic polypeptides and endogenous allosteric modulators such as the 
extracellular pH [40] and ionic strength [41]. Cooperative activation of CaSR is carried out by 
divalent and trivalent metals such as La3+, Gd3+, Ba2+, Cd2+, Co2+, Fe2+, Ni2+ and Pb2+ (but not Fe3+ 
or Hg2+) [42] with varying efficacies. Al3+ is considered a weak CaSR agonist since it can activate 
CaSR at mM concentrations [43]. Pb2+ is a potent CaSR activator with an EC50 of ~100 µM and 
therefore, can cause the toxicity by its ability to replace other cations [43, 44]. The potency of 
CaSR agonists can vary in various cells types. For example, in parathyroid, Mg2+ and Ca2+ have 
similar potency, but in sheep parafollicular cells of the thyroid, the potency is ranked as 
Gd3+>Ba2+>Ca2+>>Mg2+ [45].  
Polycations and molecules with a high positive-charge density, such as polylysine (EC50  < 
1 µM) [46], are more potent agonists than those with a lower charge density, such as Mg2+, which, 
with its larger hydration radius that ‘dilutes’ its positive charge, requires concentrations twofold 
to three-fold higher than Ca2+ to be effective. Endogenous polyamines, such as spermine, 
spermidine and putrescine, are also CaSR agonists [37]. With four positive charges, spermine is 
the most potent of these compounds (the EC50 is ~500 µM in the presence of 0.5 mM Ca
2+).  
Polyamines are produced endogenously by bacteria in the gut and by many cell types in the body. 
Antibiotic such as neomycin [47, 48], G418, gentamycin and tobramycin [49] are polycationic 
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compounds and act as antagonists. It is of note that, at concentrations that are typically added to 
cell-culture growth media, streptomycin can significantly activate the CaSR, as can G4ll [50], 
which is often used as a selection agent for mammalian cells. Furthermore, aromatic and aliphatic 
L-amino acids such as L-Phe and L-Trp is known to increase the sensitivity of CaSR for Ca2+  and 
are considered as positive allosteric modulators of the receptor [41]. Synthetic positive allosteric 
modulators such as calcimimetics are known to left-shift, whereas the negative allosteric 
modulators, known as calcilytics, right-shift the concentration-response curve of Ca2+ [30].  Recent 
work by Zhang et al. has reported a novel Tryptophan derivative as a co-agonist for CaSR’s 
activation [8].  
The architecture of a homodimeric GPCR consists of an extracellular domain (ECD) 
consisting of lobe 1 and 2 (comprising of the first 612 amino acids in CaSR), the 7 
transmembrane domains (TMDs) (comprises of residues 613 to 862 in CaSR), and the 
intracellular domain (ICD) (comprises of residues 863 to 1068 in CaSR). A conserved 
nine Cys residue-rich domain connects the ECD with TMD. The signaling is resulted 
by activation of GPCR and consequent dissociation of trimeric G-proteins.  
















1.2.3.1 Non-essential metal Pb2+ interferes with Ca2+ dependent functions 
The cGPCRs are potential targets for Pb2+ due to their direct activation by binding to Ca2+, 
or indirect modulation by interactions with other CABPs modulators, as seen in the case of 
calmodulin (CaM) [44]. Consequently, Pb2+ can interfere with downstream Ca2+ signaling 
pathways through the displacement of Ca2+, or through opportunistic binding of Pb2+ to regions 
besides the Ca2+ binding sites [44]. The interactions between Pb2+ and CaBPs or proteins involved 
in Ca2+-signaling pathways are based on three potential modes of Pb2+ activity as follows: (i). Pb2+ 
may occupy Ca2+-binding sites, altering the structure of the protein and inhibiting the activity of 
the protein. (ii). Pb2+ may occupy Ca2+-binding sites and mimic Ca2+, thereby falsely activating 
the protein and perturbing downstream activities. (iii). Pb2+ may bind with proteins in sites other 
than Ca2+-binding sites, thereby altering the conformation and function of the protein. Pb2+ is 
known to activate Ca2+ associated neuronal proteins at low concentrations and deactivate at higher 
concentrations, as characterized by a bell curve. Pieces of evidence also suggest that Pb2+ interacts 
with CaM, either through ionic displacement or through opportunistic binding, which likely 
disrupts a wide range of downstream activities [44]. 
1.2.4 Ca2+ signaling mediated by CaSR 
CaSR mediates diverse downstream signaling pathways which regulate critical cellular 
processes including secretion, apoptosis, chemotactic responses, cell proliferation, cytoskeletal 
rearrangements, ion channel activity, the control of gene expression and cell differentiation [51, 
52]. Ca2+o can trigger CaSR-mediated intracellular signaling pathways, including activation of 
phospholipases C, A2, and D, and various mitogen-activated protein kinases (MAPKs), as well as 
inhibition of cAMP production [53-58]. CaSRs have been reported to be present not only in the 
11 
key tissues involved in Ca2+o homeostasis (e.g., parathyroid gland, kidneys, bone) but also in other, 
non-homeostatic tissues (e.g., brain, skin) [38, 53, 59-71]. 
During the ‘on’ reactions, stimuli induce both the entry of external Ca2+ and the formation 
of second messengers that release internal Ca2+ that is stored within the endoplasmic/sarcoplasmic 
reticulum (ER/SR) (Figure 1.3). Most of this Ca2+ is bound to buffers, whereas a small proportion 
binds to the effectors that activate various cellular processes. During the ‘off’ reactions, Ca2+ leaves 
the effectors and buffers and is removed from the cell by various exchangers and pumps. The 
Na+/Ca2+ exchanger (NCX) and the plasma membrane Ca2+-ATPase (PMCA) extrude Ca2+ to the 
outside, whereas the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) pumps Ca2+ back into 
the ER [23] (Figure 1.3). Mitochondria, on the other hand, sequester Ca2+ rapidly through a 
uniporter, and this is then released more slowly back into the cytosol to be dealt with by the 
SERCA and the PMCA. Ins(1,4,5)P3R, inositol-1,4,5-trisphosphate receptor and ryanodine 
receptor control the extruding of calcium from ER while SERCA replenishes the calcium store. 
The on and off reaction allows for a unique Ca2+i oscillation that can be used to detect the CaSR 
activation.  
GPCRs are known to activate Gα proteins such as Gαi Gαq and Gα12/13 to carry out different 
signaling and biological effects in various regions of a cell and in different cells (Figure 1.5). 
CaSR inhibits adenylyl cyclase and activates extracellular signal-regulated kinase (ERK) through 
Gαi and phospholipase C is activated through Gαq, therefore, increasing intracellular Ca
2+ (Ca2+i), 
diacylglycerol (DAG) levels and activating phospholipase A2 (Figure 1.5). Finally, Gα12/13 
activates Rho-dependent phospho-lipase D and L-amino acid-induced Ca2+ mobilization [55, 72] 
(Figure 1.5).  
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Approximately 30% of therapeutic drugs used clinically directly target GPCRs; therefore, 
it is of paramount importance to understand the mechanisms by which GPCRs are regulated [73]. 
Functional cooperativity of CaSR (i.e., based on biological activity determined using functional 
assays rather than a direct binding assay), particularly the functional positive homotropic 
cooperative response to Ca2+o, is essential for the receptor’s ability to respond over a narrow 
physiological range of Ca2+o (1.1-1.3 mM) [54]. CaSR has an estimated hill coefficient of 3-4 for 
its regulation of biological processes such as activating intracellular Ca2+ signaling and inhibiting 
PTH release. CaSR has been shown to be cooperatively regulated by aromatic amino acids such 
as L-Phe and L-Trp [74]. 
1.2.5 Evolution of CaSR  
CaSR is found in a variety of vertebrate species, including mammal, bird, reptile, 
amphibian, and fish. CaSR-like proteins are found in sea urchin, fruit fly, round-worm and 
tunicates [75]. Among the CaSR nucleotide sequences of 42 vertebrate species available from 
public databases, all vertebrate CaSRs (tetrapod and fishes) are grouped together and share the 
most recent common ancestor with the CaSR-like proteins of chordate (urochordates and 
cephalochordates) [76]. According to the detailed sub-group phylogenetic tree of CaSR and CaSR-
like protein sequences, a distinctive indel in the ECD and noticeable variation in ICD length were 
observed (Figure 1.6, Figure 1.7). Among different species, the 7TM domain is the most 
conserved region with 85-91% identity, and ECD shows the identity of 70-77% [75]. The ICD is 
the least conserved with variable length (Figure 1.6, Figure 1.7).  
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Of the 1059 amino acid residues of the matured human CaSR, 44% sites are completely 
conservative during the evolution including the nine cysteine residues in cysteine rich (CR) domain 
and the predicted calcium-binding site 1 (S147, S170, D190, Y218, E297) [77] (Figure 1.7). Most 
of these conserved sites are buried inside the protein in 3D structure, which might be necessary for 
the maintenance of protein structure and function (Figure 1.7). The calcium binding site 1 overlap 
with the L-Trp binding site determined in CaSR crystal structure which is located in the cleft 
Figure 1.5 CaSR mediated signaling through G-proteins 
GPCRs are known to activate Gα proteins such as Gαi Gαq and Gα12/13 to carry out 
different signaling and biological effects in various regions of a cell and in different cell. 
CaSR inhibits adenylyl cyclase and activates extracellular signal-regulated kinase (ERK) 
through Gαi and phospholipase C is activated through Gαq, therefore, increasing 
intracellular Ca2+ (Ca2+i), diacyl glycerol (DAG) levels and activating phospholipase A2. 
Finally, Gα12/13 activates Rho dependent phospho-lipase D and L-amino acid-induced Ca
2+ 
mobilization. Channels in the ER such as the IP3R, RyR and SERCA allows for the 









































between the two lobes of VF [78] (Figure 1.7). The other metal-binding sites determined by CaSR 
crystallization or predicted by computational approach are relatively conserved but with slight 
heterogeneity, which might be related to the alteration of habitat during evolution.  
Figure 1.6 Conservative amino acid sites of vertebrate CaSR (in red) displayed in hCaSR-ECD  
(PDB ID: 5FBK), (A) the front view and (B) the back view. The predicted Ca2+ binding sites 




Figure 1.7 The alignment of deduced amino acid sequence of the CaSR from different species.  
The underlined sequence is signal peptide. The black boxes indicate the indel spot in ECD and 
ICD individually. “-”, gaps in alignment. [4] 
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1.2.6 CaSR gene 
As shown in Figure 1.8, CaSR gene (CASR) encodes for calcium-sensing receptor and is 
a ~100-kb spanning single-copy gene that maps to human 3q13.3-21. Out of the eight exons, exons 
2 to 7 encode the CaSR protein of 1068 amino acids (Figure 1.8). Exons 1A and 1B are able to 
encode for two alternative 5′- untranslated region (UTR) that may splice to a common segment 
encoded by exon 2 [31]. Exon 2 contains 242 nucleotides of the 5′-UTR upstream of the ATG 
translation initiation codon [31].  
1.2.7 Alternative Transcripts 
 CASR is expressed in multiple tissues and organs at various levels. The variation of 
expression of CASR gene as multiple alternative transcripts in multiple tissues/organs hint at the 
ability to diversify its functions and regulations. In addition to the wild type variant II CASR, low 
abundant variant I exists which contains additional 10 amino acid inserted after amino acid 536 in 
Figure 1.8 Genetic make-up of CaSR.  
It is a ~100-kb spanning single copy gene that maps to human 3q13.3-21. Exons 2 to 7 
encode the CaSR protein of 1068 aa. [4] 
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the CaSR (GenBank #U20760). This variant I is known to function similarly to variant II [31]. 
While, in human kidney, both the 5.4-kb transcript and the 10-kb transcript are similarly 
predominant [31]. The use and presence of the two promoters in CaSR gene allow for variation in 
the transcription of alternative 5′ UTR exons (1A and 1B) [31]. The real-time PCR (qPCR) analysis 
has shown that exon 1B-transcripts in human parathyroid cells were significantly more expressed 
than exon 1A-containing transcripts. The 5.4 and 10-kb transcripts in human parathyroid adenomas 
and normal glands use exon 1A exclusively as shown by northern blot analysis, while the 4.2-kb 
transcripts are either derived from 1A or 1B [31]. 5.4 and 4.2-kb sized transcripts are derived from 
the use of the two alternative polyadenylation sites in the 3′ UTR tract [31].  
An exon 3-deleted CASR transcript has been reported in thyroid TT cells, placental 
cytotrophoblast, and in parathyroid, thyroid, and kidney [31]. This protein is poorly expressed and 
does not traffic to the cell surface. Another alternative transcript of CaSR exists in human 
keratinocytes where exon 5 is deleted (with a 77-amino acid in-frame deletion in the exodomain). 
The relative amounts of full-length is lowered during keratinocyte differentiation and the 
alternatively spliced variant is shown to cause the full-length protein to be less responsive to Ca2+. 
This variant of CaSR is also known to be upregulated in skin and kidney in the knockout mice and 
is shown to compensate for the absence of the full-length CaSR in bone and cartilage [31].  
1.2.8 CaSR monomer and dimer 
CaSR has been detected as a monomer at various molecular weight depending upon the 
amount of glycosylation. 100-120 kDa are known as the unglycosylated form of CaSR, 130-140 
kDa are an immature form of CaSR that are glycosylated with mannose forms of carbohydrates 
and 150-160 kDa are mature forms of CaSR glycosylated with complex carbohydrates [51, 79]. 
These mature forms are expressed at the cell surface [80]and the immature ones are proteolyzed. 
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A functional CaSR is expressed as a homodimer at greater than 200 kDa which may represent a 
dimer or an oligomer.  
1.2.9 Disorder of Ca2+ homeostasis and CaSR 
Over 225 mutations in the Ca2+-sensing receptor result in hypercalcemic or hypocalcemic 
disorders, such as familial hypocalciuric hypercalcemia, neonatal severe primary 
hyperparathyroidism, and autosomal dominant hypocalcemic hypercalciuria (Figure 1.9). 
Abnormal function of CaSR is associated with Ca2+ homeostatic disorders. Loss-of-function 
mutations in CaSR lead to potentially fatal neonatal severe primary hyperparathyroidism, while 
gain-of-function mutations cause autosomal dominant hypocalcemia [81, 82]. However, not all the 
mutations detected from patients are disease related, and some nucleotide diversity can be a rare 
allele of single nucleotide polymorphism. For example, a CaSR variant (Glu250Lys) identified in 
FHH and ADHH probands were demonstrated to be a functionally neutral polymorphism [83]. 
1.2.10 Cancer and CaSR  
CaSR is a master regulator of Ca2+ homeostasis, and additionally, it affects the cellular fate 
through control over proliferation, differentiation, apoptosis and chemotaxis [66]. Therefore, 
CaSR has a pivotal role in the regulation of cancer expression. There are many single nucleotide 
polymorphisms (SNPs) in CaSR that are associated with cancer. Three common nonsynonymous 
SNPs (rs1801725, rs1042636, and rs1801726) have been the primary research targets for cancer 
risk, but inconsistent results have been reported in MEDLINE, EMBASE, Web of Science, 
Scopus, and the HuGE databases [84]. rs1801725 (A986S, 2956G.T) is where T allele is associated 
with higher levels of serum calcium, colorectal adenoma, whereas rs1042636 (R990G, 2968A.G) 
mostly present in Asians, induces a gain-of-function mutation associated with primary 
hyperparathyroidism and calcium stone formation [84]. It is shown to be lower in colorectal 
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adenoma. On the other hand, rs1801726 (Q1101E, 3403C.G) is a common polymorphism in 
African ethnicity and is less carried in prostate cancer patients. Patients with this SNP have 
increased risk of colorectal adenoma. Another polymorphism called rs17251221 (1378–1412A.G) 
is an SNP in introns. rs1801725 induces a gain-of-function mutation associated with total serum 
Physiological role Disorders associated
Figure 1.9 Physiological role and clinical relevance of CaSR. Adapted from [5]  
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calcium concentration, and stone multiplicity in patients with nephrolithiasis, noticeable 
association with prostate and breast cancer increased risk [84].  
CaSR expression and mechanism are highly dubious in various cancer cells. In prostate, 
testicular, ovarian, and breast cancer, CaSR promotes proliferation and inhibition of apoptosis, 
thus, acting as an oncogene [2] (Figure 1.10). In parathyroid, colorectal cancer and 
neuroblastomas, CaSR expression is reduced and thus, CaSR functions as a tumor suppressor [2] 
(Figure 1.10). CaSR may act as the mediator of the anti-tumorigenic effect of calcium in these 
cancers. Loss of expression of CaSR in neuroblastomas and colorectal cancer is epigenetic. 
However, in parathyroid cancer, CaSR expression is not affected by epigenetic or genetic 
mechanisms [2]. For example, in colon cancer, 69% CaSR gene showed methylation and showed 
an inverse correlation with the degree of differentiation. The methylation was significantly 
correlated with reduced mRNA and protein expression of CaSR. The study showed a significant 
role of epigenetic silencing of CASR in colorectal carcinogenesis [85]. Besides, meta-analysis 
studies investigating association of CASR polymorphisms with cancer risks have presented many 
inconclusive results. The role of CASR polymorphisms as a tumor suppressor or an oncogene is 
known to differ by cancer site and environmental condition. High calcium intake is shown to 
reduce the risk of colorectal cancer development as E-cadherin stimulated by CaSR is known to 
interact with β-catenin, an important proto-oncogene [84]. The increased expression of CaSR by 
high calcium levels is known to promote MCF-7 breast cancer cells and PC3 and C4-2B prostate 
cancer cells that are known to metastasize to the bone. These cancer cell proliferation process is 
linked to extracellular signal-regulated kinases 1 and 2 (ERK 1/2) phosphorylation [84].  
The role of CaSR in cancer is directly related to its role at the regulation of synthesis of the 
parathyroid hormone-related peptide (PTHrP) (81). PTHrP, a peptide growth factor, binds to the 
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binding region of PTH. It is able to increase the expression of receptor activator of nuclear factor 
κ B ligand (RANKL), a tumor necrosis factor cytokine family. This, in turn, stimulates the 
osteoclastic bone resorption [86]. PTHrP is associated with osteolytic bone destruction and 
releasing of bone-derived growth factors [2]. PTHrP causes humoral hypercalcemia of malignancy 
(HHM) which is a common complication found in breast, prostate, lung, kidney cancer and 
myelomas [87]. Several studies implicate the role of Ca2+o and CaSR in cancer bone metastasis of 
breast, prostate, lung, and kidney with an incidence of 65-40% [88]. Stephen Paget’s theory on 
“seed and soil” postulates the importance of the microenvironment (soil), in the secondary site in 
organ-specific metastasis [89]. The blood plasma Ca2+ concentration is ~2.2-2.6 mM whereas, the 
bone plasma is around 10 mM and 20 mM in extracellular space of bone tissue [22]. High Ca2+ 
could act as a favorable microenvironment for the metastasized cells. Feng et al also showed CaSR 
expression to be higher in the bone metastasis than in the primary prostate tissues [90]. 
Furthermore, Liao et al showed a higher proliferation of skeletal metastatic cells, PC3, in increased 
Ca2+ condition as compared to LNCaP cells that metastasize to lymph nodes, and this mechanism 
is mediated by CaSR as shown by the decrease in proliferation when CaSR is knocked-down [91]. 
In addition to prostate cancer, CaSR has been shown to be highly expressed in patients with 
primary renal cell tumors with bone metastasis in comparison to lung metastases or no metastases. 
Further, the proliferation and migration induced by Ca2+ treatment in RCC cells obtained from 
patients with bone metastasis, was inhibited by CaSR inhibitor NPS2143 [92].  
Various pathways have been implicated in promoting tumor by CaSR activation. However, 
the exact mechanism is obscure. In malignant or normal ovarian epithelial cells, the CaSR 
activation induces proliferation by activation of the ERK1/2 pathway [93, 94]. The osteoblastic 
metastases in prostate cancer is caused by CaSR mediated stimulation through PTHrP. PTHrP is 
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higher in prostate tumors as compared to healthy prostate epithelial cells, and PTHrP associated 
proliferation has been accounted for in PC3 cells and not LNCaP cells [95]. The PTHrP could 
mediate the transactivation of epithelial growth factor receptor (EGFR) and ERK1/2 [96]. It has 
been shown that knockdown of PTHrP in PC3 cells inhibits epithelial-to-mesenchymal transition 
(EMT) and tumor progression [97]. Further, CaSR mediated Akt [91] and Rho [98] signaling 
pathway is also associated with tumor proliferation. 
1.3 Challenges faced in studying CaSR 
There are many challenges to studying CaSR. First, it is a large membrane protein with 
1068 amino acids. Therefore, it is difficult to separate it from the cells due to their hydrophobic 
transmembrane domain. Further, a large amount of aggregation of the 7TM region occurs due to 
Figure 1.10 The role of CaSR as oncogene or suppressor in cancer [2] 
CaSR expression and mechanism are highly dubious in various cancer cells. In prostate, 
testicular, ovarian, and breast cancer, CaSR promotes proliferation and inhibition of 
apoptosis, thus, acting as an oncogene. In parathyroid, colorectal cancer and 
neuroblastomas, CaSR expression is reduced and thus, CaSR functions as a tumor 
suppressor 
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the heating process and thus reduce the solubility of the protein. Second, CaSR is highly 
cooperative with high hill coefficient (~ 3); therefore, when we study the mechanism, we are 
looking at multiple binding sites. Third, it is highly heterogeneous with many variants and isoforms 
with varying functional capabilities depending on the tissue-type. Fourth, CaSR is a dynamic 
receptor and undergoes a multitude of actions involving folding, glycosylation, dimerization, 
trafficking, and endocytosis. CaSR has multiple binding partners involved in a wide range of 
downstream signaling. These partners are known to bind not only various transmembrane or 
intracellular loop exposed to cytosol but are known to bind differentially spatially depending on 
which part of life-cycle CaSR is present in. Last but not the least, studying CaSR in cancer is 
complicated as it is found to be low in endogenous expression, for example, 7-8 folds lower in 
PC3 cells as compared to wild type. In addition, studying Ca2+ is challenging as it binds with low 
binding affinity and cannot be measured directly with fluorescence. Ca2+ signaling is further 
complicated as Ca2+ not only acts as a primary messenger but also the secondary messenger.  
Using techniques such as RT-PCR and mass-spectrometry is highly dependent on the 
amount of expression of the transcript or proteins or their kinetics. For example, in co-
immunoprecipitation and mass spectrometry may not be able to provide a complete snapshot of 
the putative CaSR interactome. They have obvious limitations with likely detection of partners 
with only high binding affinity and slow dissociation constants. This results in less prospect of 
detection of transient interactions, as well as likely detection of interaction of more abundant 
partner as compared to lower abundant ones. Due to the absence of the native state of CaSR as the 
lysis destroys the plasma membrane and cannot provide accurate and adequate membrane 
environment with detergent, the binding can be perturbed. Also, there is the possibility of 
interactors being washed out during the Co-IP process and un-specific binding and detection due 
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to general enrichment in the cell. This can result in the incomplete recruitment of protein 
complexes and the absence in the detection of some of the known CaSR partners in our experiment. 
The mass-spectrometry utilized in our study is incapable of separating the divergent forms of CaSR 
with various post-translational modifications, which can indirectly impact the interactors over its 
lifecycle. The LC-MS has a typical dynamic range of detection at 4-6 orders of magnitude which 
is much lower as compared to the protein concentration range in biological samples at 12 orders 
of magnitude [99]. Also, using an online database for annotations have limitations since the known 
knowledge is not complete. The generation of complicated networks of inter-related and similar 
terms can be overwhelming and can produce convoluted results.  
1.4 Background on Gap Junction 
Gap junctions (GJ) are integral membrane proteins which assist in communication and 
coordination between cells through processes including, exchange of metabolites and electrical 
signal (Figure 1.3). In humans, GJs are expressed in all tissues except differentiated skeletal 
muscle, erythrocytes, and mature sperm cells (Figure 1.11) [100]. GJ proteins consist of 
intercellular aqueous channels between adjacent cells that permit the exchange of hydrophilic 
molecules such as ions, and metabolites (ATP, NAD+, small peptides and nucleotides), and 
secondary messengers (Ca2+, cAMP, IP3) of less than 1kDa [100]. They are known to modulate 
wide range of functions such as immune response, inflammation, memory, apoptosis, water 








Figure 1.11  Connexins are divided into three major families (α, β and ϒ)  
Around 21 connexin genes have been identified in humans categorized as a α, β, γ, 
δ or ε isoform based on their sequence homology and length of the CL. Each of the 
isoforms have distinct physiological properties and regulation responses. 
Therefore, the unique properties of GJ function and regulation such as their 
selectivity for small molecules, voltage dependent gating, and response to Ca2+, 
pH and phosphorylation is determined by its connexin composition. 
Table 1.2 Various families of gap junction and their expression patterns 
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3Figure 1.12  Structure of Gap Junction 
 
A. Gap Junction forms a channel with head-head docking of the two hemichannels 
(connexons). The hydrophobic interactions at the extracellular domains drive 
hemichannels to redock into dodecameric channels B. Connexins are formed by four 
transmembrane domains connected by extracellular loops and a cytosolic loop. [11] 
exchange of hydrophilic molecules such as ions, and metabolites (ATP, NAD+, small 
peptides and nucleotides), and secondary messengers (Ca2+, cAMP, IP3) of less than 
1kDa 
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1.4.1 Structure of Gap Junction  
Docking of head to head of two hexameric connexins form GJ proteins in vertebrates 
whereas, in non-vertebrates, they are formed by innexins [101]. The hydrophobic interactions at 
the extracellular domains drive hemichannels to redock into dodecameric channels [102]. Proteins 
with sequence homology to innexins in vertebrates are called pannexins which can form 
intercellular channels [101]. Each connexin consists of four α-helical transmembranes (TM) 
domains connected by two extracellular loops (EL) and a cytoplasmic loop (CL) with both N-and 
C-terminus facing the cytosol [103]. Intermolecular interactions between two adjoining connexons 
involve both EL1 and EL2 domains. EL1 and EL2 are connected via intra-connexin disulfide 
bonds between six highly conserved Cys residues, three in each loop. The channel interior, that 
connects between adjacent cells, is tightly isolated due to to the presence of numerous hydrogen 
bonds and salt bridges [100]. The TM domains and the EL's are highly conserved among the 
connexin families. N-terminus is relatively conserved, whereas, the CL and C-terminus vary 
significantly between the isoforms. Currently, around 21 connexin genes have been identified in 
humans categorized as a α, β, γ, δ or ε isoform based on their sequence homology and length of 
the CL (Figure 1.11Figure 1.11) [103]. Each of the isoforms has distinct physiological properties 
and regulation responses. Therefore, the unique properties of GJ function and regulation such as 
their selectivity for small molecules, voltage-dependent gating, and response to Ca2+, pH, and 
phosphorylation is determined by its connexin composition [103].  
1.4.2  Connexin26 and related disorders   
Connexin26 (Cx26) is the second smallest, and one of the most ubiquitous members of the 
GJ protein β-family distributed in cochlea, skin, liver, placenta, brain, and breast (Figure 1.11) 
[104]. Hereditary mutations in human Cx26 is associated with skin disorders and non-syndromic- 
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and syndromic- deafness (Figure 1.13) [104]. Cx26 are also implicated in cancers where Cx26 
had an inverse relation with cancer into human breast tumor cell line, for example, in breast cancer 
[105] and bladder cancer [106]. Therefore, understanding the gating mechanism of Cx26 or any 
GJ's can be exploited for the therapeutic target of numerous disorders. Connexin26 is the only GJ 
protein with an x-ray crystal structure and this was made possible due to its short CT as compared 
with other connexins. The flexibility of the cytoplasmic domains has been a challenge for the 
crystal structure. [102, 107]. The N-domain serves as the plug as demonstrated by Oshima et al. 
where its deletion mutation resulted in no electrical activity in paired Xenopus oocytes and reduced 
dye transferring capability in Hela cells [102].  This was also supported by Maeda et al through a 
3.5 Ao crystal structure [108]. 
 
Figure 1.13  Various disease related mutations are present in Cx26 [15].  
 
Keratitis Ichthyosis Deafness (KID) syndrome (black), Palmoplantar 
keratoderma with deafness (red), Vohwinkel’s syndrome (blue) and Bart 
Pumphrey Syndrome (BPS) (purple) 
29 
1.5 Challenges faced in studying Cx26 
Connexins are large membrane proteins which prefer the state of oligomerization. This 
makes it difficult to express and purify due to low solubility. The expression especially in E.coli. 
and insect cells is challenging due to the fact that bacteria lack a proper mechanism for eukaryotic 
protein folding, translocating, trafficking, disulfide bond formation, and post-translational 
modifications. Also, the phospholipid composition in bacteria and insects varies from that of 
eukaryotic cells. These may result in improper surface expression of membrane proteins such as 
connexins. Understanding their mechanism is limited due to the unavailability of their dynamic 
structures. This again is resulted due to the heavy glycosylation, dynamic structures, high 
instability, oligomerization and large molecular size. For example, the closed-form structure is 
unavailable. Additionally, understanding the calcium modulation is a challenge due to its weak 
binding and that Ca2+ binding has high on- and off- rate. Furthermore, calcium is silent 
spectroscopically, which makes the study a challenge. 
1.6 Overview of the dissertation, and major question to be addressed  
In this dissertation, in order to understand the regulatory role of Ca2+ on important 
membrane proteins such as CaSR and Cx26, we addressed many challenges and carried out several 
approaches to tackle them.  
CHAPTER I is an overview of the background of Ca2+ homeostasis, Ca2+ signaling, 
calcium-sensing receptor and connexin26. CaSR is a versatile receptor that allows control of serum 
Ca2+ concentration at the microscopic level and is known to be modulated by divalent cations and 
amino acids. It’s expression and function are highly diverse in various tissues and pathological 
conditions. Cx26 is a gap junction protein that allows for intra- and extra- cellular communication. 
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Both CaSR and Cx26 are integral membrane proteins that regulated the normal functioning of a 
cell.  
The recent advancement in its study such as the crystal structure obtained in 2016 has 
expanded our knowledge on the function of CaSR at a molecular level to some degree, highlighting 
its modulation through divalent cations such as Ca2+ and Mg2+, and Trp-derivative ligand as co-
agonist. However, the agility of this receptor as a multifunctional receptor comes from many 
factors such as (i) diversity in transcripts and expression levels in various tissues, organs and 
species, (ii) various modes of regulation such as multitude of agonists and co-agonists, (iii) 
disease-mutations that affect its signaling and expression and (iv) wide range of spatially and 
temporally modulated downstream signaling molecules attributing to diverse intricate control. An 
in-depth understanding of differential molecular function, genomic organization, expression and 
interaction with its microenvironments is necessary in order to help us design and develop organ- 
or tissue-specific therapeutics and targeting methods against CaSR related maladies. 
CHAPTER II describes the project on understanding the global effect of Ca2+o on protein-
protein interaction network of CaSR. We attempt at establishing the first CaSR interactome. Co-
immunoprecipitation using recombinant FLAG-CaSR and anti-FLAG antibody, and proteomics 
were utilized to quantify the difference in downstream signaling pathways. This was further 
studied using gene ontology and statistics to obtain information on function, location and pathways 
associated with the enriched proteins. We address question such as: 
a) How do we optimize co-immunoprecipitation to achieve the optimal enrichment of CaSR 
and its interactors? 
b) What are CaSR interactors during its cellular biosynthesis and trafficking?  
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c) Will prolonged exposure to Ca2+o or deprivation of Ca2+o using EGTA affect the 
biosynthesis of other interactors and regulators of CaSR?  
d) Can CaSR regulate its biosynthesis due to prolonged signaling?  
e) Does CaSR act as a communicator between the intra- and extra- cellular Ca2+ signaling? 
f) What is the implication of enrichment of some proteins with the treatment of Ca2+o? 
g) What are biological pathways most affected with Ca2+o? 
CHAPTER III is a project investigating the CaSR mediated signaling in HEK293 cells and 
endogenous CaSR mediated signaling in thyroid cancer cells. This chapter attempts at 
characterizing the Gαq mediated signaling and examining the molecular difference in the CaSR to 
explain the differences. The biostatistical methodology was employed for precise measurement of 
the Ca2+ oscillation pattern and further immunoassays and calcium sensor such as FURA-2 AM 
were used to monitor intracellular signaling mediated by CaSR. Effect of various CaSR-related 
drugs was monitored to understanding Ca2+ signaling mediated by CaSR in different cell types. 
The questions addressed in this chapter are: 
h) How do Ca2+, Mg2+ and amino acids modulate the mechanism of WT CaSR? 
i) How does CaSR mediated signaling differ in thyroid cancer cells? 
j) How species- and tissue-specific is the expression and signaling of CaSR? 
k) Do the CaSR-related drugs carry similar potency in all cell types?  
l) Can we use bio-statistics to quantitate the difference?  
m) Is the differential signaling due to expression?  
n) Is the cause of the differential CaSR mediated signaling splice variants? 
CHAPTER IV is a project on the molecular investigation of CaSR in the prostate cancer cell, 
PC3. We examine the CaSR from RNA to DNA level and study the signaling as compared to the 
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WT in HEK293 cells. This chapter probes the Gαq mediated signaling mediated by CaSR by 
employing calcium sensors such as FURA-2 AM and CaSR related drugs. We also delve into the 
difference in global proteomics difference between the Ca2+ and EGTA treatment conditions as 
well as cell types. The questions addressed in this chapter are: 
o) Does PC3 express WT CaSR? 
p) Do CaSR in PC3 have similar signaling as WT? 
q) If not, what is the reason behind it? 
r) Is the differential signaling due to the presence of splice variant? 
s) Is the differential signaling due to proteomics difference? 
t) How does Ca2+o affect the global proteomics in HEK293 cells and PC3 cells?  
u) Do the CaSR-related drugs carry similar potency in all cell types?  
CHAPTER V is a project on gap junction, Cx26. We aimed at optimizing expression and 
purification of this challenging membrane protein using a bacterial system. We also characterized 
the protein stability and used it for biophysical assays to understand the gating through Ca2+o and 
CaM. We address questions such as: 
v) What parameters can optimize the expression of hCx26? 
w) What detergents and strategies are optimal for purification of hCx26? 
x) What are the biophysical characteristics/stability of the purified protein? 
y) What is the stoichiometry, metal binding affinity and metal selectivity of the hCx26?  
z) How does Ca2+ induce conformational changes, stability, and assembly? 
aa) What is the major mechanism of  interacts between CaM/Ca2+ and Cx26? 
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2 CHAPTER II: GLOBAL EFFECT OF EXTRACELLULAR CALCIUM ION ON 
CALCIUM-SENSING RECEPTOR INTERACTOME INVOLVED IN RECEPTOR 
MATURATION AND TRAFFICKING 
2.1 Abstract  
The calcium-sensing receptor (CaSR) maintains systemic calcium (Ca2+) homeostasis by 
integrating Ca2+-signaling from changes in extracellular Ca2+ concentrations to intracellular 
signaling networks which is critical for many (patho)physiological processes in multiple organs 
including parathyroid, kidney, bone, brain, and skin. Agonist-driven insertional signaling results 
in the mobilization of the intracellular pool of nascent CaSR to its functional form at the plasma 
membrane in the chronic presence of extracellular calcium. Little is known on the CaSR 
interactomes associated with regulators of calcium ion (Ca2+) storage and transport during its 
biosynthesis and trafficking, and the effect of Ca2+o perturbation on these interactomes. To identify 
CaSR interacting partners, the recombinant FLAG-tagged CaSR (transfected in HEK293 cells) 
was immunoprecipitated and subjected to high-resolution mass spectrometry and extensive 
bioinformatics analysis. Two different reagents —(i) 4 mM Ca2+o and (ii) 2 mM EGTA—were 
used to perturb the Ca2+o concentration and the results were compared. Combining the results from 
both treatments, 106 proteins were identified as putative CaSR interactors with ≥ two-fold 
enrichment over the negative control (transfection with empty pcDNA3.1). Markedly, 65% of 
these 106 proteins had higher abundance with 2-43 folds in samples treated with Ca2+ as compared 
to EGTA. Gene ontology analysis revealed that these CaSR-interactors are most significantly 
enriched in the endoplasmic reticulum (ER) with predominant molecular functions of GTPase 
activity, GTP binding, cadherin binding involved in cell-cell adhesion, and unfolded protein 
binding. The KEGG pathways enriched was the protein processing in the ER which was supported 
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by the biological processes enriched such as the protein folding in the ER. On the contrary, 31% 
of the 106 proteins were upregulated with < 1.5-fold change irrespective of the presence of added 
Ca2+ or EGTA. These interactors are enriched in the extracellular matrix, focal adhesion, ribosome, 
and mitochondrial inner membrane and are involved in RNA binding, structural constituent of 
ribosome, heat shock protein binding, and ATPase activities. Interestingly, this study identified 98 
novel CaSR interactors (e.g., Rab18, Rab5C, Rab6, heat-shock proteins, Dnaj, vesicle-associated 
membrane protein-associated protein A/B, 14-3-3 γ, SERCA, E3 ubiquitin ligases (CHIP, RanBP2 
and AMFR), tubulins, and voltage-dependent anion-selective channel protein 2) that were earlier 
reported in the literature as GPCR interactors. This indicates an overlapping signaling cascades 
and trafficking between the protein and other members of the GPCR family. Eight previously 
known CaSR interactors, namely Gαi, Gβ2, 14-3-3 θ, 14-3-3 ζ, 14-3-3 ε, 14-3-3 γ, calnexin and p24 
were also revalidated in this study. Moreover, 98 novel putative CaSR interactors were detected. 
With literature mining, we find that these novel CaSR interactors may regulate co-translational 
translocation (SRP complex, Sec61, GRP78, palmitoyl-transferase, oligosaccharyl-transferases, 
glucosidases, glycosyltransferase), calnexin cycle (calnexin, protein disulfide isomerase, 
glucosyltransferase), ER/Golgi trafficking (Rab6, VAMP-associated proteins), endocytosis 
(Rab18, Rab5c, clathrin heavy chain), degradation pathway (E3 ubiquitin ligase STUB1, RanBP2 
and heat shock proteins) and Ca2+ handling (SERCA, TMCO1, VDAC2, TIMM50). Taken 
together, our findings surmise the role of Ca2+o in CaSR-mediated modulation of the proteostasis 
and CaSR-interactome through a series of events—differential signal transduction mediated by 
activation of CaSR via Ca2+o perturbation, modifications in regulatory proteins maintaining Ca
2+ 
homeostasis, stimulation of cellular activities such as the biosynthesis and trafficking or changes 
in the binding affinity of interactors to CaSR due to alteration of the Ca2+o concentration. Taken 
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together, our findings largely extend the repertoire of CaSR biosynthesis and trafficking revealing 
previously unknown major players and potential mechanism for the mobilization of nascent CaSR 
from the ER that is induced by extracellular Ca2+ mediated CaSR signaling. Our findings may 
serve as potential therapeutic targets for pathologies resulting in hypercalcemia and hypocalcemia 
in the overall G-protein coupled receptor family that CaSR belongs to. 
 
2.2 Introduction 
2.2.1 Calcium-sensing receptor and its mediated signaling 
Calcium-sensing receptor (CaSR) is a class-C, G-protein coupled receptor (GPCR) that 
maintains a tight cellular Ca2+ homeostasis with a 10,000 fold electrochemical gradient between 
the extracellular (1.1 to 1.4 X 10−3  M) and cytosolic (10−7 to 10−8 M) Ca2+ concentrations in the 
cell [20]. Ca2+o, acting as an extracellular first messenger [30], activates CaSR at a half-maximal 
concentration of 3-4 mM as mentioned in chapter I. Henceforth, CaSR mediated intracellular 
signaling is induced through the association of CaSR-intracellular loops with heterotrimeric G 
proteins, Gq/11, Gi/o, G12/13, and Gs. [39] (Figure 1.5). Through Gq/11, the CaSR activates 
phospholipase C, increases cytosolic Ca2+ (Ca2+cyt) and DAG (diacylglycerol) levels, and activates 
phospholipase A2. Through Gi/o, the CaSR inhibits adenylyl cyclase, decreases cAMP production, 
and activates extracellular signal-regulated kinase (ERK). Through G12/13, it activates Rho-
dependent phospholipase D and amino acid-induced Ca2+ mobilization [69, 72]. This functional 
diversity allows CaSR to regulate Ca2+i concentrations in various cellular compartments, 
including, the cytosol (Ca2+cyt), ER (Ca
2+
ER) and mitochondrial (Ca
2+
mito). These perturbations of 
Ca2+ concentrations act as intracellular signal messenger [34] and in turn controls the critical 
cellular processes including secretion, apoptosis, chemotactic responses, cell proliferation, 
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cytoskeletal rearrangements, ion channel activity, the control of gene expression, and cell 
differentiation [51, 52].  
2.2.2 CaSR mediated intracellular Ca2+ mobilization 
Stimulation of CaSR elicits Ca2+ mobilization from intracellular stores such as the ER [54], 
which causes acute increase in the Ca2+cyt [109]. The decrease in Ca
2+internal stores results in the 
store-operated channel (SOC) mediated Ca2+ influx followed by an increase in Ca2+cyt [110].This 
further activates the influx through the plasma membrane channels, therefore, resulting in a 
sustained rise in [Ca2+cyt]. Extended increase in [Ca
2+
cyt] can cause overstimulation of the cellular 
responses and cytotoxicity, and therefore, needs tight control by Ca2+-binding proteins, pumps, 
and channels in the plasma membrane, ER and Golgi [109].  
2.2.3 Unique features of CaSR sensitization, desensitization and ADIS 
CaSR is an exceptional receptor with minimal functional desensitization in the chronic 
presence of agonist [111-113], and it can distinguish as small as ~200 μM fluctuations in [Ca2+o]. 
These unique properties are integrative effects of its highly cooperative activation with Ca
2+
o with 
Hill coefficient of 3 [38, 66, 114] and its distinctive intracellular Ca
2+ signaling and trafficking 
machinery involving various regulators [115]. Agonist driven insertional signaling (ADIS) is a 
phenomenon where the agonist such as the Ca2+ in case of CaSR, augment the plasma membrane 
insertion of the receptor [116]. It has been implied that ADIS regulates the two unique features of 
CaSR, the signal cooperativity as well as the time course and extent of signal desensitization [116]. 
This finding suggests that CaSR trafficking and signaling is directly associated with each other. 
Few proteins have been identified as regulators for CaSR trafficking, but much information is 
largely missing.  
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2.2.4 CaSR life cycle and known regulators in trafficking 
The regulation of the abundance of CaSR can occur at various stages of its life-cycle such 
as modulation of transcription, the stability of mRNA, translation efficiency, ER quality control 
(ERQC) and degradation at proteasome or lysosome [116]. CaSR undergoes a dynamic life-cycle 
with anterograde transport of nascent receptors from the ER, Golgi and ER-Golgi intermediate 
compartments (ERGIC) to the plasma membrane, and with subsequent retrograde transport to 
lysosome or proteasome for degradation [115] [8] (Figure 2.1). Prolonged exposure to Ca2+o 
induces ADIS which mobilizes the intracellular pool of CaSR to enhance anterograde trafficking 
[115]. First, the CaSR undergoes the ERQC during the co-translational and immediate post-
translational period. To date, the known proteins involved in this process are small GTP binding 
proteins (Rabs, Sar1, and ARFs), cargo/chaperones (p24A, RAMPs) and interacting proteins (14-
3-3 proteins, CaM). Second, CaSR endocytosis is facilitated by G protein receptor kinases (GRKs), 
protein kinase C and β-arrestins. Finally, CaSR is degraded by proteasome or lysosome by 
ubiquitination by E3 ubiquitin ligase, dorfin [117] (Figure 2.1, Table 2.1).  
It is critical to further determine the rest of the CaSR interactors and to understand the 
effects of Ca2+o perturbation on CaSR mediated proteostasis. Not only is CaSR exposed to its 
primary agonist, Ca2+ in the plasma membrane but also in the ER, therefore, [Ca2+ER] plays a major 
role to induce its active conformation and dictate the life of CaSR[116]. CaSR acts as a mediator 
and induces intricate crosstalk between the Ca2+o and intracellular Ca
2+ signaling, which is 
modulated through CaSR interactomes and regulators associated with Ca2+ handling and 
trafficking throughout various stages of the dynamic life cycle of CaSR. To address this and to 
illustrate the first comprehensive protein-protein interaction network for CaSR, we employed 
treatments of 4 mM Ca2+o and 2 mM EGTA on HEK293 cells transfected with either recombinant  
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Times Assay Used Function CaSR domain Ref. 




Functional Trafficking/signaling Unknown (Lorenz et al., 2007) 
Caveolin Co-IP Structural/scaffolding/ 
Trafficking/signaling 
Intracellular 
loop 1 and 3 
 
(Kifor et al., 1998; Kifor 







Trafficking C-terminal (Huang et al., 2006) 




C-terminal (Awata et al., 2001; 
Hjalm et al., 2001; Pi et 
al., 2002) 
GRK-2 Functional Signaling Intracellular 
domain 
(Lorenz et al., 2007) 
GRK-4 Functional Signaling Intracellular 
domain 
(Lorenz et al., 2007) 
Kir4.1 Y2H, Co-IP, 
Functional 
K channel C-terminal (Huang et al., 2007a) 
Kir4.2 Y2H, Co-IP, 
Functional 
K channel C-terminal (Huang et al., 2007a) 
PI-4-
Kinase 
Co-IP, Signaling Unknown (Huang et al., 2002) 
PKC Functional Signaling C-terminal (Lorenz et al., 2007) 
RAMP1 Co-IP, Functional Structural/trafficking ECD and TM (Bouschet et al., 2005) 
RAMP3 Co-IP, Functional Structural/trafficking ECD and TM (Bouschet et al., 2005) 
RGS 
proteins 
Functional Signaling Unknown (Huang et al., 2002; 
Huang et al., 2004) 
Rho Co-IP Signallling Unknown (Huang et al., 2002) 
14-3-3 Yeast two-hybrid 
screen, CaR tail 
pull-down 
studies, Co-IP 






(Grant et al., 2011; 
Arulpragasam et al., 
2012) 
CaM GST, Co-IP, 
Functional 
Signaling/Stabilize C-terminal (Huang et al., 2010) 
P24A Co-IP Stabilize/ trafficking C-terminal (Stepanchick and 
Breitwieser, 2010) 




Functional, RNAi Trafficking/signaling possible ECD (Zerial and McBride, 
2001; Grosshans et al., 
2006) 
Dorfin Co-IP, Functional Trafficking Intracellular 
loop, C-
terminal 
(Huang et al., 2006) 




Cell migration and adhesion 
in cancer cells (trafficking??), 
Signaling 
Unknown (Tharmalingam et al., 
2011) 
 
Table 2.1 List of known CaSR interactors. Adapted from [8] 
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FLAG-tagged CaSR pcDNA3.1 or empty pcDNA3.1 (negative control) and subjected them to co-
immunoprecipitation with anti-FLAG antibody and liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS). The proteome identified were further analyzed using extensive 
bioinformatics tools to understand the gene ontology of the CaSR-mediated pathways and 
functions. The identified molecules suggest a major role of chronic exposure of Ca2+o in amplifying 
anterograde trafficking of CaSR and possibly a bias towards Gαi signaling pathway. Our study re-
Figure 2.1  Known CaSR interacting proteins through its life-cycle (Adapted from [14]) 
CaSR undergoes a dynamic lifecycle with anterograde transport of nascent receptors from 
the ER, Golgi and ER-Golgi intermediate compartments (ERGIC) to the plasma membrane, 
and with subsequent retrograde transport to lysosome or proteasome for degradation. 
Prolonged exposure to Ca2+o induces ADIS which mobilizes the intracellular pool of CaSR 
to enhance anterograde trafficking. First, the CaSR undergoes the ERQC during the co-
translational and immediate post-translational period regulated by small GTP binding 
proteins (Rabs, Sar1 and ARFs), cargo/chaperones (p24A, RAMPs) and interacting proteins 
(14-3-3 proteins, CaM). Second, CaSR endocytosis is facilitated by G protein receptor 
kinases (GRKs), protein kinase C and β-arrestins. Finally, CaSR is degraded by proteasome 




















































enforces the concept by Brown and MacLeod that CaSR senses Ca2+ not only in the plasma 
membrane but also within the intracellular stores [66].  
 
2.2.5 Hypercalcemia and hypocalcemia  
Higher serum Ca2+ is termed as hypercalcemia. Hypercalcemia is ranked as mild (2.60-
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Table 2.2 List and details of previous attempt on mass spectrometry optimization 
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or 14 mg/dL) [118]. This condition occurs during irregular Ca2+ homeostasis and is known to be 
caused due to malignancy or hyperparathyroidism in 90% of the cases.  It occurs in almost 30% 
of patients with malignancy, including commonly in lung cancer, multiple myeloma, renal cell 
carcinoma, breast cancer, and colorectal cancer [119, 120]. 80% of these malignancies associated 
hypercalcemia is contributed to an increased parathyroid hormone-related peptide (PTHrP) [119]. 
On the other hand, total blood calcium below 8.5 mg/dL or ionized blood calcium below 
4.6 mg/dL is referred to as hypocalcemia[121, 122]. This condition has been shown to occur in 
about 30% of patients with advanced prostate cancer [123]. Both conditions are closely associated 
with CaSR. Our experiment may contribute to the examination of the differential CaSR 
interactome involved in ADIS-mobilization mediated by hypercalcemic condition at 4 mM Ca2+o 
and hypocalcemia condition at 2 mM EGTA in pathologies such as cancers and secondary 
hyperparathyroidism.  
2.3 Challenges and previous attempts 
. As mentioned in chapter I, several obvious limitations exist in the method involving co-
immunoprecipitation and mass spectrometry, including, likely detection of partners with only high 
binding affinity and slow dissociation constants which can result in less prospect of detection of 
transient interactions. Likely detection of interaction of more abundant partner as compared to 
lower abundant ones and the CaSR is not being in native state as the lysis destroys plasma 
membrane and thereby, cannot provide accurate and adequate membrane environment with 
detergent. There is also possibility of interactors being washed out during the Co-IP process, and 
incorrect detection due to un-specific binding and general enrichment in the cell. The mass-
spectrometry utilized in our study is incapable of separating the divergent forms of CaSR with 
various post-translational modifications, which can indirectly impact the interactors over its life-
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cycle. The LC-MS has a typical dynamic range of detection at 4-6 orders of magnitude which is 
much lower as compared to the protein concentration range in biological samples at 12 orders of 
magnitude [99]. Also, using an online database for annotations have limitations since the known 
knowledge is not complete. The generation of complicated networks of inter-related and similar 
terms can be overwhelming and can produce convoluted results.  
Previous attempts were made by Dr. Jie Feng and some in collaboration with me for the 
Co-IP and mass spectrometry (Table 2.2). The number of unique peptides for CaSR detected were 
limited to 12 with Dr. Wu in Georgia Tech and 10 with Dr. Zhou from Clark Atlanta University. 
Anti-ADD CaSR antibody for endogenous CaSR in 5001 was used.  
2.4 Major questions addressed in this chapter 
a) How do we optimize co-immunoprecipitation to achieve the optimal enrichment of CaSR 
and its interactors? 
b) What are CaSR interactors during its cellular biosynthesis and trafficking?  
c) Will prolonged exposure to Ca2+o or deprivation of Ca2+o using EGTA affect the 
biosynthesis of other interactors and regulators of CaSR?  
d) Can CaSR regulate its biosynthesis due to prolonged signaling?  
e) Does CaSR act as a communicator between the intra- and extra- cellular Ca2+ signaling? 
f) What is the implication of enrichment of some proteins with the treatment of Ca2+o? 
g) What are the biological pathways most affected with Ca2+o? 
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2.5 Materials and Methods: 
2.5.1 Plasmids and reagents 
6-8 µg of empty pcDNA3.1 and human CaSR with FLAG-tag (between Asp371 and Thr372) 
in pcDNA3.1 were used for transfection in 100 mm dish for negative and positive controls, 
respectively. The purified plasmids were prepared using the Mini-Prep Kit (Qiagen, Toronto, 
Canada). 
2.5.2 Cell culture 
Monolayer culture of HEK293 cells were purchased from American Type Culture 
Collection (ATCC CRL-1573) and cultured with high glucose (4.5 g/L) Dulbecco’s Modified 
Eagle Medium (DMEM) (Invitrogen, Carlsbad, California) supplemented with 10 % fetal bovine 
serum (Atlanta Biologicals) in a humidified environment at 37 °C with 5 % CO2. Transient 
transfection was performed using lipofectamine 3000 in the same medium following the 
manufacturer’s protocol (Invitrogen, Carlsbad, California). 48 hours post-transfection, the cells 
were washed with Hank’s Balanced Salt Solution (HBSS) (Sigma-Aldrich, Canada) at 37 °C, 
incubated in starving medium-low glucose DMEM, 0 mM Ca2+ with 0.1 % BSA for 30 minutes 
and finally treated with 4 mM Ca2+ or 2 mM EGTA for 2 hours. For ubiquitination assay, HEK293 
cells with stably CHIP knocked down were provided by Li Zhou from Dr. Jun Yin’s lab (GSU). 
These cells were cultured in DMEM with 10% FBS.  
2.5.3 Antibodies  
Anti-FLAG antibody, mouse (Sigma-Aldrich, Canada) was used to precipitate the 
CaSR/interactor complex. Anti-CaSR C0493, mouse (Abcam, Cambridge, MA, USA) and Anti-
GAPDH mouse (Abcam, Cambridge, MA, USA) were used for western blot. Anti-GRP78 rabbit 
(Abcam, Cambridge, MA, USA), anti-CHIP mouse (Santa Cruz), anti-ubiquitin mouse (Santa 
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Cruz) anti-VAPA rabbit (Thermo fisher) and anti-14-3-3 eta rabbit (Abcam, Cambridge, MA, 
USA) antibodies were used in the western blot and immunostaining experiments. Goat anti-mouse 
Alexa Fluor 488, Alexa fluor 647, or Alexa fluor 550–conjugated secondary antibodies 
(Invitrogen) were used in immunostaining. 
2.5.4 Total protein extracts 
Transfected HEK293 cells from 90-100 % confluent 100 mm dishes were harvested after 
the treatment with 4 mM Ca2+ or 2 mM EGTA. They were washed with ice cold Phosphate-
buffered saline (PBS) with 0 mM Ca2+ 3 times. 600 μL of 10 mM Sodium β-glycerophosphate, 50 
mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% Triton X-100, 2 mM Na3VO4, 
50 mM NaF, 10 mM sodium pyrophosphate supplied with proteinase inhibitor cocktail (Roche, 
Basel, Switzerland) was used to lyse cells for 30 min in ice with frequent vortex and subsequently 
centrifuged to pellet cell debris. Cleared cell lysates were subjected to anti-FLAG 
immunoprecipitation prior to immunoblotting 
2.5.5 Coimmunoprecipitation 
For each condition, a total of 1.0 mg of total protein was used as measured by Bradford 
assay. Anti-FLAG antibody (10ug) and 50 µL Protein G Dynabeads (Thermo Fisher) were 
incubated for 30 minutes at room temperature in 200ul PBS and 0.01% Tween20 and washed once 
with lysis buffer. Antigen was added and incubated for 10 hours at 4°C. Next day, the beads were 
washed two times with lysis buffer and two times with PBS. 10% beads were suspended in 30 ul 
of 2X sample buffer with 5% β-mercaptonol and heated for 10 min at 100 degrees. Rest of the 90 
% bead was used for LC-MS/MS. 
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2.5.6 LC-MS/MS (Co-IP bead) 
This work was supported by Georgia Institute of Technology’s Parker H. Petit Institute for 
Bioengineering and Bioscience including the Systems Mass Spectrometry Core Facility. Peptides 
were analyzed with Nano-High Pressure Liquid Chromatography-Tandem Mass Spectrometry 
(nano-LC-MS/MS).  Briefly, the peptides were loaded onto an in-house packed column (40 cm 
long X 75 μm ID X 360 OD, Dr. Maisch GmbH ReproSil-Pur 120 C18-AQ 3.0 µm beads) 
analytical column (Thermo Scientific) using a Dionex nanoLC system (Thermo Scientific). A flow 
rate of 0.300 μL/min with a linear acetonitrile gradient from 8 to 27% in 0.1% formic acid for 120 
min was used. The column output was connected to a Q Exactive Plus mass spectrometer (Thermo 
Scientific) through a nanoelectrospray ion source. The mass spectrometer was controlled by 
Xcalibur software (Thermo, 4.0.27.19) and operated in the data-dependent mode in which the 
initial MS scan recorded the mass-to-charge ratios (m/z) of ions over the range of 350–1750 at a 
resolution of 70 000 with a target value of 1 × 106 ions and a maximum injection time of 100 ms. 
The 10 most abundant ions were automatically selected for subsequent higher-energy collision 
dissociation (HCD) with the energy set at 28 NCE. The MS/MS settings included a resolution of 
35 000, a target value of 5 × 105 ions, a maximum integration time of 108 ms, and an isolation 
window was set at 3.0 m/z. Ions with undetermined charge, z = 1, 8, and z > 8 were excluded.  
2.5.7 Cell preparation for mass spectrometry (MS) 
The cell pellet was collected from HEK293 cells (transfected with CaSR pcDNA3.1 and empty 
pcDNA3.1) and PC3 cells after treating with 4mM Ca2+ and 2 mM EGTA. The following sample 
prep and analysis was carried out by Emory Integrated Proteomics Core [124, 125]. They were 
vortexed in urea lysis buffer (8 M urea, 100 mM NaH2PO4, pH 8.5), including HALT protease 
46 
and phosphatase inhibitor cocktail (Pierce). Protein supernatants were transferred to 1.5-ml 
Eppendorf tubes, subjected to centrifugation at 14,000 rpm for 1 min and sonicated (Sonic 
Dismembrator, Fisher Scientific) 3 times for 5 s with 15-s intervals of rest at 30% amplitude to 
disrupt nucleic acids. Samples were subsequently vortexed. Protein concentrations were 
determined by the bicinchoninic acid (BCA) method, and samples frozen in aliquots at 80 °C. 
Protein homogenates (100 mg) were then treated with 1 mM dithiothreitol (DTT) at 25°C for 30 
min, followed by 5 mM iodoacetimide (IAA) at 25°C for 30 min in the dark. Protein was digested 
with 1:100 (w/w) lysyl endopeptidase (Wako) at 25°C overnight. Samples were then diluted with 
50 mM NH4HCO3 to a final concentration of less than 2 M urea and further digested overnight 
with 1:50 (w/w) trypsin (Promega) at 25°C. Resulting peptides were desalted with a Sep-Pak C18 
column (Waters) and dried under vacuum.  
2.5.8 LC-MS/MS (cell pellet) 
This work was supported by Georgia Institute of Technology’s Parker H. Petit Institute for 
Bioengineering and Bioscience including the Systems Mass Spectrometry Core Facility. Each 
sample was analyzed by nano LC-MS/MS with a Waters NanoAcquity HPLC system interfaced 
to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and eluted over a 75μm 
analytical column at 350nL/min; both columns were packed with Luna C18 resin (Phenomenex). 
The mass spectrometer was operated in the data-dependent mode in which the initial MS scan 
recorded the mass-to-charge ratios (m/z) of ions over the range of 300–1600 at a resolution of 70 
000 with a target value of 3 × 106 ions and a maximum injection time of 120 ms. The 15 most 
abundant ions were automatically selected for subsequent higher-energy collision dissociation 
(HCD) with the energy set at 25 NCE. The MS/MS settings included a resolution of 17,500, a 
47 
target value of 1 × 105 ions, a maximum integration time of 120 ms, and an isolation window was 
set at 1.5 m/z. Ions with undetermined charge, z = 1, and z > 8 were excluded. 
2.5.9 MaxQuant for Label-Free Proteome Quantification 
Data files for the samples were analyzed using MaxQuant v1.5.2.8 with Thermo Foundation 2.0 
for RAW file reading capability. The search engine Andromeda was used to build and search a 
concatenated target-decoy UniProt Knowledgebase (UniProtKB) containing both Swiss-Prot and 
TrEMBL human reference protein sequences (90,411 target sequences downloaded April 21, 
2015), plus 245 contaminant proteins included as a parameter for Andromeda search within 
MaxQuant [126]. Methionine oxidation (+15.9949 Da), asparagine and glutamine deamidation 
(+0.9840 Da), and protein N-terminal acetylation (+42.0106 Da) were variable modifications (up 
to 5 allowed per peptide); cysteine was assigned a fixed carbamidomethyl modification (+57.0215 
Da). Only fully tryptic peptides were considered with up to 2 mis-cleavages in the database search. 
A precursor mass tolerance of ± 20 ppm was applied prior to mass accuracy calibration and ± 4.5 
ppm after internal MaxQuant calibration. Other search settings included a maximum peptide mass 
of 6,000 Da, a minimum peptide length of 6 residues, 0.05 Da tolerance for high resolution MS/MS 
scans. The false discovery rate (FDR) for peptide spectral matches, proteins, and site decoy 
fraction were all set to 1 percent. Quantification settings were as follows: re-quantify with a second 
peak finding attempt after protein identification has completed; match full MS1 peaks between 
runs; a 0.7 min retention time match window was used after an alignment function was found with 
a 20 min retention time search space. The label free quantitation (LFQ) algorithm in MaxQuant 
[126, 127]was used for protein quantitation. The quantitation method only considered razor and 
unique peptides for protein level quantitation. The total summed protein intensity was also used to 
assess overall signal drift across samples prior to LFQ normalization. Retention time internal 
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standards were identified by searching against a small database containing the isotopic peptide 
standard sequences, keratins, and brain specific spectrins with fixed modification of +8.014 Da 
(Lys) and +10.008 Da (Arg) using Proteome Discoverer 1.4. Briefly, precursor mass tolerance was 
± 10 ppm, fragment ion tolerance was 0.05 Da, and FDR was enforced by Percolator [128] at 1%, 
enabling identification of MS/MS spectra for 14 of the 15 standard peptides. Thermo .MSF files 
were imported as peptide searches into Skyline 3.1 [129] with chromatograms within 2 min of a 
MS/MS match to one of the standard peptides. Identified peak boundaries were visually checked 
and adjusted as necessary, and precursor (M, M+1, and M+2) isotopic peak areas were exported. 
These areas were summed, and each peak area was divided by the average area of the 
corresponding peak across all runs to calculate aggregate signal responsiveness within the run. 
2.5.10 Immunoblotting 
A total input protein of 50 µg and 30 µl of the 10 % bead samples were loaded in 8.5 % 
acrylamide gels and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDs-
PAGE) to separate proteins, then transferred to nitrocellulose membranes. The membranes were 
blocked with 3 % nonfat milk (w/v) in TBS for 2 hours at room-temperature with constant shaking. 
The antibodies of interest were diluted in 3 % non-fat milk (w/v) and 0.2% Tween-20 in TBS 
(TBST). Anti-CaSR C0493, mouse (Abcam, Cambridge, MA, USA) was used at 1:700 dilution 
and HRP-conjugated mouse secondary antibody was used (Sigma-Aldrich, United States) at 
1:3000 dilution to probe CaSR. For, GAPDH, anti-GAPDH mouse (Abcam, Cambridge, MA, 
USA) was used at 1:3000 dilution and HRP-conjugated mouse secondary antibody was used 
(Sigma-Aldrich, United States) at 1:10,000 dilution. For CHIP, anti-CHIP mouse (Santa Cruz) was 
used at 1:100 or 500 dilution and HRP-conjugated mouse secondary antibody was used at 1:2000 
dilution. For GRP78, anti-GRP78 rabbit antibody (Abcam) was used at 1 µg/mL and HRP-
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conjugated rabbit was used at 1:2000 dilution. Similarly, anti 14-3-3 eta rabbit antibody (Abcam) 
was used at 1:1000 dilutions and HRP-conjugated rabbit was used at 1:2000 dilution. For ubiquitin, 
anti-ubiquitin mouse antibody (Santa Cruz) was used at 1:100 or 500 dilutions were used and and 
HRP-conjugated mouse was used at 1:2000 dilution. Membranes were incubated with the primary 
and secondary antibodies for 1 hour at room-temperature with constant shaking, and finally 
washed with TBST. Secondary antibody was visualized using ECL detection reagents (GE 
healthcare, Little Chalfont, UK) developed on X-OMATTM imaging film (Kodak, Rochester, NY). 
2.5.11 Immunostaining 
HEK293 cells were grown on 20 × 20 mm coverslips placed in 6-well plates one day before 
the transfection. Cells were subjected to transfection and after 48 h were treated for 
immunostaining. Cells were washed with ice cold PBS and fixed with 3.7 % formaldehyde for 15 
min at room temperature, followed by wash with PBS three times. Cells were permeabilized using 
0.2 % Triton X in PBS for 10 min at room temperature. Mouse anti-FLAG monoclonal antibody 
was diluted 1000 times and incubated with cells overnight at 4°C or 1 h at room temperature to 
stain the CaSR. Similarly, 2.5 µg/mL anti-GRP78 (rabbit). 1:100 anti-CHIP (mouse), 2 µg/mL 
anti-VAPA (rabbit) and 1:200 anti-14-3-3 eta (rabbit) antibodies were used in the respective 
experiments. The cells were subsequently washed with PBS and stained with goat anti-mouse 
Alexa fluor 488, alexa fluor 647, or alexa fluor 550 –conjugated secondary antibodies at 5 µg/mL 
for 1 hour at room temperature. Nuclei were stained with 4′,6-diamidino-2-phenylindole. 
Fluorescence was visualized using a Zeiss LSM700 confocal microscope. 
2.5.12 Quantitation of immunostaining 
The images were processed using Image J and zen lite. The stain of interest were in RGB 
or given pseudo RGB in zen lite. Henceforth, the stains were split in image J, given RGB for two 
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stains of interest and analyzed using surface plot. The 2D peaks in the plot represent the position 
and intensity of the stain and is compared. Further, plugin coloc2 is used to obtain Pearson’s 
coefficient after deducting the background.  
2.5.13 Ca2+ and CaM binding site prediction 
For Ca2+ binding site prediction, CaPS (Calcium Pattern Search) was used. This algorithm 
developed by Dr. Shenghui Xue identified Ca2+ binding motifs in proteins based on unique patterns 
that are known in various proteins. Calmodulin target database 
(http://calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html) was used to predict the CaM binding 
sites. This website provides various motif classes using sequence homology analyses available in 
the database.  
2.5.14 Protein identification, label-free quantitation and statistical analysis 
LC-MS/MS Q-Extractive Orbitrap was used. Raw data files were analyzed using 
MaxQuant version 1.6.3.3 with Thermo Foundation 2.0 for RAW file reading capability. Intensity 
of each protein for each treatment condition was averaged from three negative control IP samples 
and three CaSR IP samples. The missing values were imputed as previously described using 
Perseus [130]. Enrichment of proteins was considered significant if the intensities had at least two-
fold difference, i.e., log2(HEK293 + CaSR-FLAG pcDNA / Hek293 + pcDNA3.1) ≥ 1.00. P-
values were calculated using a two-sided Student’s t test of a null hypothesis that there is no 
difference in protein relative abundance between the two groups. For robust stringency, we 
employed a P < 0.05, a requirement of minimum PSM of 2 for no less than two replicates and 
identification with at least one unique peptide. 
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2.5.15 Functional annotation of identified protein partners  
Protein-protein interaction was performed using Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) version 10.0. Interaction network view was used to identify 
and visualize the degrees of interaction amongst the 106 putative CaSR interactors (homo sapiens). 
STRING uses evidence from experimental and knowledge-based databases to provide the 
confidence in functional associations or interaction through the Edge Confidence. Size of colored 
nodes represent evidence of known or predicted 3-dimensitional protein structure.  
The Database for Annotation, Visualization, and Integrated Discovery (DAVID), version 
6.8, was used for the functional annotation and analysis of enrichment of 106 proteins determined 
as putative CaSR interactors. The set of total proteins identified and quantified (n = 625) was used 
as the background. The numbers of 106 proteins of interest and background lists are compared in 
each functional cluster. A two-tailed modified fisher’s exact test (EASE score of 1) with 
classification stringency at “medium” were employed to generate statistically significant 
enrichment annotations and to categorize them under annotation terms: cellular compartments, 
biological processes, molecular function and KEGG pathways. Correction for multiple hypothesis 
testing was carried out using standard false discovery rate control methods. A Bonferroni-corrected 
P ≥ 0.05 and an enrichment ≥ 1.3 were used as a cut-off [131].  
2.5.16 Rich club analysis for understanding presence of significant rich hubs in network 
This was carried out in collaboration with Shrikant Pawar from the Department of Biology. 
Proteins and its interactions with confidence values from String 9.1 were inputted in Cytoscape to 
construct an interactome. A degree centrality measure was applied and 6 sub-interactomes (Figure 
1: A, B, C, D, E and F) were constructed with degree measures varying between 1-5, 6-10, 11-15, 
16-20, 21-25 and >25. Power-law distribution analysis was performed on each of the sub-
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interactomes to generate pearsons correlation coefficient values (Figure 1: Ai, Bi, Ci, Di, Ei and 
Fi) between number of nodes and betweeness centrality measure. Further, a rich-club coefficient 
values were generated for each of these sub-interactomes. The rich-club coefficient is the ratio, for 
every degree k, of the number of actual to the number of potential edges for nodes with degree 
greater than k.  
Where, E is the number of edges between the nodes of degree greater than or equal to k, 
and N is the number of nodes with degree greater than or equal to k. The rich-club coefficient was 
calculated by Python library, NetworkX. 
 
2.6 Results  
2.6.1 Identification of potential CaSR interactors 
CaSR interactome was studied using HEK293 cells transfected with a FLAG-tagged CaSR 
pcDNA3.1 (positive control) or an empty pcDNA3.1 (negative control). Cells were treated with 4 
mM Ca2+ (based on previously reported half maximal CaSR-activating Ca2+o concentration) or 2 
mM EGTA (to chelate Ca2+o), followed by immunoprecipitation with anti-FLAG antibody, LC-
MS/MS, and gene ontology analysis (Figure 2.2). All experiments were run in triplicate. When 
cells were transfected with CaSR, an equivalent amount of total CaSR (input) (Figure 2.3A. upper 
panel, duplicate shown, third in Figure 2.3B) and immunoprecipitated CaSR (output) (Figure 2.3, 
lower panel, duplicate shown) were detected for both treatment conditions, Ca2+ and EGTA. CaSR 
was observed at > 250 kDa molecular weight as opposed to its monomer at 120-160 kDa 
(depending on its level of glycosylation maturation); this could have resulted due to formation of 
a complex or oligomerization. Similarly, the MS intensity (averaged over three replicates) detected 
Equation 2. 1 
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for CaSR output was 9.43 ± 0.833 X 109 in the presence of Ca2+ as compared to 7.67 ± 0.751 X 
109 in EGTA. Although CaSR was not identified in the negative control, comparable GAPDH 
blots for total input was observed (Figure 2.3, middle panel, duplicate shown). Immunostaining 
show proper transfection of HEK293 cells and presence of CaSR throughout the cells after the 
treatment with 4 mM Ca2+ (Figure 2.3). Immunostaining result for EGTA treatment was not 
possible due to cells not attaching to the coverslip.  
A total of 625 proteins detected by LC-MS/MS were sorted and 106 were identified as 
reliable CaSR interactors. For this, we employed successive stringencies to ensure robust 
upregulation, reproducibility, and detection: (i) the treatments and IP for the positive and negative 
controls were performed in triplicates, (ii) identified proteins were at least two-fold enriched in the 
CaSR transfected samples over the negative controls, (iii) a two tailed t-test with P ≤ 0.05 between 
the groups being compared was considered statistically significant, (iv) proteins had a minimum 
peptide spectrum matches (PSMs) of two for at least two replicates, and (v) proteins were identified 
with at least one unique peptide.  
In Figure 2.4A and B, the volcano plots depict significantly enriched (log2 intensity 
(CaSR/pcDNA3.1) ≥ 1, -log10(P) ≥ 1.3) potential CaSR interactors in the presence of Ca2+ (Figure 
2.4A, red dots) and EGTA (Figure 2.4B, green dots). 88% of these proteins were highly enriched 
by ≥ three-fold. CaSR had the highest log2 intensity (fold change) in both samples treated with 
either 4 mM Ca2+ [log2 intensity (CaSR/pcDNA3.1) = 11.61 ± 1.07, -log10(P) = 3.05] or 2 mM 
EGTA [log2 intensity (CaSR/pcDNA3.1) = 14.32 ± 0.76, -log10(P) = 3.85]. Out of 106 CaSR 
interacting partners, 46 were exclusively identified in the presence of Ca2+, 13 exclusively in the 
presence of EGTA, and 48 were found common in both conditions (Figure 2.4C).  
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2.6.2 Analysis of differentially expressed proteins due to presence of 4 mM Ca2+ 
The 106 proteins identified as putative CaSR interactors with high confidence were further 
evaluated for their differential expression levels between Ca2+ and EGTA treatments (Figure 
2.5A). Remarkably, in the presence of Ca2+, 65 % of these proteins were significantly up-regulated 
at varying degrees from ≥ eight-fold [log2 intensity (Ca
2+/EGTA) = ≥ 3] to 1.5 folds [log2 intensity 
(Ca2+/EGTA) = 0.58] (Figure 2.5C, Table 2.9). 12 proteins were up-regulated by ≥ 8-fold [log2 
intensity (fold change) = ≥ 4] (red open circles), 9 between 4-8-fold [log2 intensity (fold change) 
= < 4 ≥ 2] (magenta open circles), 21 between 2-4-fold [log2 intensity (fold change) < 2 ≥ 1.5] 
(orange open circles) and 26 between 1.5-2 fold [log2 intensity (fold change) < 1.5 ≥ 0.58] (green 
Figure 2.2  The overview of the experimental workflow.  
CaSR interacting proteins characterized using co-immunoprecipitation and MS detection. 
HEK293 cells transfected with FLAG-tagged CaSR pcDNA3.1 (positive control) or empty 
pcDNA3.1 (negative control) were subjected with 4mM Ca2+o and 2mM EGTA. The proteins 
identified using LC-MS/MS that were highly enriched in positive control by ≥ 2 folds were 
assessed as putative CaSR interacting proteins. For functional enrichment study, the complete 
list of CaSR interacting proteins were analyzed using the DAVID database. Further, the 
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open circles). Only 5 that were up-regulated in the presence of EGTA by ≥ 1.5 folds [log2 intensity 
(fold change) = ≤ - 0.58] (left quadrant, blue open circles). 31% were detected with less than 1.5-
fold change in abundance in the two conditions [log2 intensity (Ca
2+/EGTA) = < 0.58 and > -0.58] 
(grey closed circles). The size of the circles represents the degree of up-regulation. This group of 
proteins comprised of important transducer of Ca2+ signaling in the cytosol, regulators of Ca2+ in 
the ER and mitochondria, and chaperones and ubiquitin proteins implicated in trafficking and 
protein recycling (Table 1). Conversely, there were only 5 that were up-regulated in the presence 
of EGTA by ≥ 1.5-fold [log2 intensity (Ca
2+/EGTA) = ≤ - 0.58]. These proteins included 14-3-3 -
θ (YWHAQ), -ζ (YWHAZ), -ε (YWHAE), Tubulin α-1C (TUBA1C) and THO complex subunit 
4 (ALYREF) (Figure 2.5A, Table 2.9). Interestingly, 31 % proteins were detected with less than 
1.5-fold change in abundance [log2 intensity (Ca
2+/EGTA) = < 0.58 and > -0.58]; irrespective of 
the presence of Ca2+o or EGTA, comprising primarily of ribosomal proteins (e.g., RPS20, RPL22, 
RPL23 and RPS3), tubulins (e.g., TUB-A1B, A4A, B, B4A and B8) and heat shock proteins (e.g., 
HSP-A1A, A6, A7, A8 and 90AB1) The function of these proteins must have less correlation with 
Ca2+o. 
In order to test whether the interactions we observed were true and not due to overall 
increase in the abundance of the proteins in cell due to treatments, LC-MS/MS was carried out on 
the total lysate of cells after respective treatments with Ca2+o and EGTA. The 106 proteins of 
interest did not show significant change in the abundance (Figure 2.5B). Similarly, bioinformatic 
tool, Calcium Pattern Search (CaPS) was utilized to search any existing Ca2+ binding sites on the 
106 putative interactors in order to verify if the CaSR interactions were dependent on Ca2+ binding.  
Only 10 proteins consisting of heat shock proteins, Dnaj and DNA dependent protein kinase 





Figure 2.3.  Co-immunoprecipitation experiments verified by western blot 
Ca2+ (4mM) +        +       - -
EGTA (2mM) - - +      +
Total Input (50 μg):
IP and IB: CaSR
IB: GAPDH
IB: CaSR
Total output (10% bead):
+       +        - -
- - +      +
Total Input (50 μg):
IP and IB: CaSR
IB: GAPDH
IB: CaSR
Total output (10% bead):
(HEK293 cells transfected with)
FLAG-CaSR pcDNA3.1 Empty pcDNA3.1
A.Co-immunoprecipitation experiments using anti-FLAG antibody on total cell 
extracts from HEK293 followed by western blot analysis with anti-CaSR antibody and 
anti-GAPDH (as control) was carried out in triplicates (duplicate representative blot is 
shown.). Western blot result indicates an equivalent amount of CaSR input (B, upper 
panel) in positive control for both Ca2+ and EGTA treatments and equivalent total 
protein input (middle panel, GAPDH, 50 µg total) in all conditions. Output CaSR is 
presented in positive control (C, lower panel) in both Ca2+ and EGTA treatments. 
Majority CaSR was observed at >250KDa molecular weight which could have resulted 
due to it formation of a complex or due to oligomerization. B. Third replicate for Co-
IP experiments using anti-FLAG antibody on total cell extracts (50 µg) from HEK293 
followed by western blot analysis with anti-CaSR antibody and anti-GAPDH (as 
control) was carried out in triplicates (only single replicate shown). Flowthrough for 
CO-IP experiment. It shows that there was a loss of some CaSR during the process of 
IP. However, since we used same amount of antibody and bead, the result from MS 
should be normalized. 
Ca2+ (4mM) +      -
EGTA (2mM) - +
Total Input (50 μg):
IP and IB: CaSR
IB: GAPDH
IB: CaSR
Total output (10% bead):
Total Input (50 μg):
IP and IB: CaSR
IB: GAPDH
IB: CaSR
Total output (10% bead):
(HEK293 cells transfected with)
CaSR-pcDNA3.1 Empty-pcDNA3.1
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Figure 2.4  106 CaSR interactors are enriched by ≥ 2 folds 
Insert: Venn diagram represents the number of proteins detected in each of the conditions. 
Volcano plot of CaSR interactors (n=3) enriched in 4 mM Ca2+ (A, red dots) and 2 mM 
EGTA perturbation (B, green dots) in pairwise experiments versus negative control (n=3). 
Total of 625 proteins are plotted (A and B). 106 specific interactors of CaSR were 
determined to be significantly enriched with p ≤ 0.05 and at least 2 folds over the average 
of the negative control. 94 were determined in the presence of 4 mM Ca2+ (A, red dots), 
61 in the presence of 2 mM EGTA (B, green dots) and out of which 48 were common in 
both the conditions. 88 % out of the 106 proteins were highly upregulated by ≥ 3 folds. 
CaSR was most enriched. 
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 A total of 106 potential interactors of CaSR are plotted in volcano plot where the x-axis is 
log2 intensity (Ca
2+/EGTA) and y-axis is -log10(p-value). A significant differential 
expression was observed between the treatment conditions. 65 % were significantly up-
regulated by ≥ 1.5 folds in the presence of extracellular Ca2+. Out of these, 12 proteins were 
up-regulated by ≥ 8 folds [log2 intensity (fold change) = ≥ 4] (red open circles), 9 between 
4-8 folds [log2 intensity (fold change) = < 4 ≥ 2] (magenta open circles), 21 between 2-4 
folds [log2 intensity (fold change) < 2 ≥ 1.5] (orange open circles) and 26 between 1.5-2  
 
Figure 2.5 A. Volcano plot of CaSR interactors (n=3) differentially enriched at various 
degrees in the presence of 4 mM [Ca2+]o  or 2 mM EGTA.   
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folds [log2 intensity (fold change) < 1.5 ≥ 0.58] (green open circles). Only 5 that were up-regulated 
in the presence of EGTA by ≥ 1.5 folds [log2 intensity (fold change) = ≤ - 0.58] (left quadrant, 
blue open circles). 31% were detected with less than 1.5 folds change in abundance in the two 
conditions [log2 intensity (Ca
2+/EGTA) = < 0.58 and > -0.58] (grey closed circles). The size of 
the circles represents the degree of up-regulation. B. Log2 intensity(Ca
2+/EGTA) for total cell 
lysate after the treatments. Minimal change observed between the treatment groups. C Venn 
diagram of the distribution of proteins differentially up-regulated in Ca2+. 
  
2.6.3 Gene ontology study of potential CaSR binding partners  
Gene ontology enrichment analysis was carried out using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) 6.8 version. A two-tailed modified Fisher Exact 
test (EASE score threshold of 1) with classification stringency at “medium” were employed to 
generate statistically significant enrichment annotations. Correction for multiple hypothesis testing 
was carried out using standard false discovery rate control methods. A Bonferroni-corrected P ≤ 
0.05 and an enrichment ≥ 1.3 were used as a cut-off [131]. The functional annotation cluster was 
generated separately for the 65% and 31% potential CaSR interactors out of the 106 derived from 
log2 intensity (Ca
2+/EGTA) ≥ 0.58 and log2 intensity (Ca
2+/EGTA) < 0.58 and > 0.58, respectively 
and compared. A Bonferroni-corrected P ≤ 0.05 and an enrichment ≥ 1.3 were used as a cut-off. 
The numbers on top of each bars represent the number of genes involved. A. represents the 
enrichment annotation for cellular compartment, B. represents biological processes, C. represent 
molecular function and D. represents pathway. Presence of Ca2+o revealed a contrasting effect on 
the enrichment classifications, namely, cellular compartment, molecular function and biological 
process. The up-regulated gene clusters were most significantly enriched in the ER membrane and 
cell-cell adherens junction in the presence of Ca2+o (Figure 2.7A, Table 2.5). Concomitantly, the 
biological processes such as the protein folding in the ER, ER unfolded protein response and cell-
cell adhesion were enriched in the presence of Ca2+o (Figure 2.7B, Table 2.4). Molecular function 
analysis for these proteins revealed significant enrichment in GTP binding, GTPase activity and 
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cadherin binding in the presence of Ca2+o (Figure 2.7C, Table 2.6Error! Reference source not 
found.). The most significant KEGG pathway was protein processing in the ER (Figure 2.7D). 
This may suggest that Ca2+o augments the CaSR trafficking and its interactions with regulators 
involved in Ca2+ handling and trafficking in the ER.    
  
The 31% proteins that were < 1.5 fold upregulated between the Ca2+o and EGTA treatment 
conditions had marked significant enrichment in extracellular matrix, ribosome, ribosomal subunit 
and focal adhesion (Figure 2.7C, Table 2.5). In parallel, biological process attributed to ribosome 
such as translation, rRNA processing and SRP-dependent cotranslational protein targeting to 
membrane were enriched for this group (Figure 2.7B, Table 2.6). On the other hand, molecular 
functions: ATPase activity, structural constituent of ribosome and heat shock protein binding were 
Accession Protein Type Ca2+ binding sequence
Q14739.2
Integral nuclear envelope inner 




glutathione ATPase Pseudo NYLLISWLIVHMDHVIAKELE
Q9Y5M8.3
Signal recognition particle
receptor subunit beta loop NNNRGNSLTLID
P78527.3
DNA-dependent protein kinase 
catalytic subunit loop DGDPSDRMEVQE
P08107.5
Heat shock 70 kDa protein 
1A/1B EF_hand_like DIDANGILNVTATD
P11142.1
Heat shock cognate 71 kDa 
protein EF_hand_like DIDANGILNVSAVD
Q9Y4P3.1
Transducin beta-like protein 
2 EF_hand_like DFSSNGKYLATCAD
P10809.2
60 kDa heat shock protein, 
mitochondrial loop NTSKGQKCEFQD
Q99615.2
DnaJ homolog subfamily C 
member 7 EF_hand_like
DLDEEGMNMGDFD
P17066.2 Heat shock 70 kDa protein 6 EF_hand_like DIDANGILSVTATD
Table 2.3 10 proteins out of 106 that contained Ca2+ binding 
site using Ca2+ Pattern Search (CaPS) 
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enriched (Figure 2.7C, Table 2.5). The most significant KEGG pathway was ribosome-related 
(Figure 2.7B, Table 2.4). Therefore, we can deduce that these processes are ubiquitous and 









Biological Process Gene In Liganded condition Gene In Un-Liganded condition
cell-cell adhesion HSP90AB1, YWHAZ, VAPA, RAN, 
VAPB, EEF2, HSPA1A, YWHAE, PCBP1, 
LRRC59, EEF1G, HSPA5, TMPO, PTPN1, 
HSPA8
HSP90AB1, YWHAZ, PCBP1, HSPA1A, 
HSPA5, TMPO, YWHAE, PRDX1, HSPA8
translation RPS27, RPS16, RPL23, SLC25A5, 
SLC25A6, SLC25A3, RPS27L, SLC25A1, 
RPL38, RPS5, RPS3
SLC25A5, SLC25A6, RPS27L, RPL38, 
RPS5, RPS3, RPS27, RPL23, RPS17, 





RPS27, RPS16, RPL23, SRPRB, RPL38, 
RPS5, RPS3
RPS27, RPL23, RPS17, RPL22, RPS14, 
RPL38, RPS20, RPS5, RPS3
response to unfolded 
protein
HSP90AB1, HSP90AA1, HSPA6, 
DNAJA1, FAF2, HSPD1, HSPA8




TUBB, TUBB8, TUBA1B, TUBA1C, 
TUBB4B
TUBB, TUBB8, TUBA1B, TUBA1C, 
TUBB4B
protein refolding HSP90AA1, HSPA6, HSPA1A, HSPD1, 
HSPA8
HSP90AA1, HSPA6, HSPA1A, HSPD1, 
HSPA8
protein folding in 
endoplasmic reticulum
HSP90B1, PDIA3, VAPA, HSPA5, CANX
rRNA processing RPS27, RPL23, RPS17, RPL22, RPS14, 
RPS27L, RPL38, RPS20, RPS5, RPS3
protein folding HSP90AB1, HSP90AA1, GANAB, PDIA3, 
BAG2, DNAJC7, DNAJA1, CANX, HSPA8
ribosomal small 
subunit assembly
RPS27, RPS17, RPS14, RPS27L, RPS5
Table 2.4 Genes involved in the biological process enrichment analysis 








ontologies among the 65% CaSR 
interactors upregulated by ≥ 1.5 
folds in presence of 4 mM Ca2+, 
(Red bars) as compared to EGTA 
and 31% CaSR interactors 
upregulated by < 1.5 folds 
between Ca2+ and EGTA 
treatment (Blue bars) were 
examined with DAVID to obtain 
annotation enrichments. A 
Bonferroni-corrected P ≤ 0.05 
and an enrichment ≥ 1.3 were 
used as a cut-off. The numbers 
on top of each bars represent the 
number of genes involved. 
Representation of the enrichment 
annotation for cellular 
compartment (A), biological 
processes (B), molecular 
function (C) and pathway (D) are 
shown. 
Figure 2.6 Overrepresented gene-
ontologies among the 65% CaSR 
interactors upregulated by ≥ 1.5 













FKBP8, SPTLC1, VAPA, VAPB, ERLIN2, ERLIN1, 
SRPRB, CANX, TECR, HSP90B1, SEC61B, RAB18, 
ATP2A2, PGRMC1, LRRC59, RPN1, RPN2, 
HSPA5, TMPO, PTDSS1, DDOST, MGST2
cell-cell adherens 
junction
HSP90AB1, YWHAZ, VAPA, RAN, VAPB, EEF2, 
HSPA1A, YWHAE, PCBP1, LRRC59, EEF1G, 
HSPA5, TMPO, PTPN1, HSPA8
HSP90AB1, YWHAZ, PCBP1, HSPA1A, 




NDUFA4, SLC25A5, SLC25A6, SLC25A3, SLC25A1, 
TIMM50, ATP5A1, HSPD1, VDAC2, RPS3, 
HADHB
NDUFA4, ATP5J2, SLC25A5, SLC25A6, 
SLC25A3, ATP5C1, SLC25A1, ATP5A1, 
HSPD1, RPS3
ribosome RPS27, RPS16, RPL23, RPS27L, RPL38, CANX, 
RPS3
RPS27, RPL23, RPS17, RPL22, RPS14,









RPL22, PCBP1, RPS5, GAPDH, HSPA8, 
RPS3
melanosome HSP90AB1, YWHAZ, HSP90AA1, 
GANAB, PDIA3, RPN1, HSPA5, 
YWHAE, PRDX1, CANX, HSPA8
Table 2.5 Genes involved in the cellular compartment enrichment analysis 
between 94 and 61 proteins enriched in Ca2+ and EGTA treatment 
condition, respectively 
Molecular Function Gene In Liganded condition Gene In Un-Liganded condition
GTP binding HSP90AB1, EEF1A1, GNAI3, HSP90AA1, RAB5C, RAN, 
EEF2, SRPRB, TUBB, RAB18, RAB6B, TUBB8, TUBA1B, 
TUBA1C, TUBB4B
GTPase activity EEF1A1, TUBB, GNAI3, RAB18, GNB2, RAB5C, RAN, EEF2, 
RAB6B, TUBB8, TUBA1B, TUBA1C, TUBB4B
G-protein coupled receptor 
binding
GNAI3, DNAJA1, HSPA1A, STUB1, HSPA8
C3HC4-type RING finger 
domain binding
DNAJA1, HSPA1A, HSPA8
MHC class II protein complex 
binding
HSP90AB1, HSP90AA1, YWHAE, HSPA8 HSP90AB1, HSP90AA1, YWHAE, HSPA8
heat shock protein binding HSP90AB1, DNAJC7, HSPA6, HSPA1A, HSPA8 HSP90AB1, DNAJC7, HSPA6, HSPA1A, HSPA8
protein domain specific 
binding
TUBB, YWHAZ, YWHAG, GNAI3, VAPA, YWHAQ, ATP1A1, 
HSPA5, YWHAE
TUBB, YWHAZ, YWHAG, YWHAQ, HSPA5, KPNB1, 
YWHAE
ATPase activity ATP5J2, HSP90AA1, ATP5C1, HSPA1A, ATP5A1, 
HSPD1, HSPA5, HSPA8
cadherin binding involved in 
cell-cell adhesion
HSP90AB1, YWHAZ, VAPA, RAN, VAPB, EEF2, HSPA1A, 
YWHAE, PCBP1, LRRC59, EEF1G, HSPA5, TMPO, PTPN1, 
HSPA8
HSP90AB1, YWHAZ, PCBP1, HSPA1A, HSPA5, TMPO, 
YWHAE, PRDX1, HSPA8
unfolded protein binding HSP90AB1, HSP90B1, HSP90AA1, HSPA6, DNAJA1, 
HSPA1A, HSPD1, HSPA5, UGGT1, CANX, HSPA8, TUBB4B
HSP90AB1, HSP90AA1, HSPA6, DNAJA1, HSPA1A, 
HSPD1, HSPA5, CANX, HSPA8, TUBB4B
enzyme binding HACD3, ATP2A2, VAPB, HSPA6, HSPA1A, PTPN1, HSPA5, 
YWHAE, STUB1, HSPA8, RPS3
HACD3, ATP2A2, HSPA6, PRKDC, HSPA1A, HSPA5, 
KPNB1, YWHAE, HSPA8, RPS3
structural constituent of 
ribosome
RPS27, RPS16, RPL23, SLC25A5, SLC25A6, SLC25A3, 
RPS27L, SLC25A1, RPL38, RPS5, RPS3
SLC25A5, SLC25A6, RPS27L, RPL38, RPS5, RPS3, 
RPS27, RPL23, RPS17, RPL22, RPS14, SLC25A3, 
SLC25A1, RPS20
Table 2.6 Genes involved in the molecular function enrichment analysis 





Figure 2.7  Overrepresented gene ontologies among the 91 CaSR interactors upregulated 
by ≥ 2 fold in presence of 4 mM Ca2+o, (red bars) and 61 in presence of 2 mM EGTA (blue 
bar) over the negative control were examined with DAVID  
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2.6.4 STRING analysis for interaction networks 
A visual representation of protein-protein interaction for putative 106 CaSR interactors was 
generated using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (Figure 
2.8). Spheres or nodes of different colors represent proteins. Large nodes represent proteins with 
known 3D structure while small nodes represent proteins with unknown structure. The thickness 
of lines between the nodes denotes “edges” and represents the confidence score for a true 
interaction based on available evidence. The thicker and darker the edge is, the confidence score 
for a true interaction based on available evidence is higher. The network edge confidence is ranked 
between 0 and 1, 1 being the most confident score. The strength of connecting nodes is not 
represented by the length or the location of the nodes.  106 proteins scored a medium local 
clustering coefficient of 0.551 with 633 edges and a PPI enrichment P < 1.00E-16 (Table S 5). 
The106 putative CaSR interactors scored a medium local clustering coefficient of 0.551 with 633 
edges and a PPI enrichment P < 1.00E-16 (Table S 5). Differentially enriched protein groups were 
input separately into STRING tool to test their PPI. There was no particular trend, however, all 
groups had medium to high network edge confidence of 0.714, 0.481, 0.356 and 0.498 for ≥ eight-
fold, 4-8 fold, 2-4 fold and 1.5-2 fold enriched groups [log2 intensity (Ca
2+/EGTA)], respectively 
(Figure 2.10). The edge confidence for 31 % of the proteins that were < 1.5 fold enriched [log2 
intensity (Ca2+/EGTA) < 0.58 and > -0.58] was 0.637 (Figure 2.9) and that for 65 % protein group 
highly enriched ≥ 1.5 fold in the presence of Ca2+o was 0.496 (Figure 2.10).   
2.6.5 Re-validation of known CaSR interactors 
Six previously known CaSR interactors involved in signaling and trafficking were re-
validated, namely, Gαi [132-134], Gβ2 [132-134], 14-3-3 θ [135], 14-3-3 ζ [135],  14-3-3 ε [135],  
14-3-3 γ [135], p24 [136] and calnexin [14] (Table 2.1). G-proteins, Gαi, and Gβ2 were detected 
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exclusively in the presence of Ca2+o. Heterotrimeric G-proteins are known GPCR interactors [132-
134] and activated GPCRs transduce downstream signaling through GTP-bound Gα and Gβγ 
dissociation. Gαi mediates inhibition of the cAMP dependent pathway through inhibition of 
adenylate cyclase [137]. On the other hand, Gβ2 is a part of Gβϒ complex that is widely expressed 
in cytoplasm, nucleus and cytoplasmic surface of the plasma membrane [138]. It modulates 
activity of effectors and regulators, including enzymes and several forms of potassium and calcium 
ion channels [139]. Gβ2 is closely associated with microtubule assembly and plays potential role 
in regulation of cell proliferation, and microtubule and mitotic spindle organization in mammalian 
cells [140]. Zha et. al. reported a non-canonical role of Gβ—as a substrate recognition factor to 
recruit a specific substrate to a cullin-RING E3 ubiquitin ligase for GPCR regulation [141]. 14-3-
3 θ and 14-3-3 ζ belong to ubiquitously expressed chaperones family, 14-3-3, known to play 
important role in regulation of cell signaling events and cellular trafficking [142, 143]. 14-3-3 θ is 
a known GPCR-interactor, including, melatonin receptor 1B [133] and glucagon receptor [132]. 
14-3-3 θ and 14-3-3 ζ were detected in both the presence and absence of Ca2+o but were 
significantly down regulated in the presence of Ca2+o. Arulpragasam et. al. characterized their 
negative roles in CaSR dependent SRE activation through CaSR tail binding and distinctive 
function of 14-3-3 ζ in lowering CaSR membrane expression [135]. p24 family is a type 1 
transmembrane protein which interacts with cargo and COPI or COPII coatomers and have been 
shown to interact with CaSR as a limiting factor in CaSR trafficking in the early secretory pathway 
and suggested to assist in transportation to and from the ERGIC [136].   
2.6.6 Novel CaSR interactors validated by other GPCR study 
The major significance of our study is the identification of several novel CaSR interactors 
(Table 1). This knowledge can provide new opportunities for understanding the function and 
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regulation of CaSR as well as provide insight on the crosstalk between signaling pathways within 
an interactome. Some of these novel interactors have been validated for other families of GPCR, 
which adds to the significance of our work, indicating them as functionally relevant. Most of these 
interactors were up-regulated in the presence of Ca2+o by varying degrees and were shown to be 
enriched in the ER, cell-cell adherens junction or mitochondrial inner membrane and associated 
with ER quality control, trafficking and Ca2+ homeostasis. Vesicle-associated membrane protein-
associated protein-A and -B (VAPA and VAPB) was enriched solely in the presence of Ca2+o by 
> 3 folds. VAPA is known to be involved in androgen receptor intracellular trafficking [144] and 
also oxysterol-binding protein related protein 3 is known to bind to VAPA to modify export from 
the ER [144]. Similarly, in the previous study, VAPB was identified as glucagon [132] and 
melatonin receptor type 1A [133] interactor. Ras-related proteins, Rab- 1, 7 and 11a are known 
CaSR interactors [145, 146]. We detected three other Rab isoforms (5C, 6 and 18) upregulated by 
> 2.5 folds in the presence of Ca2+o. Different isoforms of Rab proteins have been found as GPCR 
interactors including Rap-1A and Rab-10 [132, 133]. Another scaffolding and chaperone protein, 
calnexin is spotted in both the conditions, but upregulated in the presence of Ca2+o by > 1.5 folds. 
It is a known melatonin receptor interactor 1A and 1B [133]. In our experiment, E3 ubiquitin 
ligases (CHIP, RanBP2 and AMFR) were detected which could be a binding partner for the Gβ2. 
Further, E3 ubiquitin ligases are known CaSR interactors and have been demonstrated with Co-IP 
and functional assays to regulate ubiquitination and degradation of CaSR through ERAD pathway 
[117].  
We also observe an upregulation of pumps that maintains the Ca2+ concentration of the ER. 
Sodium/potassium-transporting ATPase (ATP1A1/ ATP1A3/ ATP1A2) and 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2), a glucagon receptor interactor 
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[132], was also detected in our experiment in both the conditions, but are highly abundant by > 2.5  
and > 2 folds, respectively, in the presence of Ca2+o. These proteins are involved in cellular 
signaling and molecular transport. A different isoform of voltage-dependent anion-selective 
channel protein (VDAC-2), interactor of glucagon receptor [132], was detected in both in the 
presence and absence of Ca2+o , but was found to be more abundant in the presence of Ca
2+
o by 1.5 
folds. 
Membrane-associated progesterone receptor component 1 (PGRMC1) is also upregulated 
by > 2.5 folds in the presence of Ca2+o and is a known glucagon [132] and melatonin receptor [133] 
interactor. Insulin receptor substrate 4 (IRS4) is also a known melatonin receptor 1B interactor and 
is found to be equivalently upregulated in the presence and absence of Ca2+o. Elongation factor 1-
gamma (EEF1G) is also a melatonin interactor (1A) [133] and is upregulated in the presence of 
Ca2+o by 2-2.5 folds. Heat shock proteins (HSPA6, HSPA7, HSPA8, HSP90AB, HSPA1A) were 
detected in equivalently in both the conditions and therefore, must be ubiquitously present 
irrespective of the Ca2+o. HSPs are known cell surface receptor regulator including the GPCRs: α2c 
adrenergic, CB2 cannabinoid and PAR-1 protease-activated receptors [147].  Leucine-rich repeat-
containing protein 59 (LRRC59) is a known melatonin receptor type 1A interactor as shown by 
Daulat et. al. [133]. This protein is detected in both presence and absence of Ca2+o, however, is 
found to be > 2.5-fold more abundant in the 4 mM Ca2+o (Table 2.9).  Only 5 out of the 106 
interactors were up-regulated in the absence of Ca2+o. 14-3-3- θ, ζ, and ε are detected in both the 
conditions but were up-regulated in the absence of Ca2+o by ≥ 1.5 folds. On the other hand, 14-3-
3 γ is found in equivalent abundance in both the conditions. Potentially, in the absence of Ca2+o, 




Figure 2.8   A visual representation of protein-protein interaction for putative 106 CaSR 
interactors generated using STRING.  
 
A visual representation of protein-protein interaction for putative 106 CaSR interactors 
generated using STRING. Spheres or nodes of different colors represent proteins. Large nodes 
represent proteins with known 3D structure while small nodes represent proteins with 
unknown structure. The lines between the nodes represent “edges”. The thicker and darker 
the edge is, the confidence score for a true interaction based on available evidence is higher. 
The network edge confidence is ranked between 0 and 1, 1 being the most confident score. The 
strength of connecting nodes is not represented by the length or the location of the nodes. 106 
proteins scored a medium local clustering coefficient of 0.551 with 633 edges and a PPI 












Figure 2.10 A visual representation of protein-protein interaction for putative CaSR 
interactors upregulated at various degree in the presence of Ca2+o generated using 
STRING. A. ≥ four folds. B. 3-4 folds. C. 2-3 folds. D. 1.5-2 folds. 
Figure 2.9 A. A visual representation of protein-protein interaction for putative 33 CaSR 




[-log2 (Ca2+/EGTA <0.58 and > -0.58] generated using STRING had an average local 
clustering coefficient of 0.617 with 90 edges and a PPI enrichment P < 7.86E-14. (Table 
S 5).  B. STRING visualization for 61 CaSR interactors found highly abundant in Ca2+ [-
log2 (Ca2+/EGTA ≥ 0.58] with local clustering coefficient of 0.496 with 90 edges and a 


























































Reference to Figure Figure 2.8 Figure 2.9 Figure 2.10 Figure 2.9A Figure 2.9B Figure 2.9C Figure 2.9D
Number of 
interacting nodes 99 63 30 14 9 18 22
Number of edges 633 215 90 9 6 24 34
Average local 
clustering coefficient 0.551 0.489 0.637 0.714 0.481 0.356 0.498
Enrichment p-value < 1.0E-16 < 1.0E-16 1.33E-15 0.0786 3.67E-06 1.19E-06 1.10E-06
Table 2.7 Network statistic available from STRING for various groups of putative CaSR 
interactors. 
 
Groups Stringency used Number of proteins
Group A log2 intensity (Positive/negative control)-Ca2+ ≥ 1 94
Group B log2 intensity (Positive/negative control)-EGTA ≥ 2 61
Group C log2 intensity (Ca2+/EGTA)≥ 0.58 69
Group D log2 intensity (Ca2+/EGTA) ≥ - 0.58 5
Group E log2 intensity (Ca2+/EGTA) < 0.58 and > -0.58 33
Group F log2 intensity (Ca2+/EGTA)≥ 4 12
Group G log2 intensity (Ca2+/EGTA) <4 and ≥ 2 9
Group H log2 intensity (Ca2+/EGTA) <2 and ≥ 1 21
Group I log2 intensity (Ca2+/EGTA) <1 and ≥ 0.58 26
Table 2. 1  



























glucosyltransferase 1 UGGT1 15.00 8.00 0.00 0.00 0.00 4.79 0.20 4.48
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 GNB2 4.00 4.33 0.00 0.00 0.00 5.02 1.00 4.43
2015, Han 





E3 SUMO-protein ligase RanBP2 RANBP2 8.00 5.33 0.00 0.33 0.00 3.86 0.39 4.39
Tyrosine-protein phosphatase non-
receptor type 1 PTPN1 2.00 2.00 0.00 0.00 0.00 3.03 -2.00 4.24
Leucine-rich repeat-containing 







Signal recognition particle receptor 
subunit alpha SRPR 3.00 3.00 0.00 0.00 0.00 3.29 -0.41 4.11





1, 7, 11a) CaSR
Nuclear pore complex protein 
Nup155 NUP155 5.00 3.67 0.00 0.00 0.00 4.71 0.36 4.00
Signal recognition particle receptor 
subunit beta SRPRB 8.00 13.67 0.67 0.00 0.00 6.69 2.84 3.74
Guanine nucleotide-binding protein 
G(k) subunit alpha; G(i) subunit 




AO1 5.00 8.00 0.67 0.00 0.00 6.75 1.04 3.64
2015, Han 








1A and 1B 
Membrane-associated progesterone 
receptor component 1 PGRMC1 2.00 1.33 0.00 0.00 0.00 2.95 0.59 3.02
2015, Han 




Ancient ubiquitous protein 1 AUP1 3.00 5.00 0.33 0.00 0.00 3.67 1.27 2.87






ATP synthase protein 8 MT-ATP8 1.00 3.00 2.00 0.00 0.00 2.66 1.16 2.73
Erlin-1 ERLIN1 1.00 2.33 1.00 0.00 0.00 2.84 0.22 2.70
FAS-associated factor 2 FAF2 6.00 4.00 1.00 0.00 0.00 4.61 1.89 2.48
Vesicle-associated membrane 







Erlin-2 ERLIN2 9.00 13.33 3.33 0.00 0.00 7.38 4.43 2.35

















6A;RAB39A 1.00 2.67 1.33 0.00 0.00 3.19 1.26 1.96
Zerial, 
2001, CaSR
Protein disulfide-isomerase A3 PDIA3 8.00 6.00 1.33 0.00 0.00 5.19 3.28 1.60
Urotensin-2 UTS2 1.00 2.67 0.67 0.00 0.00 4.46 3.10 1.58
GTP-binding nuclear protein Ran RAN 5.00 5.67 1.33 1.00 1.00 3.07 2.23 1.52
Lamina-associated polypeptide 2, 
isoforms beta/gamma;isoform 
alpha;Thymopoietin;Thymopentin TMPO 8.00 10.00 3.00 0.33 0.00 3.17 3.40 1.51
Average PSM Relative expression Log2 (intensity ratio) between
Positive control Negative control
WT and Neg 
control in Ca
2+




 and EGTA 
(WT)
Table 2.9 Relevant upregulated proteins from 106 putative CaSR interactors with ≥ 2 folds 






Ras-related protein Rab-18 RAB18 2.00 2.00 0.33 0.00 0.00 2.15 1.70 1.51
2015, Han 




Peptidyl-prolyl cis-trans isomerase 
FKBP8;Peptidyl-prolyl cis-trans 
isomerase FKBP8 3.00 2.00 0.00 0.00 0.00 4.32 3.22 1.50
Very-long-chain enoyl-CoA 
reductase TECR 2.00 4.33 3.33 0.00 0.00 3.63 2.51 1.49
Eukaryotic initiation factor 4A-I; 
4A-II; 4A-II, N-terminally 
processed
EIF4A1;EIF4
A2 3.00 4.67 0.67 0.00 0.00 2.26 1.80 1.49
ATP synthase subunit alpha, 
mitochondrial ATP5A1 5.00 5.00 1.33 0.33 0.00 3.12 3.58 1.41
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit RPN1 13.00 14.67 5.67 0.00 0.00 7.07 5.51 1.35
Protein transport protein Sec61 
subunit beta SEC61B 1.00 2.00 1.00 0.00 0.00 3.40 2.18 1.33
WD repeat-containing protein 6 WDR6 14.00 17.00 5.00 0.67 0.00 3.53 3.46 1.30
Hemoglobin subunit beta;LVV-
hemorphin-7;Spinorphin HBB 2.00 2.33 0.67 0.00 1.33 2.26 -0.37 1.22
Sarcoplasmic/endoplasmic 





Transducin beta-like protein 2 TBL2 4.00 3.00 1.33 0.00 0.00 3.73 3.29 1.15
Endoplasmin HSP90B1 3.00 2.67 1.00 0.00 0.00 4.18 2.93 1.10
60 kDa heat shock protein, 
mitochondrial HSPD1 6.00 4.00 1.67 0.00 0.00 3.27 3.03 1.09Clathrin heavy chain;Clathrin 
heavy chain 1 CLTC 12.00 5.67 1.33 0.67 0.33 2.37 1.92 1.05
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit DDOST 5.00 2.67 1.00 0.00 0.00 2.21 1.93 1.02
Phosphatidylserine synthase 1 PTDSS1 2.00 1.67 0.33 0.00 0.00 2.41 1.99 1.00
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial C1QBP 4.00 6.00 3.33 2.67 0.67 0.66 1.70 0.98
Elongation factor 1-gamma EEF1G 4.00 2.67 0.67 0.00 0.00 3.56 3.69 0.95 2007 Melatonin 
Elongation factor 2 EEF2 4.00 1.67 0.33 0.00 0.00 3.03 2.98 0.95
40S ribosomal protein S5;40S 
ribosomal protein S5, N-terminally RPS5 4.00 4.33 4.33 1.33 0.33 2.22 3.08 0.90
40S ribosomal protein S27 RPS27 2.00 8.00 6.67 2.00 0.33 3.49 3.93 0.90
Elongation factor 1-alpha 
1;Putative elongation factor 1-
alpha-like 3
EEF1A1;EEF
1A1P5 11.00 18.00 13.67 8.67 5.67 1.95 1.39 0.90
Trifunctional enzyme subunit beta, 
mitochondrial;3-ketoacyl-CoA 
thiolase HADHB 1.00 1.67 0.67 0.67 0.33 1.16 1.79 0.89
DnaJ homolog subfamily A member 
1 DNAJA1 2.00 3.67 2.33 0.00 0.00 3.16 4.37 0.86
40S ribosomal protein S27;40S 
ribosomal protein S27-like RPS27L 1.00 2.00 1.67 0.00 0.00 3.73 2.87 0.82
Microsomal glutathione S-
transferase 2 MGST2 1.00 2.67 1.00 0.00 0.00 3.74 3.70 0.81
Lamin-B receptor LBR 3.00 3.67 0.33 0.00 0.00 3.48 3.21 0.81
Importin subunit beta-1 KPNB1 7.00 4.67 2.67 1.00 0.00 2.08 3.94 0.79
E3 ubiquitin-protein ligase CHIP STUB1 5.00 3.33 1.67 0.00 0.00 3.06 2.43 0.78
Huang et 
al, 2006 CaSR
Neutral alpha-glucosidase AB GANAB 19.00 18.00 6.00 0.00 0.00 7.22 6.63 0.76
Very-long-chain (3R)-3-
hydroxyacyl-CoA dehydratase 3 HACD3 3.00 5.67 5.00 0.67 0.00 4.42 4.97 0.72





Peroxiredoxin-1 PRDX1 4.00 5.00 3.67 2.67 1.67 0.89 1.30 0.71
Heat shock protein HSP 90-alpha HSP90AA1 4.00 3.00 2.33 0.00 0.00 3.24 2.84 0.69
Up-regulated during skeletal 
muscle growth protein 5 USMG5 2.00 2.33 0.00 0.00 0.00 3.09 1.57 0.68
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit RPN2 8.00 3.00 2.33 0.00 0.00 4.68 4.79 0.68
Monocarboxylate transporter 1 SLC16A1 2.00 2.67 2.67 0.00 0.00 4.95 4.48 0.66
Cytochrome c oxidase subunit 
NDUFA4 NDUFA4 2.00 3.67 4.33 0.00 0.00 3.22 4.54 0.66
Voltage-dependent anion-selective 





Proteasome subunit alpha type; 





ADP/ATP translocase 2;ADP/ATP 
translocase 2, N-terminally 
processed SLC25A5 6.00 9.33 6.67 2.33 1.00 2.11 2.35 0.60
Transmembrane and coiled-coil 
domain-containing protein 1 TMCO1 2.00 3.67 3.00 0.00 0.00 4.49 5.66 0.58
40S ribosomal protein S14 RPS14 7.00 10.33 11.00 7.00 1.33 0.81 2.16 0.58
Phosphate carrier protein, 
mitochondrial SLC25A3 7.00 11.33 9.33 3.00 2.00 3.63 4.38 0.52ADP/ATP translocase 3;ADP/ATP 
translocase 3, N-terminally 
processed SLC25A6 5.00 28.67 22.00 11.33 5.67 2.03 2.65 0.51
40S ribosomal protein S20 RPS20 3.00 7.33 5.33 4.00 2.00 0.75 1.18 0.47
Poly(rC)-binding protein 1 PCBP1 3.00 8.00 7.00 3.00 1.67 1.99 2.14 0.44
Heat shock cognate 71 kDa protein HSPA8 22.00 85.33 70.00 13.00 7.00 2.96 3.57 0.43
DnaJ homolog subfamily C member 
7 DNAJC7 18.00 20.00 22.00 0.00 0.00 7.08 8.23 0.38
Extracellular calcium-sensing 
receptor CASR 52.00 496.00 427.33 4.33 0.00 11.61 14.32 0.30
Insulin receptor substrate 4 IRS4 25.00 41.33 31.00 6.00 2.00 2.85 4.96 0.30
Melatonin 
receptor type 
40S ribosomal protein S3 RPS3 12.00 29.33 30.33 16.67 11.33 1.06 1.43 0.29
ATP synthase subunit gamma, 
mitochondrial ATP5C1 3.00 2.00 2.67 1.00 1.00 1.07 1.92 0.28
Heat shock protein HSP 90-beta HSP90AB1 7.00 21.33 19.00 4.33 1.33 2.34 3.81 0.26
Heat shock 70 kDa protein 1A HSPA1A 12.00 56.33 49.33 22.67 12.67 2.03 2.88 0.26
40S ribosomal protein S16
RPS16;ZNF9
0 9.00 18.00 15.67 8.67 7.33 1.28 0.93 0.26
60S ribosomal protein L22 RPL22 2.00 3.67 3.33 2.67 1.33 0.63 1.11 0.24
BAG family molecular chaperone 
regulator 2 BAG2 10.00 35.00 32.00 0.00 1.33 6.08 5.83 0.17
DNA-dependent protein kinase 
catalytic subunit PRKDC 13.00 7.67 8.33 2.00 0.33 1.53 4.98 0.13
Mitochondrial import inner 
membrane translocase subunit 
TIM50 TIMM50 3.00 3.33 1.00 0.00 0.00 3.23 2.37 0.13
Glyceraldehyde-3-phosphate 
dehydrogenase GAPDH 4.00 3.67 2.33 0.67 0.33 2.23 2.38 0.12
60S ribosomal protein L38 RPL38 5.00 12.33 13.33 5.33 3.67 1.07 1.05 0.11
60S ribosomal protein L23 RPL23 4.00 12.33 9.00 6.33 5.67 1.21 1.69 0.09
Tubulin beta-4B chain;Tubulin 
beta-4A chain
TUBB4B;TU
BB4A 3.00 12.33 12.67 6.33 2.00 1.64 3.57 0.09
RalA-binding protein 1 RALBP1 1.00 2.00 1.33 0.00 2.33 7.16 -0.21 0.08
GPALPP motifs-containing protein 
1
GPALPP1
1.00 4.00 3.33 0.00 0.00 9.40 9.03 0.07
Tubulin beta chain;Tubulin beta-
2B chain;Tubulin beta-2A chain
TUBB;TUBB
2B;TUBB2A 4.00 53.00 56.33 25.00 9.00 1.92 3.48 0.01
Heat shock 70 kDa protein 
6;Putative heat shock 70 kDa 
protein 7
HSPA6;HSP
A7 1.00 2.67 2.00 0.00 0.00 1.97 2.88 -0.02
Tubulin beta-8 chain TUBB8 2.00 2.33 2.33 0.33 0.33 2.61 4.73 -0.02
14-3-3 protein gamma;14-3-3 
protein gamma, N-terminally 
processed YWHAG 1.00 1.67 2.00 0.00 0.00 2.04 2.75 -0.04
Tubulin alpha-1B chain;Tubulin 
alpha-4A chain
TUBA1B;TU
BA4A 1.00 56.00 61.33 23.00 14.00 1.85 3.28 -0.12
ATP synthase subunit f, 
mitochondrial
ATP5J2;ATP
5J2-PTCD1 3.00 3.33 2.67 0.00 0.00 3.08 4.90 -0.18
Tricarboxylate transport protein, 
mitochondrial SLC25A1 3.00 3.67 5.00 0.00 0.00 2.51 5.30 -0.33
40S ribosomal protein S17-like;40S 
ribosomal protein S17
RPS17;RPS17
L 4.00 3.33 2.33 0.33 0.00 0.03 4.97 -0.53
Activated RNA polymerase II 
transcriptional coactivator p15 SUB1 2.00 1.67 2.67 1.33 0.00 1.53 3.13 -0.53







BA1B 2.00 2.33 3.00 0.33 0.00 3.16 4.54 -0.99





14-3-3 protein zeta/delta 14-3-3 ζ YWHAZ 4.00 4.00 8.33 0.00 0.33 3.72 4.54 -1.38
THO complex subunit 4 ALYREF 6.00 2.33 9.00 2.67 1.00 -0.94 1.49 -1.69
75 
2.6.7 Rich Hub study 
A rich club is a set of high-degree nodes that are more densely interconnected than 
predicted by the node degrees alone [148]. The rich-club nodes may form a hub that is used by the 
other components in the network to influence each other. A Power-law distribution curve of the 
constructed 6 networks shows a strong positive correlation between the number of nodes (y axis) 
and the node-specific degree (x axis), Pearson correlation coefficient values ranging from 0.7-0.9. 
As the networks get sparse, correlation is improved suggesting that the frequency of nodes 
negatively correlates with the connection degree indicating a few number of nodes have the 
majority of the interactions in the network and therefore may form a connection hub. To investigate 
the significance of the discovered rich-club, the rich-club coefficient of the interactome networks 
was compared to that of randomly generated networks with similar degree distribution. The rich-
club coefficient of all the six networks ranged from 0.3-0.4, while that of random network was 
recorded to be 0.07, the rich-club coefficient reveals the presence of significant rich hubs in sub-
interactomes.  
Four proteins, HSPA8, HSPA5, HSP90AB1, and HSP90AA1 were seen to be part of most 
enriched hub (Figure 2.11).  HSPA8 functions as a chaperone and binds to nascent polypeptides 
to facilitate correct folding. It also functions as an ATPase in the disassembly of clathrin-coated 
vesicles during transport of membrane components through the cell [149]. HSPA5 is involved in 
the correct folding of proteins and degradation of misfolded proteins via its interaction with 
DNAJC10/ERdj5, probably to facilitate the release of DNAJC10/ERdj5 from its substrate and acts 
as a key repressor of the ERN1/IRE1-mediated unfolded protein response [150]. HSP90AB1 and 
HSP90AA1 are molecular chaperones that promotes the maturation, structural maintenance and 
proper regulation of specific target proteins involved for instance in cell cycle control and signal 
76 
transduction. It undergoes a functional cycle that is linked to its ATPase activity. This cycle 
probably induces conformational changes in the client proteins, thereby causing their activation. 
Figure 2.11   Rich hub analysis for CaSR interactome and degree centrality distribution of 
String interacted proteins .  
 A degree centrality measure was applied and 6 sub-interactomes (Figure 1: A, B, C, 
D, E and F) were constructed with degree measures varying between 1-5, 6-10, 11-
15, 16-20, 21-25 and >25. Power-law distribution analysis was performed on each 
of the sub-interactomes to generate Pearson’s correlation coefficient values (Figure 
1: Ai, Bi, Ci, Di, Ei and Fi) between number of nodes and betweenness centrality 
measure. Degree centrality distribution of all the String interacted proteins. 
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They interact dynamically with various co-chaperones that modulate its substrate recognition, 
ATPase cycle and chaperone function [151]. 
2.6.8 Validation of some of the detected proteins 
2.6.8.1 Coimmunoprecipitation and Western blot 
We selected few novel putative CaSR interactors which are involved in trafficking, quality 
control or signaling to re-validate with western blot of the co-immunoprecipitated product. 
HEK293 cells transfected with 6 µg of FLAG-CaSR or empty pcDNA3.1 was treated with either 
Ca2+ or EGTA and lysed. The 1.5 mg lysate was subjected with co-immunoprecipitation using 10 
µg of FLAG-antibody overnight in 50 µL of dyna bead solution. SDS-Page gel was run for 50 µg 
of total lysate. 30 µL 2X SDS-sample buffer was used to elute the bound proteins after washing 
and 25 µL of the eluate was used for SDS-Page gel for each treatment conditions.  
30 kDa blot for 14-3-3 ε if any in the immunoprecipitation is concealed by overpowering 
25 kD antibody light chain blot (Figure 2.12). The 14-3-3 ε blot at much higher molecular weight 
where we saw CaSR blots, so could be a complex. GRP78 is present in both the positive controls 
in Ca2+ and EGTA treatment but band is not quantitative (Figure 2.12). The GRP78 blot at much 
higher molecular weight where we saw CaSR blots, so could be a complex. CHIP is present in 
both the positive controls in Ca2+ and EGTA treatment but band is not quantitative (Figure 2.13). 
But we saw the CHIP blot at much higher molecular weight where we saw CaSR blots, so could 
be a complex. IP3R is present in both the positive controls in Ca
2+ and EGTA treatment but band 
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Figure 2.12 Validation for 14-3-3 ε and GRP78 
HEK293 cells transfected with 6 µg of FLAG-CaSR or empty pcDNA3.1 was treated 
with either Ca2+ or EGTA and lysed. The 1.5 mg lysate was subjected with co-
immunoprecipitation using 10 µg of FLAG-antibody overnight in 50 µL of dyna bead 
solution. SDS-gel was run for 50 µg of total lysate. 30 µL 2X SDS-sample buffer was 
used to elute the bound proteins after washing and 25 µL of the eluate was used for 
SDS-gel for each treatment conditions. Western blot was analyzed using 14-3-3 3 ε 
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Figure 2.13 validation for CHIP and IP3R 
HEK293 cells transfected with 6 µg of FLAG-CaSR or empty pcDNA3.1 was treated 
with either Ca2+ or EGTA and lysed. The 1.5 mg lysate was subjected with co-
immunoprecipitation using 10 µg of FLAG-antibody overnight in 50 µL of dyna bead 
solution. SDS-gel was run for 50 µg of total lysate. 30 µL 2X SDS-sample buffer was 
used to elute the bound proteins after washing and 25 µL of the eluate was used for 
SDS-gel for each treatment conditions. Western blot was analyzed using CHIP at 
1:500 dilution and IP3R at 1:1000 antibodies. 
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2.6.8.2 Immuno-staining 
HEK293 cells transfected with 2.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 mm 
coverslips was starved and then treated with Ca2+. The cells were subjected to immunostaining 
using mouse anti FLAG-antibody at 1:1500 dilution and rabbit anti GRP7/Bip8 at 2 µg/mL. 
Secondary goat anti mouse Alexa fluor 488 at 4 µg/mL and secondary goat anti rabbit Alexa fluor 
Figure 2.14  A. Co-localization of FLAG-CaSR and endogenous GRP78  
 
HEK293 cells transfected with 2.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 mm 
coverslips was treated with Ca2+. The cells were subjected to immunostaining using mouse 
anti FLAG-antibody at 1:1500 dilution and rabbit anti GRP78 at 2 µg/mL. Secondary goat 
anti mouse Alexa fluor 488 at 4 µg/mL and secondary goat anti rabbit Alexa fluor 647 at 4 
µg/mL were used. Image-J was used to process the co-localization. Yellow represents co-
localization. Surface plot of pixel intensities from confocal images of the area marked in grey 
square of HEK293 cells expressing FLAG-CaSR and endogenous GRP78 after 4mM Ca2+ 
treatment show similar corresponding peaks. Co-localization is observed on the membrane 
as well as interior of cell. 
Colocalization between CaSR and Bip/GRP78 at 4mM Ca2+








647 at 4 µg/mL were used. Image-J was used to process the co-localization. Yellow represents co-
localization. To further observe the co-localization at the microscopic level, surface plot of pixel 
intensities from confocal images of the area marked in grey square of HEK293 cells was plotted. 
The cells expressing FLAG-CaSR and endogenous GRP78 after 4mM Ca2+ treatment show similar 
corresponding peaks (Figure 2.14). Co-localization is observed on the membrane as well as 
interior of cell. Similarly, CHIP after 4mM Ca2+ treatment show similar corresponding peaks in 
surface plot as well as show significant yellow in the merged image suggesting high degree of 
Figure 2.15  Membrane CaSR co-localized with endogenous STUB1 (CHIP)  
 HEK293 cells transfected with 2.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 
mm coverslips was treated with Ca2+. The cells were subjected to immunostaining using 
rabbit anti CaSR-antibody (ab137408) at 1:100 dilution and mouse anti CHIP antibody 
at 1:200 dilution. Secondary goat anti mouse Alexa fluor 488 at 4 µg/mL and secondary 
goat anti rabbit Alexa fluor 647 at 4 µg/mL were used. Image-J was used to process 
the co-localization. Yellow represents co-localization. Surface plot of pixel intensities 
from confocal images of the area marked in grey square of HEK293 cells expressing 
FLAG-CaSR and endogenous CHIP after 4mM Ca2+ treatment show similar 
corresponding peaks. Co-localization is observed on the membrane. 
 
Colocalization between CaSR and CHIP at 4 mM Ca2+
Pearson’s  coefficient = 0.73
CaSR
BIP
CaSR (Ex: 594) CHIP(Ex: 488) Merged
Surface Plots
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colocalization of CHIP with CaSR. In order to figure out where the co-localization is taking place, 
we carried out the study with ER and CaSR. Surface plot of pixel intensities from confocal images 
of the area marked in grey square of HEK293 cells expressing FLAG-CaSR and ER after 4mM 
Ca2+ treatment show similar corresponding peaks. Co-localization is observed on the interior of 
cell. Not only is the ER and CaSR localized, but for the same cells, ER and Bip is also observed.  
 
Figure 2.16  CaSR co-localized with ER.  
 
HEK293 cells transfected with 2.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 mm 
coverslips was treated with Ca2+. The cells were subjected to immunostaining using mouse 
anti FLAG-antibody at 1:1500 dilution and ER tracker dye at 1 µM. Secondary goat anti 
mouse Alexa fluor 488 at 4 µg/mL was used. Image-J was used to process the co-
localization. Yellow represents co-localization. Surface plot of pixel intensities from 
confocal images of the area marked in grey square of HEK293 cells expressing FLAG-
CaSR and ER after 4mM Ca2+ treatment show similar corresponding peaks. Co-
localization is observed on the interior of cell. 
Colocalization of CaSR and ER at 4 mM Ca2+
CaSR ER
Pearson’s  coefficient = 0.74
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Colocalization of Bip and ER at 4 mM Ca2+
Figure 2.17  Colocalization of Bip and ER at 4mM Ca2+ 
HEK293 cells transfected with 2.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 
mm coverslips was treated with Ca2+. The cells were subjected to immunostaining using 
mouse anti FLAG-antibody at 1:1500 dilution and ER tracker dye at 1 µM. Secondary 
goat anti mouse Alexa fluor 694 at 4 µg/mL was used and pseudo color red was given 
for image-J processing. Image-J was used to process the co-localization. Yellow 
represents co-localization. Surface plot of pixel intensities from confocal images of the 
area marked in grey square of HEK293 cells expressing Bip and ER after 4mM Ca2+ 
treatment show similar corresponding peaks. Co-localization is observed on the 
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Figure 2.18 Colocalization of VAPA and CaSR at 4mM Ca2+ 
HEK293 cells transfected with 1.5 µg of FLAG-CaSR or empty pcDNA3.1 in 20 × 20 mm 
coverslips was treated with Ca2+. The cells were subjected to immunostaining using mouse anti 
FLAG-antibody at 1:1500 dilution and anti VAPA antibody at 2µg/mL. Secondary goat anti 
mouse Alexa fluor 647 and anti-rabbit Alexa fluor 550 at 4 µg/mL were used. Surface plot of 
pixel intensities from confocal images of the area marked in grey square of HEK293 cells 
expressing VAPA and CaSR after 4mM Ca2+ treatment show similar corresponding peaks.  
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2.6.9 ER oscillation mediated by CaSR 
Figure 2.20 ER oscillation is triggered by the extracellular Ca2+ perturbation at 4 mM Ca2+ 
((as observed by a recombinant red sensor which is not yet published) 
This oscillation coordinates with the intracellular Ca2+ oscillation mediated by CaSR. This 
ER oscillation mediated by CaSR activation must code for cellular processes involved in 
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Figure 2.21  The schematic model of CaSR mediated signaling, ER quality control and ADIS of 
CaSR invoked through extracellular Ca2+ perturbation. 
Identified proteins from the experiment are colored; dark brown representing ≥ 17 folds, brown 
representing ≥ 5 and < 17 folds and light brown representing ≥ 1.5 and < 5 folds enrichment 
(log2(Ca
2+/EGTA)-positive controls). Treatment of 4 mM Ca2+ influenced the CaSR interactome 
involved in biosynthesis, trafficking and Ca2+ handling. A.CaSR is activated with 4 mM 
extracellular Ca2+. B. CaSR mediated G-protein signaling: Ca2+induces CaSR mediated 
phospho-lipase C(PLC) activation and subsequently, IP3 invoked release of Ca
2+ from the ER. 
Additionally, Ca2+ dependent Gαi invoked inhibition of acetyl cyclase is induced. Ca
2+ handling 
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Alteration in Ca2+ER induce amplification of CaSR biosynthesis in the ER.  C. Co-translational 
translocation: The newly synthesized polypeptide bound to the signal recognition particle (SRP) 
is directed to the ER membrane to the Sec complex by the SRP receptor. Release of SRP and SRP 
receptor allows translocation.After processing of signal sequence by signal peptidase (SP) 
complex, the oligosaccharyl transferases (OST: DDOST and RPN1/2) and palmitoyl-transferase-
SPTLC1 catalyzes the transfer of oligosaccharides. GRP78 chaperones CaSR polypeptide to ER 
lumen. Glucosidases GANAB allows for the removal of outermost glucose residues. D. Calnexin 
cycle: Lectin chaperones calnexin (CNX) and/or calreticulin (CLTC) along with GRP78 promotes 
proper folding by preventing aggregation and premature export from the ER. PDIA3, a protein 
disulfide isomerase catalyzes the disulfide formation. Next, innermost glucose is cleaved by 
glucosidase and the CaSR is released from the cycle. UGGT, a glucosyl transferase acts as a 
check- point where improperly folded CaSR is re-glucosylated. E. Degradation pathway: 
Terminally misfolded CaSR undergo ERAD and are ubiquitinated through E3 ligases STUB1 and 
RanBP2, or, CaSR from the plasma membrane can be endocytosed assisted by Rab5, Rab18 and 
clathrin heavy chain-CLTC. F. ER-exit: Properly folded CaSR anterograde trafficking from the 
ER to the Golgi assisted by VAPA and VAPB as well as chaperone proteins p24A. Rab6 assist in 
retrograde trafficking from Golgi to the ER. Similarly, 14-3-3 allows the CaSR to retain in the ER 
in the absence of Ca2+. 
Heterotrimeric G-proteins are known GPCR interactors [132-134] and activated GPCRs 
transduce downstream signaling through GTP-bound Gα and Gβγ dissociation. G-proteins, Gαi, 
and Gβ2 are detected exclusively in the presence of Ca
2+, up-regulated at 12.5- and 22-folds, 
respectively. Gαi mediates inhibition of the cAMP dependent pathway through inhibition of 
adenylate cyclase [137]. On the other hand, Gβ2 is a part of Gβϒ complex that modulates activity 
of effectors and regulators, including enzymes and several forms of potassium and calcium ion 
channTable 2. 2 The heat map of proteins involved in the working modelels [139] and  Gβϒ 
inhibitor, gallein is shown to block the signaling induced anterograde trafficking [14]. Gβ2 is 
closely associated with microtubule assembly [140] and substrate recognition to recruit a specific 
substrate to a cullin-RING E3 ubiquitin ligase for GPCR regulation [141]. We know that Gq/11 
activates phospholipase C, which in turn transduce the inositol triphosphate (IP3) induced Ca
2+
ER 
release causing increase in the Ca2+cyt. Physiologically, ER lumen Ca
2+ concentration is 
maintained within the 100–500 µM range, whereas, the cytosolic at 5-50 nM [152] through a large 
number of Ca2+ binding proteins that act as chaperones and buffers [153]. Many of the channels 
and pumps involved in sustaining the Ca2+ concentration at the ER and cytoplasm such as SERCA, 
TMCO1 and VDAC are enriched in the presence of Ca2+. This must be a compensatory mechanism 
to maintain the Ca2+ homeostasis. One of the most ubiquitous isoforms of SERCA with highest 
Ca2+ affinity, namely, ATP2A2 (SERCA-2b) [154] is found to be enriched at 2.3 folds. SERCA is 
a known class B, GPCR (glucagon receptor) interactor [132]. Modulation of SERCA activity and 
expression level maintains the resting Ca2+cyt concentration by rapid re-uptake of Ca
2+ into the 
ER once the ER/SR Ca2+ is released into the cytoplasm [154]. In gain of function mutation of 
CaSR, SERCA expression is known to increase [155]. Additionally, our result show a 1.5-folds 
enrichment of an ER transmembrane channel, TMCO1, which is known to respond to the ER 
luminal Ca2+ overloading by homo-tetramerization and by functioning as Ca2+ load-activated 
Ca2+ (CLAC) release channel maintaining ER Ca2+ homeostasis [156]. Therefore, TMCO1 and 
SERCA may work opposing to each other to maintain the Ca2+ concentration in the ER and cytosol. 
We propose that the CaSR mediated G-protein signaling is directly linked with CaSR ER quality 




2.6.10 CHIP ubiquitination of CaSR 
CHIP (carboxyl terminus of Hsc70-interacting protein) or STUB1 is a E3 ubiquitin ligase 
targeting the misfolded chaperone substrates which direct them towards proteasomal degradation. 
Protein names Gene names
Log2 [positive/negative control] -
Ca2+






Vesicle-associated membrane protein-associated 
protein A VAPA 5.19 -0.53 5.42
UDP-glucose:glycoprotein glucosyltransferase 1 UGGT1 4.79 0.20 4.48
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 GNB2 5.02 1.00 4.43
E3 SUMO-protein ligase RanBP2 RANBP2 3.86 0.39 4.39
Signal recognition particle receptor subunit alpha SRPR 3.29 -0.41 4.11
Ras-related protein Rab-5C RAB5C 4.31 1.18 4.10
Signal recognition particle receptor subunit beta SRPRB 6.69 2.84 3.74
Guanine nucleotide-binding protein subunits G(k); 
G(i) alpha-1; G(i) alpha-2; G(o) alpha GNAI3 6.75 1.04 3.64
Serine palmitoyltransferase 1 SPTLC1 3.04 0.59 2.74
Vesicle-associated membrane protein-associated 
protein B/C VAPB 3.34 1.00 2.37
78 kDa glucose-regulated protein HSPA5 4.25 2.69 2.30
Sodium/potassium-transporting ATPase subunit 
alpha-1; alpha-3; alpha-2 ATP1A1 4.76 1.81 2.20
Ras-related protein Rab-6A;Ras-related protein Rab-
6B;Ras-related protein Rab-39A RAB6B 3.19 1.26 1.96
Protein disulfide-isomerase A3 PDIA3 5.19 3.28 1.60
Ras-related protein Rab-18 RAB18 2.15 1.70 1.51
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 RPN1 7.07 5.51 1.35
Protein transport protein Sec61 subunit beta SEC61B 3.40 2.18 1.33
Sarcoplasmic/endoplasmic reticulum calcium 
ATPase 2 ATP2A2 6.81 6.36 1.18
Endoplasmin HSP90B1 4.18 2.93 1.10
Clathrin heavy chain;Clathrin heavy chain 1 CLTC 2.37 1.92 1.05
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit DDOST 2.21 1.93 1.02
40S ribosomal protein S27 RPS27 3.49 3.93 0.90
DnaJ homolog subfamily A member 1 DNAJA1 3.16 4.37 0.86
E3 ubiquitin-protein ligase CHIP STUB1 3.06 2.43 0.78
Neutral alpha-glucosidase AB GANAB 7.22 6.63 0.76
Calnexin CANX 6.57 6.69 0.71
Heat shock protein HSP 90-alpha HSP90AA1 3.24 2.84 0.69
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 RPN2 4.68 4.79 0.68
Voltage-dependent anion-selective channel protein 
2 VDAC2 3.11 3.03 0.66
Extracellular calcium-sensing receptor CASR 11.61 14.32 0.30
Heat shock 70 kDa protein 1A HSPA1A 2.03 2.88 0.26
60S ribosomal protein L22 RPL22 0.63 1.11 0.24
BAG family molecular chaperone regulator 2 BAG2 6.08 5.83 0.17
14-3-3 protein gamma;14-3-3 protein gamma, N-
terminally processed YWHAG 2.04 2.75 -0.04
14-3-3 protein epsilon YWHAE 4.42 4.91 -0.80
14-3-3 protein theta YWHAQ 4.68 7.46 -1.08
14-3-3 protein zeta/delta YWHAZ 3.72 4.54 -1.38
Table 2.10 The heat map of proteins involved in the working model 
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It is a U-box type E3 ligase that carried out a function of a chaperone [157]. CHIP is known to 
attenuate ATP hydrolysis and inhibit the cycle of Hsc70/Hsp70 [157]. Additionally, it is a known 
target for Hsp90 and Hsp70 for 26S proteasomal degradation [157]. Only dorfin has been identified 
as a degradation enzyme related with CaSR. We identified an upregulation of CHIP interaction 
with CaSR in the presence of Ca2+ suggesting a new proteasomal degradation pathway possibly 
dependent on Ca2+. We collaborated with Dr. Jun Yin and Li Zhou where we obtained the CHIP 
knocked down HEK293 cells. We expect to observe a change in the level of ubiquitination which 
appears as a smear for various degree of ubiquitination on CaSR. Unfortunately, our experiments 
still require optimization. We did not observe obvious changes between the CHIP knocked down 
HEK293 cells and the normal HEK293 cells. Additionally, we did not detect any distinct change 
in the smear due to Ca2+ (Figure 2.22, Figure 2.23). 
For future, we will have to optimize the presence of the oligomer CaSR as it acts as a limit 
for the observation of a clear smear for ubiquitination. Also, the western blot has to be optimized 
to obtain a clear band. Furthermore, it is important to obtain the knock in of CHIP in the experiment 
which for some reason has not been able to achieve especially in the shCHIP knocked down 
HEK293 cells. The negative control for HEK293 cells without CaSR transient transfection does 
not provide a good result as well. Therefore, the Co-IP has to be improved, possibly with more 
stringent washing or using anti-CHIP antibody to pull out CaSR. 
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Figure 2.22 Ubiquitination of CaSR by CHIP assay trial I. 
 
Ca2+ (4 mM) +         - +            - +          - +           - +          -
EGTA (2 mM)    - +        - +         - +         - +          - +
CaSR OE (8 µg) +        +        +           +         +          +        +           +          - -












Ca2+ (4 mM) +         - +            - +          - +           - +          -
EGTA (2 mM)    - +        - +         - +         - +          - +
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Antibody heavy chain 
Antibody light chain 
Ca2+ (4 mM) +         - +            - +          - -
EGTA (2 mM)    - +        - +         - +        +         
CaSR OE (8 µg) +        +        +           +         +          +        +           




Ubiquitination of CaSR is evidently higher in the presence of 4 mM Ca2+ as compared to 2 
mM EGTA in HEK293 cells and ShCHIP HEK293 cells. OE of CHIP in HEK293 cells and 
CHIP KD HEK293 cells do not have apparent change in ubiquitination, respectively. 
Therefore, these results do not support our hypothesis of CHIP ubiquitination of CaSR. OE 
of both CaSR and CHIP in ShCHIP HEK293 cells in the presence of 4 mM Ca2+, which 
supports our hypothesis. Results from Li matched my results but his OE of CaSR and CHIP 
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Figure 2.23 Ubiquitination of CaSR by CHIP 
Trial III 
ShCHIP HEK293 has good KD of CaSR. CaSR total is seen but disproportionate in total 
input for some reason. Not sure what 130-150 kDa species is as it is present throughout the 
negative control and IB of CaSR, Ub in total. CaSR IP is present in all samples but not same 
throughout. Negative control is clean but 100 kDa blot is seen meaning it is not CaSR. 
Ubiquitin does not have any trend between Ca2+ and EGTA. Also, no trend between CHIP 
KD or control 
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2.6.11 Ca2+ and CaM binding sites prediction on CHIP and GRP78 
 
 
Figure 2.24  Ca2+ binding sites predicted for CHIP (2C2L) using GG  
2559    4854   9497   9500   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
ASN57B ASN57C SO41305B SO41305B (related four residue type and IDs in the file: 
2c2l.pdb)
-27.481 8.422 24.124(psdCa coordinates)
2.212 (psdCa-O)
4039    4054   4063   4175   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
SER237B GLU239B LEU240B ASP254B (related four residue type and IDs in the file: 
2c2l.pdb)
21.530 6.261 27.633(psdCa coordinates)
2.392 (psdCa-O)
8629    8644   8653   8765   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
SER237D GLU239D LEU240D ASP254D (related four residue type and IDs in the file: 
2c2l.pdb)
-16.417 -55.688 44.579(psdCa coordinates)
2.397 (psdCa-O)
3583    3611   3648   3649   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
GLN182B HIS185B GLU189B GLU189B (related four residue type and IDs in the file: 
2c2l.pdb)
32.962 18.472 93.141(psdCa coordinates)
2.491 (psdCa-O)
8173    8201   8238   8239   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
GLN182D HIS185D GLU189D GLU189D (related four residue type and IDs in the file: 
2c2l.pdb)
-4.234 -68.020 -20.756(psdCa coordinates)
2.497 (psdCa-O)
1744    1759   1768   1880   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
SER237A GLU239A LEU240A ASP254A (related four residue type and IDs in the file: 
2c2l.pdb)
27.025 -18.768 37.034(psdCa coordinates)
2.748 (psdCa-O)
6334    6349   6358   6470   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
SER237C GLU239C LEU240C ASP254C (related four residue type and IDs in the file: 
2c2l.pdb)
-10.912 -30.655 35.097(psdCa coordinates)
2.755 (psdCa-O)
8552    8553   8557   8576   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
ASP227D ASP227D ILE228D ASP230D (related four residue type and IDs in the file: 
2c2l.pdb)
-6.642 -57.204 36.758(psdCa coordinates)
2.800 (psdCa-O)
3962    3963   3967   3986   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
ASP227B ASP227B ILE228B ASP230B (related four residue type and IDs in the file: 
2c2l.pdb)
31.236 7.755 35.593(psdCa coordinates)
2.803 (psdCa-O)
5872    5878   5882   5943   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
CYS181C GLN182C GLN182C GLU189C (related four residue type and IDs in the file: 
2c2l.pdb)
-35.300 -61.654 -10.270(psdCa coordinates)
2.909 (psdCa-O)
1282    1288   1292   1353   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
CYS181A GLN182A GLN182A GLU189A (related four residue type and IDs in the file: 
2c2l.pdb)
2.006 12.051 82.207(psdCa coordinates)
2.910 (psdCa-O)
264    9482   9483   9484   (related four ligand oxygen atom IDs in the file: 2c2l.pdb)
ASN57A SO41305A SO41305A SO41305A (related four residue type and IDs in the 
file: 2c2l.pdb)
11.288 -59.966 47.495(psdCa coordinates)
2.953 (psdCa-O)
(PDB: 2C2L) 
7514    7516   7807   7809   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
THR485B THR485B THR525B THR525B (related four residue type and IDs in the file: 5o4p.pdb)
47.691 21.207 34.662(psdCa coordinates)
2.019 (psdCa-O)
4046    4064   4078   4252   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
GLY36B TYR39B SER40B SER64B (related four residue type and IDs in the file: 5o4p.pdb)
86.368 26.244 42.612(psdCa coordinates)
2.184 (psdCa-O)
44    49   1105   1335   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
ASP34A LEU35A THR171A GLU201A (related four residue type and IDs in the file: 5o4p.pdb)
69.713 -5.626 -0.123(psdCa coordinates)
2.491 (psdCa-O)
4033    4038   5088   5318   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
ASP34B LEU35B THR171B GLU201B (related four residue type and IDs in the file: 5o4p.pdb)
83.367 20.948 42.197(psdCa coordinates)
2.491 (psdCa-O)
5317    5492   5493   8040   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
GLU201B ASP224B ASP224B SO4603B (related four residue type and IDs in the file: 5o4p.pdb)
84.122 18.045 48.175(psdCa coordinates)
2.842 (psdCa-O)
7738    7755   7769   7785   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
ASP515B GLY517B ASN520B ASN522B (related four residue type and IDs in the file: 5o4p.pdb)
43.090 10.177 29.432(psdCa coordinates)
2.843 (psdCa-O)
1500    1504   1528   1548   (related four ligand oxygen atom IDs in the file: 5o4p.pdb)
ASP224A ASP224A ALA229A ASP231A (related four residue type and IDs in the file: 5o4p.pdb)
69.990 -0.853 -6.204(psdCa coordinates)
2.887 (psdCa-O)
PDB: 5o4p




Calcium pattern search, on online search engine designed by Dr. Xue was used to find the 
putative Ca2+ binding sites. GG (Graph theory and Geometry) uses the graph theory and geometric 
parameters to identify oxygen clusters on Ca2+ sites [158] using the crystal structure provided. We 
show that a Ca2+ binding site was predicted in CHIP and GRP78. But, 14-3-3 eta does not have 
any sites (Figure 2.24, Figure 2.25, Figure 2.26). This could explain to an extent and suggests 
that change in extracellular Ca2+ resulted in intracellular and ER Ca2+ which further allowed these 
proteins to be activated.  
CaM binding database was used to predict the CaM binding domains. This search engine 
uses sequence homology to tabulate the putative CaM binding sites on protein of interest. We 
found multiple CaM binding domains with high score in CHIP (Figure 2.27). Again, this suggests 
that with the CaSR mediated extracellular Ca2+ perturbation, the CaM which is a Ca2+ dependent 
protein, activates CHIP for its cellular function of ubiquitinating CaSR.  
 
7369    7373   7375   7379   (related four ligand oxygen atom IDs in the file: 
2c63.pdb)
SEP4P SEP4P SEP4P LEU5P (related four residue type and IDs in the file: 
2c63.pdb)
5.951 -5.648 16.816(psdCa coordinates)
2.334 (psdCa-O)
4969    4983   5313   5315   (related four ligand oxygen atom IDs in the file: 
2c63.pdb)
GLN166C THR168C THR210C THR210C (related four residue type and IDs in the 
file: 2c63.pdb)
20.287 51.024 -2.087(psdCa coordinates)
2.438 (psdCa-O)
Figure 2.26  No Ca2+ binding sites was predicted for 14-3-3 eta using GG. 
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Figure 2.27 Motif score for putative CaM binding sites in E3 Ubiquitin Ligase CHIP 
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2.6.12 Mass spectrometry analysis for intra-cellular Ca2+ pertubation 
These experiments were first batches of optimization for Co-IP. A trial was conducted for 
co-immunoprecipitation of FLAG-CaSR after treatment of extracellular 2 mM Ca2+ and 2 mM 
EGTA, and subsequently same treatments for intracellular after lysis of cells. The trail was 
repeated on different month and Orbitrap XL was used to generate the LC MS/MS for both on 
different days. Three stringencies were applied to obtain proteins upregulated in Ca2+ condition: 
(i) log2 intensity (Ca
2+/EGTA) > 0.584, (ii) log2 intensity (positive/negative controls)-Ca
2+ > 0.584, 
and (iii) PSM (Ca2+) > 10. Unfortunately, the resulting proteins between the two trials were only 
four out of the total 128 and 127 obtained, respectively. These four proteins were cytoplasmic 
dynein 1 heavy chain 1, translation initiation factor 5B, Myosin-9 and phosphatase. This result 
implies that our experiment was not reliable.  
A second trial consisted of an additional 10 mM Ca2+ treatment apart from the 2 mM Ca2+ 
and 2 mM EGTA. Interestingly, even if the PSM of CaSR was lower by 3-fold in 10 mM Ca2+ as 
compared to other two treatments, there were number of proteins such as the 14-3-3 family (ζ, ε 
and θ) and CaM that were increased by greater than 3-fold when the extra- and intra- cellular Ca2+ 
was perturbed to 10 mM (Figure 2.28, Table 2.11). Higher Ca2+ is known to be used for greater 
IP of CaSR in previous literature. But this contradicted our result, thereby, suggesting a direct 
correlation of Ca2+ with the interaction.  
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Figure 2.28 IP of CaSR and Co-IP of CaM in Trial II with intra- and extra-0cellular 
Ca2+ perturbation 
Two plates for each condition were lysed for 30 min. 1.2 mg protein were used for 
IP using 10 µg of anti-FLAG antibody. The antibody was first incubated with dyna 
bead for 30 min at RT and subsequently, washed with lysis buffer. Antigen was 
added and incubated overnight at 4 degrees. The beads were washed and heated in 
sample buffer for 10 min at 70 degrees. All the samples were added with 10 mM 
DTT and 40 mM IAA and incubated in dark and RT for few hours.  
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Equivalent amount of total input of CaSR and CaM were observed (Figure 2.28). IP of CaSR for 
10% bead produced multiple bands with the use of DTT and IAA. Ignoring the common bands in 
negative control HEK293, the major CaSR oligomer is absent in 2mM Ca2+ condition, possibly 
an error in western blot. Also, 10mM has similar amount of CaSR oligomer as the 2 mM EGTA 
condition which contradicts the MS result.  
2.7 Discussion 
To the best of our knowledge, this is the first comprehensive proteomics study examining 
the role of Ca2+ on CaSR interactome. During the experimental design and analysis, we employed 
rigorous and careful considerations to identify putative interactors of CaSR. All experiments were 
conducted in triplicates, appropriate negative controls were used to identify and avoid background 
signals, magnetic beads were used as they give a low background of the contaminant proteins 
[159], a very stringent statistical analysis was employed, and a total lysate MS/MS was conducted 
to circumvent the un-specific binding due to general enrichment in the cell. In our study, we 
employed co-immunoprecipitation, LC-MS/MS and gene ontology to report novel CaSR 
interactors, study the influence of chronic exposure of extracellular Ca2+ and provide a putative 
relative quantitative measure of the interactions. The major significance of our study is the 
identification of 100 novel CaSR interactors, many of which have been validated for other 
members of GPCR family. This adds to the significance of our work, indicating them as 
functionally relevant. Additionally, eight previously known CaSR interactors involved in signaling 
and trafficking were re-validated, namely, Gαi [132-134], Gβ2 [132-134], 14-3-3 θ [135], 14-3-3 ζ 
[135],  14-3-3 ε [135],  14-3-3 γ [135], p24 [136] and calnexin [14]. Most importantly, we observe 
an enrichment ranging from 2- 43 folds in 65% of the 106 total proteins in the presence of 
extracellular Ca2+. These proteomes are affiliated with (i) the signal transduction, (iii) regulatory 
98 
intracellular proteins maintaining Ca2+ handling and (iii) quality control of the maturation of CaSR 
in the ER and trafficking to the plasma membrane. 
ERQC is a surveillance system which monitors proper folding of membrane protein and its 
trafficking to the membrane or facilitation of degradation of misfolded proteins. CaSR trafficking 
is dynamic and it undergoes ADIS where the intracellular pool of CaSR is mobilized to the plasma 
membrane due to exposure to Ca2+ [115, 116]. ER chaperones and regulators are dependent on the 
optimal Ca2+ER concentration for proper post-translational processing, folding and export of 
proteins [160] [161], and Ca2+ER concentration depletion is known to inhibit the proteins involved 
in folding and maturation. The gene ontology study showed that Ca2+ enriched the protein 
processing in the ER pertaining to protein folding and ER unfolded protein response. In keeping 
with our results, we propose that the treatment of Ca2+ as compared to EGTA manifests in the 
enrichment in proteins involved in the co-translational translocation and calnexin cycle in the ER, 
anterograde and retrograde trafficking in the ERGICs and degradation pathways in the cytosol 
[162]. Signal recognition particle (SRP) receptor is enriched by 17 folds and it may direct nascent 
CaSR polypeptides to the Sec complex (enriched by 2.5 folds) on the ER membrane. After the 
release of SRP and SRP receptor, the polypeptide signal sequence is known to be processed by 
signal peptidase (SP) complex. Oligosaccharyl transferases (OSTs: DDOST and RPN1/2, enriched 
by 2-4 folds)) and palmitoyl-transferase (SPTLC1, enriched by 7 folds) which catalyzes the 
transfer of oligosaccharides are identified as CaSR interactors. Glycosylation blocker, tunicamycin 
has been shown to impede the anterograde trafficking as well [14]. We can concur that enrichment 
of SPTLC1 interaction with CaSR could be a result of overall upregulation of its expression as 
observed in total cell lysate. HSPA5/GRP78 is a major ER chaperone and its expression level has 
direct impact on compensatory activities of mitochondrial and ER [163]. In this study GRP78 is 
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enriched by 5 folds and may direct CaSR polypeptide to ER lumen where glucosidases (GANAB, 
enriched by 1.7 folds) catalyzes the removal of outermost glucose residues. Next, polypeptides 
undergo calnexin cycle where lectin chaperones, calnexin (CANX, enriched by 1.6 folds) and/or 
calreticulin (CLTC) along with GRP78 which can promote proper folding by preventing 
aggregation and premature export from the ER. Calnexin is known to have high Ca2+ binding 
affinity [164] and is known to interact transiently with varieties of soluble non-native conformers 
of glycoproteins. Calnexin cycle also contain PDIA3. It is a protein disulfide isomerase which 
catalyze the disulfide formation  [165] and is enriched by 3 folds in the presence of Ca2+. This step 
follows the cleavage of the innermost glucose by glucosidase and release of the CaSR from the 
calnexin-cycle. UGGT, a glucosyl transferase acts as a checkpoint where improperly folded CaSR 
is re-glucosylated and this enzyme is enriched by 22 folds in the presence of Ca2+.  
The properly folded CaSR exits the ER through anterograde trafficking to the Golgi assisted 
by VAP family proteins, VAPA (enriched by 43 folds) and VAPB (enriched by 5 folds) and by 
chaperone protein, p24A (enriched by 7 folds). p24 family is a type 1 transmembrane protein which 
interacts with cargo and COPI or COPII coatomers and have been shown to interact with CaSR as 
a limiting factor in CaSR trafficking in the early secretory pathway and suggested to assist in 
transportation to and from the ERGIC [136].  p24A is not presented in the 106-list due to low PSM 
of 1. VAP-A/B are involved in vesicle trafficking, membrane fusion, protein complex assembly, 
and cell motility [166]. VAPA is known to be involved in androgen receptor and oxysterol-binding 
protein related protein 3 trafficking from the ER [144]. Similarly, in the previous study, VAPB 
was identified as interactors of glucagon [132] and melatonin receptor type 1A [133]. Rabs are 
ubiquitously expressed, largest monomeric small GTPases and are involved in vesicle mediated 
transport including targeting, tethering and fusion of transport vesicles with acceptor membrane 
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[167]. Rab- 1, 7 and 11a are known CaSR interactors [145, 146]. Rab6 is associated with retrograde 
translocation from the Golgi to the ER and intra-Golgi transport [168] and are enriched by 4 folds 
in the presence of Ca2+. Another protein involved with CaSR trafficking through ERGIC is 14-3-
3 proteins. 14-3-3 family are known to play important role in regulation of cell signaling events 
and cellular trafficking [142, 143]. They have negative roles in CaSR dependent SRE activation 
through CaSR tail binding and 14-3-3 ζ has distinct function in lowering CaSR membrane 
expression [116, 135, 169]. Interestingly presence of extracellular Ca2+ decreased 14-3-3 proteins 
interaction with CaSR. We show that 14-3-3 (ζ, θ and ε) binds CaSR in Ca2+ dependent manner 
and may retains CaSR to ER in the absence of Ca2+ by disruption of the contact. 
Finally, terminally misfolded CaSR proteins may undergo ER associated degradation by 
ubiquitination through E3 ligases. GPCRs are known to undergo agonist-induced ubiquitination 
leading to internalization and lysosomal degradation [170]. E3 ubiquitin ligases, STUB1/ CHIP 
and RanBP2 were found to be enriched by 1.7 and 21 folds, respectively. Several GPCRs 
including, adenosine, dopamine-, P2Y, PAR1, glucagon, GABA, mGluRs and CaSR receptor are 
known to interact with various ubiquitin [170]. Recent work by Mukherjee et al. has reviewed the 
Ca2+ dependent regulation of ubiquitin and role of calcium binding protein such as CaM in its 
regulation [171]. Our result complements their list by adding Ca2+ dependent interaction of 
RanBP2 and STUB1 to CaSR. The desensitization of CaSR occurs through endocytosis from the 
plasma membrane by Ras-related proteins and clathrin heavy chain (CLTC). In this study, we show 
an enrichment of Ca2+ dependent regulators of endocytosis: Rab5, Rab18 and CLTC by 17, 3 and 
2 folds, respectively. Rab5 is known to be involved in modulation of half-life of clathrin-coated 
pits on plasma membrane forming the vesicle [172]. Additionally, Rab5 also regulates the 
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attachment of early endosomes to and the motility along the microtubules [173]. Rab18 is also 
involved in apical endocytosis/recycling during early endosome [174].   
Our study identifies several HSPs as CaSR interactors such as Hsp-A1A, A6/7, A8, 
90AA1and 90AB1. Heat shock proteins (HSPs) are a family of molecular chaperones that bind 
transiently and assist in folding, stabilization, translocation and degradation of target proteins 
[175]. In previous studies, increased expression of Hsp70 is shown to reduce agonist but not 
antagonist binding to the alpha2A adrenergic receptor (α2A-R), therefore, providing an evidence 
for uncoupling of GPCR from G-proteins during cellular stress [147]. In our experiment, Hsp may 
act as a switch to suppress the prolonged activation of CaSR to promote survival of the cells. 
Proteins involved in the Ca2+ handling and in early events in apoptosis in the mitochondria/ER 
including, VDAC, TIMM50, PGRMC1 and NDUFA4 were enriched in our experiment in the 
presence of Ca2+ [176, 177]. These results infer that CaSR mediated Ca2+ signaling may allow for 
the intracellular CaSR to associate directly or indirectly with modulators of Ca2+ handling in the 
ER and mitochondrial membrane.  
The proteins we have identified fall into the categories of proteins associated with functions 
mentioned in the review by Wu et. al. where it points out several distinguishing characteristics of 
GPCR trafficking to the plasma membrane. Cell surface targeting is involved with (1) proteins 
such as RAMPs, ER chaperones and accessory proteins which assist in stabilizing receptor 
conformation, facilitating maturation and promoting delivery to the surface [178-180], (2) post-
translational modifications, such as N-liked glycosylation, are known to be associated with GPCR 
delivery to the plasma membrane [181]. (3) GPCR cell surface targeting is associated with 
microtubule networks [182] and that GPCR  interact with tubulin for cell-surface movement [183]. 
(4) GPCR folding/assembly as well as its ability to pass through the ER quality-control system 
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may be influenced by dimerization [7]. (5) Specific motifs embedded within the receptors direct 
the exit of GPCRs from the ER [178, 184, 185].  
Some other proteins known as GPCR binding proteins are PGRMC1 and IRS4 which are 
directly or indirectly associated with various cellular pathways. IRS4 belongs to insulin receptor 
substrate (IRS) family [186] and is localized in the cytoplasm. It is known to recruit and activate 
various adapter molecules or enzymes, such as phosphoinositide 3-kinase (PI3K) and mitogen-
activated protein kinase (MAPK) to facilitate glucose uptake [187, 188], lipid metabolism [189] 
and cell proliferation [190] upon insulin stimulation. It also binds to ubiquitin-specific protease 18 
(USP18) in nucleus to diminish the blunting effect of USP18 on IFN-a-induced Jak/STAT 
signaling [191]. LRRC59 facilitates transport of cytosolic fibroblast growth factor 1 (FGF1) 
through nuclear pores by interaction with Kpns and movement of LRRC59 along the ER and NE 
membranes [192]. 
The Co-IP assay developed and used for generation of the putative CaSR interactors is an 
improvement as compared to the previous attempts made till 2017. There was a marked increase 
in the number of unique peptides for CaSR detected from 12 with Dr. Wu in Georgia Tech and 10 
with Dr. Zhou from Clark Atlanta University to 52 with Dr. Seyfried in Emory. A crucial aspect 
to note is that the antibody used in the latter case was anti-FLAG antibody as compared to anti-
ADD CaSR antibody for endogenous CaSR in 5001 in previous cases. This increased IP points 
out that the specificity of an antibody plays the most crucial role in the success of IP as well as Co-
IP. In order to study the endogenous CaSR, especially in the pathological cells, it would require 
additional optimization with anti-CaSR antibody. A new CaSR antibody is being developed 
currently in rabbit using CaSR ECD protein that will have greater affinity than the anti-ADD CaSR 
antibody. Steps such as amount of antibody, amount of antigen, time of incubation and stringent 
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washing steps need to be considered for optimization. The optimization I have attained improved 
not only is the detection but also decreased the amount of cells and the number of plates used from 
initial ten to one plate per treatment. This has cut the cost of the experiment as well as manual 
labor. Additionally, prevention of loss of sample was optimized. In gel digestion, using Thermon 
kit, membrane/cytosol extraction kit, UFLC separation, or cross-linking proved to decrease the 
detection, most possibly due to sample loss during the dilutions resulted by extensive steps. 
We can say that with all the strategies applied, our experimental approach is not a complete 
snapshot of the putative CaSR interactome. Several limitations exist which may explain the 
incomplete recruitment of protein complexes and the absence in the detection of some of the 
known CaSR partners in our experiment such as some of the g-proteins. Our whole cell lysate 
MS/MS result validate that G-proteins including Gq/11, Gi1, Gi3, Gs, Gγ12 and Gγ5 are expressed 
at low abundance in cells with an average PSM count of less than 1 and the Gi2, Gβ2, and Gβ2-
like-1 proteins have higher average PSM counts of 3-27, therefore, resulting in robust detection. It 
is known in previous studies that it is a challenge for the G-protein detection and have been 
observed in natural membrane environment with intact receptors using tandem affinity purification 
[133]. Further, our result supports earlier study of CaM interaction with CaSR in intracellular Ca2+ 
dependent manner which was missing in our study [3]. Similarly, filamin A and B were detected; 
filamin A with more robust PSM between (6-46) and was enriched in the presence of 4 mM Ca2+. 
However, there was no significant change between the positive and negative controls, implying an 
un-specific enrichment of abundant filamin (total lysate MS/MS had high average PSM count of 
80). CaM is known to bind to the same binding region as the filamin-A or Gβγ -subunits within 
the mGluR7a C terminus [193]. This could be the reason why we only detected Gβγ -subunits. 
Additionally, we observe incomplete immunoprecipitation of total CaSR (Figure S3) which may 
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result in the incomplete picture. Also, the enrichment we observe are relative quantification and 
may be affected by binding affinities and may not directly co-relate with the function. Further, we 
can also not negate the fact that the putative CaSR binding partners detected may be due to direct 
or indirect interactions. Further studies and validation are warranted to examine the mechanism of 
each interactors individually.  
For future work, it is necessary to obtain CaSR monomer in order to achieve a distinct 
detection of the IP and Co-IP and for detection of ubiquitination. Also, assay needs to be developed 
for avoiding heavy and light chain of antibody in order to prevent overlap between them and the 
protein of interests. This initial information attained on putative CaSR interactors provides 
multitude of novel pathways that CaSR is biologically involved in such as the CHIP ubiqitination, 
role of VAPA trafficking, sumolyation of CaSR by RanBP2, endocytosis by Rab5C, etc. The 
immuno-fluorescence and western blot of the Co-IP results suggest the co-localization and 
interactions of CaSR with interactors such as CHIP, GRP78 and 14-3-3 eta proteins. However, the 
role of extracellular Ca2+ on these interactions are not apparent. Additionally, the location of the 
interactors has to be analyzed and we hypothesize that these would be present in ER/Golgi region 
at higher Ca2+. Secondly, the trafficking mechanism needs to be deciphered by focusing on the 
role of Ca2+ on the interaction of specific proteins in ER vs those in ER/Golgi for anterograde and 
retrograde trafficking.  
 
2.8 Major conclusion 
Sustained Ca2+ increase in cytosol can induce mitochondrial meditated apoptosis via 
protein such as calcineurin or by mitochondrial Ca2+ overload [194]. Therefore, protein 
homeostasis is directly altered due to [Ca2+] regulation in the ER and cytosol. This is presented 
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during several diseases including diabetes mellitus, vascular and neurological diseases [195], and 
therefore, regulators for Ca2+ handling and trafficking can be used as novel therapeutics target. In 
this study we have been able to provide the first protein-protein interaction network for CaSR at a 
larger scale. Our work surmises the role of Ca2+o and CaSR in modulating the proteome expression 
levels which may have manifested due to differential signal transduction mediated by activation 
of CaSR via Ca2+o, changes in regulatory proteins maintaining Ca
2+ homeostasis and stimulation 
of cellular activities such as the trafficking of CaSR itself to various compartments. Known CaSR 
and GPCR interactors novel for CaSR re-validates our work and indicates overlapping signaling 
cascade and trafficking. 98 novel putative CaSR interactors were identified. The results recognized 
distinct effect of Ca2+o on CaSR interactions with 65% enriched by Ca
2+
o involved in processing in 
the ER. Whereas, 31% Ca2+o independent interactors were involved in ribosomal pathway.  The 
results demonstrated that the 14-3-3 proteins interaction with CaSR is negatively correlated with 
Ca2+o. The first protein-protein interaction (PPI) network obtained had strong confidence of 0.551 
and a PPI enrichment P < 1.00E-16. Additionally, the identified novel regulators and pathways for 
CaSR that are extracellular Ca2+ signaling dependent were co-translational translocation (SRP, 
Sec61, GRP78), ubiquitination (CHIP), calnexin cycle, glycosylation, trafficking, endocytosis and 
calcium handling. Taken together, this study offers an insight into the interconnection of GPCR 
function, intracellular trafficking, and potential targets for Ca2+ homeostasis related pathogenesis 
of diseases. Additionally, this study may offer an insight into the overall GPCR function, 




3 CHAPTER III: CHARACTERIZATION OF CALCIUM-SENSING RECEPTOR 
MEDIATED SIGNALING IN HEK293 AND THYROID CANCER CELLS 
 
3.1 Abstract  
   CaSR a class C, G-protein coupled receptors (GPCR) regulates Ca2+ and Mg2+ 
homeostasis which are indispensable processes that regulate multitude processes in cells for 
normal functioning. More than 400 mutations in CaSR are associated with abnormal metal 
homeostasis, including familial hypocalciuric hypercalcemia (FHH), neonatal severe 
hyperparathyroidism (NSHPT), and autosomal dominant hypocalcemia (ADH). Moreover, CaSR 
is intimately associated with various cancers. The systemic Ca2+ homeostasis through CaSR is 
mediated by three hormones, namely, calcitonin (CT), parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D3 (1,25-(OH)2D3). In this work, we first study intracellular Ca
2+ response 
facilitated by CaSR activation via extracellular Ca2+, Mg2+ and tryptophan derivative (l-1,2,3,4-
tetrahydronorharman-3-carboxylic acid, TNCA) in HEK293 cells with transfected wild type 
(human parathyroid) CaSR. EC50 of CaSR for Ca
2+ was 4 mM with a Hill number of 3 and for 
Mg2+ EC50 was 13 mM and Hill number of 2.9. Presence of 0.5 mM and 1.5 mM Ca
2+ was able to 
influence the potency of Mg2+ by decreasing EC50 for Mg
2+ to 7.5 and 5.9 mM respectively, which 
proved the cooperative nature between Ca2+ and Mg2+. Moreover, TNCA was able to act as a co-
agonist and reduce the EC50 for both Ca
2+ and Mg2+, but more significantly for Mg2+ by 2.5 folds. 
Oscillation study with site-directed mutations at the highly conserved Mg2+ binding sites derived 
from CaSR crystal structure, which overlap the ADH related residues, E228I and E229I, resulted 
in impediment of the Ca2+/Mg2+ CaSR sensing as well as CaSR mediated Mg2+ evoked Ca2+i 
mobilization and Ca2+ oscillation.  
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Coupling and regulation between extra- and intra- cellular Ca2+ sensing and calcitonin is 
imperative in endocrine cells such as the C cells. Calcitonin maintains the systemic Ca2+ 
homeostasis by inhibiting the function of bone-resorbing osteoclasts, increasing Ca2+ excretion by 
kidneys and stimulation of calcitriol (1,25-(OH)2D3) production. Ca
2+ sensing through voltage 
gated channel have been extensively studied in C-cells, including rat and human medullary thyroid 
cancer cells (6-23, TT, respectively) but contradictory and little information is known about CaSR 
mediated Ca2+i response due to extracellular Ca
2+. Cell lines derived from tumors represent a 
critical tool to understand the oncogenic mechanism as well as preclinical tool to understand to 
study efficacy of new therapies in vitro and in vivo. We report an altered CaSR expression level 
with four-fold lower expression in both 6-23 and TT cells as compared to wild type CaSR stably 
transfected in HEK293 cells (5001) or transiently transfected in HEK293 cells. Moreover, CaSR 
in 6-23 displays oligomer and lacks monomers even in reducing condition unlike CaSR in TT and 
the wild type. CaSR surface expression of CaSR in both C cells is low relative to the cytosolic 
CaSR or membrane expression in 5001 and transiently transfected wild type CaSR in HEK293 
cells. We examined the endogenous CaSR mediated intracellular Ca2+ response pattern at various 
extracellular Ca2+ concentrations and monitored the changes with the use of CaSR allosteric 
agonist (cinacalcet) and antagonist (NPS-2143). We further investigated the role of calmodulin 
(CaM), a CaSR regulating protein, by monitoring the intracellular Ca2+ response pattern with CaM 
inhibitor, W7, treatment. TT cells demonstrated CaSR mediated transient peaks at 5 and/or 7.5 
mM extracellular Ca2+ by < 30 % of the cells (n=23). Whereas, addition of 10 µM cinacalcet 
evoked the transients at 2 mM Ca2+ in 88% of the cells and resulting in 40% increase in the 
amplitude as compared to other treatments (n=24). NPS2143 was able to inhibit the Ca2+ response 
at 7.5 mM and preincubation with 50 µM W7 was able to impede the agonistic behavior of 
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cinacalcet, clarifying the case that cinacalcet and W7 have additive effect on one mechanism, the 
CaSR mediated signaling.   
 A highly non-synchronous CaSR mediated oscillatory behavior was revealed in 6-23 cells. 
These cells contained a mixture of CaSR with variable activity, some with low EC50 for Ca
2+ at 
0.5 mM and a lower Hill number of 1.5 and some that were un-responsive to Ca2+. Using R-
programming, Ca2+i were quantitated. We report that cinacalcet can up-regulate the Ca
2+
i response, 
percentage of cells responding and increase oscillation frequency. Pre-incubation with W7 is able 
to down-regulate the effects of cinacalcet. NPS-2143 was unable to completely inhibit Ca2+i 
response, suggesting an alternative Ca2+ sensing mechanism. Interestingly, CaSR in both the C 
cells were selective to Ca2+ and not to Mg2+ implying biased signaling. These results (1) validates 
the oscillation and transient peaks were partially but to a greater extent CaSR mediated in C- cells 
and (2) establishes role of calmodulin in CaSR mediated signaling. Our findings provide an 
important insight into potential differential modes of modulation of intracellular Ca2+ signaling 
and thereby, control of calcitonin, through regulation of endogenous CaSR activation in 
pathologies related to dysregulation of Ca2+ homeostasis.  
3.2 Introduction  
3.2.1 CaSR mediated signaling and oscillation  
Various Gα proteins, such as Gαi, Gαq/11 and Gα12/13, associated with CaSR intracellular 
loops carry out diverse signaling and biological effects in cells. CaSR inhibits adenylyl cyclase 
and activates extracellular signal-regulated kinase (ERK) through Gαi and phospholipase C is 
activated through Gαq, therefore, increasing intracellular Ca
2+, diacyl glycerol (DAG) levels and 
activating phospholipase A2. Finally, Gα12/13 activated Rho and phospholipase D [55]. CaSR 




This results from the Ca2+ release from ER which is triggered by GPCR mediated phospholipase-
C derived inositol 1,4,5-triphosphate (IP3) [196] and Ca
2+ entry through the store operated channels 
in cell membrane [197]. IP3 is generated by cleavage of phosphatidylinositol 4,5-bisphosphate and 
it binds to IP3 receptors (IP3Rs) on the membrane of the ER/SR which allow for a rapid flow of 
Ca2+ out of the ER/SR, and a consequent rise in cytosolic [Ca2+cyt]. Cytosolic Ca
2+ concentrations 
([Ca2+]cyt) in resting cells are maintained at levels ranging from 1,000-10,000 times lower than 
extracellular concentrations. This gradient across the plasma membrane required to maintain Ca2+i 
homeostasis and regulate Ca2+ signaling involves influx of Ca2+ from the extracellular medium via 
Ca2+ channels. The release or sequestration of internal Ca2+ levels within internal Ca2+ stores (ER 
or SR) is mediated by the IP3 receptors (IP3R) and the ryanodine receptors (RyR), and cytosolic 
Ca2+ homeostasis is further maintained by the actions of proteins, including the plasma membrane 
Ca2+-ATPase (PMCA), the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), the 
secretory pathway Ca2+-ATPase (SPCA), and the Na+/Ca2+ exchanger (NCX), among others. 
Therefore, the two major mechanisms namely, Ca2+ induced Ca2+ release (CICR) from ER/SR and 
Ca2+ release induced Ca2+ entry from plasma membrane regulate the oscillation. This characteristic 
oscillation is known to be varied depending on the cell type and conditions.  
3.2.2 Thyroid cancer  
Thyroid cancer is more common in women than in men (3 out of 4 cases) and occurs 
between the age of 25 and 65 years old (https://www.cancer.org/cancer/thyroid-cancer/about/key-
statistics.html) . About 2% of thyroid cancers occur in children and teens. About 52,070 new cases 
of thyroid cancer (14,260 in men and 37,810 in women) and about 2170 deaths from thyroid cancer 
(1020 men and 1150 women) were estimated in United States for 2019.  Medullary carcinoma of 
the thyroid comprises of around 4% to 10% of all thyroid cancers in the United States [198].  
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3.2.3 History of calcium-sensing mechanism in medullary thyroid cancer cells 
Medullary thyroid cancer (MTC) is derived from parafollicular thyroid C-cells. C-cells 
from thyroid gland is one of the most prominent CaSR expressing homeostatic tissues. ~ 75% to 
95% patients with medullary thyroid cancer show a thyroid nodule in the upper portion of the 
gland where C cells are located [198]. ~ 70% will have cervical lymphadenopathy and few patients 
will show symptoms of dysphagia, hoarseness, or respiratory difficulty [198]. These cancers do 
not respond to radioactive iodine (RAI; as they do not express sodium-iodine symporter) [199], 
conventional chemotherapy or suppressant to thyroid stimulating hormone (TSH, as C cells do not 
contain the receptor) [198]. The management of this cancer is through total thyroidectomy [198] 
or the metastatic and progressive MTC is managed by FDA approved kinase inhibitors with 
significant side effects [200, 201]. This ailment results in hyperparathyroidism and hypercalcemia. 
Imaging modalities such as magnetic resonance imaging, ultrasound and computed monography 
are not sensitive enough to determine [199]. Therefore, further understanding of its biological 
mechanism of the pathology in C-cells is warranted in order to develop better treatment conditions. 
The C-cells produce a hormone called calcitonin (CT) which is a biochemical marker for 
MTCs [199]. CT along with parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 (1,25-
(OH)2D3) are three hormones that regulates cellular Ca
2+ homeostasis. CT works opposing to PTH. 
PTH increases the serum calcium by enhancing bone resorption and absorption of calcium from 
the gut and reducing renal calcium excretion [202], on the other hand, CT reduces serum Ca2+ by 
inhibiting the function of bone-resorbing osteoclasts, increasing Ca2+ excretion by kidneys and 
stimulation 1,25-(OH)2D3 production [203-205]. CT is the only hormone known to decrease serum 
Ca2+ in humans [6]. It is found that patients with MTCs have high serum calcitonin level due to 
the consequence of the disease. Massively elevated levels of serum CT is found in MTCs and no 
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detectable hypocalcemia or influence on bone-mineral density is found [6, 206]. CaSR in C cell 
mediates Ca2+o evoked stimulation of this hypocalcemic hormone, CT [207]. It is also known that 
CT hypocalcemic action is species specific where the action is greater in rodents than humans 
[207]. Apart from CaSR, L-type calcium channel is known to sense Ca2+ in C cells [6]. There have 
been many contradicting studies conducted on two established MTC cell lines, namely, with 
human medullary thyroid carcinoma cell line TT and rat medullary thyroid carcinoma cell line 6-
23 [208]to understand the Ca2+ sensing and CaSR mediated intracellular responses.  
3.2.3.1 TT cells 
The TT cells resemble parafollicular C cells and calcitonin secretion is shown to be present 
[209]. In a study by Haller-Brem et al. in 1987 show that TT cells are Ca2+ insensitive where 
neither Ca2+i nor CT is affected by extracellular Ca
2+. In TT, the rise of Ca2+ from 0.5 to 3 mM 
does not affect the Ca2+i, CT and calcitonin gene-related peptide (CGRP) (Figure 3.1) [13]. On 
the contrary, CT and CGRP release were shown to be dose-dependent on Ca2+i in TT only when 
electropermeabilized or when ionomycin was used [13]. Ionomycin is able to mobilize Ca2+ from 
intracellular stores. This indicates a defect in the Ca2+ signal transduction in the TT cell line, lack 
of extracellular Ca2+ sensitivity resulting in defective Ca2+i release, but not the intracellular Ca
2+ 
sensitivity. TT cells were shown to lack voltage-dependent L-type calcium channels and DHP-
sensitive voltage-dependent Ca2+ channel (Figure 3.2) [6, 210]. It has been shown that TT cells 
display DHP-insensitive, voltage-dependent Ca2+ channel with low activation threshold and fast 
inactivation kinetics [211]. These depolarization-induced voltage-dependent Ca2+ currents are 
quickly inactivated unlike that in 6-23 cells. Also, no conductivity is observed through the T-type 
Ca2+ channels [6]. A physiological level of Ca2+ cannot elicit any action potential and/or depolarize 
TT cells [211]. Only in 1996, Freichel et al showed the involvement of CaSR in Ca2+ sensing in 
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TT where a truncated CaSR variant, CaSRb with 5.4 kilobase mRNA was identified [212]. 
Contrary to earlier mentioned studies, this study showed Ca2+i transients and/or oscillation to 3 
mM Ca2+o and CaSR agonists including, Gd
3+, La3+ and neomycin as monitored by Fura-2 [212]. 
Additionally, calcitonin increase was observed with 3 mM Ca2+o with an added time course and 
with La3+ and Gd3+ in dose-dependent manner. Moreover, recent work by Desai et al in 2014 
showed that healthy TT cells displayed higher intracellular Ca2+ to 1.5 mM Ca2+ in the presence 
of cinacalcet and neomycin (CaSR agonist) than the TT cells with siRNA knockdown of RAMP 
(receptor activity modifying protein), a CaSR regulator [16] as monitored using Fluo-4AM 
(Figure 3.3). Ca2+ sensing at higher Ca2+o concentration is missing in these studies.  
3.2.3.2 Rat MTC cells 
6-23 cells respond to rise in Ca2+ from 0.5 to 3 mM with a transient intracellular Ca2+ peak 
[13] and an increase in CT and calcitonin gene-related peptide (CGRP) (Figure 3.1). Another 
study by Eckert et al in 1989 showed that pre-incubation of 6-23 cells with 1 µM glucagon or 1 
mM 8-bromo-cAMP caused intracellular calcium oscillation when Ca2+o was raised to 3 mM but 
only showed a simple biphasic response with 3 mM Ca2+ alone [213]. These oscillations were 
perturbed by using EGTA to chelate Ca2+o or by addition of calcium channel blocker to block 
voltage-dependent calcium channels (Figure 3.2) [213]. Both 8-bromo-cAMP and glucagon 
induced cAMP pathway activation through Gs. Non-inactivating dihydropyridine (DHP)-
sensitive, high threshold Ca2+ channels couple the intra and extra- cellular Ca2+ in 6-23 cells [211]. 
Extracellular Ca2+ sensitivity saturates at 3-4 mM Ca2+ and declines with higher extracellular Ca2+ 
[6]. A study by Thomsen in 2012 examined the biased CaSR mediated signaling in 6-23 cells 
[214]. Six CaSR mediated signaling were studied including Gq/11, Gi/o, Gs, extracellular signal-
regulated kinases (ERK1/2), Ca2+i mobilization and calcitonin secretion [214]. They showed that 
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strontium as compared to calcium biases the signaling to ERK1/2 and another pathway 
independent of Gq/11 and Ca2+ mobilization [214]. There was also increased potency of strontium 
to mediate CT secretion and possibly using a different signaling mechanism than calcium [214]. 
These studies were primarily based on response to calcitonin, IP1 and cAMP secretion.   
Figure 3.1  Effect of extracellular Ca2+ on intracellular Ca2+, CT and CGRP in rat MTC 6-
23 cell and human MTC TT cells. [13] 
TT cells are Ca2+ insensitive where neither Ca2+i nor CT is affected by extracellular Ca
2+. In 
TT, the rise of Ca2+ from 0.5 to 3 mM does not affect the Ca2+i, CT and calcitonin gene-
related peptide (CGRP). On the contrary, CT and CGRP release was shown to be dose 
dependent on Ca2+i in TT only when electropermeabilized or when ionomycin was used. 
Ionomycin is able to mobilize Ca2+ from intracellular stores. This indicates a defect in the 
Ca2+ signal transduction in the TT cell line, lack of extracellular Ca2+ sensitivity resulting in 
defective Ca2+i release, but not the intracellular Ca
2+ sensitivity. Rat MTC 6-23 cells respond 
to rise in Ca2+ from 0.5 to 3 mM with a transient intracellular Ca2+ peak and increase in CT 
and calcitonin gene-related peptide (CGRP). 
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MTC cells have varying Ca2+ sensing characteristics. In 1991, Fajtova et al used rMTC 44-
2 cells to show that at basal state of Ca2+ at 0.5 mM resulted in cytosolic Ca2+ at 53 nM with 27% 
cells having spikes or oscillations (Figure 3.5) [12]. With changes of Ca2+o from 0.5 mM to 4 mM, 
84% cells showed rise in Ca2+i by 2- to 10- folds as monitored by Fura-2 [12]. These responses 
were hampered by Ca2+ channel blockers cadmium and nifedipine (Figure 3.4) [12]. Also 20 mM 
K+ elevation resulted in similar waveform [12]. Both results suggest the presence of voltage-gated 
Ca2+ channel in rMTC 44-2 cells. These cells displayed complicated Ca2+i oscillations ranging 
from < 1/min to 1/min. They suggest that the discrepancy between the rMTCs, 44-2 and 6-23, cell 
lines could have resulted due to culture conditions or differential Ca2+ sensing mechanism. 
Moreover, rMTC 44-2 cells are known to show no IP1, IP2 or IP3 generation when Ca
2+ is increased 
above 1 mM [6]. This result further pointed to the possibility that oscillation is mediated by 
voltage-gated channel rather than IP3, or cAMP. Also, 44-2 cells showed a 9-kilobase mRNA of 
Figure 3.2  Ca2+ channel in 6-23 and TT cells [6].  
Changes in extracellular Ca2+ within physiological range do not affect membrane 
potential of TT cells.  6-23 cells respond to 1.2-1.8 mM Ca2+ that elicits action potentials 
and or depolarizes cells by ~ 10 mV. Ca2+ channel blocker isradipine (PN) and agonist 
Bay K 8644 (Bay) were used to explore the channel activity. The results state that TT lack 
extracellular Ca2+ sensitive channel as compared to 6-23 cells.  
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full CaSR [6]. Additionally, primary parafollicular sheep cells also has shown that CaSR activation 
results in increased intracellular Ca2+ and L-type calcium channels are responsible for this increase 
[45].  
 
Intracellular calcium mobilization caused by extracellular calcium is the key event in CT 
secretion in 6-23 cells as demonstrated by inhibition of 82% vs 48% calcitonin when stimulated 
by Ca2+ and Sr2+, respectively in the presence of BAPTA-AM (calcium chelator) and absence of 
Figure 3.3  TT cells show intracellular Ca2+ modulation to 1.5 mM Ca2+ with CaSR 
agonists 1 µM cinacalcet and 100 µM neomycin as monitored by Fluor-4 and RAMP 
knockdown attenuates the signal [16] 
Figure 3.4  Involvement of Ca2+ 
channels in rMTC 44-2 cells as shown 
through attenuation by channel 
blockers Cd2+ and Nifed  [12] 
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extracellular Ca2+ [214]. Similarly, in TT cells CT is shown to be dose-dependent on La3+ and Gd3+ 
whereas CT increased at 3 mM Ca2+ with increasing time course. Interestingly, rMTC 44-2 cells 
are known to have no sensitivity to Mg2+ [215]. Additionally, sheep parafollicular primary C-cells 
were used to study the Ca2+ sensing varying potency of CaSR activation by various divalent cations 
was shown such that Gd3+>Ba2+>Ca2+>>Mg2+ [45]. This paper also indicates the role of L-type 
voltage-gated channel and Gq/11 in the response to extracellular calcium by using channel blocker 
nimodipine and phosphatidylcholine PLC inhibitor, D609, respectively [45]. This study monitored 
serotonin (5-HT) and phospho-kinase C for CaSR mediated signaling response. The reduced Mg2+ 
sensitivity in the light of 92% sequence similarity between rat and bovine CaSR and intact Ca2+ 
binding sites could be resultant of tissue specific post-translational modifications or differential 
CaSR regulatory protein. This work also suggests that MTC cells as compared to the parafollicular 
primary cells are more excitable like neuron cells.  
 
Figure 3.5   Intracellular Ca2+ response to extracellular Ca2+ in rMTC 44-2 cells show 
heterogenous response [12] 
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Two of the major intracellular signals in C cells are intracellular Ca2+ and cAMP which are 
closely coordinated with cellular function [6]. The efficiency of signal transduction can be 
modified through modulation in receptor number, receptor function, desensitization or antagonistic 
or synergistic interactions between different signaling systems [216]. It has been found that 
increase in IP1, IP2 or IP3 is absent with extracellular Ca
2+ treatment above 1 mM in 44-2 cells 
[217]. It is to note that Ca2+ flux can be regulated by phosphorylation of Ca2+ channels or 
component linked to protein kinase such as voltage-dependent channel, cAMP-dependent 
phosphorylation or phosphorylation of G-protein [6]. Mechanism underlying complex oscillation 
in intracellular Ca2+ is still obscure.  
Many of these studies have been conducted using various calcium sensors such as Fura-2 
and fluor-4 or by using various inhibitors and methodologies. This could result in a discrepancy 
between the studies. In our work, we investigate the study of endogenous CaSR mediated Ca2+i 
response mechanism further in the thyroid cancer C-cells using Fura-2 due to various Ca2+o 
concentrations from 0 to 20 mM and effect of CaSR associated agonist and antagonist. We use 
single-cell imaging and have aimed at understanding the role of CaM in CaSR mediated Ca2+ 
signaling in C cells.  
3.2.4 CaSR and CaM 
CaM (CaM) is an intracellular protein that is dependent on changes in cytosolic Ca2+ levels 
and in turn, regulates numerous Ca2+-signaling activities. It has two globular domains which 
contain two cooperatively paired EF-Hand motifs, allowing it to bind up to four Ca2+ ions [218]. 
The EF-hand site contains 29-residue helix-loop-helix structure which is highly conserved. The 
Ca2+ binding site consists of twelve residues out of which those in relative positions 1, 3, 5, 7, 9 
and 12 coordinates Ca2+. The equilibrium between conformational states and the interaction with 
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the target proteins is made possible by the apparent flexibility of trans-domain linker region 
(residues 76-84). The Ca2+-CaM complex regulates biological processes associated with signal 
transduction, cell division, nerve growth, cell death, inflammation, memory, immune response and 
muscle contraction. The CaM reversibly or irreversibly binds its targets which possess regions of 
net positive charge, moderate hydrophilicity and moderate to high helical hydrophobic moments. 
Targets for holo-CaM contain amphipathic α helices with two suitably spaced and oriented 
hydrophobic anchors which can insert into the methionine rich pockets [219]  and utilizes both N- 
and C-domains. CaM plays an important role in the calcium-signaling network, the extent of which 
remains to be fully mapped and understood.  
3.2.5 CaM mediated GPCR signaling   
An ionotropic glutamate receptor family (iGluR) called N-methyl-D-aspartate (NMDA) is 
a fundamental receptor involved in synaptic plasticity, LTP, learning and memory. CaM is 
activated by the influx of Ca2+ through NMDAR subsequently, binding CaMKII. Additionally, the 
negative feedback loop produced by the Ca2+/CaM complexation inactivates the NMDAR receptor 
by displacing α-actinin from the C0 domain of the NR1 subunit of the receptor [220]. A G protein-
coupled receptor known as the metabotropic glutamate receptors (mGluR’s) bind the 
neurotransmitter L-glutamate for its activity. mGluR7 plays an important role in synaptic plasticity 
and neurotransmission in the CNS. PICK1 which regulates mGluR by recruiting PKCα for 
phosphorylation of mGluR7 at Ser-862 [221], competes with the Ca2+/CaM for the same binding 
site on mGluR7, where binding of the Ca2+/CaM complex releases G protein C-tail Gβ and Gγ 
units. Additionally, CaM regulates the activity of calcium-sensing receptor (CaSR), which belongs 
to the family C of GPCRs along with mGluR. Huang et al. in 2010 showed that CaM interacted 





[3]. CaM inhibitor, as well as CaMBD mutations, perturbed the oscillation pattern in a wild type 
(Figure 3.6). A potential CaSR- CaM binding domain (CaMBD) between 881-894 was predicted 
using the CaM binding domain database. This peptide at the C-terminus of CaSR was used to 
prove the interaction with CaM in 1-8-14 binding mode [3]. This binding was shown to affect the 
secondary and tertiary structure of this region. Most importantly, CaM had a significant effect on 
CaSR trafficking at the plasma membrane [3].  
CaM not only influenced the Ca2+o
 mediated signaling via CaSR, but also the L-Phe 
induced signaling. Zhang et al. in her (dissertation) work showed that with the incubation with 
W7, the L-Phe induced sinusoidal oscillation transitioned to transient peaks as monitored with 
single cells imaging using FURA-2 AMAM. Furthermore, confocal imaging of the ADIS induced 
Figure 3.6 Ca2+ oscillation of CaSR for CaMBD mutants and with the use of CaM 
inhibitor W7 in HEK293 cells transfected with the corresponding pcDNA3.1 . [3] 
CaMBD mutants decreased the oscillation frequency and W7 resulted in 
transient peak 
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by Ca2+ was in the presence of L-Phe was perturbed by W7. W7 also reduced the ERK1/2 activity 
induced by L-Phe. The Ca2+ induced internalization was not affected by the pre-treatment of W7 
with or without L-Phe. Various C-terminus CaSR mutants were generated: F881E/V894E, 
F881E/T888E, F881E/T888E/V894. Most HEK293 cells transfected with these mutants showed 
transient peaks as their responses to the increase of [Ca2+]o. The addition of L-Phe could not start 
the oscillation at lower Ca2+ or increase the oscillation frequency as in case of the WT. The work 
also showed a direct negative relation of the mutants with the filamin binding.  
3.2.6 CaSR-associated drugs 
3.2.6.1 Cinacalcet 
Cinacalcet (CCT) (Figure 3.7) binds to the transmembrane domain on CaSR and increases 
its potency and/or affinity of Ca2+ [222, 223]. It is the first calcimimetic approved by the Food and 
Drug Administration to treat patients suffering from secondary hyperparathyroidism in end-stage 
kidney disease [224]. Its side effect consists of hypocalcemic effect [225]. Studies show that CCT 
affected the distribution and trafficking of CaSR between the cell membrane and the endoplasmic 
reticulum rather than the biosynthesis of the receptor. CCT is an allosteric modulator of CaSR that 
increases the receptor’s sensitivity to Ca2+ by shifting the response curve to the left and has been 
reported to induce its effect at a lower concentration of Ca2+ at 1.2 mM [226]. The experiment 
indicated that long-term treatment of the cells with CCT caused the redistribution of CaSR from 
the cell membrane to the endoplasmic reticulum–nuclear area. CCT affected the distribution and 
trafficking of CaSR between the cell membrane and the endoplasmic reticulum rather than the 
biosynthesis of the receptor [226]. At full concentration Ca2+ of 1.2 mM, the receptor would 
already be occupied by its primary agonist, and therefore, the effect of CCT might be masked 
[226]. CCT treatment might cause apoptosis of the esophageal cells as it was described in other 
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cell types [227]. CCT mediated by CaSR was also shown to trigger intrinsic mitochondrial related 
apoptotic pathway, and this pathway is modulated by Bcl-xL anti-apoptotic pathway in prostate 
cancer cells [227]. 
3.2.6.2 NPS-2143 
NPS-2143 is a selective antagonist of CaSR with anticancer [92], and anti-inflammatory 
activities (Figure 3.7) [228]. It acts allosterically to dampen the sensitivity of CaSR to Ca2+ and 
therefore, shifts the EC50 to the right. It does not affect the PTH secretion at very low or high levels 
of Ca2+o, but they do stimulate secretion of PTH under normocalcemic conditions. It is a potential 
drug for osteoporosis. It has been studied that NPS 2143 is effective in promoting trafficking of 
CaSR mutants to the cell membrane, but it negatively modulates CaSR signaling [229]. There is a 
contradictory study where the drug did not cause any change [230] or reduced [231] the expression 
of CaSR gain of function mutants. This finding suggests that the effect of NPS 2143 is mutant-
specific. Additionally, NPS 2143 corrects the signaling defects in HEK293 transfected with Gα11 
mutated protein causing ADH2 and uveal melanoma.  
3.3 Challenges 
CaSR is a large membrane protein with 1068 amino acids. The presence of low endogenous 
expression of CaSR in cancer cells as well as heterogeneity is limiting when you are trying to 
characterize it and escalates the challenges for the bio-molecular techniques used in this chapter. 
CaSR experiences dynamic action involving folding, glycosylation, dimerization, trafficking, and 
Figure 3.7 Cinacalcet and NPS 2143 
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endocytosis. These dynamics causes variation in its molecular qualities. Lastly, CaSR has a 
multitude of binding partners involved in downstream signaling, therefore deciphering one that is 
causative of the differential signaling is almost impossible. There is a limitation of methods as 
well. The sensitivity of RT-PCR and PCR can be affected by many parameters such as primer 
specificity, heterogeneity of transcripts, annealing temperature, quality of RNA extracted, 
handling of RNA. Mass spectrometry data is affected by glycosylation, antibody specificity, 
sample handling 
 
3.4 Major Questions addressed in this chapter 
a) What is the characteristic wild type CaSR mediated Ca2+ signaling in HEK293? 
b) How do divalent cations and CaSR associated drugs impact the signaling? 
c) Do human and rat thyroid cancer cells respond the same way in terms of CaSR mediated 
signaling? 
d) Is the differential response due to expression level or presence of variants? 
e) Do the CaSR- and CaBP related drugs carry similar potency in all cell types?  
f) Can we use biostatistics to quantitate the difference?  
3.5 Materials and Method 
3.5.1 Cell culture and transfection 
HEK293, 6-23, TT cells were seeded on 22 × 40 mm coverslips in 60 mm culture dishes 
and cultured in 5% CO2 at 37 ºC in respective media. HEK293 cells were cultured in high glucose 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal bovine serum 
(FBS) with 100 μg/ml penicillin-streptomycin. 6-23 cells were cultured in high glucose DMEM 
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containing 15% heat-inactivated horse serum, 2.5% FBS, and 100 μg/ml penicillin-streptomycin. 
TT cells were cultured in F12K medium from ATCC with 10% fetal bovine serum (FBS) with 100 
μg/ml penicillin-streptomycin. For immunostaining assays, the cells were grown on 20 × 20 mm 
coverslips that were placed in 6-well plates one day before the transfection. CaSR-pcDNA and its 
mutants were transfected using Lipofectamine 3000TM (Invitrogen) according to the 
manufacturer’s instructions. Cells were incubated for 48 h in respective media without or after 
transfection. 
3.5.2  [Ca2+]i responses in single cells measurements 
The method is adapted from Huang et al.[232]. The wild type CaSR or its mutants were 
transiently transfected into HEK293 cells grown on coverslips and cultured for 48 h. On the other 
hand, C cells with endogenous CaSR were seeded on coverslips. Subsequently, the cells were 
incubated for 15-20 min using 4 μM FURA-2 AM. 2 mL of 10 mM HEPES, 140 mM NaCl, 5 mM 
KCl, 1.0 mM MgCl2, 1 mM CaCl2 and pH 7.4) was used a physiological saline buffer for loading 
the dye. The coverslips were mounted in a chamber with 0 mM Ca2+ buffer on the stage of a Leica 
DM6000 fluorescence microscope. The cells were illuminated with 340 or 380nm light alternately, 
and the fluorescence at 510 nm an emission wavelength was recorded in real time. This recording 
was taken for each of the increased concentration of Ca2+o added for the experiment in the presence 
or absence of drugs. The ratio of the emitted fluorescence intensities resulting from excitation at 
both wavelengths (340/380) was utilized as the proportional change in [Ca2+]i and was further 
plotted as a function of [Ca2+]o in kgraph. All experiments were performed at 37°C. Three 
successive fluctuations in [Ca2+]i after the initial peak was considered the oscillation. 
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3.5.3  [Ca2+]i changes triggered by [Mg2+]o in single CaSR-transfected cells 
The method is adapted from Huang et al.[232]. The wild type CaSR or its mutants were 
transiently transfected into HEK293 cells grown on coverslips and cultured for 48 h. On the other 
hand, C cells with endogenous CaSR were seeded on coverslips. Subsequently, the cells were 
incubated for 15-20 min using 4 μM FURA-2 AM. 2 mL of 10 mM HEPES, 140 mM NaCl, 5 mM 
KCl, 1.0 mM MgCl2, 1 mM CaCl2 and pH 7.4) was used a physiological saline buffer for loading 
the dye. The coverslips were mounted in a chamber with 0 mM Ca2+ buffer on the stage of a Leica 
DM6000 fluorescence microscope. The cells were illuminated with 340 or 380nm light alternately, 
and the fluorescence at 510 nm an emission wavelength was recorded in real time. This recording 
was taken for each of the increased concentration of Ca2+o added for the experiment in the presence 
or absence of drugs. The ratio of the emitted fluorescence intensities resulting from excitation at 
both wavelengths (340/380) was utilized as the proportional change in [Ca2+]i and was further 
plotted as a function of [Ca2+]o in kgraph. All experiments were performed at 37°C. Three 
successive fluctuations in [Ca2+]i after the initial peak was considered the oscillation. [Mg
2+]o was 
increased in a stepwise manner in the presence or absence of 0.25 mM CaSRL in buffer (10 mM 
HEPES, 155 mM NaCl, 5 mM KCl, 2 mM NaH2PO4, 0 mM MgCl2 and pH 7.4). The ratio of the 
emitted fluorescence intensities resulting [233]. The ratio of the emitted fluorescence intensities 
resulting from excitation at both wavelengths (340/380) was utilized as the proportional change in 
[Mg2+]i and was further plotted as a function of [Ca
2+]o in kgraph. All experiments were performed 




3.5.4 Determination of the effect of CaRL (TNCA) on Mg2+-evoked [Ca2+]i signaling by 
stimulation of CaSR in cell populations  
Changes in the [Ca2+]i produced by extracellular Mg
2+ ([Mg2+]o) in a population of cells 
were measured by fluorimetry as described previously [234, 235]. A cell line stably expressing 
CaSR (5001) was seeded on 13.5 x 20-mm coverslips and cultured in dishes filled with DMEM. 
After reaching 95% confluence, cells were washed three times using loading buffer (20 mM 
HEPES (pH 7.4), 125 mM NaCl, 5 mM KCl, 1.25 mM CaCl2, 1 mM MgCl2, 1 mM NaH2PO4, 1% 
glucose, and 1% BSA) and subsequently incubated with 4 μM FURA-2 AM/4 μM pluronic F127 
for 20 minutes at 37 °C to enable sufficient dye loading in the same buffer. After removing the 
excess FURA-2 AM, coverslips with cells were diagonally positioned in a quartz cuvette filled 
with 3 ml experimental buffer (125 mM NaCl, 5 mM KCl, 0.5 mM CaCl2, 0.5 mM MgCl2, 1% 
glucose, and 1% BSA).  Measurements of FURA-2 AM fluorescence at 510 nm when excited at 
340 or 380 nm were performed on a QM1 fluorescence spectrophotometer (PTI). The emission 
ratio of 340/380 was calculated and used to reflect the changes in [Ca2+]i  when different 
concentrations of [Mg2+]o were applied to the cells.  
To examine the co-activation of CaSR by CaSRL and [Mg2+]o or [Ca
2+]o, different 
concentrations of CaSRL were placed in the experimental buffer with a fixed concentration of 
Ca2+o and varying concentrations of  Mg
2+
o, or vice versa, as described in the results section. The 
effects of other ligands were analyzed by comparing the changes in [Ca2+]i produced by [Mg
2+]o 
alone or by co-application of Mg2+ with other ligands.   
3.5.5 Determination of ERK1/2 phosphorylation  
The 5001 cell line with stably expressed hCaSR, HEK293 cells transiently transfected wild 
type CaSR or 6-23 cells with endogenous CaSR was starved in serum-free DMEM medium 
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supplemented with 0.2% (w/v) BSA overnight, followed by washing 3-times with HBSS and a 
subsequent 10 minute HBSS incubation on the morning of the second day. To induce ERK1/2 
phosphorylation, varying concentrations of Ca2+ or Mg2+o (0-50 mM) or Ca
2+
o (0-30 mM) with or 
without 0.5 mM CaSRL were added to cells and incubated for 10 minutes at 37 °C. The cells were 
then lysed with Pierce RIPA buffer (Thermo Scientific). Total protein concentration was measured 
using the Bio-rad assay. Lysates containing 100 µg of total protein were loaded onto 4-20 % 
gradient SDS-PAGE gels for separation. After electrophoresis, proteins on the gel were transferred 
to nitrocellulose membranes and further analyzed by western blotting. Anti-phospho-p44/42 ERK 
(1:1000 dilution) and anti-p44/42 (1: 2000) polyclonal antibodies were utilized as probes to detect 
the phosphorylated ERK1/2 and total ERK1/2 respectively. A chemiluminescent detection method 
(AP Conjugate Substrate Kit, Bio-Rad) was applied to detect phospho-ERK1/2 and total–ERK1/2. 
The respective bands on western blots were evaluated by densitometry. The EC50 of [Mg
2+]o or 
[Ca2+]o-dependent responses were obtained by fitting the [Mg
2+]o  or [Ca
2+]o concentration-
response curves with the Hill equation.  
3.5.6 Immunoassays 
3.5.6.1 Western blot 
The transfected cells grown on 60-mm plates were washed with PBS and lysed with 10 
mM sodium β-glycerophosphate, 50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 
1% Triton X-100, 2 mM Na3VO4, 50 mM NaF, 10 mM sodium pyrophosphate supplied with 
proteinase inhibitor cocktail (Roche, Basel, Switzerland) and 1X protease inhibitor cocktail on ice 
for 30 min. Cell debris was removed by centrifugation at 13,000 rpm for 10 min at 4 °C. The 
supernatants were denatured in SDS sample buffer (60 mM Tris-HCl, 2% SDS, 10% glycerol, 5% 
β-mercaptoethanol, 0.1% bromphenol blue) at 100°C for 10 min under reducing conditions and 
127 
subjected to 8.5% SDS-PAGE. The proteins resolved by SDS-PAGE were subsequently electro-
transferred to a nitrocellulose membrane (Thermo Scientific). The membrane was blocked using 
3% non-fat milk (Bio-Rad) in TBS. The CaSR on the blot was detected by incubation with a 1:700 
dilution of monoclonal anti-CaR antibody (C0493, Abcam) followed by horseradish peroxidase-
conjugated, goat anti-mouse secondary antibody. CaSR was visualized with an enhanced 
chemiluminescence detection reagent according to the manufacturer's instructions (Pierce 
Biotechnology). 
3.5.7 Immunostaining 
HEK293 cells and cancer cells were grown on 20 × 20 mm coverslips placed in 6-well 
plates. Cells subjected to transfection (if experimental design required it) and after 48 h treated for 
immunostaining. Cells were washed with ice-cold PBS and fixed with 3.7 % formaldehyde for 15 
min at room temperature, followed by a wash with PBS three times. Cells were permeabilized 
using 0.2 % Triton X in PBS for 10 min at room temperature. Mouse anti-FLAG monoclonal 
antibody was diluted 1000 times, anti-CaSR ADD at 1:3000, anti-CaM at 1:2000 were used and 
incubated with cells overnight at 4°C to stain the CaSR. The cells were subsequently washed with 
PBS and stained with goat anti-mouse Alexa 488–conjugated or goat anti-rabbit Alexa 594 
secondary antibody for 1 hour at room temperature. Nuclei were stained with 4′,6-diamidino-2-
phenylindole. Fluorescence was visualized using a Zeiss LSM780 confocal microscope. 
3.5.7.1 ERK1/2 
`Thirty-six hours post-transfection of monolayers of HEK293 cells with CaSR or its 
mutants, cells were incubated in serum-free high glucose DMEM medium supplemented with 
0.2% w/v BSA at 37o C overnight. On the following day, cells were first incubated with HBSS for 
30 min, followed by stimulation with varying levels of CaCl2 (0-20 mM) with or without L-Phe (5 
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mM) for 10 min. At the end of the Ca2+o stimulation, cells were lysed with RIPA lysis buffer 
(Millipore, CA, USA). In total, 150 µg aliquots of lysate protein were loaded into either a 12.5% 
SDS-gel or a 4%-12.5% gradient gel for PAGE and analyzed by western blotting with an 
antiphospho- p44/42 ERK polyclonal antibody (Cell signaling Technology, Beverly, MA, USA) 
diluted (1:2000). A chemiluminescent method (AP Conjugate Substrate Kit) was employed to 
detect the phospo-p44/42 proteins. Quantitative analysis of the results was performed using ImageJ 
software (National Institutes of Health). The responses were normalized to the maximal effect 
observed with Ca2+o alone. The EC50 of Ca
2+
o-dependent responses was calculated by fitting the 
Ca2+o concentration-response curves with the Hill equation 
 
where ΔS is the total signal change in the equation, Kd is the apparent binding affinity, n is the 
Hill coefficient, and [M] is the free metal concentration. 
3.5.8 Biostatistics 
In collaboration with Yan Hai from Department of biostatistics, calcium oscillations data 
was analyzed using 380 only with R (version 3.5.1). Based on oscillation patterns, the spikes were 
filtered by satisfying the conditions that the amplitude of spikes must be at least 0.1 of the 
maximum amplitude and single spike duration is at least 35 seconds for each treatment type. The 
oscillations start was considered if there are at least three spikes within a certain calcium 
concentration. Then the distribution (percentage of cells) of calcium oscillation, oscillation start 
point, oscillation endpoint and frequency (peaks/min) for each treatment type were calculated. 
Equation 3. 1 
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3.6 Results 
3.6.1 CaSR and CaSR mediated intracellular Ca2+ response in HEK293 cells 
3.6.1.1 Ca2+ signaling due to divalent cations  
 
Divalent cations are known agonists of CaSR. Ca2+ is the primary activator which is able 
to activate CaSR with EC50 ~4 mM and hill number of 3. In 2016, our lab crystallized Mg
2+ and a 
tryptophan derivative, TNCA, bound ECD domain of CaSR. Our CaSR mediated signaling study 
Figure 3.8  Ca2+ and Mg2+ potentiate CaSR mediated intracellular Ca2+ oscillation 
A. CaSR mediated oscillation induced by extracellular Ca2+ (upper panel) and Mg2+ (lower 
panel) measured by imaging single cell calcium oscillation with FURA-2 AM using 
HEK293 cells transfected with CaSR. Normalized response curve at various conditions.  
Table 3.1 EC50 and Hill number for Mg
2+ evoked intracellular 
oscillation under various Ca2+ concentrations 
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by Mg2+ re-validated the idea that CaSR is indeed modulated by Mg2+, however, with a lower 
potency than Ca2+ with EC50 of 13 mM and lower hill number of 2.9 (Figure 3.8). With site-
directed mutations, E228I, E229I, at the Mg2+ binding sites, we were able to validate the binding 
sites for Mg2+. Additionally, presence of 0.5 mM and 1.5 mM Ca2+ was able to potentiate potency 
of Mg2+ by decreasing EC50 for Mg
2+ to ~7.5 and 5.9 mM respectively, which further proved the 
cooperative nature between Ca2+ and Mg2+ (Figure 3.8). Not only did we show the CaSR mediated 
signaling increase in case of Ca2+i oscillation, but also through Erk1/2 phosphorylation.  
Ligand specific intracellular signaling cascades occurs in response to extracellular stimuli-
followed by ligand activation GPCRs, thereby catalyzing the exchange of GDP for GTP on the Gα 
subunit, leading to a decreased affinity of Gα for Gβϒ. The GTP-bound Gα and Gβϒ to interact 
with several downstream effectors, including adenylyl cyclases, phosphodiesterases, 
phospholipases, tyrosine kinases, and ion channels [236, 237]. This diverse effectors of GPCR 
makes it a potential druggable target for numerous pharmaceutical compounds [238, 239].  
Figure 3.9  TNCA potentiates [Mg2+]o- or [Ca
2+]o-evoked [Ca
2+]i responses  
 
 
TNCA potentiates [Mg2+]o- or [Ca
2+]o-evoked [Ca
2+]i responses in a population assay in 
5001 cells measured by FURA-2 AM acetoxymethyl (AM) in the absence (black square) 
or presence of Phe (blue triangular) or TNCA (red closed circle). 
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3.6.1.2 Ca2+ signaling due to novel tryptophan derivative, TNCA/CaRL 
Furthermore, we showed cooperative activation between the metals and tryptophan-based 
compound known as TNCA. The TNCA was shown to increase the sensitivity of Ca2+ and Mg2+, 
thus acted as a co-agonist (Figure 3.9, Figure 3.10). In the presence of 0.25 mM TNCA, the EC50 
Figure 3.10  A representative oscillation pattern from a single HEK293 cell stimulated with 
various concentrations of extracellular Ca2+ or Mg2+ in the absence and presence of 0.25 mM 
TNCA.  
Figure 3.11  Potentiation of TNCA on [Mg2+]o-evoked [Ca
2+]i responses in WT and 
mutants using single cell imaging 
 
 A. TNCA potentiates [Ca
2+]i  responses of both WT CaSR or mutant E228I to [Mg
2+]o 
stimulation in the single cell imaging assay in the absence of basal [Ca2+]o. B.  Membrane 
expression of CaSR, mutant E228I and double mutant E228I/E229I. Blue: DAPI staining 
cell nuclei. Green: hCaSR immunoreactivity 
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were decreased to 2.3 mM and 4.55 mM for Ca2+ and Mg2+, respectively. Interestingly, TNCA 
was able to rescue the CaSR activity in the impaired mutants (Figure 3.11, Figure 3.12). 
3.6.1.3 Ca2+ signaling in the presence of cinacalcet  
Cinacalcet is a known agonist of CaSR and the only FDA approved drug targeting 
secondary hyperparathyroidism. It has been used for patients with chronic kidney disease. It 
potentiates sensitivity of CaSR by decreasing the EC50 and shifting the concentration-response 
curve for extracellular Ca2+ to the left (Figure 3.13). The oscillation distributes between 0.5 to 3 
mM Ca2+, with the majority starting at 1mM and ending at 1 mM. Additionally, 80 % of the cells 
undergo oscillation frequency of 1.5-2.0 peaks/min (Figure 3.13). Therefore, cinacalcet caused 
the enhanced activity of the cells along with the early termination of oscillation as compared to the 
wild type. 
Figure 3.12   Potentiation of TNCA on [Mg2+]o-evoked [Ca




A) TNCA potentiates [Mg2+]o-evoked [Ca
2+]i responses in CaSR mutant E228I and the double 
mutant E228I/E229I analyzed using fluorimetry in cell population assay in 0.5 mM basal [Ca2+]o. 
(B) Calcium and (or) TNCA potentiate the [Mg2+]o -stimulated intracellular calcium responses 
in the single cell imaging assay.  
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3.6.1.4 Ca2+ signaling in the presence of NPS-2143 
NPS-2143 is a known antagonist of CaSR with an IC50 of 43 nM. It is known to stimulate 
the parathyroid hormone secretion from bovine parathyroid cells with EC50 of 41 nM. 10 µM of 
NPS-2143 was used in the Ca2+ mixture. It was able to completely abolish CaSR mediated 
intracellular oscillation in HEK293 cells (Figure 3.13).  
3.6.1.5 Ca2+ signaling in the presence of W7, a CaM inhibitor  
CaM is known CaSR binding partner in Ca2+ condition and is predicted to bind at 
intracellular C-tail of CaSR at 868-TIEEVRCSTAAHAFKVAARATLRRSNVSRKRSSS-901 
[240]. Huang et al in 2010 have shown CaM/Ca2+ to be an important modulator for membrane 
expression of CaSR [3]. Its binding region overlaps with the phosphorylation site T888 and 
previous paper has shown it to be important for stabilizing CaSR. Our work by using W7, a CaM 
inhibitor shows a decrease in the overall number of oscillatory cells. The oscillation distributes 
between 1 to 5 mM Ca2+, with the majority starting at 2 mM and ending at 4 mM (Figure 3.13). 
Additionally, 40 % of the cells undergo oscillation frequency of 0.5-1 peaks/min (Figure 3.13). 
Therefore, W7 caused the delay in oscillation frequency as well as the overall activity of the cells 
as compared to the wild type. We also carried out functional study with Co-IP where we showed 
the binding of CaM in Ca2+ dependent manner which supports the earlier study.  
3.6.1.6 Additive change in Ca2+ signaling in the presence of cinacalcet and W7  
We show that W7 is able to retard the efficacy of cinacalcet by preincubating the cells for 
30 min with 50 µM W7 (Figure 3.13). The overall oscillation distribution, starting point, end point 
and oscillation frequency were found to be in between the response of W7 and cinacalcet. This 
also suggests that cinacalcet is able to partially rescue the inhibition of CaM.  
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3.6.2 CaSR and CaSR mediated intracellular Ca2+ response in thyroid cancer cells 
CaSR has been shown to play a role in tumor growth, invasion and metastasis of several 
cancers including prostate cancer, breast cancer, thyroid cancer, etc. In this study, we investigate 
and carry out the comparative analysis of the CaSR mediated Ca2+ signaling in cancer cells as 








































































Figure 3.13  CaSR mediated oscillation pattern for wild type CaSR transfected in 
HEK293 cells due to extracellular Ca2+ and or CaSR associated drugs 
and effect of CaSR associated drugs. 
Oscillation Cell distribution shows that wild type CaSR oscillates between 2-10 mM 
extracellular Ca2+and frequency between 1-1.5 peaks/minute. With addition of 
cinacalcet the distribution is narrow between 0.5-3 mM and the frequency is increased 
by 2 folds. With addition of W7 the distribution is narrow between 1-5 mM and the 
frequency is decreased by 1fold.  With addition of NPS2143 the distribution is completely 
obliterated. With addition of cinacalcet and pre-incubation of W7, the distribution lies 
between the response of cinacalcet and W7. The start and end points shift to left with all 



















































































expression, signaling from heterogeneity in oscillation pattern, frequency, start and end of 
oscillation. 
Medullary tumors are the third most common of all thyroid cancers and makeup about 3% 
of all thyroid cancer cases (https://www.endocrineweb.com/conditions/thyroid-cancer/thyroid-
cancer-medullary-cancer). Unlike papillary thyroid cancer and follicular thyroid cancer that arise 
from thyroid hormone-producing cells, medullary thyroid cancer originates from the parafollicular 
or C cells of the thyroid. It has a low cure rate. 10-year survival rates are 90% when all the disease 
is confined to the thyroid gland, 70% with spread to cervical lymph nodes and 20% when spread 
to distant sites. CaSR not only inhibits PTH secretion but also enhances the secretion of calcitonin 
from thyroid parafollicular C-cells. Calcitonin is a calcium-decreasing hormone.  
In a study by Haller-Brem et al. in 1987 shows that 6-23 cells respond to a rise in Ca2+ from 
0.5 to 3 mM with a transient [13]. In TT, the rise of Ca2+ from 0.5 to 3 mM did not affect the Ca2+i. 
The calcitonin and calcitonin gene-related peptide (CGRP) release was shown to be dose 
dependent on Ca2+i when electropermeabilized or when ionomycin was used [13]. Ionomycin is 
able to mobilize Ca2+ from the intracellular store. This result indicates a defect in the Ca2+ signal 
transduction in the TT cell line. Another study by Eckert et al. in 1989 showed that pre-incubation 
of 6-23 cells with 1 µM glucagon or 1 mM 8-Bromo-cAMP caused intracellular calcium oscillation 
when Ca2+o was raised to 3 mM [213]. These oscillations were perturbed by using EGTA to chelate 
Ca2+o or by addition of calcium channel blocker to block voltage-dependent calcium channels 
[213]. Both 8-bromo-cAMP and glucagon induce cAMP pathway activation. rMTC 6-23 cells are 
calcitonin secreting line derived from transplantable WAG/Rij rat strain medullary thyroid 
carcinoma. Only in 1996, Freichel showed the involvement of CaSR in Ca2+ sensing in both of 
these cells. TT cells were shown to lack voltage-dependent L-type calcium channels [6, 210]. 
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Thomsen et al. in 2012 showed that strontium biases CaSR signaling toward ERK1/2 signaling 
and possibly another pathway independent of Gq/11 signaling and [Ca2+]i mobilization [214]. 
Furthermore, truncated CaSR variant, CaSRb has been identified in TT cells [212]. In our study, 
we study the Ca2+ sensing mechanism further through CaSR in the C-cells.  
3.6.2.1 CaSR mediated Ca2+ signaling in human thyroid cancer TT cell 
We observed an interesting transient CaSR mediated peak with the increment of [Ca2+]o 
(Figure 3.14). The application of CaSR associated drugs and W7 were able to evidently perturb 
the number of responding cells as well as the Ca2+ concentration at which the response occurred. 
Ca2+ alone was able to evoke transients at 5 mM and 7.5 mM with low percent of cells, 22% and 
9 %, respectively. Cinacalcet was not only able to increase the number of responding cells to 88%, 
but also potentiate these transients to 2 mM. The efficacy was upregulated as the Ca2+i rise was 
almost 40% greater than in other treatment conditions. NPS-2143 was able to limit the activation 
to mostly 5 mM and completely eradicate the response at the 7.5 mM. It also lowered the number 
of responding cells to 7%. W7 seemed to potentiate the response to 1, 2 and 3 mM but limited the 
responding number of cells to less than 17%. On the other hand, pre-incubating the cells with W7 
for 30 min dramatically impeded the cinacalcet effect, validating the role of CaSR mediated 
signaling in Ca2+ sensing responses. Our results indicate the important function of CaM in CaSR 
functioning in human thyroid cancer cells. Like rMTC 44-2 cells, TT cells were insensitive to 
Mg2+ implying biased signaling. 
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Figure 3.14 CaSR mediated signaling pattern in TT cells at various Ca2+ concentrations and 
various drugs 
0   0.5 1     2          3           4           5            7.5        10        20    [Ca2+] (mM)       0   0.5 1     2          3           4           5            7.5        10        20    [Ca2+] (mM)       
0   0.5 1     2          3           4           5            7.5        10        20    [Ca2+] (mM)       0   0.5 1     2          3           4           5            7.5        10        20    [Ca
2+] (mM)       
0   0.5 1     2          3           4           5            7.5        10        20    [Ca2+] (mM)       
0   0.5 1     2          3           4           5            7.5        10        20    [Mg 2+] (mM)       
Ca2+ Alone Ca
2+ Cinacalcet 
Ca2+ + W7 Ca2+ + Cinacalcet + W7 
Ca2+ + NPS-2143 
Mg2+ Alone 
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3.6.2.2 CaSR and CaSR mediated intracellular Ca2+ signaling in rat thyroid cancer cells 
CaSR mediated intracellular signaling in rat 6-23 cells were highly heterogeneous with 
regards to not only the cell stock obtained from ATCC and passage of the cells but also amongst 
the cells from the same batch (Figure 3.16). To examine the CaSR mediated oscillation, 6-23 cells 
were seeded, incubated with FURA-2 AM and titrated with varying Ca2+ concentrations. Early 
passaged cells from stock obtained in 2017 displayed three distinct groups of signaling where 64% 
of the cells had over-activated CaSR with EC50 of 0.73 mM and Hill number of 1.5 for Ca
2+. This 
is almost four-fold lower in the EC50 as compared to the wild type and also is two-fold lower in 
cooperativity. Unlike the earlier reports of the requirement of the inducer of cAMP for oscillation, 
the cells were capable of oscillating in the presence of [Ca2+]o alone. 
The heterogeneity was also clearly observed when the oscillation frequency was compared 
between the three groups of cells with three distinct patterns (Figure 3.16). The majority of the 
cells (group A), were overactivated cells and the oscillation frequency were distributed from 0.-
2.5 peak/min with 55% of those overactivated cells responding with 1.6-2.0 peak/min. The wild 
type CaSR has a frequency at 1.1-1.5 peaks/minute. The receptor seemed to desensitize at 15-30 
mM Ca2+ as the oscillation frequency is almost 0-0.5 peaks/min. We observed that in group B and 
C which represented 18% each, had limited frequency to 0-0.5 peaks/minute at 1.5-2.5 mM Ca2+. 
The frequency increased to 1 peaks/minute in the presence of 15-30 mM high Ca2+ concentration 
for both B and C. These results show that CaSR with varying sensitivity is present in 6-23. Not 
only was the CaSR mediated intracellular calcium oscillation hyper-active, but also CaSR 
mediated ERK1/2 indicated hyperactivity even at 0 mM Ca2+ with a steady increase in the ERK 
phosphorylation with the gradual increase in [Ca2+]o. 
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Interestingly, 6-23 cells did not show any agonistic behavior of Mg2+ in the absence of Ca2+ 
(Figure 3.18).  However, 0.5mM Mg2+ was able to induce transition peaks in the presence of 1mM 
Ca2+. This could indicate that the divalent cation binding domain of CaSR in 6-23 cells to be 
different from the wild type. They could be specific for Ca2+ and with the increase in Mg2+, Ca2+ 
is displaced from the binding pocket and therefore, CaSR is de-activated. This could also imply 
that the Mg2+ have biased signaling. This is interesting and is supported as McGhee et al. in 1997 
also illustrated the potency of CaSR activation of various divalent cations as 

















































Figure 3.15  CaSR mediated intracellular Ca2+ response in 6-23 cells.  
CaSR mediated oscillation, 6-23 cells were seeded, incubated with FURA-2 AM 
and titrated with varying Ca2+ concentrations. Most of the cells (group A), were 
overactivated cells and the oscillation frequency were distributed from 0.-2.5 
peak/min with 55% of those overactivated cells responding with 1.6-2.0 
peak/min. 
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The reduced Mg2+ sensitivity in the light of 92% sequence similarity between rat and bovine CaSR 






















 Figure 3.16, Hill curve of the response fitted and oscillation frequency of the response 
The EC50 of CaSR for Ca2+ was 0.73 mM as compared to wild type at 3 mM. The wild type 
CaSR has a frequency at 1.1-1.5 peaks/minute. The receptor seemed to desensitize at 15-30 
mM Ca2+ as the oscillation frequency is almost 0-0.5 peaks/min. We observed that in group 
B and C which represented 18% each, had limited frequency to 0-0.5 peaks/minute at 1.5-
2.5 mM Ca2+. The frequency increased to 1 peaks/minute in the presence of 15-30 mM high 
Ca2+ concentration for both B and C. 
Figure 3.17  ERK1/2 phosphorylation in 6-23 and comparison with HEK293 cells 
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or differential CaSR regulatory protein. This paper also indicates the role of L-type voltage gated 
channel and Gq/11 in the response to extracellular calcium by using channel blocker nimodipine 
and phosphatidylcholine PLC inhibitor, D609, respectively. This study used 5-HT and phosphor-
kinase C for CaSR mediated signaling response. 
 
 
Figure 3.18 ERK and effect of Mg2+in intracellular Ca2+ signaling in 6-23 
6-23 cells did not show any agonistic behavior of Mg2+ in the absence of Ca2+.  




We collaborated with Yan Hai to use R-programming to quantitate the complicated peaks 
in the second batch of 6-23 from ATCC. Our results show a clear effect of cinacalcet in the number 
of responsive cells increasing by ~ 25% and increasing the oscillation frequency between 1-2 
peaks/minute (Figure 3.19). Similarly, we observe the partial down-regulatory effect of NPS-2143 
where the number of cells responding is drastically decreased to < 15% and oscillation frequency 
Oscillation Cell distribution shows that endogenous CaSR oscillates between broad 1-20 mM 
extracellular Ca2+and frequency between 1-1.5 peaks/minute. With addition of cinacalcet the 
percentage of the cells increase, and the frequency is increased by 1.5 folds. With addition of 
W7 the percentage of the cells decrease, and the frequency and percentage of cells is 
decreased.  With addition of NPS-2143, oscillation is not completely obliterated. With addition 
of cinacalcet and pre-incubation of W7, the distribution lies between the response of cinacalcet 
and W7. Oscillation start is broad but brings to maximum at 2 mM for cinacalcet and W7. The 









































































































Calcium + W7 + Cinacalcet
Figure 3.19  Oscillation pattern of endogenous CaSR in 6-23 cells due to extracellular Ca2+ 
and or CaSR associated drugs 
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decreased to 0-0.5 peaks/minute. W7 on its own is able to change the oscillation pattern but doesn’t 
have a specific trend. However, the W7 had an evident effect on cinacalcet agonism by decreasing 
the number of responding cells to 25% and decreasing the oscillation frequency to 0.5-1 
peaks/minute. This indicates a significant role of CaM in inducing CaSR mediated oscillation in 
6-23 cells. As compared to the wild type transiently transfected in HEK293 cells, the oscillation 
pattern is more convoluted. This might suggest an additional Ca2+ sensing mechanism in 6-23 cells. 
Like rMTC 44-2 cells, the second batch of 6-23 cells displayed complex Ca2+i response.  
 
Figure 3.20  Oscillation frequency calculated between 1.5-2.5 mM and 15-30 mM Ca2+ in 
6-23. 
Group A had higher oscillation frequency distribution at 1.1-2.5 peaks/min at 1.5-2.5 mM 
Ca2+. At higher Ca2+ of 15-30 mM induced much lower oscillation. Other groups B and C 
had lower oscillation frequency. 
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3.6.3 Comparison of the differential oscillation pattern between C cells and HEK293 cells  
Differential oscillation pattern was observed between the two cell lines for Ca2+ signaling 
where they had similar frequency distribution with Ca2+. However, cinacalcet affects responding 
cell number for 6-23 and shifts distribution to the left for HEK293. Additionally, the cinacalcet 
affects similarly to frequency changes. Complete reduction of CaSR mediated signaling was 
observed due to NPS2143 in HEK293, but only partial obstruction of the CaSR mediated 
HEK293, N < 10
6-23, N < 30
HEK293, N < 10
6-23, N < 30
Figure 3.21 Comparison of differential oscillation pattern between 6-23 and HEK293 cells 
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signaling in distribution as well as frequency. Similarly, as in 6-23, cinacalcet increases the 
number of cells responding by 60% in TT cells and NPS2143 only partially obstructs response.   
3.6.4 Dissecting the basis of differential CaSR mediated signaling in C cells  
3.6.4.1 Expression of wild type in HEK293 and 5001  
 
5001 in HEK293 cells stably transfected with wild type CaSR. HEK293 cells are 
transiently transfected with FLAG-hCaSR pcDNA3.1. Western blot results show comparative total 
CaSR in both the cells types. Using two different antibodies show that anti-FLAG is much more 
specific for our assays. We observe plasma membrane CaSR stained in Figure 3.22. 
HEK293 transfected with CaSR-FLAG 
ICC: Anti-CaSR ADD ICC: Anti-flag antibody 
 Figure 3.22  Immunostaining of CaSR in HEK293 cells 
Efficiency of anti-ADD antibody for immunostaining is not as strong as using anti-
FLAG antibody 
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3.6.4.2 Comparison of Expression of CaSR in thyroid cancer cell types 
Expression of CaSR in thyroid cancer cells was compared with the wild type in HEK293 
cells as shown in Figure 3.23. Expression of endogenous CaSR was lower by four folds in thyroid 
cancer cells. Interestingly, the monomer CaSR from the total had a slightly lower molecular weight 
in TT, similar to PC3. No monomers were detected for 6-23. The less molecular weight CaSR 
suggests that the CaSR detected in total are more likely immature less glycosylated CaSR. This is 
further supported by the immunostaining results of endogenous CaSR in thyroid cancer cells. TT 
and 6-23 cells were stained with anti-CaSR ADD antibody (1:3000 dilution) in permeabilized and 
non-permeabilized conditions. CaSR-FLAG pc DNA3.1 was transfected to examine the insertion 
of CaSR in the plasma membrane. Most CaSR were detected within the cell in permeabilized 
Figure 3.23 Western blot of total cell lysates in various cell lines 
-250
-130
25-100 µg of total lysates from about 100% confluent cells were loaded to 7.5% SDS Page 
gel in reducing condition (5% β-mercaptonal). Oligomers at > 250 kDa in all except PC3 and 
monomers 110-130 kDa were observed in all except 6-23 cells. 
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condition and the significantly lower amount was observed in the plasma membrane in both 6-23 
and TT cells in non-permeabilized conditions (Figure 3.24, Figure 3.25).  
TT cells un-transfected  
and non-permeabilized 
 
TT cells transfected with CaSR-FLAG 
 and non-permeabilized 
 
ICC: Anti-CaSR ADD antibody 
Ex: 488 (CaSR) 
Ex: 405 (DAPI; nucleus) 
TT cells un-transfected  
and permeabilized 
 
Figure 3.24  Evaluating Expression level and effect of overexpression of CaSR in TT cells 
 Cells were seeded to 20X20 coverslips and stained with anti-mouse Alexa fluor 488 






6-23 cells un-transfected  
and non-permeabilized 
 
ICC: Anti-CaSR ADD antibody 
Ex: 488 (CaSR) 
Ex: 405 (DAPI; nucleus) 
 
Figure 3.25   Evaluating Expression level and Effect of overexpression of CaSR in 6-23 
 
6-23 cells transfected with CaSR-FLAG  
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3.6.4.3 Characterization of role of CaM as CaSR modulator in the differential CaSR 
mediated signaling between C cells and HEK293 cells.  
3.6.4.3.1 CaM expression in thyroid cancer cells 
Huang et al. in 2010 have demonstrated that CaM interacts with CaSR in a Ca2+ dependent 
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Figure 3.26  Immunostaining of CaM and CaSR in TT cells 
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mutations, hinders CaSR mediated intracellular oscillation by decreasing the oscillation frequency 
[3]. Since we observed CaM dependent Ca2+i response in the human and rat thyroid medullary 
cancer cells, we further investigated the CaM binding with co-immunoprecipitation and 
immunostaining.  
3.6.4.3.2 CaM expression in TT cells 
CaM was visualized using immunostaining with anti-CaM antibody (Figure 3.26).  We 
observed CaM throughout the cell and the merged image shows some co-localization of the CaSR 
and CaM. The images were taken in LSM800 with plan-apochromat 40X/1.4 oil DIC. Since the 
protein staining was everywhere, it is challenging to locate the definite co-localization. 




3.6.4.3.3 CaM expression in 6-23 cells 
CaM was visualized using immunostaining with anti-CaM antibody (Figure 3.28).  We 
observed CaM throughout the cell and the merged image shows some co-localization of the CaSR 
and CaM. The images were taken in LSM800 with plan-apochromat 40X/1.4 oil DIC. Since the 
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Figure 3.28 Immunostaining of CaSR and CaM in 6-23 
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3.6.4.3.4 Comparison of differential effects of CaM inhibitor in C cells and HEK293 cells 
W7 is unable to perturb C cells response to Ca2+o, possibly because of initial low 
activation. However, W7 demonstrates strong perturbation of CaSR mediated cinacalcet effect in 
C cells therefore, canceling its effect. This supports that CaM modulates CaSR in C cells.  
 
Figure 3.29 Surface plot and colocalization of whole ROI with Pearson’s coefficient 
of 0.63 in 6-23 cells 
153 
3.6.4.3.5 Optimization of co-immunoprecipitation of CaSR in order to study the interaction of 
CaM with CaSR  
Three different anti-CaSR antibodies (C0493, 183355 and ADD) were examined and 
compared for the efficiency of immunoprecipitating FLAG-CaSR (). The cells were transfected 
with FLAG-CaSR pcDNA3.1, lysed and subjected to overnight binding with agarose A/G bead 
with the respective antibodies. We demonstrated that 183355 has the most optimal 
immunoprecipitation followed by C0493. However, with the endogenous CaSR such as in PC3, 
the input is low as well as has almost no immunoprecipitation.  
Figure 3.30 Comparison of differential effects of CaM inhibitor in C cells and HEK293 cells. 
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For the next experiment efficiency of anti-FLAG antibody was compared with the 183355 as well 
as we examined the co-immunoprecipitation of CaM with CaSR. The experiment was performed 
in duplicate. First, anti-FLAG antibody is identified to be almost 10 times higher in 
immunoprecipitation efficiency with HEK293 cells transfected with FLAG-CaSR using 
lipofectamine 2000. Un-transfected HEK293 was used as control. It was also observed that the 
flow-through (supernatant collected after the over-night binding process) contained a greater 
amount of unbound CaSR in samples with anti-CaSR 183355 antibody indicating that anti-FLAG 
antibody had greater efficiency of binding the CaSR.  
Figure 3.31 Optimization of co-IP of CasR with various antibodies. Anti-FLAG 
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3.6.4.3.6 Interaction of CaM with CaSR in TT cells 
 In order to study the interaction in vitro, TT cells at 100% confluency in 10 cm dish were 
lysed and subjected to co-immunoprecipitation using the anti-CaSR 183355 antibody using dyna 
10% Bead
Ca2+   +      +     +        - - +      +      - -
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Figure 3.32 Optimization of co-IP, selecting antibodies 
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bead in the presence or absence of Ca2+. The experiment was conducted in duplicate. The result is 
not conclusive. Firstly, the immunoprecipitation of CaSR was not optimal since the anti-CaSR 
antibody is known to be weaker than the recombinant anti-FLAG antibodies. We observed CaM 
in the total and flow-through. In the duplicate experiments performed, we found a discrepancy of 
the CaM co-immunoprecipitated with CaSR irrespective of the presence of Ca2+ and CaM (Figure 
3.33).   
 
Figure 3.33    Co-IP of both CaSR not successful in WB. Co-IP of CaM in 
EGTA condition anti CaSR 183355 
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3.6.4.3.7 Ca2+ dependent interaction of CaM with CaSR in 6-23 
 In order to study the interaction in vitro, 6-23 cells at 100% confluency in 10 cm dish were 
lysed and subjected to co-immunoprecipitation using the anti-CaSR 183355 antibody using dyna 
bead in the presence or absence of Ca2+(Figure 3.34). The experiment was conducted in triplicate. 
Firstly, we show that the immunoprecipitation of CaSR was not optimal since the amount of CaSR 
observed to be bound to the bead was less than 20 times instead of being enriched. However, with 
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Figure 3.34 Ca2+ dependent CaM interaction with CaSR 
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3.6.5 Exploring the possibility of splice variant using RT-PCR in 6-23 
More than 230 germline mutations are encoded by CASR gene that is associated with a 
variety of human disorders associated with abnormal Ca2+ homeostasis, making CaSR an 
important potential therapeutic target for a plethora of conditions [241]. Apart from being 
expressed in organs such as parathyroid, kidney, bones, heart, intestine, breast, neurons, liver, lung, 
etc, CaSR is highly expressed in cancer cells upon the initiation of bone metastasis[242]. CaSR may 
be involved in phenomena that allow for the development of many types of benign or malignant 
tumors, from parathyroid adenomas to breast, prostate, and colon cancers[243]. Studies have 
shown significant higher CaSR expression in metastatic prostate and breast cancer tissues found 
in the bone than that in the primary cancer tissues[90]. Therefore, CaSR in prostate and breast act 
as an oncogene, whereas, in parathyroid and colon act as a tumor suppressor. We explored the 
possibility of mutations or splice variants of CaSR in the thyroid cancer cells to inquire if this was 
a reason for the Ca2+ signaling and downstream pathways such as IP production and ERK pathways 
to be significantly different between the CaSR in cancer cells and native CaSR transiently 
transfected in HEK293.  
Figure 3.35 Mammalian RNA contain poly A 
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Primers were designed to encompass each of the seven exons of CaSR, as shown in the 
(Figure 3.36). We used polyA enrichment of the RNA while isolation and conducted reverse 
transcription to obtain the cDNA. A two-time PCR with nesting method was used to amplify the 
signal. Due to the low transcript, the first PCR usually does not generate the good signal for 
Figure 3.36  Primers were designed targeting each exon of CaSR from 2-7 
Figure 3.37 Flowchart for RT-PCR 
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endogenous CaSR transcript amplification as compared to 5001 (stably transfected HEK293 with 
wild type CaSR). Only exons 2, 3, 4 and 6 were able to obtain the expected PCR product for CaSR. 
Many bands were obtained, suggesting unspecific amplification. The bands from 2, 3, 4, and 6 
exons were sequenced using sanger sequencing. We verified that the transcript of CaSR in 6-23 is 
isoform I precursor an additional 10 amino acid insertion. In addition to the wild type isoform II 
EXON:       2-3             4                                            3-4            .          
Expected








EXON:       4             6                      7            
.          
Expected








Figure 3.38  Nested PCR for 6-23. Bands corresponding to yellow bars were sequenced 
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CASR, low abundant isoform I exist which contains an additional 10 amino acid inserted after 
amino acid 536 in the CaSR (GenBank #U20760) 
(https://www.ncbi.nlm.nih.gov/protein/NP_001171536.1). This insertion is known to be rare and 
as to my knowledge, does not affect the function of CaSR [31]. The partial sequencing obtained 
from other bands does not imply any significant change in CaSR in 6-23 cells.  The grey 






YGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECI                              61 Exon 2 
 
RYNFRGFRW               70   Exon 3 




QFKSFLRTIPNDEHQATAMADIIEYFRWNWVG              210  Exon 4 
TIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLI  280 
KEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKE  350 
FWEETFNCHLQEGAKGPLPVD 
TFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNV  .....................420 
YLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVE     
 
AWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYS               
IINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSG                           Exon 5 
 
FSREPLTFVLSVLQVPFSNCSRDCLAGT.............................................560     
RKGIIEGEPTCCFECVECPDG        Exon 6 
 
Figure 3.39  Sequencing covered for 6-23 after RT-PCR 
Figure 3.40 Workflow for Nested PCR strategy 
162 
 Exon2: 131-557 (427) 
UTR 
AAGGCATCAC 







ATGGCATTTTATAGCTGCTGCTGGGTCCTCTTGGCACTCACCTGGCAC       E-2-1.1Fwd (1-8) 
ACCTCTGCCTACGGGCCAGACCAGCGAGCCCAAAAGAAGGGGGACATTATCCTTGGGGGGCTCTTTCCTA 
TTCATTTTGGAGTAGCAGCTAAAGATCAAGATCTCAAATCAAGGCCGGAGTCTGTGGAATGTATCAG     
  
Exon3: 558-864 (307) 
GTA           E-3-1Fwd (3) 
TAATTTCCGTGGGTTTCGCTGGTTACAGGCTATGATATTTGCCATAGAGGAGATAAACAGCAGCCCAGCC E-3-2Fwd (3-9) 
CTTCTTCCCAACTTGACGCTGGGATACAGGATATTTGACACTTGCAACACCGTTTCTAAGGCCTTGGAAG 
CCACCCTGAGTTTTGTTGCTCAAAACAAAATTGATTCTTTGAACCTTGATGAGTTCTGCAACTGCTCAGA E-3-1Rev (1-8) 
GCACATTCCCTCTACGATTGCTGTGGTGGGAGCAACTGGCTCAGGCGTCTCCACGGCAGTGGCAAATCTG E-3-2 Rev (1) (3-9) 
CTGGGGCTCTTCTACATTCCCCAG            
 
Exon4: 865-1749(885) 
GTCAGTTATGCCTCCTCCAGCAGACTCCTCAGCAACAAGAATCAAT        E-4-2Fwd (2) 
TCAAGTCTTTCCTCCGAACCATCCCCAATGATGAGCACCAGGCCACTGCCATGGCAGACATCATCGAGTA 
TTTCCGCTGGAACTGGGTGGGCACAATTGCAGCTGATGACGACTATGGGCGGCCGGGGATTGAGAAATTC  




TCGCTCTGAAGGCTGGGCAGATCCCAGGCTTCCGGGAATTCCTGAAGAAGGTCCATCCCAGGAAGTCTGT E-4-4Fwd (4)   
CCACAATGGTTTTGCCAAGGAGTTTTGGGAAGAAACATTTAACTGCCACCTCCAAGAAGGTGCAAAAGGA E-4-4.1Fwd (4-11)   
CCTTTACCTGTGGACACCTTTCTGAGAGGTCACGAAGAAAGTGGCGACAGGTTTAGCAACAGCTCGACAG 
CCTTCCGACCCCTCTGTACAGGGGATGAGAACATCAGCAGTGTCGAGACCCCTTACATAGATTACACGCA 
TTTACGGATATCCTACAATGTGTACTTAGCAGTCTACTCCATTGCCCACGCCTTGCAAGATATATATACC E-4-3Rev (2) (2-10) 
TGCTTACCTGGGAGAGGGCTCTTCACCAATGGCTCCTGTGCAGACATCAAGAAAGTTGAGGCGTGGCAG 
Figure 3.41  Primers designed through exon 1-7. Color represent sets of forward and reverse 
primers. 
Exon5: 1750-1980 (231) 
G 
TCCTGAAGCACCTACGGCATCTAAACTTTACAAACAATATGGGGGAGCAGGTGACCTTTGATGAGTGTGG 
TGACCTGGTGGGGAACTATTCCATCATCAACTGGCACCTCTCCCCAGAGGATGGCTCCATCGTGTTTAAG E-5-2Fwd (5) 
GAAGTCGGGTATTACAACGTCTATGCCAAGAAGGGAGAAAGACTCTTCATCAACGAGGAGAAAATCCTGT E-5-1.1Rev (4-11)   
GGAGTGGGTTCTCCAGGGAG         E-5-1Rev (4)   
 
Exon6: 1981-2104 (124) 
 
CCACTCACCTTTGTGCTGTCTGTCCTCCAG (10 amino acid) 
GTGCCCTTCTCCAACTGCAGCCGAGACTGCCTGGCAGGGACCAGGAAAGG      E-6-1Fwd (6) (6-12)        
GATCATTGAGGGGGAGCCCACCTGCTGCTTTGAGTGTGTGGAGTGTCCTGATGGGGAGTATAGTGATGAG E-5/6-2Rev (5) (6-12)    
ACAG 
 
Exon7: 2105-4915 (2811) 
ATGCCAGTGCCTGTAACAAGTGCCCAGATGACTTCTGGTCCAATGAGAACCACACCTCCTGCATTG 
CCAAGGAGATCGAGTTTCTGTCGTGGACGGAGCCCTTTGGGATCGCACTCACCCTCTTTGCCGTGCTGGG                
CATTTTCCTGACAGCCTTTGTGCTGGGTGTGTTTATCAAGTTCCGCAACACACCCATTGTCAAGGCCACC         (Liao) 
AACCGAGAGCTCTCCTACCTCCTCCTCTTCTCCCTGCTCTGCTGCTTCTCCAGCTCCCTGTTCTTCATCG 
GGGAGCCCCAGGACTGGACGTGCCGCCTGCGCCAGCCGGCCTTTGGCATCAGCTTCGTGCTCTGCATCTC 
ATGCATCCTGGTGAAAACCAACCGTGTCCTCCTGGTGTTTGAGGCCAAGATCCCCACCAGCTTCCACCGC   
AAGTGGTGGGGGCTCAACCTGCAGTTCCTGCTGGTTTTCCTCTGCACCTTCATGCAGATTGTCATCTGTG   
TGATCTGGCTCTACACCGCGCCCCCCTCAAGCTACCGCAACCAGGAGCTGGAGGATGAGATCATCTTCAT E-7-4Fwd (7) 
CACGTGCCACGAGGGCTCCCTCATGGCCCTGGGCTTCCTGATCGGCTACACCTGCCTGCTGGCTGCCATC 
TGCTTCTTCTTTGCCTTCAAGTCCCGGAAGCTGCCGGAGAACTTCAATGAAGCCAAGTTCATCACCTTCA  E-7.2-2Fwd (6) 










GGTGGAGGACCCTGAAGAGTTGTCCCCAGCACTTGTAGTGTCCAGTTCACAGAGCTTTGTCATCAGTGGT   









CaSR ADD Fwd 2016-05-27 CAATTGCAGCTGATGACGACT 75 4
CaSR ADD Rev 2016-05-27 CCTCATCAGAGTACTGGGAG 4
CaSR Ab SP5484P Fwd 2016-05-27 TATTCATTTTGGAGTAGCA 76 2
CaSR Ab SP5484P Rev 2016-05-27 GCAAATATCATAGCCTGTAACC 3
CaSR Ab ab79829 Fwd 2016-05-27 GTGGGCACAATTGCAGCTGA 58 4
CaSR Ab ab79829 Rev 2016-05-27 AGATGAGTTCACTGAAGTCGAT 4
CaSR Oda-98-1 Fwd 2016-05-27 AGGAAGTCTGTCCACAATGG 608 4
CaSR Oda-98-1 Rev 2016-05-27 CAATGATCCCTTTCCTGGTC 6
CaSR Bradbury-98-1 Fwd 2016-05-27 CTGGCGTGCATCTTCTTCAA 638 7 
CaSR Bradbury-98-1 Rev 2016-05-27 GTTTTCTGTAACAGTGCTGC 7
CaSR Liao-06 Fwd-1 2016-05-27 CAACCTGCAGTTCCTGCTGG 206 7
CaSR Liao-06 Rev-1 2016-05-27 TGGCATAGGCTGGAATGAAGG 7
CaSR Liao-06 Fwd-2 2016-05-27 TTGAAAATCCGGGGGAGAG For 28S x
CaSR Liao-06 Rev-2 2016-05-27 ACATTGTTCCAACATGCCAG For 28S x
CaSR Exon1-2 Fwd-1 2016-05-27 GCCAGGAAGGACCGCACG 281 1-2
CaSR Exon1-2 Rev-1 2016-05-27 CAGCTAGGAGTTTGGAGGCT 1-2
CaSR Exon1-2 Fwd-2 2016-05-27 AGGAGGCCTCTGCATGATGTGGC 360 2-2
CaSR Exon1-2 Rev-2 2016-05-27 ACAGACTCCGGCCTTGATTTGA 2-2
Table 3.3 Primers designed to study Exon 1 & 2, to replicate previous research on exons 
5 & 7, and to study Antibody specificity (exon2, 3 & 4) 
 
Name Primers Expected base pair Stop Length Tm GC% Start
CaSR E7-3.1-1 Fwd 2016-10-17 CTCATCTTCTTCATCGTCTG
26 20 58 45 6
CaSR E7-3.1-1 Rev 2016-10-17 GGATGGCAATCACCTCTA
53 97 18 58 50 79
CaSR E7-3.1-2 Rev 2016-10-17 CACCTTGAAAGCGTGAG
179 222 17 58 52.9 205
CaSR E7-3.1-3 Rev 2016-10-17 CTTCGCTGTTGCTCTTG 
294 337 17 58 52.9 320
CaSR E7-3.1-4 Rev 2016-10-17 GCTCATCAAAGCTCAGTG
473 517 18 58 50 499
CaSR E7-3.1-5 Rev 2016-10-17 GAGTTCTGGTGCGTAGAA
519 563 18 59 50 545
CaSR E7-3.1-6 Rev 2016-10-17 GTCAGATCTAAGTCCGTTTC
604 650 20 57 45 630
CaSR E7-3.1-7 Rev 2016-10-17 CTCTGTGAACTGGACACTA 
710 755 19 58 47.4 736
CaSR E7-3.1-8 Rev 2016-10-17 CCAGTCTTCTCCTTCCAT 
785 829 18 58 50 811
CaSR E6-1 Fwd 2016-10-17 GTGCCCTTCTCCAACTG
38 17 59 58.8 21






3.7 Discussion and major conclusion 
Understanding the mechanistic functioning of CaSR is vital for drug discovery not only for 
CaSR related disorders but also for overall GPCR family-related pathologies. Cell lines derived 
from tumors represent a critical tool to understand the oncogenic mechanism as well as a 
preclinical tool to study the efficacy of new therapies in vitro and in vivo. In this chapter, we 
examined the CaSR mediated intracellular signaling mechanism in HEK293 cells and thyroid 
cancer cells. The intracellular calcium oscillation facilitated by CaSR activation via [Ca2+]o, Mg
2+ 
and tryptophan derivative (TNCA) is characterized in wild type CaSR in HEK293 cells. EC50 of 
CaSR for Ca2+ was 4 mM with a Hill number of 3, and for Mg2+ EC50 was 13 mM and Hill number 
Name Primer Sequence Expected bp Start Stop Length Tm GC%
CaSR E-2-1 Fwd 09-07-16 CTCAAGGACCACCCACATTAC 247 43 64 21 62 52.4
CaSR E-2-1 Rev 09-07-16 GACCCAGCAGCAGCTATAAA 250 270 20 62 50
CaSR E-2-2 Fwd 09-07-16 CCAAACTCCTAGCTGTCTCATC
201 195 217 22 62 50
CaSR E-2-2 Rev 09-07-16 CAGACTCCGGCCTTGATTT
396 415 19 62 52.6
CaSR E-3-1 Fwd 09-07-16 GTATAATTTCCGTGGGTTTCGC 179 1 23 22 62 45.5
CaSR E-3-1 Rev 09-07-16 GCAGAACTCATCAAGGTTCAAAG 180 203 23 62 43.5
CaSR E-3-2 Fwd 09-07-16 TGCCATAGAGGAGATAAACAGC 181 43 65 22 62 45.5
CaSR E-3-2 Rev 09-07-16 CCACCACAGCAATCGTAGA
224 243 19 62 52.6
CaSR E-4-1 Fwd 09-07-16 CAGACTCCTCAGCAACAAGAA 587 21 42 21 62 47.6
CaSR E-4-1 Rev 09-07-16 AGAAAGGTGTCCACAGGTAAAG 608 630 22 62 45.5
CaSR E-4-2 Fwd 09-07-16 TTCAAGTCTTTCCTCCGAACC 204 46 67 21 62 47.6
CaSR E-4-2 Rev 09-07-16 CATGCTGGATCTCTTCCTCATC 250 272 22 62 50
CaSR E-4-3 Fwd 09-07-16 CCCAGTACTCTGATGAGGAAGA 532 239 261 22 62 50
CaSR E-4-3 Rev 09-07-16 GGCAATGGAGTAGACTGCTAAG 771 793 22 62 50
CaSR E-5-1 Fwd 09-07-16 AGCACCTACGGCATCTAAAC 195 8 28 20 62 50
CaSR E-5-1 Rev 09-07-16 GAACCCACTCCACAGGATTT 203 223 20 62 50
CaSR E-5/6-1 Fwd 09-07-16 AGCACCTACGGCATCTAAAC 302 8 28 20 62 50
CaSR E-5/6-1 Rev 09-07-16 GGACACTCCACACACTCAAA 310 330 20 62 50
CaSR E-5/6-2 Fwd 09-07-16 TGGCTCCATCGTGTTTAAGG 194 123 143 20 62 50
CaSR E-5/6-2 Rev 09-07-16 CCATCAGGACACTCCACAC 317 336 19 62 57.9
CaSR E-7-1 Fwd 09-07-16 CCTACCTGCTGCTGCTATTATG 632 2015 2037 22 62 50
CaSR E-7-1 Rev 09-07-16 GCTGTGGCTTAGAGAGGTTAAG 2647 2669 22 62 50
CaSR E-7-2 Fwd 09-07-16 CTTTGTGCTGGGTGTGTTTATC 577 152 174 22 62 45.5
CaSR E-7-2 Rev 09-07-16 CTGGCATAGGCTGGAATGAA 729 749 20 62 50
CaSR E-7-3 Fwd 09-07-16 CTTCATCGTCTGGATCTCCTTC 795 710 732 22 62 50
CaSR E-7-3 Rev 09-07-16 CCCAGTCTTCTCCTTCCATTT 1505 1526 21 62 47.6
Table 3.4 New Primers designed to study Exon 2 through 7 
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of 2.9. Presence of 0.5 mM and 1.5 mM Ca2+ was able to potentiate the efficacy of Mg2+ by 
decreasing EC50 for Mg
2+ to 7.5 and 5.9 mM respectively, which proved the cooperative nature 
between Ca2+ and Mg2+. Mg2+ is a known allosteric modulator of many GPCRs. Mg2+ is known to 
increase the binding affinity of receptors to their agonists including in opioid receptors [244], beta-
2 andrenergic receptor [245]and dopamine D2 receptor [246] and generally not effective on 
antagonist binding. Mg2+ is also known to bind G-proteins directly to modulate GPCRs. Here in 
our work, we validate the Mg2+ binding pockets described in the first crystal of hCaSR ECD 
domain [247]. Two Mg2+ binding sites are shown. Site 1 is at the dimerization interface of 
subdomain 2 where Mg2+ coordinates with S240 and four water molecules with an ideal Mg2+ 
coordination geometry. Site 2 found on the periphery of subdomain 1 and Mg2+ coordinates with 
S84, backbones of I81, L87 and L88 and two water molecules. Furthermore, site 3 is described as 
conserved (E228, E231 and E241) acidic patch where Gd3+ was observed to bind. This patch is close 
to the subdomain 2 dimerization interface adjacent to site 1. Oscillation study with site-directed 
mutations (E228I or E229I/E229I double mutant) at site 3, which is also related to ADH resulted 
in impediment of the Ca2+/Mg2+ CaSR sensing as well as CaSR mediated Mg2+ evoked Ca2+i 
mobilization and calcium oscillation. Moreover, TNCA was able to act as a co-agonist and reduce 
the EC50 for both Ca
2+ and Mg2+, but more significantly for Mg2+ by 2.5-fold. TNCA is observed 
to be bound to S147, A168, S170 and Y218 in hCaSR ECD [247]. Previous studies have shown that 
aromatic amino acids including, L-Phe, L-Trp and L-Tyr, are able to allosterically regulate the 
extracellular Ca2+ sensing in CaSR [248] by binding at the Venus-fly trap domain near the 
orthosteric site to potentiate the activity of extracellular Ca2+ on various downstream pathways 
[74, 248-250]. GPCRs such as GABAB is modulated by aromatic (L-Phe) and aliphatic (L-Leu 
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and L-Ile) amino acids [251]. Here, TNCA shows about 1000-fold more potency than Phe in 
reducing the Mg2+ or Ca2+ activation of CaSR.  
In the second part of the chapter, we examined the CaSR mediated Ca2+ sensing in 
transfected HEK293 cells, human (TT) and rat thyroid medullary cancer cells (6-23) by monitoring 
intracellular Ca2+ response to extracellular Ca2+ as well as CaSR associated drugs. It is known that 
CaSR is expressed and functions in tissue- and pathology- specific manner. Using R-programming, 
Ca2+i peaks for the 6-23 cells and manual counting for TT cells with prominent peaks were 
quantitated. The oscillation distribution by hCaSR in HEK293 cells (n= > 5) was shifted to the 
lower Ca2+ concentrations of 0.5 to 3 mM by cinacalcet instead of 2 to 10 mM in lone Ca2+ 
treatment implying the potency of cinacalcet to enhance stimulation of CaSR mediated signaling. 
Cinacalcet also increased the oscillation frequency from 0.5-2 peaks/minute to 1-2.5 peaks/minute. 
Previous studies have noted that calcimimetic agents increase the intracellular calcium 
concentration in a dose dependent manner [252]. Antagonist (NPS-2143) was able to completely 
obstruct the Ca2+ sensing. W7, an inhibitor of CaM, a CaSR regulating protein was able to decrease 
the oscillation frequency to 0-1 peaks/minute as shown by Huang et al [3]. We report for the first 
time that W7 is able to obstruct the cinacalcet overactivation partially, or that cinacalcet can rescue 
the W7 inhibition.   
Effectiveness of divalent cations such as Ca2+ and Mg2+ metal ions as well as CaSR 
associated drugs and the role of CaM in inducing CaSR activation as observed as Ca2+i is 
ambiguous in C cells. Changes in Ca2+i is directly associated with hormone production in C cells. 
Therefore, understanding the efficacy and potency of CaSR in alteration in Ca2+i is imperative for 
drug discovery associated with CaSR dysfunction in MTC cells. Previous works have suggested a 
dominant L-type voltage gated channel as Ca2+ sensing mechanism in 6-23 and its absence in TT 
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cells. Another study showed Ca2+i transients and/or oscillation to 3 mM Ca
2+
o and CaSR agonists 
including, Gd3+, La3+ and neomycin as monitored by Fura-2 [212]. Additionally, calcitonin 
increase was observed with 3 mM Ca2+o with an added time course and with La
3+ and Gd3+ in dose-
dependent manner. Moreover, recent work by Desai et al in 2014 showed that normal TT cells 
displayed higher intracellular Ca2+ to 1.5 mM Ca2+ in the presence of cinacalcet and neomycin 
(CaSR agonist) than the TT cells with siRNA knockdown of RAMP (receptor activity modifying 
protein), a CaSR regulator [16] as monitored using Fluo-4AM. Ca2+ sensing at higher Ca2+o 
concentration is missing in these studies.  
TT cells demonstrated CaSR mediated transient peaks at 5 and/or 7.5 mM extracellular 
Ca2+ by < 30 % of the cells (n=23). Whereas, the addition of 10 µM cinacalcet evoked the transients 
at 2 mM Ca2+ in 88% of the cells and resulting in 40% increase in the amplitude as compared to 
other treatments (n=24). NPS2143 was able to inhibit the Ca2+ response at 7.5 mM and 
preincubation with 50 µM W7 was able to impede the agonistic behavior of cinacalcet, implying 
that cinacalcet and W7 have an additive effect the CaSR mediated signaling. On the other hand, a 
highly non-synchronous CaSR mediated oscillatory behavior was revealed in 6-23 cells in the first 
batch obtained in 2017. These cells contained a mixture of CaSR with variable activity, some with 
low EC50 for Ca
2+ at 0.5 mM and a lower Hill number of 1.5 and some that were un-responsive to 
Ca2+. The intracellular Ca2+ responses were erratic with sharp peaks similar to rMTC 44-2. On the 
other hand, rMTC 44-2 cells are known to show no IP1, IP2 or IP3 generation when Ca
2+ is 
increased above 1 mM [6], but a study by Thomsen in 2012 examined 6-23 and monitored IP1 
generation in 6-23. This study also reported that strontium as compared to calcium biases the 
signaling to ERK1/2 and another pathway independent of Gq/11 and Ca2+ mobilization [214]. 
There was also increased potency of strontium to mediate CT secretion and possibly using a 
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different signaling mechanism than calcium [214]. These studies were primarily based on response 
to calcitonin, IP1 and cAMP secretion. In our study, we report a pattern of Ca
2+
i, the knowledge of 
which can allow us to decipher CT and IP1 responses as well. Extracellular Ca
2+ sensitivity 
saturates at 3-4 mM Ca2+ and declines with higher extracellular Ca2+ [6] which was not observed 
in our study.  
Again, using R-programming, Ca2+i peaks for cells with prominent peaks were quantitated 
in 6-23 (n= > 16). We report that cinacalcet can up-regulate the Ca2+i response of cells and the 
percentage of cells responding is increased by 25% and increases oscillation frequency from 0-0.5 
peaks/minute to 1-2 peaks/minute. Pre-incubation with W7 can down-regulate the effects of 
cinacalcet by 50% and also down-regulate the oscillation frequency from 1-2 peak/minute to 0.5-
1 peaks/minute. NPS-2143 was able to inhibit Ca2+i response by 65%. The remaining response 
suggests an alternative Ca2+ sensing mechanism which has been previously reported in 6-23 as 
well as other rMTC 44-2 cells [6] as the L-type voltage-gated channel. Interestingly, CaSR in both 
the C cells were selective to Ca2+ and not to Mg2+ implying biased signaling. This has also been 
previously shown in sheep parafollicular primary C-cells where the Ca2+ sensing varying potency 
of CaSR activation by various divalent cations was shown such that Gd3+>Ba2+>Ca2+>>Mg2+ [45].  
Next, efforts were made to dissect the molecular reason behind the above-mentioned 
difference in Ca2+ sensing between HEK293 cells and C cells. We firstly report four-fold lower 
expression of endogenous CaSR in both 6-23 and TT cells as compared to stably wild type CaSR 
transfected HEK293 cells (5001) or transiently transfected HEK293 cells. 6-23 is missing the 
CaSR monomers even in reducing condition, implying a varying molecular composition of CaSR. 
CaSR immunostaining results show that surface expression of CaSR in both C cells is low relative 
to the cytosolic CaSR or membrane expression in 5001 and transiently transfected wild type CaSR 
169 
in HEK293 cells. Our results (1) validates the oscillation and transient peaks were partially but to 
a greater extent CaSR mediated in C- cells, and (2) re-validates that CaSR functions tissue- and 
species- specifically. Our findings provide an important insight into potential differential modes 
of modulation of intracellular Ca2+ signaling and thereby, control of calcitonin, through regulation 
of endogenous CaSR activation in pathologies related to dysregulation of Ca2+ homeostasis. 
Interestingly, the second batch of 6-23 from ATCC in 2018 showed a differential Ca2+i response 
than the first batch. One way of explaining this difference is that 18-36% of the cell lines are 
usually misidentified or cross-contaminated with other cell lines, thus this could have 
compromised our results. This has been shown in previous studies [253-255].  
Next, we examined the role of CaM in CaSR mediated signaling in C cells. Co-localization 
of CaSR and CaM in TT and 6-23 cells show a significant Pearson’s coefficient of 0.78 and 0.63, 
respectively. Surface plot of the intensity of minuscule co-localized spots also supports that the 
two proteins exist at close contact. We also provide evidence of co-immunoprecipitation of CaM 
with endogenous CaSR in 6-23 in the presence of 2 mM Ca2+. This is the first direct evidence of 
role of CaM in CaSR mediated Ca2+ sensing in 6-23 cells. However, the co-immunoprecipitation 
of CaM with CaSR in TT cells were not successful. This could be resulted due to lower expression 
level and non-optimized condition for CaSR immunoprecipitation in TT cells. Additionally, it has 
been a challenge to use anti-CaSR antibody for CaSR immunoprecipitation which is > 10-fold less 
efficient than using anti-FLAG antibody in recombinant CaSR in HEK293 cells. Further, we used 
RT-PCR method to characterize the CaSR in 6-23 but due to a low transcript, the sequencing was 
partial. However, we showed for the first time that 6-23 contained CaSR with isoform I with 10 
amino acid insertion in its 6th exon. For this I collaborated with Dr. Yu Li from Emory and 
Xiaojuan Tan to optimize RT-PCR for low transcript gene. First, primers with were re-designed 
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with 18-24 bases, 45-60% GC content, starting and ending with G/C pair and with melting 
temperature at ~60°C. The high RNA concentration and poly-A primer was used to enrich cDNA 
from pathological cells.  
All in all, we show that oscillation distribution pattern is highly differential implying tissue- 
and species-specific function of CaSR. NPS-2143 was unable to completely inhibit Ca2+i response 
suggesting an alternative Ca2+ sensing mechanism in C cells. C cells respond with an increase in 
the number of responding cells to cinacalcet and additionally, an increase in frequency in 6-23 
cells. Mg2+ is unable to activate the Ca2+ mobilization in C cells implying biased signaling. We 
also established for the first time that CaM binds with CaSR and modulates CaSR mediated 
signaling in C cells and demonstrated lower expression level and differential mode of 




4 CHAPTER IV: CALCIUM-SENSING RECEPTOR IN PROSTATE CANCER: ITS 
CHARACTERIZATION, PROTEOMICS AND ROLE IN BONE METASTASIS 
4.1 Abstract 
 The calcium-sensing receptor (CaSR) mediated [Ca2+]o signaling is known to play a role in 
tumor growth, invasion and metastasis of several cancers including prostate cancer (PCa). PCa is 
one of the leading causes of death in men. Higher CaSR has been observed in prostate cancer 
tissues metastasizing to bones as compared to normal prostate or primary prostate cancer tissues 
without bony metastasis. In this study, we aimed at understanding the intracellular Ca2+ signaling 
mediated by CaSR and molecular characterization in PCa, which is largely missing. PC3 cell line 
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derived from prostate tumors metastasizing to bones can represent a critical tool to understand the 
oncogenic mechanism and Ca2+ sensing. We report that the CaSR mediated Gαq/11 associated Ca
2+
i 
response, such as the intracellular calcium transients/oscillation and IP1 are absent in PC3. 
Additionally, the CaSR mediated ERK1/2 signaling in PC3 is impeded as compared to the wild 
type in HEK293 cells. In order to explore if these variabilities were derived from differential 
expression, we used immune-assays and RT-PCR for molecular characterization. We report that 
CaSR in PC3 is a monomer in non-reducing condition with a lower molecular weight of 110 kDa 
suggesting that endogenous CaSR may exist as a potential variant with splicing or lower 
glycosylation which results in its incapability to form an oligomer. Immunostaining results show 
that most CaSR is expressed within the cell as compared to functional plasma membrane CaSR. 
Using RT-PCR we validated that a full CaSR with all seven exons is present. These results lean 
towards the possibility that the lack of Ca2+ sensing is due to CaSR in PC3 predominantly existing 
intracellularly in an immature stage.  
We further show that PC3 is able to generate an oligomer CaSR when transiently 
transfected. However, this overexpression of wild type CaSR in PC3 cells or application of CaSR 
agonists such as TNCA and cinacalcet cannot rescue the intracellular Ca2+ response which further 
indicates that CaSR in PC3 may lack other necessary regulators required for the Ca2+ signaling. 
Next, we used mass spectrometry we characterize the overall proteome of PC3. A total of 3327 
proteins were detected. Gαq is not detected however, CaM and other G-proteins such as Gαi-2, 
Gαs and Gβ are detected with strong MS/MS count. But, CaSR was not detected with PSM of 0 
which supports the retarded Ca2+ sensing and low transcript generated in RT-PCR. Only 22 (e.g., 
programmed cell death protein 6 (PDCD6), BH3 interacting domain death agonist (BID), mitogen-
activated protein kinase1 (MAPK1), mitochondrial import inner membrane transmembrane 
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(TIMM13), E3 ubiquitinating-protein ligase UBR5, exosome complex component MTR3 
(EXOSC6), coiled-coil domain containing protein 86 (CCDC86), and histidine-tRNA ligase 
(HARS)) were at least two-fold up-regulated in expression in the presence of Ca2+ and 17 (e.g., 
deubiquitinating protein (VCPIP1), BAG family chaperone regulator (BAG3)) were 
downregulated in the presence of Ca2+. Because we were interested in prognosis markers, we 
compared the known markers in prostate cancer from the human protein atlas. We found two 
proteins, Epoxide hydrolase 1 (EPHX1) and Catebhol O-methyltransferase (COMT) with good 
abundance with the stringency of ≥ 4 average PSM and with average LFQ intensity in the range 
of 109. These markers were decreased with the Ca2+ treatment in PC3 by < 0.9-fold as compared 
to one treated with EGTA. However, these were ≥ 3-fold increased as compared to HEK293 cells. 
Isoforms of other good prognostic markers including the ubiquitin (RNF114), Ubiquitin-
conjugating enzyme (UBE2D2/3) and SLCs were detected with good stringencies.  
Next, we used gene ontology on the MS results to understand the role of extracellular Ca2+ 
in alteration of proteomics in PC3 cells as compared to HEK293 cells. We noted that global 
proteome is generally upregulated in PC3 as compared to HEK293 cells. In the presence of Ca2+, 
≥ 4-fold upregulated proteins are associated with pathways including, trans-Golgi network vesicle 
budding and citric acid cycle. Further, in vivo studies were conducted to understand and re-enforce 
involvement of CaSR in PC3 colonization in bones by preventing cell apoptosis of cancer cells, 
inhibiting invasion, and promoting mesenchymal-epithelial transition. My work showed a 
significant decrease in tumor growth when injected in mouse tibia with PC3 with CaSR 
knockdown as compared to the control knockdown. Our work indicates that even in the presence 
of normal CaSR, PC3 displays unique Ca2+ signaling that is independent of Gαq, possibly 
undergoing signaling bias.  
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4.2 Introduction 
4.2.1 Prostate Cancer 
Prostate cancer is the second leading cause of cancer-associated deaths in American men, with 
metastatic prostate cancer having poor survival rate; the median survival rate of around 3 years 
and 30% for 5-year survival rate [89, 256]. Prostate cancer microscopic lesions are localized to 
prostate. However, the prostate cancer cells metastasize exclusively to bones primarily to spine, 
femur, pelvis, rib cage, skull and humerous [257]. This causes problems such as bone fractures, 
pain, spinal cord compression and bone marrow suppression [88, 258]. Causing disabling pain and 
complications. Unfortunately, there is no cure for skeletal metastasis of prostate cancer and the 
application of radiation, hormonal manipulations and/or chemotherapy are only palliative [259].  
 
 
Figure 4.1 GPCR dimerization essential for many functions such as trafficking, 
signaling, ligand binding, cooperativity and internalization. Adapted from [7] 
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4.2.2 Prostate Cancer, CaSR and Ca2+o 
Ca2+ signaling is associated with tumor progression through processes including 
proliferation through induction of early response genes FOS, JUN and MYC in G1 cycle [260]. It 
is also involved in invasiveness and migration as Ca2+ controls phosphorylation of contractile 
proteins and induces matrix metalloproteinases [261]. Ca2+ signaling also plays an important role 
in cell death in case of greater cytosolic Ca2+ accumulation such as in-case of the defect in SERCA 
pump [262]. PTEN loss is associated with IP3R degradation [263]. The processes thus involved 
with Ca2+ signaling allow for the development of resistance to cancer therapies.  
Several studies implicate the role of Ca2+o and CaSR in prostate cancer bone metastasis. 
Stephen Paget’s theory on “seed and soil” postulates the importance of the microenvironment 
(soil), in the secondary site in organ-specific metastasis [89]. The blood plasma Ca2+ concentration 
is ~2.2-2.6 mM whereas, the bone plasma is around 10 mM and 20 mM in extracellular space of 
bone tissue [22]. Osteoclasts are known to generate extracellular Ca2+ from the matrix during bone 
resorption resulting in up to 40 mM local Ca2+ concentration [264]. High Ca2+ could act as a 
favorable microenvironment for the metastasized cells. Calcium homeostasis is an indispensable 
process that is regulated through the Calcium-Sensing Receptor (CaSR) which is a class C, G-
protein coupled receptors (GPCR). This critical homeostasis regulates three of the important 
cellular processes that determine the cellular fate such as cell proliferation, differentiation and 
apoptosis [30, 66].  
46 years ago, the accompaniment of secondary hyperparathyroidism (SHPT) in late-stage 
prostate cancer patients (6) has been described and recent clinical reports show the increased level 
of serum PTH in advanced prostate cancers [265]. The probable mechanism for this association is 
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the activation of CaSR due to hypocalcemia caused by osteoblastic lesion in skeletal sites of 
metastatic prostate cancer and which in turn results in increased PTH production and secretion 
[227, 265]. Additionally, PTH is known to increase the cell proliferation of human prostate cancer 
in vitro (7) and promote bone metastasis in xenograft mouse model of prostate cancer (80). 
Therefore, down-regulation of PTH secretion through modulation of CaSR activity could work to 
obstruct SHPT in prostate cancer patients [227]. Same study also shows that cinacalcet trigger 
mitochondria-related apoptotic pathway mediated by CaSR and modulated by Bcl-xL anti-apototic 
pathway [227]. PTHrP is known to be the chief mediator of hypercalcemia related malignancy and 
osteolysis [259]. In bones, Ca2+ plays a critical role in osteoblasts [10, 233, 266] and is known to 
be associated indirectly through PTH or other endocrine factors [267]. Extracellular Ca2+ and 
CaSR were shown to play an essential role in potentially protecting osteoblasts against apoptosis 
by monitoring their effects on proliferation and bone formation [268]. However, the role of CaSR 
in bone is unclear.  
In 2001, a 5.2 kb transcript of CaSR similar to that in parathyroid CaSR was verified in 
PC3 and LNCaP prostate cancer cell using northern analysis [259]. The same study verified a 480 
bp transcript of CaSR using RT-PCR and subsequently, CaSR protein was validated by western 
blot results [259]. This study was directed in understanding the CaSR mediated parathyroid 
hormone related protein (PTHrP) release induced by CaSR agonists Ca2+, neomycin, and spermine. 
They showed a dose-dependent PTHrP secretion with maximal stimulation at 7.5-10mM Ca2+ 
[259]. The requirement of higher Ca2+ level around resorbing osteoclast could be the result of the 
natural high Ca2+ present around that area. This high Ca2+ requirement has also been seen in normal 
keratinocytes [269], normal cervical epithelial cells [270],  oral squamous cancer cells [271], JEG-
3 cells [272], and H-500 rat Leydig cells [273], which is used as a model for hypercalcemia of 
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malignancy. CaSR was shown to be associated with prostate cancer. However, this study failed to 
look at the detailed expression of CaSR as compared to the wild type. Feng et al. in 2014, also 
showed CaSR expression to be higher in the bone metastasis than in the primary prostate tissues 
metastasis with microarray data [274]. [90]. Furthermore, Liao et al. in 2006, had shown a higher 
proliferation of skeletal metastatic cells, PC3, in increased Ca2+ condition as compared to LNCaP 
cells that metastasize to lymph nodes, and this mechanism is mediated by CaSR as shown by the 
decrease in proliferation when CaSR is knocked-down [91]. Along with PTH, another Ca2+ 
homeostasis related hormone, calcitonin, and calcitonin receptor (CTR) abundance known to be 
upregulated in malignant prostates, and positively correlate with Gleason grade of prostate cancer 
[275]. Calcitonin is also associated with various cancer regulated processes such as the tumor 
growth, invasion, angiogenesis, chemoresistance and metastasis [276-278]. It was shown that PC3 
cells lacked CTR[275]. In addition to prostate cancer, CaSR has been shown to be highly expressed 
in patients with primary renal cell tumors with bone metastasis in comparison to lung metastases 
or no metastases. Further, the proliferation and migration induced by Ca2+ treatment in RCC cells 
obtained from patients with bone metastasis was inhibited by CaSR inhibitor NPS2143 [92].  
4.2.3 PC3 and LNCaP cells lines 
Prostatic cancers are usually adenocarcinomas that form gland and express markers for 
androgen receptor (AR) and prostate-specific antigen (PSA) [279]. On the other hand, another 
form of prostate cancer is prostatic small cell neuroendocrine carcinoma (SCNC) which do not 
form glands and are negative for AR and PSA [279]. This SCNC is extremely aggressive and 
present in locally advanced disease or distant metastasis and patients usually die within months of 
diagnosis [280, 281]. These do not respond to hormonal therapy [282, 283] and occurs as a minor 
population in prostatic epithelial malignancies. These are small, with fine chromatin pattern, scant 
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cytoplasm and nuclear molding [279]. These account for less than 1% of prostate cancer but is 
recurrent in patients with conventional prostatic adenocarcinoma and who take hormonal therapy.  
PC3 [284] is a epithelial cell used as a model for PCa with spectrum of aggressive form and with 
AR dependence. On the other hand, LNCaP [285, 286], also an epithelial cell, is used as a model 
for indolent form of PCa with castration-resistance. Study by Tai et al in 2011 showed that PC3 
have features of SCNCs and LNCaP with conventional adenocarcinoma [279].   
4.2.4 Ca2+ signaling in bone environment 
 
 
4.2.5 Prognosis of prostate cancer 
The most common screening used for early detection of PCa is prostate-specific antigen 
(PSA). But higher PSA levels are also present in non-malignant conditions such as benign prostatic 
hyperplasia (BPH) [274, 287]. Other prognostic markers for PCa include performance status (PS) 
score, hemoglobin level, age factor, albumin, lactate dehydrogenase (LDH), Gleason score, pain 
intensity and metastasis characteristics [288]. For biomarker profiling, cDNA microarray between 
50 normal and neoplastic protease specimen and three typical prostate cancer cells, including PC3, 
Figure 4.2  Extracellular Ca2+ induced CaSR mediated signaling in bone cells [10] 
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LNCaP, and DU-145 were conducted. Common genes such as the tumor suppressor PTEN and 
CDH1 (E-cadherin) were downregulated, and proto-oncogene MYC and fatty acid synthase were 
up-regulated [274]. Further hepsin, a transmembrane serine protease and pim-1, a serine/threonine 
kinase were also correlated with PCa [274].  Other related gene mutations in MYC, RB1, MET, 
BRCA1/2 and ATM are known [289, 290].  
4.2.6 The human protein atlas on prostate cancer proteome 
According to the proteome analysis using TCGA transcriptomics data and antibody-based 
protein data, they suggest a prognostic based on transcriptomics data from 494 patients, 134 genes 
associated with unfavorable prognosis and only 25 genes associated with favorable prognosis 
(https://www.proteinatlas.org/humanproteome/pathology/prostate+cancer).  
4.2.7 CaSR alternative splicing 
CaSR gene (CASR) encodes for calcium-sensing receptor and is a ~100-kb spanning single 
copy gene that maps to human 3q13.3-21. Out of the eight exons, exons 2 to 7 encode the CaSR 
protein of 1068 amino acids. Exons 1A and 1B are able to encode for two alternative 5′- 
untranslated region (UTR) that may splice to a common segment encoded by exon 2 [31]. Exon 2 
contains 242 nucleotides of the 5′-UTR upstream of the ATG translation initiation codon [31]. 
CASR is expressed in multiple tissues and organs at various levels. The variation of expression of 
CASR gene as multiple alternative transcripts in multiple tissues/organs hint at the ability to 
diversify its functions and regulations. A splice variant with an exon 3-deleted CASR transcript in 
thyroid TT cells, placental cytotrophoblast, and in parathyroid, thyroid, and kidney [31, 291] 
causes poorly expressed and trafficking of CaSR to the cell surface. Another alternative transcript 
of CaSR exists in human keratinocytes where exon 5 is deleted (with a 77-amino acid in-frame 
deletion in the exodomain) [292]. The relative amounts of full-length is lowered during 
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keratinocyte differentiation and the alternatively spliced variant is shown to cause the full-length 
protein to be less responsive to Ca2+. This variant of CaSR is also known to be upregulated in skin 
and kidney in the knockout mice and is shown to compensate for the absence of the full-length 
CaSR in bone and cartilage [31].  
 
4.2.8 Alternative splicing 
Alternative splicing (AS) of pre-mRNAs is extensively prevalent throughout most 
eukaryotes, occurring in 40-60% of all genes [293] and in as many as ~95% of human multi-exon 
Table 4.1 20 genes with highest significance associated with favorable 




genes [294]. This has allowed for the high levels of tissue specificity and functional diversity in 
higher organisms [295]. AS plays a vital role in many cellular functions including the regulation 
of neuronal development [296], metabolism [297], immunity [298], and signaling pathways 
through changes in protein-protein interactions [296, 299].  
4.2.9 Proteomics 
Mammalian cell lines are an indirect means to understand the much larger and fundamental 
biological processes. These processes are dictated by proteomics and cellular response that are 
common or differential. By using mass spectrometry, we can identify and quantify proteins in a 
global manner which can further indicate the molecular processes that are altered between such 
systems. Many previous works have used global proteomics but have been either limited with their 
number of detected proteins, such as Bukart et al. [300] compared seven cell lines and detected 
~2000-4000 proteins per cell line and were limited to more abundant proteins. The human genome 
consists of about 20,000 genes with much more complex proteomes. It has been estimated that a 
single cell can express about 10,000 proteins [301]. Geiger el al in 2012 characterized over 10,000 
proteins in each cell lines. The same group also characterized potential biomarkers for breast 
cancer [302]. In our work, we employ the latest proteomics technique to achieve further 
understanding of the proteostasis affected by the Ca2+o in PC3 as well as compare the proteome 
between PC3 and HEK293 cells. This may allow us to uncover the biomarkers pertaining to 
prostate cancer.  
4.3 Challenges 
As mentioned in chapter III, the challenges of studying CaSR in the endogenous form in 
pathological cells is the four-fold lower expression level, heterogeneity of CaSR transcripts and 
variants, dynamic CaSR lifecycle, and multitude binding partners involved in signaling. There is 
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a limitation of methods as well. The sensitivity of RT-PCR and PCR can be affected by many 
parameters such as primer specificity, heterogeneity of transcripts, annealing temperature, quality 
of RNA extracted, handling of RNA. Mass spectrometry data is affected by glycosylation, 
antibody specificity, sample handling 
 
4.4 Major Questions addressed  
1. How do the characteristic feature of CaSR in prostate cancer cell different from the wild 
type CaSR? 
2. Do CaSR mediated signaling follows the conventional scheme in prostate cancer cells? 
3. How do divalent cations and drugs impact CaSR mediate signaling? 
4. Is the differential response due to expression level or presence of variants? 
5. How does Ca2+o affect the proteostasis of PC3 cells?  
6. How does the proteomics of PC3 cells differ from HEK293 cells? 
 
4.5 Materials and Methods 
4.5.1 Antibodies  
Anti-FLAG antibody, mouse (Sigma-Aldrich, Canada) was used to precipitate the 
CaSR/interactor complex. Anti-CaSR C0493, mouse (Abcam, Cambridge, MA, USA) and Anti-
GAPDH mouse (Abcam, Cambridge, MA, USA) were used for western blot.  
4.5.2 Total protein extracts 
Transfected HEK293 cells from 90-100 % confluent 100 mm dishes were harvested after 
the treatment with 4 mM Ca2+ or 2 mM EGTA. They were washed with ice-cold Phosphate-
buffered saline (PBS) with 0 mM Ca2+ 3 times. 600 μL of 10 mM Sodium β-glycerophosphate, 50 
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mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% Triton X-100, 2 mM Na3VO4, 
50 mM NaF, 10 mM sodium pyrophosphate supplied with proteinase inhibitor cocktail (Roche, 
Basel, Switzerland) was used to lyse cells for 30 min in ice with frequent vortex and subsequently 
centrifuged to pellet cell debris. Cleared cell lysates were subjected to anti-FLAG 
immunoprecipitation before immunoblotting 
4.5.3 Cell culture and transfection 
HEK293 cells were seeded on 22 × 40 mm coverslips in 60 mm culture dishes and cultured 
in 5% CO2 at 37 ºC in respective media. HEK293 cells were cultured in high glucose Dulbecco’s 
modified Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal bovine serum (FBS). CaSR-
pcDNA with flag tag was transfected using Lipofectamine 3000TM (Invitrogen) according to the 
manufacturer’s instructions. Cells were incubated for 36-48 h in respective media after 
transfection. 
4.5.4 Cell lysis 
10 mM Sodiumβ-glycerophosphate, 50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EDTA 
(pH 8.0), 1% Triton X-100, 2 mM Na3VO4, 50 mM NaF, 10 mM Sodium pyrophosphate supplied 
with Sigma proteinase inhibitor cocktail was used to lyse cells for 30 min in ice with frequent 
vortex. For each condition, ~1-2 mg total protein was used. antibody (flag 10ug) and dyna bead 
was incubated for 30 min incubation of at room temperature in 200ul PBS and 0.01% Tween20 
and washed once with lysis buffer. Antigen was incubated overnight at 4 degrees. Or, the Dyna 
bead, lysate and antibody were incubated at 4 degrees overnight. Next day, the beads were washed 
two times with lysis buffer and 1 time with PBS with Ca2+ or EGTA. Or for the [Ca2+]o perturbation 
experiment, cells were incubated with 0.1% BSA Ca2+ depleted DMEM (low glucose) for 30 min 
and Ca2+ and EGTA were added to the medium and incubated for 2 h at 37 degrees. After overnight 
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incubation, the beads were washed four times, two with lysis buffer and two with PBS without 
additional Ca2+ or EGTA.  
10% beads were suspended in 30 ul of 2X sample buffer with 5% beta mercaptonol and 
heated for 10 min at 70 or 100 degrees.   
4.5.5 RNA preparation 
Illustra RNAspin Midi RNA Isolation kit (GE Healthcare) was used to separate the RNA 
from the PC3 cells as described by the manufacturer’s protocol. 6 X 106 cells were lysed using 
buffer RA1 and β-mercaptoethanol. After vortexing vigorously, the chaotropic salts in the lysis 
buffer break open the cells and inhibit RNases. β-mercaptoethanol helps to inhibit RNases and 
break up RNA-protein complexes. The lysate was filtered by centrifugation through an RNAspin 
filter unit. 70% ethanol was added to the cleared lysate and applied to a silica column. The 
chaotropic salt in the lysis buffer plus the ethanol promotes binding of RNA > 200 nucleotides 
long to the silica membrane. Denatured proteins are collected in the flowthrough following 
centrifugation. After the addition of ethanol, a stringy precipitate may become visible. All the 
precipitate were loaded onto the column. The membrane was desalted using desalting buffer to 
wash away salts. RNase-free DNase I was added to digest membrane-bound DNA and incubated 
briefly at room temperature. Finally, the column was washed to inactivate DNase, then washed 
with a low-salt buffer containing ethanol to remove residual salts and other contaminants. After 
drying the membrane, the purified total RNA was eluted using RNase-free water and immediately 
placed on ice or frozen. 
4.5.6 RT-PCR 
Purified RNA is a mixture of mRNA and rRNA. In mammalian system, poly-A enrichment 
is used to enrich the mRNA and separate the rRNA out. Next, Superscript III (Thermo Scientific) 
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was used to isolate RNA and KOD hot start was used to carry out PCR. The protocol was as 
described by the manufacturer.  A 20-μl reaction volume as used for 500 ng of mRNA. 1 μl of 
oligo(dT)20 (50 μM), 500 ng mRNA, 1 μl 10 mM dNTP mix (10 mM each dATP, dGTP, dCTP 
and dTTP at neutral pH) sterile, 13 ul distilled water was added to a nuclease-free microcentrifuge 
tube. The mixture was heated to 65°C for 5 minutes and incubate on ice for at least 1 minute.  The 
contents of the tube were collected by brief centrifugation and 4 μl 5X First-Strand Buffer, 1 μl 
0.1 M DTT, 1 μl RNaseOUT™, Recombinant RNase Inhibitor (Cat. no. 10677-019, 40 units/μl) 
were added. The solution was mixed by pipetting gently up and down. The tube was incubated at 
50°C for 30–60 minutes. Finally, the reaction was inactivated by heating at 70°C for 15 minutes.  
The cDNA (0.794 ug/ul) was used as a template for amplification in PCR. To remove RNA 
complementary to the cDNA, E. coli RNase H was added at 1 μl (2 units) and incubated at 37°C 
for 20 minutes. PCR reaction tube was prepared by adding 10X PCR Buffer [200 mM Tris-HCl 
(pH 8.4), 500 mM KCl], 3 μl 25 mM MgCl2, 5 μl 2 mM dNTP,1.5 ul Sense primer (10 μM) 1.5 
μl, Antisense primer (10 μM), 1 μl KOD hot-start polymerase (5 U/μl) (Novagen), 2 μl cDNA, 31 
μl autoclaved-distilled water to make a 50 μl solution. The reaction was heated to 95°C for 2 
minutes to activate polymerase and again 95°C for 20 sec to denature. The annealing was carried 
out at 56 °C for 30 sec. 30 cycles of PCR was used for an extension at 70 for 60 sec each cycle.   
4.5.7 Immunoblotting 
A total input protein of 50 ug and 30 ul of the 10 % bead samples were loaded in 8.5 % 
acrylamide gels and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDs-
PAGE) to separate proteins, then transferred to nitrocellulose membranes. The membranes were 
blocked with 3 % nonfat milk (w/v) in TBS for 2 hours at room-temperature with constant shaking. 
The antibodies of interest were diluted in 3 % non-fat milk (w/v) and 0.2% Tween-20 in TBS 
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(TBST). Anti-CaSR C0493, mouse (Abcam, Cambridge, MA, USA) was used at 1:700 dilution 
and HRP-conjugated mouse secondary antibody were used (Sigma-Aldrich, United States) at 
1:3000 dilution to probe CaSR. For, GAPDH, anti-GAPDH mouse (Abcam, Cambridge, MA, 
USA) was used at 1:3000 dilution and HRP-conjugated mouse secondary antibody was used 
(Sigma-Aldrich, United States) at 1:10,000 dilution. Membranes were incubated with the primary 
and secondary antibodies for 1 hour at room temperature with constant shaking and finally washed 
with TBST. The secondary antibody was visualized using ECL detection reagents (GE Healthcare, 
Little Chalfont, UK) developed on X-OMATTM imaging film (Kodak, Rochester, NY). 
4.5.8 Immunostaining 
HEK293 cells were grown on 20 × 20 mm coverslips placed in 6-well plates one day before 
the transfection. Cells subjected to transfection and after 48 h treated for immunostaining. Cells 
were washed with ice-cold PBS and fixed with 3.7 % formaldehyde for 15 min at room 
temperature, followed by a wash with PBS three times. Cells were permeabilized using 0.2 % 
Triton X in PBS for 10 min at room temperature. Mouse anti-FLAG monoclonal antibody was 
diluted 1000 times and incubated with cells overnight at 4°C to stain the CaSR. The cells were 
subsequently washed with PBS and stained with goat anti-mouse Alexa 488–conjugated secondary 
antibody for 1 hour at room temperature. Nuclei were stained with 4′,6-diamidino-2-phenylindole. 
Fluorescence was visualized using a Zeiss LSM780 confocal microscope. 
The stains were analyzed using Image J. After splitting the channels, the red and green 
channels were given rainbow RGB and were analyzed for the surface plot for the area of interest 
for co-localization. The corresponding peaks corroborate the co-localization of the two stains and 
therefore, of two proteins. Similarly, after splitting the channels, plugin coloc2 was used to analyze 
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the Pearson’s coefficient between two channels. Channels other than red or green were given 
Pseudo RGB using zenlite for Image J to read.  
4.5.9 IP1 assay 
HEK293 cells and PC3 cells were seeded in 24-well plates at 3 x 105 cells per well in 500 µl 
of culture medium. After transfection with WT CaSR or its various mutants, cells were further cultured 
for 24 hours at 37°C. Cell monolayers were first washed with Ringer’s buffer without calcium (121 
mM NaCl, 2.4 mM K2HPO4, 0.4 mM KH2PO4, 10 mM HEPES, 5.5 mM glucose, 1.2 mM MgCl2) and 
then incubated for 1 hour at 37 C in stimulation buffer (140 mM NaCl, 5 mM KCl, 10 mM LiCl2, 
0.55 mM MgCl2, 10 mM HEPES) containing varying concentrations of CaCl2. After treatment, cells 
were lysed for 30 min at 37°C with 50 µl of 2.5% IP1 ELISA Kit Lysis Reagent (CIS Bio International, 
Gif-sur-Yvette, France). The accumulation of IP1 was measured using an immunoassay based on 
competition between free IP1 and horseradish peroxidase (HRP) conjugated IP1 for binding to the 
monoclonal anti-IP1 antibody. The results for IP1 were expressed as percentage inhibition of IP1-HRP 
binding = [1-IP1-HRP binding in stimulated cells/IP1-HRP binding in unstimulated cells] x 100. 
4.5.10 Mass spectrometry 
LC-MS/MS Q-Extractive Orbitrap was used. LFQ intensity of each protein for each 
treatment condition was averaged from two total lysate samples from each from HEK293 and PC3 
cells in treated with Ca2+ or EGTA. The missing values were imputed as previously described 
using Perseus [130]. Enrichment of proteins was considered significant if the intensities had at 
least two-fold difference, i.e., log2(Ca
2+/EGTA) -PC3 or log2 (PC3/HEK293)-Ca
2+ ≥ 1.00. For 
robust stringency, we employed a requirement of minimum PSM of 2 for no less than two 
replicates and identification with at least one unique peptide. 
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4.5.11 Gene ontology 
Protein-protein interaction was performed using the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) version 10.0. Interaction network view was used to identify 
and visualize the degrees of interaction amongst the upregulated proteome (homo sapiens). 
STRING uses evidence from experimental and knowledge-based databases to provide confidence 
in functional associations or interaction through the Edge Confidence. Size of colored nodes 
represent evidence of known or predicted 3-dimensional protein structure.  
The Database for Annotation, Visualization, and Integrated Discovery (DAVID), version 
6.8, was used for the functional annotation and analysis of enriched proteins. The set of total 
proteins identified and quantified (n = 3327) was used as the background. The numbers of enriched 
proteins of interest and background lists are compared in each functional cluster. A two-tailed 
modified fisher’s exact test (EASE score of 1) with classification stringency at “medium” was 
employed to generate statistically significant enrichment annotations and to categorize them under 
annotation terms: cellular compartments, biological processes, molecular function and KEGG 
pathways. Correction for multiple hypothesis testing was carried out using standard false discovery 
rate control methods. A Bonferroni-corrected P ≥ 0.05 and an enrichment ≥ 1.3 were used as a cut-
off [131].  
4.5.12 CaSR knock down 
Using shRNA technology, CaSR was knocked down in PC3 luc cells. pLKO.1-CaSR was 
co-transfected into HEK293T cells with psPAX2 and pMD2 plasmids. The target gene was as 




4.6.1 CaSR mediated intracellular signaling in PCa cells is arrested 
4.6.1.1 Intracellular Oscillation is inhibited in PCa cells 
The PC3 cells with endogenous CaSR show little to no response to the increasing Ca2+ in 
terms of the CaSR mediated intracellular oscillations (Figure 4.3). PC3 cells (prostate cancer cells 
Figure 4.3 Intracellular Ca2+ response to extracellular Ca2+ by PC3 with endogenous CaSR (A) 
or that triansiently transfected with GFP-CaSR (B) 
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that metastasize to bones) display heterogeneity where 98% of the cells do not oscillate, 2% of 
them carry out the sinusoidal oscillation with low frequency at ~5 or 10 mM [Ca2+]o and 3% carry 
out transient peak at ~ 10-20 mM Ca2+ (n=50). Interestingly, we observe 50% of LNCaP cells 
(Prostate cancer cells that metastasize to lymph nodes) responding with a transient at a high Ca2+ 
concentration of 30 mM (n=27) with 0.5 units (340/380 ratio) height (). We further exempted the 
idea that a CaSR variant caused this discrepancy by transiently transfecting PC3 and LNCaP cells 
with wild type CaSR with 1.5-2 ug of DNA (Figure 4.3, Figure 4.5). The GFP-CaSR transfected 
PC3 cells do not display any oscillations, only rise in intracellular Ca2+ in 2% of the PC3 cells at 
B 
A 
50% LNCaP cells with endogenous CaSR showed intracellular Ca2+ response at 30 mM. 
4.5 2 % LNCaP cells transfected with wild type GFP-CaSR showed minimal response 
with transient Ca2+ peaks at 3 and 7.5 mM Ca2+ 
 
D
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Figure 4.5  Intracellular response by LNCaP cells 
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20 mM which could be washed away with 0mM Ca2+. These raises were variable in amplitude 
with 0.1-0.4 units (340/380 ratio) rise from the baseline. A clear oscillation at 5 mM was observed 
in only 1 cell out of the 43 transfected cells examined. But the pattern did not represent the WT 
and with 0.20 units (340/380 ratio) (Figure 4.3). LNCaP cells interestingly responded by 16% 
with increased intracellular Ca2+ transients by lower Ca2+ concentrations of 3 or 7.5 mM with ~0.5 
units (340/380 ratio) height in LNCaP cells (Figure 4.5).  This suggests a significant difference in 
intracellular signaling or a dysfunctional Ca2+ sensing machinery in prostate cancer cells irrelevant 
to the region of metastasis with different Ca2+ environments. Also, the mechanism of Ca2+ sensing 
is differential between the PC3 and LNCaP cells.  Similarly, Mg2+ and TNCA had no effect on 
CaSR mediated intracellular oscillation in these cells.  
4.6.1.2 CaSR mediated inositol monophosphate (IP1) accumulation in PC3 
Additionally. to examine the function of CaSR, IP1 accumulation was studied in PC3 and 


























































Figure 4.6 IP1 accumulation in PC3 is absent even in the present of CaSR 
agonist TNCA 
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metabolite of IP3 induced by activation of a phospholipase C (PLC) cascade through CaSR (Figure 
4.6). IP1 accumulation is absent in PC3, which supports the oscillation data and indicates that CaSR 
in PC3 is unable to induce Gαq/11 mediated signaling.  
 It has been studied in the past that Gαq/11 was only present in RWPE-1 and LNCaP prostate 
cancer cells, but not in PC3 cells [303].  We checked the Gαq/11 expression level in PC3 using 
immunoblot and MS. We show contradictory result where immunoblot (Figure 4.7) shows the 
presence whereas, MS does not.  
 
4.6.1.3 CaSR mediated ERK1/2 in PC3 
CaSR mediates ERK phosphorylation through Gαi. It is a well-characterized signal and is 
known to affect another downstream signaling. We observe that the ERK1/2 is stunted in PC3 as 
compared to the wild type (Figure 4.8). This further support that PC3 lack Ca2+ sensing through 








Figure 4.7 Expression of Gαq in PCa cells 
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Figure 4.8 ERK in PC3 and comparison to HEK293 cells and 6-23 cells 
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4.6.2 Dissecting the basis of differential CaSR mediated signaling in prostate cancer cells and 
HEK293 cells.  
4.6.2.1 Expression of CaSR in PC3 
4.6.2.1.1 Western blot 
Figure 4.9  CaSR expression in PC3 cells as 
compared to WT in HEK293 cells 
-250
-130
A. Immunoblot of CaSR using anti-CaSR antibody 
C0493 in total lysate obtained from various cells at 
25-100 µg. A and B; CaSR in PC3 is > 6-fold lower 
in expression. C. Endogenous CaSR is unable to form 
a dimer but when PC3 is transiently transfected by 
WT hCaSR pcDNA3.1, the oligomer is seen as well 
as the endogenous CaSR is seen as a monomer at 
lower molecular weight of 110 kDa rather than WT 





Expression of endogenous CaSR was examined using the western blot of the total CaSR 
obtained from PC3 cells after the lysis. Anti CaSR – C0493 antibody was used for blotting 
endogenous CaSR. Two plates for PC3, TT and 6-23 samples were lysed and one plate for 5001. 
100 µg was loaded for each cancer sample and 25 µg for 5001 sample (Figure 4.9). The expression 





PC3 transfected with FLAG-CaSR 
Non-permeabilized 
 
PC3 transfected with FLAG-CaSR 
Non-permeabilized 
 
ICC: Anti-CaSR ADD antibody 





Figure 4.10 Detection of endogenous and transiently transfected CaSR on the membrane of 
PC3 
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wild type CaSR or the PC3 transiently transfected with wild type CaSR. We also observe the 
molecular difference in the monomers; CaSR in PC3 has lower molecular weight at 110 kDa as 
compared to the wild type CaSR at 130-150 kDa in HEK293 or PC3 transiently transfected. 
Interestingly, overexpression of recombinant wild type CaSR in PC3 was able to form an 
oligomer unlike the endogenous CaSR in PC3. These results may indicate the presence of splicing 
or lower glycosylation in endogenous CaSR to result in the lower molecular weight. Our result 
also suggests that PC3 has glycosylation enzymes needed to glycosylate the WT CaSR so that the 
defect may lie on the endogenous ones. Previous studies by Liao et al. has shown the expression 
of PC3, but they do not specifically indicate the molecular weight they detected. However, they 
validate that PC3 with bony metastasis has higher CaSR as compared to C4-2B, an androgen-
independent variant of LNCaP that metastasizes to bone [91, 304, 305].   
4.6.2.1.2 Immunostaining  
We observe endogenous CaSR on the membrane but in lower amount as compared to the 
wild type transiently transfected in HEK293 or PC3 cells (Figure 4.10). Overexpressing wild type 
CaSR in PC3 increases the amount of staining. Using anti-FLAG antibody, we can see a membrane 
expression of CaSR on PC3 cells, but the transfection efficiency is low where the number of 
transfected CaSR is low. Anti-FLAG antibody is more efficient at staining the FLAG-CaSR as 
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compared to the anti-ADD as determined in Chapter III. The reason for not being able to observe 
a significant difference between anti-ADD stained transfected and endogenous CaSR in PC3 must 
be due to in-efficiency of transfection.  









AGGAGGCCTCTGCATGATGTGGCTTCCAAAGACTCAAGGACCACCCACATTACAAGTCTGGATTGAGGAA  CaSR E-2-1Fwd 
GGCAGAAATGGAGATTCAAACACCACGTCTTCTATTATTTTATTAATCAATCTGTAGACATGTGTCCCCA 




ATGGCATTTTATAGCTGCTGCTGGGTCCTCTTGGCACTCACCTGGCAC        CaSR E-2-1Rev 
ACCTCTGCCTACGGGCCAGACCAGCGAGCCCAAAAGAAGGGGGACATTATCCTTGGGGGGCTCTTTCCTA 
TTCATTTTGGAGTAGCAGCTAAAGATCAAGATCTCAAATCAAGGCCGGAGTCTGTGGAATGTATCAG    CaSR E-2-2 Rev 
  
Exon3: 558-864 (307) 
GTA 
TAATTTCCGTGGGTTTCGCTGGTTACAGGCTATGATATTTGCCATAGAGGAGATAAACAGCAGCCCAGCC CaSR E-3-1/E-3-2 Fwd 
CTTCTTCCCAACTTGACGCTGGGATACAGGATATTTGACACTTGCAACACCGTTTCTAAGGCCTTGGAAG 
CCACCCTGAGTTTTGTTGCTCAAAACAAAATTGATTCTTTGAACCTTGATGAGTTCTGCAACTGCTCAGA CaSR E-3-1/Rev 
GCACATTCCCTCTACGATTGCTGTGGTGGGAGCAACTGGCTCAGGCGTCTCCACGGCAGTGGCAAATCTG CaSR E-3-2/Rev 
CTGGGGCTCTTCTACATTCCCCAG            
 
Exon4: 865-1749(885) 
GTCAGTTATGCCTCCTCCAGCAGACTCCTCAGCAACAAGAATCAAT       CaSR E-4-1Fwd 
TCAAGTCTTTCCTCCGAACCATCCCCAATGATGAGCACCAGGCCACTGCCATGGCAGACATCATCGAGTA  CaSR E-4-2Fwd 
TTTCCGCTGGAACTGGGTGGGCACAATTGCAGCTGATGACGACTATGGGCGGCCGGGGATTGAGAAATTC 




TCGCTCTGAAGGCTGGGCAGATCCCAGGCTTCCGGGAATTCCTGAAGAAGGTCCATCCCAGGAAGTCTGT   
CCACAATGGTTTTGCCAAGGAGTTTTGGGAAGAAACATTTAACTGCCACCTCCAAGAAGGTGCAAAAGGA 
CCTTTACCTGTGGACACCTTTCTGAGAGGTCACGAAGAAAGTGGCGACAGGTTTAGCAACAGCTCGACAG  CaSR E-4-1Rev 
CCTTCCGACCCCTCTGTACAGGGGATGAGAACATCAGCAGTGTCGAGACCCCTTACATAGATTACACGCA 




Exon5: 1750-1980 (231) 
G 
TCCTGAAGCACCTACGGCATCTAAACTTTACAAACAATATGGGGGAGCAGGTGACCTTTGATGAGTGTGG CaSR E-5-1Fwd CaSRE-5/6-1Fwd 
TGACCTGGTGGGGAACTATTCCATCATCAACTGGCACCTCTCCCCAGAGGATGGCTCCATCGTGTTTAAG  
GAAGTCGGGTATTACAACGTCTATGCCAAGAAGGGAGAAAGACTCTTCATCAACGAGGAGAAAATCCTGT CaSR E-5-1Rev 
GGAGTGGGTTCTCCAGGGAG           
 
 
Exon6: 1981-2104 (124) 
CCACTCACCTTTGTGCTGTCTGTCCTCCAG (10 amino acid) 
GTGCCCTTCTCCAACTGCAGCCGAGACTGCCTGGCAGGGACCAGGAAAGG CaSRE-6-1Fwd        
GATCATTGAGGGGGAGCCCACCTGCTGCTTTGAGTGTGTGGAGTGTCCTGATGGGGAGTATAGTGATGAGCaSRE-5/6-1Rev CaSRE-5/6-2Rev    
ACAG 
Exon7: 2105-4915 (2811) 
ATGCCAGTGCCTGTAACAAGTGCCCAGATGACTTCTGGTCCAATGAGAACCACACCTCCTGCATTG 
CCAAGGAGATCGAGTTTCTGTCGTGGACGGAGCCCTTTGGGATCGCACTCACCCTCTTTGCCGTGCTGGG    
              
CATTTTCCTGACAGCCTTTGTGCTGGGTGTGTTTATCAAGTTCCGCAACACACCCATTGTCAAGGCCACC CaSR E-7-2Fwd         (Liao) 
AACCGAGAGCTCTCCTACCTCCTCCTCTTCTCCCTGCTCTGCTGCTTCTCCAGCTCCCTGTTCTTCATCG 
GGGAGCCCCAGGACTGGACGTGCCGCCTGCGCCAGCCGGCCTTTGGCATCAGCTTCGTGCTCTGCATCTC 
ATGCATCCTGGTGAAAACCAACCGTGTCCTCCTGGTGTTTGAGGCCAAGATCCCCACCAGCTTCCACCGC   




GCATGCTCATCTTCTTCATCGTCTGGATCTCCTTCATTCCAGCCTATGCCAGCACCTATGGCAAGTTTGT CaSR E-7-2Rev CaSR E-7-3Fwd 
CTCTGCCGTAGAGGTGATTGCCATCCTGGCAGCCAGCTTTGGCTTGCTGGCGTGCATCTTCTTCAACAAG  
ATCTACATCATTCTCTTCAAGCCATCCCGCAACACCATCGAGGAGGTGCGTTGCAGCACCGCAGCTCACG 
CTTTCAAGGTGGCTG CCGGGC ACGCTGCGCCGCAGCAACGTCTCCCGCAAGCGGTCCAGCAGCCTTGG 
AGGCTCCACGGGATCCACCCCCTCCTCCTCCATCAGCAGCAAGAGCAACAGCGAAGACCCATTCCCACAG 
CCCGAGAGGCAGAAGCAGCAGCAGCCGCTGGCCCTAACCCAGCAAGAGCAGCAGCAGCAGCCCCTGACCC 
TCCC CA GCA CGATCTCAGCA CAGCCCA ATGCAAG A AAGGTCATCTTTGGCAGCGGCACGGT   
CACCTT ACTG GCTTTGATGAGC TCAGA G CGCCAT G CCACAGGAATTCTACGCACCAGAAC 
TCCCTGGAGGCCCAGAAAAGCAGCGATACGCTGACCCGACACCAGCCATTACTCCCGCTGCAGTGCGGGG 
AAACGGACTTAGATCTGACCGTCCAGGAAACAGGTCTGCAAGGACCTGTGGGTGGAGACCAGCGGCCAGA 






CATAAAATGGAAGGAGAAGACTGGGCTAGGGAGAAT CaSR E-7-3Rev 
GCAGAGAGGTTTCTTGGGGTCCCAGGGAAGAGGAATCGCCCCAGACTCCTTTCCTCTGAGGAAGAAGGGA 
TAATAGACACATCAAATGCCCCGAATTTAGTCACACCATCTTAAATGACAGTGAATTGACCCATGTTCCC 
TTTAAA TTAAAAAAA A GAGCC TGTGTT TGTGGTTGC TT GTCAAAGCA TGAGATCTCCA G 
GTCAG TTTGCTGTTCACCCACATCTAATGTCTCT C TCT TTCT TCCCACCCAACAGCT AGATG 
AAACTATG C TTA A TA CCT C AGTGT CAGACTGATGGGACATCA TT GCCACCA T GAGC 
TGAGAGTCTGAAAGACAGAATGT ACCAGTCC CA TG C TG AACAGACT AATTT AAATGTT 











ATTAA C AGATAA GTAT TAAAG A TTTAGCCTG TACCTAGCA AC TA CATTC ATAAATAT 
TAGTTA TATTATTAAA AAAAAA 
Figure 4.11  Primers were designed to investigate presence of DNA at each exon All 
corresponding bands matched in 5001 and cancer cell lines expect for exons 5/6 and 7-  
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4.6.2.2 Investigation of splice variant of CaSR in PC3 
Figure 4.12  Primers were designed to investigate presence of DNA at each exons. All 
corresponding bands matched in 5001 and cancer cell lines expect for exons 5/6 and 7-3 
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4.6.2.2.1 Probing DNA of coding region of CaSR in PC3 cells.  
In order to find the cause for the lower molecular weight as well as the signaling difference, 
we investigated the CaSR in PC3 at the gene level. We isolated the RNA using Illustra RNAspin 
Midi RNA Isolation kit from GE healthcare and carried out a poly-A enrichment where Superscript 
III (Thermo Scientific) was used to isolate RNA and KOD hot start was used to carry out PCR. 
We found the CaSR transcript to below. This could have resulted due to RNA being unstable. 
Therefore, we used amplification of genomic DNA first, which is more robust.  
We were able to match all corresponding bands in PC3 as compared to the positive control 
5001 except for exons 5/6 and 7-3 when we amplified CaSR fragments with CaSR specific primers 
using genomic DNA (Figure 4.12). We further went to design primers within 5/6 and 7-3 regions 
accounting for shorter probes.  
4.6.2.2.2 Probing DNA at Exon 6 and 7-3 Region of PC3 cells 
 
Figure 4.13  Exon 6 and 7-3 do not show any difference between the cell lines at DNA level 
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For genomic PCR, all exons showed prominent expected bands (Figure 4.13). This 
indicated that PC3-CaSR at the genomic level, was identical to that of positive control or wild type 
CaSR.  
4.6.2.2.3 Probing RNA spanning in all exons in prostate cancer cells 
4.6.2.2.4 Amplification between Exon ¾ and 5,6, and 7  
After many optimization and trials, we were able to obtain each corresponding band at each 
exon (Figure 4.14). This indicates that a wild type with all the fragments in all coding exons is 
present in PC3. However, since our gel was not clear, we cannot rule out the possibility of other 
CaSR variants.  
Figure 4.14   Expected bands for each exons suggest presence of CaSR without splicing.  
5 ul for 5001 and 25 ul loaded for others. 1,5% gel.  cDNA was obtained using 6-7 
times more RNA amplicon for PC3 and C4-2B with 1R primer 
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4.6.2.2.5 Sequencing RT-PCR product  
We were able to carry out sanger sequencing. The sequence covered are presented below 






   
  GTT GAG GCG TGG CAG GTC CTG AAG CAC CTA CGG CAT CTA AAC TTT ACA AAC AAT ATG GGG GAG CAG GTG ACC TTT GAT GAG TGT GGT GAC CTG GTG GGG A  < 1900Exon5 
  V   E   A   W   Q   V   L   K   H   L   R   H   L   N   F   T   N   N   M   G   E   Q   V   T   F   D   E   C   G   D   L   V   G   N 
  CAA CTC CGC ACC GTC CAG GAC TTC GTG GAT GCC GTA GAT TTG AAA TGT TTG TTA TAC CCC CTC GTC CAC TGG AAA CTA CTC ACA CCA CTG GAC CAC CCC T 
              1810         1820         1830          1840         1850         1860          1870         1880         1890  
 
 
   
  AC TAT TCC ATC ATC AAC TGG CAC CTC TCC CCA GAG GAT GGC TCC ATC GTG TTT AAG GAA GTC GGG TAT TAC AAC GTC TAT GCC AAG AAG GGA GAA AGA CT  < 2000 
     Y   S   I   I   N   W   H   L   S   P   E   D   G   S   I   V   F   K   E   V   G   Y   Y   N   V   Y   A   K   K   G   E   R   L  
  TG ATA AGG TAG TAG TTG ACC GTG GAG AGG GGT CTC CTA CCG AGG TAG CAC AAA TTC CTT CAG CCC ATA ATG TTG CAG ATA CGG TTC TTC CCT CTT TCT GA 
              1910         1920          1930         1940         1950          1960         1970         1980          1990  
 
 
   
  C TTC ATC AAC GAG GAG AAA ATC CTG TGG AGT GGG TTC TCC AGG GAG CCA CTC ACC TTT GTG CTG TCT GTC CTC CAG GTG CCC TTC TCC AAC TGC AGC CGA  < 2100Exon6 
    F   I   N   E   E   K   I   L   W   S   G   F   S   R   E   P   L   T   F   V   L   S   V   L   Q   V   P   F   S   N   C   S   R    
  G AAG TAG TTG CTC CTC TTT TAG GAC ACC TCA CCC AAG AGG TCC CTC GGT GAG TGG AAA CAC GAC AGA CAG GAG GTC CAC GGG AAG AGG TTG ACG TCG GCT 
               2010         2020         2030         2040          2050         2060         2070          2080         2090  
 
 
   
  GAC TGC CTG GCA GGG ACC AGG AAA GGG ATC ATT GAG GGG GAG CCC ACC TGC TGC TTT GAG TGT GTG GAG TGT CCT GAT GGG GAG TAT AGT GAT GAG ACA G  < 2200 
  D   C   L   A   G   T   R   K   G   I   I   E   G   E   P   T   C   C   F   E   C   V   E   C   P   D   G   E   Y   S   D   E   T   D 
  CTG ACG GAC CGT CCC TGG TCC TTT CCC TAG TAA CTC CCC CTC GGG TGG ACG ACG AAA CTC ACA CAC CTC ACA GGA CTA CCC CTC ATA TCA CTA CTC TGT C 







   
  AAT CTG CTG GGG CTC TTC TAC ATT CCC CAG GTC AGT TAT GCC TCC TCC AGC AGA CTC CTC AGC AAC AAG AAT CAA TTC AAG TCT TTC CTC CGA ACC ATC C < 1000Exon4 
  N   L   L   G   L   F   Y   I   P   Q   V   S   Y   A   S   S   S   R   L   L   S   N   K   N   Q   F   K   S   F   L   R   T   I   P 
  TTA GAC GAC CCC GAG AAG ATG TAA GGG GTC CAG TCA ATA CGG AGG AGG TCG TCT GAG GAG TCG TTG TTC TTA GTT AAG TTC AGA AAG GAG GCT TGG TAG G 
              910          920          930           940          950          960           970          980          990  
 
 
   
  CC AAT GAT GAG CAC CAG GCC ACT GCC ATG GCA GAC ATC ATC GAG TAT TTC CGC TGG AAC TGG GTG GGC ACA ATT GCA GCT GAT GAC GAC TAT GGG CGG CC  < 1100 
     N   D   E   H   Q   A   T   A   M   A   D   I   I   E   Y   F   R   W   N   W   V   G   T   I   A   A   D   D   D   Y   G   R   P  
  GG TTA CTA CTC GTG GTC CGG TGA CGG TAC CGT CTG TAG TAG CTC ATA AAG GCG ACC TTG ACC CAC CCG TGT TAA CGT CGA CTA CTG CTG ATA CCC GCC GG 
              1010         1020          1030         1040         1050          1060         1070         1080          1090  
 
 
   
  G GGG ATT GAG AAA TTC CGA GAG GAA GCT GAG GAA AGG GAT ATC TGC ATC GAC TTC AGT GAA CTC ATC TCC CAG TAC TCT GAT GAG GAA GAG ATC CAG CAT  < 1200 
    G   I   E   K   F   R   E   E   A   E   E   R   D   I   C   I   D   F   S   E   L   I   S   Q   Y   S   D   E   E   E   I   Q   H    
  C CCC TAA CTC TTT AAG GCT CTC CTT CGA CTC CTT TCC CTA TAG ACG TAG CTG AAG TCA CTT GAG TAG AGG GTC ATG AGA CTA CTC CTT CTC TAG GTC GTA 
               1110         1120         1130         1140          1150         1160         1170          1180         1190  
 
 
   
  GTG GTA GAG GTG ATT CAA AAT TCC ACG GCC AAA GTC ATC GTG GTT TTC TCC AGT GGC CCA GAT CTT GAG CCC CTC ATC AAG GAG ATT GTC CGG CGC AAT A  < 1300 
  V   V   E   V   I   Q   N   S   T   A   K   V   I   V   V   F   S   S   G   P   D   L   E   P   L   I   K   E   I   V   R   R   N   I 
  CAC CAT CTC CAC TAA GTT TTA AGG TGC CGG TTT CAG TAG CAC CAA AAG AGG TCA CCG GGT CTA GAA CTC GGG GAG TAG TTC CTC TAA CAG GCC GCG TTA T 
              1210         1220         1230          1240         1250         1260          1270         1280         1290  
 
 
   
  TC ACG GGC AAG ATC TGG CTG GCC AGC GAG GCC TGG GCC AGC TCC TCC CTG ATC GCC ATG CCT CAG TAC TTC CAC GTG GTT GGC GGC ACC ATT GGA TTC GC  < 1400 
     T   G   K   I   W   L   A   S   E   A   W   A   S   S   S   L   I   A   M   P   Q   Y   F   H   V   V   G   G   T   I   G   F   A  
  AG TGC CCG TTC TAG ACC GAC CGG TCG CTC CGG ACC CGG TCG AGG AGG GAC TAG CGG TAC GGA GTC ATG AAG GTG CAC CAA CCG CCG TGG TAA CCT AAG CG 
              1310         1320          1330         1340         1350          1360         1370         1380          1390  
 
 
   
  T CTG AAG GCT GGG CAG ATC CCA GGC TTC CGG GAA TTC CTG AAG AAG GTC CAT CCC AGG AAG TCT GTC CAC AAT GGT TTT GCC AAG GAG TTT TGG GAA GAA  < 1500 
    L   K   A   G   Q   I   P   G   F   R   E   F   L   K   K   V   H   P   R   K   S   V   H   N   G   F   A   K   E   F   W   E   E    
  A GAC TTC CGA CCC GTC TAG GGT CCG AAG GCC CTT AAG GAC TTC TTC CAG GTA GGG TCC TTC AGA CAG GTG TTA CCA AAA CGG TTC CTC AAA ACC CTT CTT 
               1410         1420         1430         1440          1450         1460         1470          1480         1490  
 
 
   
  ACA TTT AAC TGC CAC CTC CAA GAA GGT GCA AAA GGA CCT TTA CCT GTG GAC ACC TTT CTG AGA GGT CAC GAA GAA AGT GGC GAC AGG TTT AGC AAC AGC T  < 1600 
  T   F   N   C   H   L   Q   E   G   A   K   G   P   L   P   V   D   T   F   L   R   G   H   E   E   S   G   D   R   F   S   N   S   S 
  TGT AAA TTG ACG GTG GAG GTT CTT CCA CGT TTT CCT GGA AAT GGA CAC CTG TGG AAA GAC TCT CCA GTG CTT CTT TCA CCG CTG TCC AAA TCG TTG TCG A 
              1510         1520         1530          1540         1550         1560          1570         1580         1590  
 
 
   
  CG ACA GCC TTC CGA CCC CTC TGT ACA GGG GAT GAG AAC ATC AGC AGT GTC GAG ACC CCT TAC ATA GAT TAC ACG CAT TTA CGG ATA TCC TAC AAT GTG TA  < 1700 
     T   A   F   R   P   L   C   T   G   D   E   N   I   S   S   V   E   T   P   Y   I   D   Y   T   H   L   R   I   S   Y   N   V   Y  
  GC TGT CGG AAG GCT GGG GAG ACA TGT CCC CTA CTC TTG TAG TCG TCA CAG CTC TGG GGA ATG TAT CTA ATG TGC GTA AAT GCC TAT AGG ATG TTA CAC AT 
              1610         1620          1630         1640         1650          1660         1670         1680          1690  
 
 
   
  C TTA GCA GTC TAC TCC ATT GCC CAC GCC TTG CAA GAT ATA TAT ACC TGC TTA CCT GGG AGA GGG CTC TTC ACC AAT GGC TCC TGT GCA GAC ATC AAG AAA  < 1800 
    L   A   V   Y   S   I   A   H   A   L   Q   D   I   Y   T   C   L   P   G   R   G   L   F   T   N   G   S   C   A   D   I   K   K    
  G AAT CGT CAG ATG AGG TAA CGG GTG CGG AAC GTT CTA TAT ATA TGG ACG AAT GGA CCC TCT CCC GAG AAG TGG TTA CCG AGG ACA CGT CTG TAG TTC TTT 
               1710         1720         1730         1740          1750         1760         1770          1780         1790  
 
 
Y   F/K   D   D   D   D   K 
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  AT GCC AGT GCC TGT AAC AAG TGC CCA GAT GAC TTC TGG TCC AAT GAG AAC CAC ACC TCC TGC ATT GCC AAG GAG ATC GAG TTT CTG TCG TGG ACG GAG CC  < 2300Exon7 
     A   S   A   C   N   K   C   P   D   D   F   W   S   N   E   N   H   T   S   C   I   A   K   E   I   E   F   L   S   W   T   E   P  
  TA CGG TCA CGG ACA TTG TTC ACG GGT CTA CTG AAG ACC AGG TTA CTC TTG GTG TGG AGG ACG TAA CGG TTC CTC TAG CTC AAA GAC AGC ACC TGC CTC GG 
              2210         2220          2230         2240         2250          2260         2270         2280          2290  
 
 
   
  C TTT GGG ATC GCA CTC ACC CTC TTT GCC GTG CTG GGC ATT TTC CTG ACA GCC TTT GTG CTG GGT GTG TTT ATC AAG TTC CGC AAC ACA CCC ATT GTC AAG  < 2400 
    F   G   I   A   L   T   L   F   A   V   L   G   I   F   L   T   A   F   V   L   G   V   F   I   K   F   R   N   T   P   I   V   K    
  G AAA CCC TAG CGT GAG TGG GAG AAA CGG CAC GAC CCG TAA AAG GAC TGT CGG AAA CAC GAC CCA CAC AAA TAG TTC AAG GCG TTG TGT GGG TAA CAG TTC 
               2310         2320         2330         2340          2350         2360         2370          2380         2390  
 
 
   
  GCC ACC AAC CGA GAG CTC TCC TAC CTC CTC CTC TTC TCC CTG CTC TGC TGC TTC TCC AGC TCC CTG TTC TTC ATC GGG GAG CCC CAG GAC TGG ACG TGC C  < 2500 
  A   T   N   R   E   L   S   Y   L   L   L   F   S   L   L   C   C   F   S   S   S   L   F   F   I   G   E   P   Q   D   W   T   C   R 
  CGG TGG TTG GCT CTC GAG AGG ATG GAG GAG GAG AAG AGG GAC GAG ACG ACG AAG AGG TCG AGG GAC AAG AAG TAG CCC CTC GGG GTC CTG ACC TGC ACG G 
              2410         2420         2430          2440         2450         2460          2470         2480         2490  
 
 
   
  GC CTG CGC CAG CCG GCC TTT GGC ATC AGC TTC GTG CTC TGC ATC TCA TGC ATC CTG GTG AAA ACC AAC CGT GTC CTC CTG GTG TTT GAG GCC AAG ATC CC  < 2600 
     L   R   Q   P   A   F   G   I   S   F   V   L   C   I   S   C   I   L   V   K   T   N   R   V   L   L   V   F   E   A   K   I   P  
  CG GAC GCG GTC GGC CGG AAA CCG TAG TCG AAG CAC GAG ACG TAG AGT ACG TAG GAC CAC TTT TGG TTG GCA CAG GAG GAC CAC AAA CTC CGG TTC TAG GG 
              2510         2520          2530         2540         2550          2560         2570         2580          2590  
 
   
  C ACC AGC TTC CAC CGC AAG TGG TGG GGG CTC AAC CTG CAG TTC CTG CTG GTT TTC CTC TGC ACC TTC ATG CAG ATT GTC ATC TGT GTG ATC TGG CTC TAC  < 2700 
    T   S   F   H   R   K   W   W   G   L   N   L   Q   F   L   L   V   F   L   C   T   F   M   Q   I   V   I   C   V   I   W   L   Y    
  G TGG TCG AAG GTG GCG TTC ACC ACC CCC GAG TTG GAC GTC AAG GAC GAC CAA AAG GAG ACG TGG AAG TAC GTC TAA CAG TAG ACA CAC TAG ACC GAG ATG 
               2610         2620         2630         2640          2650         2660         2670          2680         2690  
 
 
   
  ACC GCG CCC CCC TCA AGC TAC CGC AAC CAG GAG CTG GAG GAT GAG ATC ATC TTC ATC ACG TGC CAC GAG GGC TCC CTC ATG GCC CTG GGC TTC CTG ATC G  < 2800 
  T   A   P   P   S   S   Y   R   N   Q   E   L   E   D   E   I   I   F   I   T   C   H   E   G   S   L   M   A   L   G   F   L   I   G 
  TGG CGC GGG GGG AGT TCG ATG GCG TTG GTC CTC GAC CTC CTA CTC TAG TAG AAG TAG TGC ACG GTG CTC CCG AGG GAG TAC CGG GAC CCG AAG GAC TAG C 
              2710         2720         2730          2740         2750         2760          2770         2780         2790  
 
 
   
  GC TAC ACC TGC CTG CTG GCT GCC ATC TGC TTC TTC TTT GCC TTC AAG TCC CGG AAG CTG CCG GAG AAC TTC AAT GAA GCC AAG TTC ATC ACC TTC AGC AT  < 2900 
     Y   T   C   L   L   A   A   I   C   F   F   F   A   F   K   S   R   K   L   P   E   N   F   N   E   A   K   F   I   T   F   S   M  
  CG ATG TGG ACG GAC GAC CGA CGG TAG ACG AAG AAG AAA CGG AAG TTC AGG GCC TTC GAC GGC CTC TTG AAG TTA CTT CGG TTC AAG TAG TGG AAG TCG TA 
              2810         2820          2830         2840         2850          2860         2870         2880          2890  
 
 
   
  G CTC ATC TTC TTC ATC GTC TGG ATC TCC TTC ATT CCA GCC TAT GCC AGC ACC TAT GGC AAG TTT GTC TCT GCC GTA GAG GTG ATT GCC ATC CTG GCA GCC  < 3000 
    L   I   F   F   I   V   W   I   S   F   I   P   A   Y   A   S   T   Y   G   K   F   V   S   A   V   E   V   I   A   I   L   A   A    
  C GAG TAG AAG AAG TAG CAG ACC TAG AGG AAG TAA GGT CGG ATA CGG TCG TGG ATA CCG TTC AAA CAG AGA CGG CAT CTC CAC TAA CGG TAG GAC CGT CGG 
               2910         2920         2930         2940          2950         2960         2970          2980         2990  
 
 
   
  AGC TTT GGC TTG CTG GCG TGC ATC TTC TTC AAC AAG ATC TAC ATC ATT CTC TTC AAG CCA TCC CGC AAC ACC ATC GAG GAG GTG CGT TGC AGC ACC GCA G  < 3100 
  S   F   G   L   L   A   C   I   F   F   N   K   I   Y   I   I   L   F   K   P   S   R   N   T   I   E   E   V   R   C   S   T   A   A 
  TCG AAA CCG AAC GAC CGC ACG TAG AAG AAG TTG TTC TAG ATG TAG TAA GAG AAG TTC GGT AGG GCG TTG TGG TAG CTC CTC CAC GCA ACG TCG TGG CGT C 
              3010         3020         3030          3040         3050         3060          3070         3080         3090  
 
 
   
  CT CAC GCT TTC AAG GTG GCT GCC CGG GCC ACG CTG CGC CGC AGC AAC GTC TCC CGC AAG CGG TCC AGC AGC CTT GGA GGC TCC ACG GGA TCC ACC CCC TC  < 3200 
     H   A   F   K   V   A   A   R   A   T   L   R   R   S   N   V   S   R   K   R   S   S   S   L   G   G   S   T   G   S   T   P   S  
  GA GTG CGA AAG TTC CAC CGA CGG GCC CGG TGC GAC GCG GCG TCG TTG CAG AGG GCG TTC GCC AGG TCG TCG GAA CCT CCG AGG TGC CCT AGG TGG GGG AG 
              3110         3120          3130         3140         3150          3160         3170         3180          3190  
 
 
   
  C TCC TCC ATC AGC AGC AAG AGC AAC AGC GAA GAC CCA TTC CCA CAG CCC GAG AGG CAG AAG CAG CAG CAG CCG CTG GCC CTA ACC CAG CAA GAG CAG CAG  < 3300 
    S   S   I   S   S   K   S   N   S   E   D   P   F   P   Q   P   E   R   Q   K   Q   Q   Q   P   L   A   L   T   Q   Q   E   Q   Q    
  G AGG AGG TAG TCG TCG TTC TCG TTG TCG CTT CTG GGT AAG GGT GTC GGG CTC TCC GTC TTC GTC GTC GTC GGC GAC CGG GAT TGG GTC GTT CTC GTC GTC 
               3210         3220         3230         3240          3250         3260         3270          3280         3290  
 
 
   
  CAG CAG CCC CTG ACC CTC CCA CAG CAG CAA CGA TCT CAG CAG CAG CCC AGA TGC AAG CAG AAG GTC ATC TTT GGC AGC GGC ACG GTC ACC TTC TCA CTG A  < 3400 
  Q   Q   P   L   T   L   P   Q   Q   Q   R   S   Q   Q   Q   P   R   C   K   Q   K   V   I   F   G   S   G   T   V   T   F   S   L   S 
  GTC GTC GGG GAC TGG GAG GGT GTC GTC GTT GCT AGA GTC GTC GTC GGG TCT ACG TTC GTC TTC CAG TAG AAA CCG TCG CCG TGC CAG TGG AAG AGT GAC T 
              3310         3320         3330          3340         3350         3360          3370         3380         3390  
 
 
   
  GC TTT GAT GAG CCT CAG AAG AAC GCC ATG GCC CAC AGG AAT TCT ACG CAC CAG AAC TCC CTG GAG GCC CAG AAA AGC AGC GAT ACG CTG ACC CGA CAC CA  < 3500 
     F   D   E   P   Q   K   N   A   M   A   H   R   N   S   T   H   Q   N   S   L   E   A   Q   K   S   S   D   T   L   T   R   H   Q  
  CG AAA CTA CTC GGA GTC TTC TTG CGG TAC CGG GTG TCC TTA AGA TGC GTG GTC TTG AGG GAC CTC CGG GTC TTT TCG TCG CTA TGC GAC TGG GCT GTG GT 
              3410         3420          3430         3440         3450          3460         3470         3480          3490  
 
 
   
  G CCA TTA CTC CCG CTG CAG TGC GGG GAA ACG GAC TTA GAT CTG ACC GTC CAG GAA ACA GGT CTG CAA GGA CCT GTG GGT GGA GAC CAG CGG CCA GAG GTG  < 3600 
    P   L   L   P   L   Q   C   G   E   T   D   L   D   L   T   V   Q   E   T   G   L   Q   G   P   V   G   G   D   Q   R   P   E   V    
  C GGT AAT GAG GGC GAC GTC ACG CCC CTT TGC CTG AAT CTA GAC TGG CAG GTC CTT TGT CCA GAC GTT CCT GGA CAC CCA CCT CTG GTC GCC GGT CTC CAC 
               3510         3520         3530         3540          3550         3560         3570          3580         3590  
 
 
   
  GAG GAC CCT GAA GAG TTG TCC CCA GCA CTT GTA GTG TCC AGT TCA CAG AGC TTT GTC ATC AGT GGT GGA GGC AGC ACT GTT ACA GAA AAC GTA GTG AAT T  < 3700 
  E   D   P   E   E   L   S   P   A   L   V   V   S   S   S   Q   S   F   V   I   S   G   G   G   S   T   V   T   E   N   V   V   N   S 
  CTC CTG GGA CTT CTC AAC AGG GGT CGT GAA CAT CAC AGG TCA AGT GTC TCG AAA CAG TAG TCA CCA CCT CCG TCG TGA CAA TGT CTT TTG CAT CAC TTA A 





Figure 4.15  PC3: part of exon 4, 5, 6 and 7 were sequence at Biology Core. An insertion was 




4.6.2.2.6 RNAseq study  
A study done in 2015 with an RNA sample from PC3 cells (OtA8101-2) in collaboration 
with Otogenetics company could not achieve high confidence mapping for CaSR. 46 million read 
were obtained for two transcripts. The read pairs mapped CaSR transcript covering exon 3 
(121976084 – 121976234). One of the reads extended ends of exon 3 to 2 nucleotides in intron 
and with last 2 bases mutated from AG to CA. The second one mapped had low confidence.  
Sequence covered
Potential Glycosylation




Figure 4.16  PC3 overall sequence covered from PCR products 
Variant Reference Gene ID  Transcript ID Coverage








The second set of study design was carried out in collaboration with Dr. Yi Li from CDC 
and work was carried out at Otogenetics in 2017 using various cell lines. RNA was extracted 
using Illustra RNA spin mini from GE healthcare. cDNA was generated using superscript III 
from thermos scientific and eight times more template from cancer cells. The result shows that 
even if 5001 had about 5 times lower read the output provided was higher. The combination of 
cDNA of other pathological cell types had poor output. Overall, the Q30 which describes the 
library material quality or the sequencing adapter was poor 
 
4.6.2.3 Proteomics study in PC3  
PC3 cells in 80% confluency were first starved and then treated with 4mM Ca2+ or 2 mM 
EGTA. We employed mass spectrometry to detect total proteins in the cell. Not only could this 
assay give us the presence of a protein but also provide the relative quantitative amount of 
abundance.  




5001 (control) 1.7M reads 1 Gb of sequencing; 
pr quality




PC3+ C4-2B 375 K reads 1 Gb of sequencing: 
0.34Gb or 3M reads
HEKn, MDA MB-
213, HUVEC, VSMC
7 M reads 1 Gb of sequencing: 
2Gb with 17 M 
reads
Table 4.3 RNAseq study on CaSR gene in various cells with endogenous CaSR  
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4.6.2.3.1 Ca2+ signaling related proteomics in PC3 
A total of 3327 proteins were detected in HEK293 and PC3 combined. In order to 
understand the implication of proteome in signaling, we examine the relative expression of Ca2+ 
signaling related proteins in PC3 and used HEK293 proteome as a positive control as we see the 
WT Ca2+ signaling in HEK293 cells. With the stringency of ≥ 2 average PSM, we note that Gαq 
is absent both in PC3 and HEK293 cells (Table 4.5Error! Reference source not found.) and 
therefore, implying its detection to be unreliable. CaM and other G-proteins such as Gαi-2, Gαs 
and Gβ are detected with strong MS/MS count. Additionally, CaSR was not detected in PC3 with 
PSM of 0, which supports the retarded Ca2+ sensing and low transcript generated in RT-PCR and 
RNAseq. On the contrary, 109 LFQ intensity was observed for HEK293 cells transfected with 
FLAG-CaSR with an average PSM of 22 (Table 4.5). Further, SERCA (ATP2A2) is present with 
strong average PSM of 20 and LFQ intensity of 109. However, IP3R and related phosphodiesterase 
and phosphatases were detected at low PSM of < 1 in both PC3 and HEK293 cells (Table 4.5).  
4.6.2.3.2 Proteomics related to prognostic markers  
Because we were interested in prognosis markers, we compared the known markers in 
prostate cancer from the human protein atlas. This database integrates human proteomic results 
from various omics technologies (mass-spectrometry, antibody-based imaging, and 
transcriptomics). According to this database, there are 25 favorable prognostic markers for PCa. 
We found two proteins Epoxide hydrolase 1 (EPHX1) and Catebhol O-methyltransferase (COMT) 
with good abundance with the stringency of ≥ 4 average PSM and with average LFQ intensity in 
the range of 109 (Table 4.4). These markers were decreased with the Ca2+ treatment in PC3 by < 
0.9-fold as compared to one treated with EGTA. However, these were ≥ 3-fold increased as 
compared to HEK293 cells. Apart from the two, we also detected isoforms of other good 
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prognostic markers, including the ubiquitin (RNF114), Ubiquitin-conjugating enzyme 
(UBE2D2/3) and SLCs with good stringencies. PC3 as compared to Ca2+ and EGTA and with 
HEK293 cells, these markers did not have a specific dependence on Ca2+.  
4.6.2.3.3 Role of Ca2+ in proteomics related to metastasis  
Bone is a well-established site of metastasis for prostate with a high Ca2+ environment of 
10-40 mM. Previous work has shown that higher extracellular Ca2+ of 2.5 mM plays a role in 
facilitating prostate cancer metastasis and localization in bone [91]. Our work in the lab by Dr. Jie 
Feng has also shown that CaSR may act to protect and facilitate localization of these tumors in 
high Ca2+ environment through reducing apoptosis and invasion of the cancer cells and allowing 
mesenchymal to epithelial transition (MET) pathway. We explored metastasis-related biomarkers 
in PC3 proteomics. Ironically, cell-adhesion proteins such as E-cadherin and integrin as well as 
biomarkers associated with MET, including, e-cadherin, catenin, actin, and vimentin were not 
upregulated in the Ca2+ treated PC3 cells. γ-catenin was not detected at all (Table 4.5). The 
Majority 



















P35221 Catenin alpha-1 CTNNA1 7.23E+08 7.31E+08 5 7 0.00E+00 4.41E+06 0 0 2.3276 -5.0297 -7.3729
P23229-7
Integrin alpha-6;Integrin alpha-6 heavy 
chain; light chain;Processed integrin alpha-
6 ITGA6 0.00E+00 0.00E+00 0 0 0.00E+00 1.76E+07 1 0.5 1.2066 2.0601 1.1365
O96019 Actin-like protein 6A ACTL6A 1.28E+09 1.11E+09 6 5.5 1.10E+09 1.00E+09 7 3.5 0.1345 -0.2226 -0.1476
P16144-4 Integrin beta-4 ITGB4 0.00E+00 1.08E+07 0 0 3.43E+09 3.33E+09 20.5 15 0.0467 8.2499 8.2726
B4DGU4 Catenin beta-1 CTNNB1 3.32E+08 2.37E+08 1.5 1.5 9.79E+08 9.51E+08 7 8 0.0414 1.5614 2.0024
P05556 Integrin beta-1 ITGB1 1.14E+08 2.80E+08 1 0.5 3.10E+09 3.13E+09 14.5 12 -0.0127 4.7663 3.4845
P26006
Integrin alpha-3; alpha-3 heavy chain; alpha-
3 light chain ITGA3 0.00E+00 0.00E+00 0 0 2.27E+08 2.30E+08 1.5 1.5 -0.0243 5.1328 5.1992
P17301 Integrin alpha-2 ITGA2 0.00E+00 5.24E+07 0 0 2.26E+09 2.43E+09 15 12.5 -0.1047 7.1362 5.535
P68133 Actin, alpha skeletal muscle
ACTA1;ACTC1;




Cad/CTF3 CDH1 4.67E+07 0.00E+00 0 0 3.41E+08 3.77E+08 1 2 -0.1436 2.869 6.1747
P63261
Actin, cytoplasmic 2;Actin, cytoplasmic 2, 
N-terminally processed ACTG1 1.23E+11 1.25E+11 111.5 119.5 1.73E+11 1.94E+11 132 118 -0.1655 0.4927 0.6256
A0A087W
UB9 Beta-catenin-like protein 1 CTNNBL1 4.07E+08 4.27E+08 1.5 3 5.96E+08 6.85E+08 4.5 5 -0.2011 0.551 0.6802
P08670 Vimentin VIM 2.26E+10 2.29E+10 47.5 49.5 1.28E+09 1.57E+09 6.5 9.5 -0.2875 -4.1421 -3.8733
C9JZR2 Catenin delta-1 CTNND1 3.28E+08 2.74E+08 1.5 1.5 1.49E+09 1.88E+09 10.5 13 -0.3332 2.1847 2.774
P60709
Actin, cytoplasmic 1;Actin, cytoplasmic 1, 
N-terminally processed ACTB 2.99E+09 2.87E+09 4 4 0.00E+00 1.23E+09 4.5 4 -7.1915 -8.4736 -1.2268
Average Intensity 
HEK293
Average MS/MS count 
HEK293 Average Intensity PC3 Log2(intensity)
Average MS/MS count 
PC3
Table 4.4 Heat map of expression of metastasis related biomarkers 
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proteins with higher LFQ intensity such as cantenin α-1 and integrin α-6 had unreliable PSM 
(Table 4.4, Table 4.5Error! Reference source not found.).  
Next, we analyzed the proteins present in PC3 and compared between treatment groups 
with Ca2+ and EGTA. Secondly, we compared the global proteomics in PC3 and compared it to 
HEK293 cells in order to understand the differences that might cause the signaling differences.  
 
4.6.2.3.4 Global Proteomics of PC3 and effect of [Ca2+]o 
We observed changes in few proteins due to the effect of presence of Ca2+. For this, we 
employed successive stringencies to ensure robust upregulation, reproducibility, and detection: (i). 
at least 2 folds change of the average between the compared groups, (ii). PSM of equal or greater 
Majority 


















P21333-2 Filamin-A FLNA 79.5 85.5 1.71E+10 1.65E+10 100 103 2.65E+10 2.93E+10 -0.147 0.6285 0.8277
O75369-2 Filamin-B FLNB 17 13 2.77E+09 2.59E+09 91.5 101.5 2.10E+10 2.26E+10 -0.1108 2.9198 3.1273
P16615
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 ATP2A2 14 13 2.55E+09 2.44E+09 23 21 5.25E+09 5.18E+09 0.0191 1.0391 1.0863
P63244
Guanine nucleotide-binding protein 
subunit beta-2-like 1; beta-2-like 1, N-
terminally processed GNB2L1 29.5 26.5 1.22E+10 1.05E+10 20.5 21 1.24E+10 1.32E+10 -0.0873 0.0293 0.3258
H0Y7A7 Calmodulin CALM2;CALM1 12 14 7.62E+09 7.88E+09 10.5 12.5 6.33E+09 6.70E+09 -0.0813 -0.267 -0.2348
P62873
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 GNB1 5 5 2.03E+09 1.92E+09 10 9.5 2.41E+09 2.55E+09 -0.0822 0.2501 0.4138
P04899
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 GNAI2 9.5 7.5 9.01E+08 8.13E+08 10 12 1.68E+09 2.02E+09 -0.2697 0.8973 1.3154
P21964-2 Catechol O-methyltransferase COMT 1 1 3.63E+08 2.84E+08 6 6.5 1073500000 1183500000 -0.1407 1.5648 2.0596
P07099 Epoxide hydrolase 1 EPHX1 1.5 0.5 2.19E+08 1.72E+08 6 5.5 1034700000 1046740000 -0.0167 2.2419 2.6041
P62879
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2; subunit 
beta-4 GNB2;GNB4 3 2.5 6.59E+08 6.44E+08 3.5 3.5 6.17E+08 6.77E+08 -0.1323 -0.0937 0.0721
P63092-3
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short;XLas GNAS 1 0 1.44E+08 6.70E+07 3 2.5 2.47E+08 2.74E+08 -0.1517 0.7809 2.0328
Q14315-2 Filamin-C FLNC 0 0 0.00E+00 0.00E+00 1.5 2.5 9.62E+07 1.01E+08 -0.0645 2.0331 3.9922
P63218
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-5 GNG5 1 1.5 2.92E+08 3.76E+08 1 1 0.00E+00 1.37E+08 -2.9641 -4.0619 -1.4631
Q9BY32 Inosine triphosphate pyrophosphatase ITPA 2 2 1.77E+08 1.69E+08 1 1.5 0.00E+00 1.11E+08 -3.8429 -4.5235 -0.6091
Q14573
Inositol 1,4,5-trisphosphate receptor type 
3 ITPR3 0.5 1.5 0.00E+00 0.00E+00 0.5 0.5 0.00E+00 5.33E+06 1.2904 -0.317 -0.9872
Q01970-2
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-3 PLCB3 0 0 0.00E+00 0.00E+00 0.5 1 0.00E+00 3.15E+07 0.1916 2.5717 2.0951
P08754
Guanine nucleotide-binding protein G(k) 
subunit alpha GNAI3 0 0 1.93E+08 1.92E+08 0.5 1 1.25E+08 1.33E+08 -0.0891 -0.6271 -0.5249
P29992
Guanine nucleotide-binding protein 
subunit alpha-11 GNA11 0.5 1 2.56E+08 2.27E+08 0 0 2.90E+07 0.00E+00 3.1503 -3.1448 -6.1233
P63096
Guanine nucleotide-binding protein G(i) 
subunit alpha-1 GNAI1 0 0.5 6.47E+07 6.75E+07 0 0 0.00E+00 2.17E+07 0.5147 -1.0628 -1.639
Q14571
Inositol 1,4,5-trisphosphate receptor type 
2 ITPR2 0.5 0.5 0.00E+00 3.07E+07 0 0 0.00E+00 3.22E+07 -0.1045 1.1117 0.0688
Q9UBI6
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-12 GNG12 0 0.5 9.56E+07 8.65E+07 0 0 0.00E+00 9.18E+07 -2.3866 -2.4461 0.0863
E7ENE0 Extracellular calcium-sensing receptor CASR 0 0 2.60E+06 5.04E+06 0 0 1.34E+08 0 3.6869 5.69 1.0497







HEK293 Log2(intensity)Average Intensity PC3
Average Intensity 
HEK293
Table 4.5 Heat map for selected protein detected in PC3 and HEK293 cells through MS. 
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to 2 in both the duplicates of the up-regulated group, (iii) at least 1 unique peptides of the up-
regulated group. We determined that 39 proteins in PC3 had a differential expression that was 
dependent on Ca2+ (Figure 4.17). 22 were at least two-fold up-regulated in expression in the 
presence of Ca2+ and 17 were downregulated in the presence of Ca2+. Gene ontology study was 
tried on these set of proteins, but we could not generate any group attributed to a particular 
biological function. Some cell death associated proteins such as programmed cell death protein 6 
(PDCD6), BH3 interacting domain death agonist (BID), mitogen-activated protein kinase1 
(MAPK1), mitochondrial import inner membrane transmembrane (TIMM13), E3 ubiquitinating-
protein ligase UBR5 were upregulated. Notably, exosome complex component MTR3 (EXOSC6), 
coiled-coil domain-containing protein 86 (CCDC86), and histidine-tRNA ligase (HARS) were 
upregulated by > 8 folds. Alongside, deubiquitinating protein (VCPIP1), BAG family chaperone 
regulator (BAG3), were down-regulated. Notably, microsomal glutathione S-transferase 1 





























































































































































































































Figure 4.17  Differential proteome in PC3 compared between Ca2+ and EGTA treatments 
PC3 were treated with Ca2+, and after tandem MS on cell lysates, Ca2+ and EGTA groups 
were compared  
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4.6.2.3.5 Upregulation of proteomes in PC3 as compared to HEK293 in Ca2+ 
464 proteins were observed as up-regulated by at least two-fold in PC3 as compared to 
HEK293 cells in Ca2+ treated conditions (Figure 4.18). 396 were commonly up-regulated in PC3 
between Ca and EGTA conditions. These processes must be Ca2+ independent and significant in 
PC3 for its distinctive cellular processes. 25 most highly expressed proteins contain the core 
histones, enolase, GAPDH, tubulin and heat shock proteins as well as proteins of the ribosome 
(2012 Geiger). 25 proteins with the lowest MS signals included several novel and uncharacterized 
proteins as well as isoforms of well-known proteins. This abundance estimation is a rough 
estimation of the actual expression levels. Also, the proteome could be incomplete, as we can 
assume that proteins with low expression levels, could not be identified.  
 




































































































































































































































































































Figure 4.18  Top 50 up-regulated proteome in PC3 as compared to HEK293 cells in Ca2+ 
PC3 and HEK293 cells transiently transfected with CaSR were treated with Ca2+, and after 
tandem MS on cell lysates, the top 50 proteins upregulated by various degrees in Ca2+ are 
plotted. 
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4.6.2.4 Functional analysis using Cytoscape and ClueGo 
Metabolic pathways such as fatty acid metabolism, amino acid metabolism and glutathione 
metabolism were highly variable (2012 Geiger), indicating differential energy production and 
biosynthetic pathways. Additionally, large difference existed in the actin cytoskeleton, which 
indicates their difference in morphology. Amongst the more constant processes involved basal 
transcription machinery and protein translation. These are fundamental and nonredundant 
pathways.  
The up-regulated proteins were input into Cytoscape and plugin ClueGo was used to derive 
the functional annotations associated with them. We show pathways associated with TCA cycle, 
trans-Golgi network vesicle budding, and triglyceride synthesis were upregulated in Ca2+ in PC3 
as compared to HEK293 cells. Instead of these pathways, the up-regulated pathways in EGTA in 
PC3 as compared to HEK293 cells were arginine/proline metabolism and amino sugar/nucleotide 












































































































































































































































































































Figure 4.20 4-fold up-regulated proteome in PC3 as compared to HEK293 cells in 4mM Ca2+.  
 
The upregulated annotations are shown above as A. Biological Process, B. Cellular 








Figure 4.21  4-fold up-regulated proteome in PC3 as compared to HEK293 cells in EGTA.  
 The upregulated annotations are shown above as A. Biological Process, B. Cellular 








4.6.2.5 In-Vivo study of the role of CaSR and extracellular Ca2+ in bony metastasis 
It has been previously shown metastasis localization is promoted by higher extracellular 
Ca2+ through CaSR mediated signaling [91, 92]. CaSR may play a role in PCa in bony metastasis. 
This was shown by Dr. Jie Feng that CaSR knockdown in PC-3 cells resulted in a decrease in 
tumor cell viability at higher Ca2+ environment and an increase in apoptosis and invasion by greater 
than 50-folds. Additionally, significant increased levels of cell-adhesion proteins, e-cadherin and 
integrin, and decreased levels of matrix metalloproteinases (MMP-2 and MMP-9) in PC-3 with 
CaSR. Furthermore, CaSR knockdown caused phenotypic changes associated with epithelial-
mesenchymal transition, i.e., decreasing E-cadherin and γ-catenin and increasing smooth muscle 
actin and vimentin.  
4.6.2.5.1 Generation of a PC3 luc CaSR knockdown cells 
Using lentiviral infection and shRNA technology, CaSR was knocked down in PC3 luc 
cells. pLKO.1-CaSR was co-transfected into HEK293T cells with psPAX2 and pMD2 plasmids. 
Figure 4.22 Generation and validation of CaSR KD in PC3 luc cells 
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The target gene was as described by Liao et al CTGGGTGTGTTTATCAAG in the seventh exon 
(Figure 4.2, Figure 4.22).  
4.6.2.5.2 Effect of Ca2+ on the metastatic biomarkers is complex 
In order to understand the role of extracellular Ca2+ on bone metastasis, we studied the 
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Figure 4.23 Effect of Ca2+ on 
prostate cancer bone metastasis 
biomarkers 
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decreased the expression of E-cadherin, γ-catenin, and vimentin, however, the N-cadherin was 
not affected (Figure 4.23). 10 mM Ca2+ had a different effect where it further decreases the 
expression in E-cadherin and vimentin whereas it increases the expression of N-cadherin and 
doesn’t have any effect on γ-catenin. This trend doesn’t support MET where E-cadherin and γ-
catenin should increase, and N-cadherin and vimentin should decrease. It offers a dynamic role 
of Ca2+ on various biomarkers suggesting more complex role. This study needs to be compared 
with PC3 luc with CaSR KD and control KD to make more sense.  
4.6.2.5.3 In-vivo study of the role of CaSR and Ca2+ in bony metastasis 
First, the PC3 cells were measured for the luciferase signal by Dr. Kanza from Dr. Daqing 
Wu’s Lab in Augusta University (Table 4.6). The firefly reading is the real number since PC3-luc 
uses a firefly luciferase vector. The Renilla reading is the background, which is extremely low, 
given the 10-second collecting time of signals. There was a ~30-fold difference between the 
control and KD cells, which may be due to many reasons, including the amounts of cell lysates 
used in the assay and different expression levels of KD vectors.  
The in-vivo work showed a significant decrease in tumor growth when injected in mouse 
tibia with PC-3 with CaSR knockdown as compared to the control knockdown. Our results strongly 
support that CaSR is involved in promoting PC-3 colonization in bones with high calcium by 
preventing cell apoptosis of cancer cells, inhibiting invasion, and promoting mesenchymal-
epithelial transition. It suggests that CaSR may serve as a potential therapeutic biomarker for PCa 
metastasis.  
RLU Firefly RLU Renilla
PC3-luc control KD 325679 766
PC3-luc CaSR KD 10195 723
Table 4.6 Luciferase reading on PC3 luc cells 
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The following experiment was conducted in collaboration with Dr. Daqing Wu in Augusta 
University. The postdoctoral fellow Kanza Manmouni conducted the experiment. Tibia of the nude 
male mouse which were 4 weeks old was injected via subcutaneous route twice a week with cells, 
either PC3 luc control or PC3 CaSR KD starting on October 3rd 2017 (Table 4.7). Subcutaneous 
injection of PBS as a negative control or bisphosphonate (zoledronic acid) at 0.2 mg/kg was carried 
out twice per week for 4 weeks. By using image J, we can say that the tumor growth is substantially 
Condition Weight (g) Oct 4 2017 Oct 9 2017 oct 13 2017 oct 16 2017 oct 20 2017 oct 23 2017 oct 27 2017 oct 30 2017
Mouse in experiment 
PC3 Ctrl luc (PBS)
2 22.6 20.3 20.26 23.2 25 25.8 24.8 24.3
3 23.8 21 22.3 24.5 25.5 26 25.3 24.5
4 24 22.6 21.3 25 26 26.7 26.5 26.2
PC3 Ctrl luc (Zoledronic acid 0.2mg/kg)
1 22.2 23.3 24.5 26.4 27.8 27.9 27.3 26.3
2 22.6 24.2 24.9 27.2 26.2 25.2 24.5 22.2
3 23 22.6 21.3 23.7 24.9 26.2 26.9 25.4
4 22.5 22.7 20.9 23 24.9 26 26.7 28
5 24.4 24.5 23.9 26.5 26.9 27.5 27.3 25.5
PC3 CaSR KD (PBS)
1 22 19.4 18.7 21 20.6 24.3 25.8 25.4
2 23.2 20.7 19 21.9 21.2 23.6 25 24
3 23 20.7 20 22.6 21.9 24.8 25 24.5
4 22.2 20.5 20 22.5 22.6 25.4 25.4 24.2
5 23.7 22 21.4 23.8 22.6 24.6 25.7 24.9
PC3 CaSR KD (Zoledronic acid 0.2 mg/kg)
1 25 23 23.2 24.2 25.4 28.4 26.9 26.5
2 21.18 19.8 19.6 21.3 22 24.5 24.5 24.2
3 25.8 23.8 24.8 26.5 26.2 27.6 27.2 27
4 23.6 21.6 19.5 22.1 21.9 23.8 23.6 23.3
5 24.5 22.6 21.8 24.4 24.5 27.7 23.6 26.2
Table 4.7 The experimental log of weights for mouse in-vivo for injection of PC3 cells 
 
216 
larger in both PC3 control and CaSR KD (Figure 4.24). This supports the idea that Ca2+ is essential 
for tumor survival and growth in bones.  
Figure 4.24  In vivo study to study the proliferation of  PC3 cells when injected in 
tibia or a mouse 
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CaSR PBS 2L 7 CaSR PBS R 6
CaSR Zol 2R 6 CaSR Zol-3R 7
Ctrl PBS 2R 6 Ctrl PBS 3R 10
Ctrl Zol 2L 7 Ctrl Zol 3L 11
Figure 4.25 H&E staining of the bone tissue from the mouse to understand the role of CaSR in 
PC3 proliferation in bone  
Representative two slices from each conditions are shown. Third slice did not have proper 
demarcated tumor, therefore, were excluded. For CaSR Zol, only 1 slice was taken. The area 
represented under the red curve is tumor in darker red. The green represent bone in tibia and 
purple represents muscle. A. PC3 luc cells with CaSR KD in PBS medium. B. PC3 luc cells with 
CaSR KD in zoledronic acid medium. C. PC3 luc cells with control KD in PBS medium and D. 
PC3 luc cells with control KD in zoledronic acid medium 
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 Next, we can see that the tumor growth is almost completely subsided with the use of 
bisphosphonate (Figure 4.24, Figure 4.25). Bisphosphonates are nonhydrolyzable pyrophosphate 
analogs. They are known to cause inhibition of osteoclast generation, maturation, and osteoclastic 
bone resorption activity [306-308]. Zoledronic acid is a new generation bisphosphonate with 
imidazole ring and high potency[309]. Our theory is that the increase in extracellular Ca2+ 
promotes the bone metastasis in PC-3 cells expressing CaSR. It can bind to hydroxyapatite and 
therefore might decrease the Ca2+ available to the cancer tissues. Therefore, bisphosphonates have 
multiple mechanisms in bone and may limit the interactions between Ca2+ and tumor cells. This 
approach partially supports the hypothesis. The previous study by Corey has shown that zoledronic 
acid may inhibit prostate cancer cell proliferation in vitro, but they were unable to show this in-
vivo [310].  H&E staining and TRAP staining on the bone tissue were conducted to have a better 


































CaSR PBS 2L 7 CaSR PBS R 6
CaSR Zol 2R 6 CaSR Zol-3R 7
Ctrl Zol 4L 7
Ctrl Zol 3L 11
Figure 4.27 TRAP staining on bone tissue from mouse tibia injected with PC3 luc with and 
without CaSR 
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4.6.2.6 Interaction of CaM with CaSR in PC3 
CaM expression was established using immunostaining where CaM and CaSR were seen 
to co-localize with a Pearson’s coefficient of 0.67 (Figure 4.28). Ca2+ dependent binding of CaM 
with endogenous CaSR in PC3 was analyzed using Co-IP and western blot validation. The Ca2+ 
dependence is not established as both conditions show the elutions at the higher molecular weight 
(Figure 4.29). This can be explained by the higher molecular weight immunoprecipitation of CaSR 
at > 250 kDa where CaM is seen in the blot.  
4.7 Discussion 
Bone is a common site of metastasis for prostate cancer cells. The Ca2+ concentration in the 
bone is 10-40 mM and this provides a unique environment for the tumor cells. The CaSR in PC3 
has been implicated in tumor proliferation and survival. In our work, we explore the intracellular 
Nucleus CaM
CaSR Merged
Figure 4.28 Co-localization of CaM with CaSR with a Pearson’s coefficient of 0.67 
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Ca2+ response of PC3, precisely the CaSR mediated responses. We report that the CaSR mediated 
Gαq associated Ca
2+
i response, such as the intracellular calcium oscillation and IP1 are absent in 
PC3. Oscillation with very low frequency was observed in 2-3% of the cells. Overexpression of 
wild type CaSR in these cells could not rescue these signaling. Apart from the intracellular Ca2+ 
response, we observe that ERK1/2 and IP1 are also missing in PC3 cells. This suggests that the 
PC3 is extracellular Ca2+ insensitive and therefore, the G-protein mediated signaling are stunted. 
CaSR associated drugs such as cinacalcet and TNCA could not rescue these signaling. To 
understand the signaling in other PCa cells, we explored the intracellular response in LNCaP cells, 
which are PCa cells that metastasize to lymph nodes. They also lack the response. However, 
previous studies have suggested that these cells have lower CaSR [91], so that could be the reason 
we observe no oscillation. However, interestingly, we observe more significant number of 
transients in 50% of the LNCaP cells at 3 mM Ca2+.  
In order to understand the molecular reason for this discrepancy in signaling, we explored 
the protein and genomic expression of CaSR as well as the overall proteomics in PC3 cells. We 
noted that CaSR monomer in PC3 occurs as a monomer in non-reducing condition and has a lower 
Figure 4.29   Interaction of CaSR with 
CaM  
10% gel. Overnight transfer. Blocked 
2 hrs with 3% milk; antibodies 
incubation with 3% BSA. Heated 
with 5% beta-mercaptanol for 10 min 
on the same and day and ran samples 
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molecular weight with 110 kDa, indicating incapability to form a dimer or presence of a variant 
with a splice-variant or lower glycosylation. WT CaSR usually shows up at 130-150 kDa. PC3, on 
the contrary, is able to generate a dimer when artificially transfected. Immunostaining showed that 
most endogenous CaSR occurs within the cell as compared to functional plasma membrane CaSR. 
These results suggest that endogenous CaSR in PC3 may deflect from the WT in molecular 
composition and this may result in obstructed Ca2+ signaling. Therefore, we further went to use 
RT-PCR to examine the expression of CaSR at the genomic level. We show that a full CaSR with 
all seven exons are present in PC3. But we cannot rule out the presence of other splice variants as 
primers were designed based on known WT CaSR for PCR. Also, mutations or small deletions 
could not be detected with this process. Unfortunately, our endeavor to use RNAseq for complete 
CaSR sequence was not successful due to the low transcript of CaSR and therefore, resulting in 
almost no detection of CaSR.  
Another possibility of lower molecular weight of endogenous CaSR in PC3 could be due to 
the presence of immature CaSR with less glycosylation. However, our result that transiently 
transfected CaSR occurred as proper molecular weight species and immunostaining showed at 
least some cells were able to express the WT CaSR at the surface, but this still could not rescue 
the g-protein signaling, suggest against the logic that glycosylation could be the reason behind the 
differential Ca2+ signaling. Other possible reason for differential signaling in PC3 cells could be 
biased signaling or defect with its regulators in the cells. In order to examine this, we carried out 
immunoassay which shows the presence of essential CaSR regulators Gαq and CaM. However, 
proteomics study in the past had shown that Gαq/11 was only present in RWPE-1 and LNCaP 
prostate cancer cells, but not in PC3 cells [303].  This is contrary to what we have found. We could 
also argue that the Gαq/11 blot obtained was slightly lower than that in LNCaP and HEK293 cells 
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which indicates a variant of Gαq/11 in PC3 resulting in the differential signaling. Proteomics study 
of PC3 cells indicates the absence of Gαq/11 but presence of Gαi. ERK1/2 is induced by Gαi and 
intracellular oscillation by Gαq/11 usually. ER Ca
2+ channel SERCA was present with reliable PSM 
and high LFQ intensity. However, IP3R detection was not reliable for PC3 cells. We cannot say 
that mass spectrometry result is a complete picture. MS may not be able to detect the Gαq/11 and 
IP3R even in HEK293, a positive control.   
Proteomics of total cell lysate was carried out and a total of 3327 proteins were detected. 
Apart from Gαq, CaM and other G-proteins such as Gαi-2, Gαs and Gβ are detected with strong 
MS/MS count. Additionally, CaSR was not detected with PSM of 0 which supports the retarded 
Ca2+ sensing and low transcript generated in RT-PCR and RNAseq. On the contrary, 109 LFQ 
intensity was observed for HEK293 cells transfected with FLAG-CaSR with an average PSM of 
22. Only 22 proteins were at least two-fold up-regulated in expression in the presence of Ca2+ and 
17 were downregulated in the presence of Ca2+.  More research is required to understand their 
implication in PC3 cells. Additionally, because we were interested in prognosis markers, proteins 
detected in PC3 were compared to known markers in prostate cancer from the human protein atlas. 
We found two proteins, Epoxide hydrolase 1 (EPHX1) and Catebhol O-methyltransferase 
(COMT) with good abundance with the stringency of ≥ 4 average PSM and with average LFQ 
intensity in the range of 109. These markers were not significantly Ca2+ dependent, as Ca2+ 
treatment in PC3 caused < 0.9-fold decrease as compared to one treated with EGTA. However, 
these were ≥ 3-fold increased as compared to HEK293 cells. Isoforms of other good prognostic 
markers including the ubiquitin (RNF114), Ubiquitin-conjugating enzyme (UBE2D2/3) and SLCs 
were detected with good stringencies.  
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We were also interested to see what cellular processes are upregulated in PC3 as compared 
to HEK293 cells. We employed gene ontology on the up-regulated proteins from MS to understand 
the role of extracellular Ca2+ in alteration of proteomics in PC3 cells as compared to HEK293 cells. 
We noted that global proteome is generally upregulated in PC3 as compared to HEK293 cells. In 
the presence of Ca2+, ≥ 4-fold upregulated proteins are associated with pathways including, trans-
Golgi network vesicle budding and citric acid cycle. This has been recently shown that TCA cycle 
is hyperactivated in PCa cells using GC-MS and RNA-seq analysis by another group[311]. This is 
shown to result due to decreased PCa epithelial cells accumulating zinc and thereby, increasing 
citrate oxidation [311]. This may allow more energy production in PC3 cells. Fatty acid uptake 
[312] and enzymes required for beta-oxidation [313] has been shown to be increased in PCa 
tumors. This can provide ATP and acetyl-coenzyme A to accelerate the citrate oxidation. 
Additional analysis and literature mining is underway to understand the upregulated proteome in 
PC3 and better understanding will be achieved if the proteome is compared between the malignant, 
normal and non-malignant cells or tissues since comparing PC3 and HEK293 are from distinctive 
origin, our analysis can be diluted.  
Further, in vivo studies were conducted to understand and re-enforce involvement of CaSR 
in PC3 colonization in bones by preventing cell apoptosis of cancer cells, inhibiting invasion, and 
promoting mesenchymal-epithelial transition. My work showed a significant decrease in tumor 
growth when injected in mouse tibia with PC3 with CaSR knockdown and the control knockdown 
in the presence of a Ca2+ chelator, Zoledronic acid. This work shows the Ca2+ dependent 
proliferation of PC3 cells in bones. The work does not show a significant change between the PC3 
with CaSR knockdown and the control knockdown as quantified by our limited two H&E staining. 
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Our work indicates that even in the presence of normal CaSR, PC3 displays unique Ca2+ signaling 
that is independent of Gαq, possibly undergoing signaling bias.  
 
 
5 CHAPTER V: REGULATION OF CONNEXIN26 GAP JUNCTION CHANNEL 
THROUGH EXTRACELLULAR CALCIUM AND CALMODULIN 
 
5.1 Abstract 
Living beings are an amalgam of processes and regulations. One of such vital biological 
processes is cellular communication which regulates hormone signaling, neural transmission and 
cell-to-cell adhesion. Gap junction (GJ) proteins consist of intercellular aqueous channels between 
adjacent cells that permit the exchange of important hydrophilic molecules such as ATP, cAMP, 
IP3, glutamate, calcium, and many more. Connexin26 (Cx26) is the second most ubiquitous GJ 
proteins, and hundreds of mutations in Cx26 is implicated in many hereditary deafness and 
dermatological disorders. Many studies have pointed out the dependence of GJ channels on 
calcium ions and CaM (CaM) for the intra- and inter-cellular communications, respectively. 
However, the mechanism is obscure. In our study, first, we aimed at optimization of the expression 
and purification of the full-length hemichannel and dodecamer Cx26. Next, we investigated the 
molecular changes and binding affinities of Cx26 to Ca2+o
 in hemichannels and intracellular 
calcium
 
activated CaM protein using resonance energy transfer. 
The expression of hemichannel Cx26 was successfully optimized using the 
C43(DE3)pLysS bacterial stain, induced with 1 mM IPTG and grown at 37oC for 18 h. 3.5% 
empigen was determined as the most suitable detergent for solubilization of intact and stable Cx26 
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membrane protein. However, the yield was limited to 0.6 mg/L and the purification was 
challenging due to the oligomerization and precipitation of the protein during the process. Using 
fluorometry, we noted that the binding affinity of the hemichannel Cx26 to Tb3+ was 1.8 µM and 
indirect Ca2+ competition of bound Tb3+ exhibited a weak Kd of 37 mM. However, we found the 
result to be questionable due to non-linearity of the fluorescence change and the protein 
concentration during the competition. Additionally, we observed the dependence of fluorescence 
of the protein on the time of pre-incubation with Tb3+. Both observations suggested protein 
conformation change or precipitation during these processes. Therefore, the result we obtained is 
not conclusive.  
In order to understand the interaction between Cx26 and CaM, wt-CaM was successfully 
purified at 37 mg/L. Effect of Cx26 peptide (residue 1 to 21, Cx26p1-21) on the domain-specific 
Ca2+-binding affinity of CaM was examined by monitoring the intrinsic fluorescence intensity 
change of Phe and Tyr.  In the presence of Cx26p1-21, the Kd of CaM to Ca
2+ increased from 1.35 
to 4.10 µM and 2.9 to 3.87 µM for the N-domain and C-domain, respectively. This suggested 
greater conformational change of the N-terminal lobe by greater than 2.5 folds than that of C-lobe 
of CaM upon Cx26p1-21 binding. Further, the interaction between CaM and Cx26 in the living cell 
was examined using bioluminescence resonance energy transfer (BRET). Interaction between 
CaM with the yellow fluorescence fusion protein, Venus-C1, and Cx26 with the Renilla luciferase 
(Rluc-C1) fusion protein was found to be insignificant. This implies that the interaction does not 
occur between the CaM and the C-terminus of Cx26. The surface plasmon resonance study showed 
no significant binding between CaM and Cx26p1-21. This preliminary result indicates that the 




Gap junctions (GJ) are integral membrane proteins which assist in communication and 
coordination between cells through processes including, exchange of metabolites and electrical 
signal. In humans, GJs are expressed in all tissues except differentiated skeletal muscle, 
erythrocytes, and mature sperm cells [100]. GJ proteins consist of intercellular aqueous channels 
between adjacent cells that permit the exchange of hydrophilic molecules such as ions, and 
metabolites (ATP, NAD+, small peptides and nucleotides), and secondary messengers (Ca2+, 
cAMP, IP3) of less than 1kDa [100]. They are known to modulate a wide range of functions such 
as immune response, inflammation, memory, apoptosis, water channels, metabolism and muscle 
contraction [100].  
5.2.1 Regulation of Cx26 hemichannel by Calcium 
It has been known since 1991 that [Ca2+]o leads to the opening of connexin hemichannels. 
Muller et al. studied the conformational change of Cx26 hexameric extracellular hemichannel 
surface using atomic force microscopy (AFM) imaging at 1.2 nm lateral resolution and discovered 
the occurrence of significant narrowing of the entrance of Cx26 from 1.5 nm to 0.6 nm in the 
Figure 5.1  A. Ca2+ induced conformational change of the extracellular Cx26 connexon 
surface [9]. B. Conformational change in Cx43 with increasing [Ca2+] [18] 
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presence of calcium  at 0.5mM (Figure 5.1A) [9]. Additionally, conformational change with 
increasing Ca2+ concentration was demonstrated in Cx43 at a higher Ca2+ concentration of 1.8 mM, 
by Thimm et al suggesting a differential sensitivities (Figure 5.1B) [18]. It was established that 
the conformational change was fully reversible and specific to Ca2+ ions. Divalent cations like 
Zn2+, Cd2+, Co2+, Ba2+ and Mg2+ have been shown to inhibit the channel activity in general with 
their increasing concentration [314-316]. Calcium also induced the formation of microdomains 
and increase in the plaque height. Intracellular and extracellular hemichannel sensitivity to calcium 
concentration differs (intra: µM and extra: mM range). This suggests that there is a different gating 
mechanism for channel closure for the extracellular surface and cytoplasmic surface [100].  
According to many types of research, the likely candidate for the plug for the GJ protein are the 
NT, CT or CL domains. Increase in Ca2+i uncouples gap junction. Dr. Xue Wang has predicted the 
potential Ca2+-binding sites in Cx26 at amino acid positions Glu42, Asp46, and Glu47 from EL1 
and Glu187 from EL2 using computational algorithm MUGSR (Figure 5.2). This predicted binding 
sites are largely conserved in many Cxs and localize within the loop gating region. Several disease 
related mutations such as deletion of Ca2+-binding residues Glu42, Glu47Lys, and Gly45Glu affect 
GJ channel function dramatically and are associated with keratitis ichrhyosis deafness syndrome. 
Peracchia et al. have suggested the effect of Ca2+ is via CaM protein modulation [317]. Inhibitors 
of CaM has shown to prevent uncoupling of GJ in a number of cell types [317]. Increasing activity 
of CaM also showed an increase in Ca2+ sensitivity of Cx32 [318].  
5.2.2 CaM  
CaM is one of the most extensively studied calcium-binding proteins. It is a small, 17 kDa, 
a bilobed protein consisting of four EF-hand motifs each binding a Ca2+ ion [317]. It is a 
ubiquitous, 148 amino acid containing protein whose sequence is well conserved in most plants 
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and animal [317]. It has the N-and C- terminals connected by an internal flexible linker domain. 
Upon binding to Ca2+, the N-and C- terminals undergo structural rearrangements exposing a 
hydrophobic binding pocket that recognizes target proteins. The conformational change supports 
CaM's Ca2+ dependent recognition mechanism and its flexibility allows in binding > 500 diverse 
set of substrates. It has also been found that CaM is able to bind some target proteins in its apo- 
form [319], suggesting the dynamic nature of CaM modulation. Its targets include 
phosphodiesterase, myosin light chain kinase, CaM kinase, calcineurin, NO synthase, etc [319]. 
The EF hand consists of 29 residues; 9 in helix, 12 in loop and 8 in the second helix [320]. The 
loops are responsible in binding to four Ca2+ ions. Ca2+ ions take on pentagonal-bipyramid 
geometry; five oxygen atoms being on the same plane, and two oxygen atoms being above and 
below the plane. It coordinates to seven oxygen from side chain residues 1, 3, 5, 9 & 12, carbonyl 
mainchain and bridged water. Positions 1, 6, and 12 most highly conserved with Asp, Gly & Glu 
[320]. Various studies have reported domain-specific affinity values by monitoring changes in 
intrinsic fluorescence of Phe and Tyr residues [321, 322]. These studies report that the C-domain 
of CaM binds Ca2+ with higher affinity (Kd ≈ 2.0) than the N-domain (Kd ≈ 10.0) [321, 323]. The 
result is consistent with the reported order of site occupancy where the binding of Ca2+ to the C-
domain is known as the rate-limiting step in Ca2+/CaM complex formation, as the on/off-rates of 
Ca2+ can be 30- to 150-fold slower for the C-domain than for the N-domain; however, binding of 
CaM with the PEP-19 enzyme appears to increase the on-rate for Ca2+ up to 40-fold, so the 
Ca2+/CaM complex formation isn’t solely regulated by temporal and spatial changes in cytosolic 
Ca2+ and CaM concentrations [324]. Several studies using peptide models have shown Holo CaM 
in the collapsed binding form binding to sites located in the second half of the intracellular loop of 
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a-subfamily connexins (Cx50p141–166, Cx44p132–153 and Cx43p136–158). This is a 1–5–10 subclass 
binding mode. Here, each number represents the presence of a hydrophobic residue [325]. 
 
5.2.3 Regulation of GJ by CaM 
The N- and C-domains are known to have different binding affinities and kinetic properties. 
This allows for CaM to differentiate between the local and global Ca2+ changes to regulate their 
targets using various interaction modes [326]. Several connexins from all subfamilies such as 
Cx43, Cx44, Cx45 and Cx50 have been shown to be modulated by CaM by indirect methods such 
as silencing CaM expression or using CaM antagonist [317]. In 2017, Zou et al showed for the 
Figure 5.2  A. Crystal structure of Cx26. B. Predicted calcium 
binding sites in Cx26 using MUGSR. Glutamate and aspartate 
residues were predicted. C. Conservation of the predicted 
residues through various connexins.  
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first-time direct interaction of Ca2+/CaM with Cx45 using bioluminescence resonance energy 
transfer (BRET) in live cells [327].  
5.2.4 Expression Systems: The host cells  
The host cell for protein synthesis impacts the quality and generation of the protein. 
Bacterial expression of proteins has many advantages with fast growth kinetics, high cell density 
cultures, inexpensive culture media and easy and fast transformation with exogenous DNA [328]. 
Furthermore, it produces a high yield of the protein lacking posttranslational modification such as 
glycosylation which may impair interpretation of NMR data and most importantly, it enables 
hetero-labeling study using NMR. However, multiple challenges are associated with expressing a 
membrane protein in bacteria. For our purpose, we needed to generate hemichannels which was 
possible with a bacterial expression system. However, with this system, usually proteins don't fold 
properly, the host lacks enzymes responsible for post-translational modifications such as 
glycosylation which may hinder expression, rare codons in mammals need to be inserted into the 
host, and synthesis of toxic proteins hinder the optimum production of proteins. Therefore, it is 
important to optimize the expression system considering the induction period, the temperature of 
expression, vectors being used, etc. The main advantage of mammalian cell expression as 
compared to bacterial expression system is that the signals for synthesis, processing and secretion 
of eukaryotic proteins are properly and efficiently recognized by mammalian cells and therefore, 
resulting in properly folded proteins [329].  On the other hand, the baculovirus expression system 
is lengthy and intensive, but it yields larger amount of recombinant protein than the bacterial 
system. 
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5.2.5 Fluorescence Resonance Energy Transfer (FRET) 
At room temperature electrons in molecules occupy the lowest vibrational energy levels of 
the ground electronic state, and when they absorb light, they are transferred to excited states. 
Figure 5.3 demonstrates the absorption process by molecules to produce either the first, S1 or 
second S2, excited states. Fluorescence contains two processes; the first absorption occurs between 
different energy levels and then subsequent emission at longer wavelengths due to the vibrational 
energy loss. Since the wavelength that is being detected is different from the incident one, 
sensitivity is much higher due to the absence of background in excitation source. It is possible to 
measure fluorescence in the 10-7 M range, which has a better limit of detection than other 
absorption spectroscopy techniques [330]. There is a linear relationship between fluorescence 
intensity (Fλ) and concentration (C) of the fluorophore only for dilute solutions of the fluorophore 
(absorbance at excitation wavelength less than 0.05), represented in the equation below:  
 
Nanoseconds is usually the range for lifetime of a fluorophore in the excited state, however, 







Figure 5.3  A. Principle of fluorescence resonance energy transfer (FRET). B. Partial 
energy-level diagram for a photoluminescent system  
Equation 5. 1 
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affected by different factors such as interactions of the fluorophore with the solvent molecules 
which will eventually affect the maximum λem, quantum yield, and lifetime. Generally, an increase 
in the polarity of the solvent (or environment) has two effects: (a) a decrease in the fluorescence 
intensity, and (b) a redshift in the λmax of emission [330]. These effects of the environment on 
fluorescence parameters have been used extensively in monitoring protein-protein interactions. 
5.2.5.1 Stoke Shift 
The absorption energy is given by Ea=hc/λa and emission energy is given by Eem = hc/λem. 
Since, Eem < Ea we have: λem > λa, where λa and λem are absorption and emission spectra peaks. 
Thus, the emission spectrum has its maximum shifted to longer wavelengths compared to the 
maximum of the absorption spectrum. The distance between this maximum absorption and 
emission spectra is called the Stokes shift [330].  
5.2.5.2 Lifetime Fluorescence Spectroscopy 
After the excitation of the molecules, they tend to remain in the excited state for a short 
time before returning to the ground state, therefore, the lifetime of the molecules in the excited 
state is equal to the mean time during which molecules remain in the excited state, and the time is 
considered as the fluorescence lifetime. This time ranges from the nanoseconds (10−9 s) to 
picoseconds (10−12 s) [330]. So, the fluorescence lifetime determines the time available for the 
fluorophore to interact with or diffuse in its environment. For the fluorophore illustrated in Figure 
5.4, the lifetime is τ = 1/ (Γ+knr), where the emissive rate of the fluorophore is called (Γ) and its 
rate of nonradiative decay to S0 is called (knr). The lifetime is an average value of the time spent 
Equation 5. 2 
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in the excited state.  The natural lifetime can be calculated from the measured lifetime (τ) and 
quantum yield (Q): τn = τ/Q 
5.2.5.3 Fluorescence Quantum Yields 
The fluorescence quantum yield is defined as the ratio of the number of photons emitted to 
the number absorbed. The fraction of fluorophores that decay through emission, and hence the 
quantum yield, is given by Q = Γ/(Γ + knr). The quantum yield can be close to unity if the 
nonradiative decay rate is much smaller than the rate of radiative decay which means is knr < Γ. 
5.2.5.4 Fluorescence Resonance Energy Transfer (FRET) 
Fluorescence resonance energy transfer (FRET) has various applications in the field of 
fluorescence such as medical diagnostics, DNA analysis, and optical imaging. FRET usually 
occurs between a donor (D) molecule in the excited state and an acceptor (A) molecule in the 
ground state. The donor molecules typically emit light at shorter wavelengths which then overlap 
with the absorption spectrum of the acceptor. Energy transfer occurs without the generation of any 
photon and it is the result of long-range dipole-dipole interactions between the donor and acceptor. 
Figure 5.5 demonstrates the RET process. In this process, the acceptor can be a non-fluorescent 
agent. The distance between the donor and acceptor is the key determinant for the extent of energy 
transfer, and the extent of spectral overlap. The spectral overlap is described in Figure 5.5 in terms 
Figure 5.4  A simplified Jablonski diagram to illustrate the meaning of quantum 
yields and lifetimes 
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of the Förster distance (R0). The efficiency of energy transfer for a single donor–acceptor pair at a 
fixed distance is E = R6o/(R
6
o + r
6), where r is the distance between the donor (D) and acceptor (A) 
and τD is the lifetime of the donor in the absence of energy transfer. Therefore, the extent of transfer 
depends on the distance (r) [330]. The Förster distances are comparable in size to biological 
macromolecules: 30 to 60 Å. For this reason, energy transfer has been used as a "spectroscopic 
ruler" for measurements of the distance between sites on proteins.  
 
5.2.5.5 BRET 
The BRET method is an advanced, non-destructive, cell-based assay technology based on 
the forster resonance energy transfer leading to a non-radiative energy transfer between an energy 
donor and an energy acceptor [330]. The energy donor is a luciferase, which emits light in the 
presence of its corresponding substrate. The energy acceptor is a fluorophore, typically a 
fluorescent protein, which absorbs light at a given wavelength and reemits light at a longer 
wavelength. To fulfill the conditions for energy transfer, the emission spectrum of the donor must 
overlap with the excitation spectrum of the acceptor. To investigate protein-protein interactions, 
Figure 5.5  Spectral overlap for fluorescence resonance energy transfer 
(RET). 
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one protein is fused to the donor and the other to the acceptor. If the two fusion proteins do not 
interact, only light emitted from the substrate transformation by the energy donor can be 
monitored. If the two fusion proteins interact and the distance between the energy donor and 
acceptor is less than 10 nm, a resonance energy transfer occurs and an additional. light signal 
corresponding to the acceptor reemission can be detected. When the energy donor and acceptor 
are fused to the same protein, an intramolecular BRET can be monitored in this double-fusion 
protein. Depending on the position at which the energy donor and acceptor are fused, structural 
rearrangements (conformational changes) within the protein of interest can be measured as 
changes of the intramolecular BRET signal. 
5.2.6 Surface plasmon resonance 
Surface Plasmon Resonance is a phenomenon that occurs when polarized light hits a metal 
film at the interface of media with different refractive indices. A light is incident upon a metal film 
through a prism and the reflected beam is collected and analyzed. At an appropriate angle 
(resonance angle), the incident light excites the surface plasmons in the sensor chip (metal film) 
and the intensity of the reflected light drops to a minimum. The electromagnetic field created by 
SPR penetrates the fluidic medium and probes molecular binding processes taking place on the 
surface and the refractive index changes in the fluidic medium. The excitation of surface plasmons 
Figure 5.6 Principle of surface plasmon resonance 
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results in a dark line in the reflected beam, and the angular position of the dark line shifts as a 
molecule binding event takes place. SPR Scanning Angle Response. SPR causes an intensity dip 
in the reflected light at the sensor surface. A shift in the curve represents molecular binding. The 
angular shift vs. time provides a good study of binding kinetics. The reverse process, molecular 
dissociation, can be studied in a similar way. Ideally for a kinetic analysis, the maximal RU signal 
should be ~ 100 RU for protein:protein, protein:DNA interactions and ~ 25 RU for small molecules 
(< 1000 – 1200 Da).  
5.3 Challenges  
As mentioned in chapter I, challenges faced in studying connexins include oligomerization, 
lower solubility and difficulty and limitations associated with expression E.coli., and insect cells 
due to the fact that bacteria lack proper mechanism for eukaryotic protein folding, translocating, 
trafficking, disulfide bond formation and post-translational modifications. Also, the phospholipid 
composition in bacteria and insects varies from that of eukaryotic cells. These may result in 
improper surface expression of membrane proteins such as connexins. These limitations in 
membrane proteins result in unavailability of crystal structures. Additionally, understanding the 
calcium modulation is a challenge due to its weak binding and that Ca2+ binding has high on- and 
off- rate. Furthermore, calcium is silent spectroscopically which makes the study challenging. 
5.4 Major aims and questions in this chapter  
a) Aim I: Optimize a full length hCx26 expression and purification system from 
bacteria  
 What parameters can optimize the expression of hCx26? 
 What detergents and strategies are optimal for purification of hCx26? 
 What are the biophysical characteristics/stability of the purified protein? 
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b) Aim II: Understanding the gating of hemichannels through Ca2+o using the hCx26 
expressed from bacteria 
 What is the stoichiometry, metal binding affinity and metal selectivity of the 
hCx26?  
 How does Ca2+ induce conformational changes, stability and assembly? 
c) Aim II: Understanding the interaction of Cx26 with CaM using synthetic Cx26 
peptide 
 What is the major mechanism of  interacts between CaM/Ca2+ and Cx26? 
5.5 Materials and methods 
5.5.1 Molecular cloning  
5.5.1.1 Recombinant hCx26 gene was cloned into pRSETA vector  
This was carried out between BamHI (5’ end of gene) and EcoRI (3” end of gene) 
restriction enzyme sites. Polymerase chain reaction (PCR) was used to amplify the hCx26 gene. 
100ul reaction mixture was obtained using 66 ul of autoclaved water, 10ul of 10X buffer, 10ul of 
2mM dNTPs, 6ul of 25mM MgSO4 , 0.5ul of ~1500ng/ul plasmid, 2ul of reverse and forward 
primers and 2ul of polymerase KOD. The forward primer designed was 
CGCGGATCCATGGATTGGGGCACACTC and the reverse was 
CCGGAATTCGACTGGTCTTTTGGACTT (Tm=56
oC). Denaturation was carried out at 94oC for 
2 min, annealing at 56oC for 30 sec, extension at 72oC for 20 sec for 30 cycles, final extension at 
72oC for 20 sec. Using double digestion, the CaSR gene was cleaved from the pRSETA vector and 
similarly, hCx26 target gene with His tag was cleaved from the pHisTrcA vector. The digested 
products were run in DNA gel, extracted and ligated with rapid ligase. Various concentrations of 
PCR product and vectors were tried. 1:7, 3:5, and 5:3 worked. The ligation reaction was allowed 
239 
to incubate at room temperature for ~3hrs. The ligated product was transformed into XL10-gold. 
Next day, a colony was inoculated into a 5ml LB and grown at 37oC o/n. DNA was extracted using 
Quick MiniPrep and sent for sequencing.  
5.5.1.2 Generation of C43(DE3)pLysS competent cells  
Plasmids from Rosetta 2(DE3) pLysS cells and C43(DE3) were isolated and pLysS was 
cleaved from the Rosetta2(DE3) pLysS. Next, C43(DE3) and the mixture with pLysS and 
Rosetta2(DE3) were co-transformed and selected.  
5.5.1.3 Cloning BRET constructs 
This was carried out using the previously described method [327]. The yellow fluorescent 
protein fusion protein expression vector pVenus-N/pVenus-C1 and the Renilla luciferase (RLuc) 
protein fusion protein expression vectors were received from Dr. Hepler (Emory University, GA). 
The mouse Cx26 plasmid in pcDNA3.1/Hygro(+) was from Dr. Veenstra (SUNY Upstate Medical 
Univesity, NY). Cx26-pVenus was synthesized by insertion of the PCR product of the mouse Cx26 
into vector pVenus-N1 at Nhe I and Xma I enzyme sites upstream of eYFP. Forward and reverse 
primers were CTA GCT AGC ATG AGT TGG AGC TTC CTG ACT and TCCC CCC GGG AAT 
CCA GAC GGA GGT CTT CCC. CaM-RLuc8 was generated by insertion of rat CaM gene into 
vector RLuc8-N1 at Xho I and BamH I. Forward and reverse primers for generation of CaM-
RLuc8 were CCG CTC GAG ATG GCT GAC CAG CTG ACC and CGC GGA TCC CTT GCG 
AGT CAT CAT CTG. All DNA sequences were verified by GENEWIZ.INC 
(www.genewiz.com).  
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5.5.2 Transformation and expression of hCx26 
Expression conditions were varied and optimized using various the competent cells, 
temperature and induction times (Figure 5.10). hCx26 plasmid was transformed into competent 
cells such as: E. coli C43(DE3), C43(DE3)pLysS, Rosetta gammi pLysS or Shuffle. A single 
colony was inoculated into 200ml or 100ml medium (LB or M9) and allowed to grow o/n (< 16hrs) 
at 37oC or 28oC at 250 rpm along with respective antibiotics. 1ml antibiotic was added into the 0.5 
L autoclaved medium. ~3.5ml was transferred into 0.5 L medium in 1 L flask at respective 
temperatures and allowed to grow at 250 rpm. When OD reached 0.9-1.2 (1.0 is optimum), 1mL 
of 1 M IPTG was added to induce expression for 16-20 hrs. Once expression was complete, the 
bacterial cells was harvested at 7000rpm for 10 min at 4oC. The pellets were stored at -80oC for 
future purification process after adding 300ul of 1M PMSF. The expression was quantified using 
western blot and SDS-page gels. (Minimal medium (M9) contained Na2HPO4, KH2PO4, NaCl, 
NH4Cl (0.5 g), MgSO4, CaCl2(1 M), FeSO4 (0.01 M), Glucose (5 g), Thiamine (0.5  mg/mL), 












Ampicillin Plate with 
Luria broth Medium
13
Figure 5.7 Workflow of expression of protein from 
bacterial strain.  
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5.5.3 Purification of hCx26 
Various buffer systems and detergents were used in order to optimize the yield and quality 
of Cx26.  
5.5.3.1 Purification of hCx26 using 2% DDM: 
Pellets was thawed on ice. ~30mL of lysis buffer (75mM Tris HCl, 30mM NaCl, pH 7.7, 
1mM PMSF and 1 ul benzononase nuclease per 50 mL) was added little at a time to homogenize 
the pellets. The mixture was ultra-centrifuged at 30,000 rpm, 4oC for 1hr. Supernatant was 
collected in a clean beaker and filtered through 0.45um filter. 10mM Imidazole was added and pH 
was adjusted to 8. 1mM PMSF, 0.05-0.1% DDM was added. Beads were prepared and washed 
with deionized water and lysis buffer with 10mM imidazole. The supernatant was combined with 
beads properly in a beaker and stirred for 2-3 hrs or o/n in cold box. The pellet was re-suspended 
gently using hand homogenizer. Solubilization buffer (10mM HEPES, 0.005% NaN3, 500mM 
NaCl, pH=7.5 2% working concentration of DDM (Stock=10%, stored at -20oC) with 1mM 
PMSF) was added. The lid was Para filmed and was allowed to shake overnight at 4oC in a circular 
shaker. Next day, solubilization buffer at pH 7.5 with 2% DDM was added to the pellet solution 
and brought the volume to ~32ml. Then ultracentrifuged it at 28,000 rpm for 1hr. The supernatant 
was filtered through 0.45um filter into a clean beaker and the pellet was stored at -20oC. 10mM 
imidazole was added to get rid of non-specific binding proteins and adjusted the pH to 8. The same 
process was carried out as done day before for the supernatant, but with 2% DDM to extract 
remaining membrane proteins. The supernatant was incubated with bead for 2-3hrs. The 
supernatant-bead mix was transferred to the column. The column was rinsed with wash buffer I 
(10mM HEPES, 500mM NaCl, 10mM Imidazole, 0.1% DDM, pH=8) and wash buffer II (10mM 
HEPES, 500mM NaCl, 0.1% DDM, 40mM Imidazole, pH=8). Finally, protein was eluted out in 
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2ml fractions in each of the five falcon tubes using 10mM HEPES, 150mM NaCl, 300mM 
Imidazole, pH 7.5. Column was cleaned using 2 M imidazole was used to clean the column, 
followed by deionized water (5X) and stored in 20% ethanol at 4oC. 
5.5.3.2 Purification of hCx26: Using 3.5% empigen 
 
The same method as above was used. After sonication, 1ml of 35% Empigen solution was 
added for every 10ml of lysate and tumbled in round rotor for 30 min -1hr. After ultracentrifugation 
at 30,000 for 1hr at 4oC, the supernatant was treated same way as above with the beads for 2-3 hrs 
or o/n in cold box. The mixture was allowed to settle in the column and washed with wash buffer 




3.5% Empigen NLS-OG System Urea/Unfolding-Refolding
Lysis Buffer 75mM Tris HCl, 30mM 
NaCl, 0.2mM EDTA,
pH 7.7
75mM Tris HCl, 30mM NaCl, 
pH 7.7
[25mM HEPES, 0.5M NaCl, 




3.5% Empigen 55mM N-laurylsarcosine, 0.2M 
NaCl, 50mM Na2HPO4, 1.09M 
glycerin, 10mM Tris, pH 9.5
→ diluted to 0.5% NLS
M Urea, 20mM Tris-HCl, 
0.5M NaCl, 2% TritonX-100, 
pH 8




0.5% NLS, 0.2M NaCl, 10mM 
Tris, pH 8
6M Guanidine HCL, 1mM 2-
mercaptoethanol, 20mM 
Tris-HCl, 0.5M NaCl, 5mM 
Imidazole pH8
Wash buffer II 10mM HEPES, 0.5M 
NaCl, 3% Empigen, 
40mM Imidazole, 
pH=8
30mM OG, 0.2M NaCL, 10mM 
Tris, pH 8
[20mM Tris, 0.5M NaCl,
20mM Imidazole, 6M Urea, 
1mM 2-Mercaptoethanol, 
pH8
4M → 2M → 0M Urea
Elution buffer 10mM HEPES, 0.15M 
NaCl, 0.3M Imidazole, 
0.1% DDM, pH 7.5
30mM OG, 0.5M Imidazole, 
10mM Tris, pH 8 500mM Imidazole
Table 5.1 Buffers used for various protein purification optimization  
243 
5.5.3.3 Purification of hCx26 Using NLS-OG System 
55 mM N-laurylsarcosine and 30 mM Octyl beta-glucoside (OG) was used to extract the 
membrane protein. Details on buffers used for this process is given in the table.  
5.5.4 Expression of wt CaM (CaM) 
Wild type CaM plasmid was transformed into BL21(DE3)pLysS (50ul) using heat shock 
method. The mixture with 1ml LB was incubated for 30 min at 37oC. 50 ul of the mixture was 
transferred dropwise on the plate and the plate was coated all over. It was incubated overnight 
(o/n) at 37o. 200ul of ampicillin (100mg/ml) was transferred into the 200ml LB, followed by 
inoculation of a single colony into the 200 ml medium. It was incubated o/n (<16hrs) at 37oC at 
200 rpm. 1ml ampicillin was added into the 1 L autoclaved LB. 20ml from the 200 ml culture was 
added into it and shaken vigorously to homogenize. It was then incubated at 37oC at 200 rpm. OD 
was checked every 1 hr until it reached 0.7 OD. 200uL of 1M Isopropyl beta-D-1-
thiogalactopyranosides (IPTG) was then added for induction. It took 3 hrs to reach ~0.7 OD and 
the expression was allowed to run for another 5 hrs. Once expression was complete, the bacterial 
cells were transferred into a clean centrifuge bottle. It was centrifuged at 7000rpm for 20 min at 
4oC. The pellets can be stored at -20oC for the future purification process.  
5.5.5 Purification of WT CaM: 
After the pellet was thawed, 30mL homogenization buffer was added to 1L of cell pellet. 
Allowed to homogenize 4oC to homogenize for 30 min using homogenization buffer (2mM EGTA, 
50mM Tris, pH 7.5, 1mM PMSF (Phenylmethylsulfonyl fluoride), 1mM DTT. The samples were 
sonicated for 20sec, followed by 5 min rest for the pellets to cool down. This process was repeated 
6 times. Sonicated samples were heated for 5min at 80-85oC. The mixture was transferred to small 
centrifuge tubes, balance and centrifuge for 17,000 rpm for 40min at 4oC. Then, supernatant and 
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pellet was separated out and stored for further analysis. 5mM CaCl2 was added to supernatant. 
Supernatant was transferred into a clean beaker and was filtered through a 0.45um. It was ready 
for running through the hydrophobic WT-CaM column.  
CaM wash buffer 1: 0.5mM CaCl2, 50mM Tris, pH 7.5 (75-100ml) 
CaM wash buffer 2: 0.5mM CaCl2, 50mM Tris, 50mM NaCl, pH 7.5 (75-100ml) 
CaM elution buffer: 50mM Tris, 5mM EGTA, pH 7.5 (75-100ml) 
Preparing column: 
The HIC WT CaM column was adjusted for the flow rate of 1-2 ml/min. The column was 
cleaned with filtered 20% ethanol (~50-75ml) to wash off the non-specific bindings, followed by 
filtered dd water (50-75ml) to remove ethanol, followed by wash buffer 1. The protein was allowed 
to run through the column overnight to ensure all the CaM is bound to the column. The column 
was washed with wash buffer 1, followed by wash buffer 2 to remove any unspecific-bound 
proteins from the column. Lastly, elution buffer was run through to elute out fractions of desired 
protein into six, 15ml falcon tube (collect 12-13ml/each). The purified CaM was dialyzed with 2L 
10mM Tris buffer at pH 7.5 at 4oC. The buffer was replaced every 1 hr three times. The last dialysis 
was left for O/N.  
5.5.6 Western Blot: 
Once the 7.5% gel is run, the gel is sandwiched between nitrocellulose membrane (0.45um) 
and filter paper. The box was filled with 1X transfer buffer and transfer chamber is run at 260mA 
for 2hrs or o/n at 22V at 4oC. Next, tris-buffered saline with 0.1% tween (TBST) buffer was used 
to rinse the membrane off the salt from transfer buffer. The membrane was blocked with 5% bovine 
serum albumin (BSA) in the TBST for 1hr at RT for any non-specific binding proteins. Anti His 
1˚ antibody mixture was prepared with 1:3000 dilution for Cx26-his-tagged protein and the 
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membrane was incubated with the antibody o/n in cold box on. The membrane was rinsed with 
TBST for 15 min on a shaker at room temperature 3 times. The membrane was incubated with 
anti-mouse 2˚ antibody for 1hr, followed by TBST washes of 3 times, 15 min each. Finally, 1ml 
substrate and 25 ul of enhancer (enzyme) mix were applied for 5min in dark. The membrane was 
dried and chemiluminescence was used to visualize the western blot. 
5.5.7 Fluorescence spectroscopy  
Steady-state fluorescence spectra were recorded using a QM1 fluorescence 
spectrophotometer (PTI) in a 1 cm path length cell with a xenon short-arc lamp at 25°C. Intrinsic 
tryptophan (Trp) emission spectra were recorded using 2 μM and 4uM protein sample in 10mM 
HEPES at pH 7.4. The Trp fluorescence spectra were recorded from 500 to 600 nm with the 
excitation wavelength at 285 nm. The slit widths were set at 1.5 and 3.0 nm for excitation and 
emission, respectively. The Tb3+ titration experiments were performed by gradually adding 1-5 μl 
aliquots of Tb3+ stock solutions (200 mM) into the protein samples (2 and 4 μM). For the Ca2+ 
competition studies, the solution containing Tb3+ and protein was set as the starting point. The 
stock solution of 1M CaCl2 with the same volume of Tb
3+ was gradually added in the initial 
mixture. The fluorescence intensity was normalized by subtracting the contribution of the baseline 
slope using logarithmic fitting.  
Equilibrium Ca2+ titrations were performed at room temperature using a previously 
described method [327]. CaM (8 μM) with Cx26p1-21 peptide (molar ratio of 1:1.2) in 50 mM 
HEPES (pH 7.4), 100 mM KCl, 5 mM nitrilotriacetic acid (NTA) and 0.05 mM EGTA was titrated 
with 15 mM or 50 mM Ca2+ solution prepared in the same buffer. The intrinsic fluorescence of 
tyrosine (λex = 277 nm, λem= 320 nm) or phenylalanine (λex = 250 nm, λem= 280 nm) was used to 
 Ca2+ free = 𝐾d.
𝐹 − 𝐹min
𝐹max − 𝐹
 Equation 5. 3 
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monitor the Ca2+ binding to the CaM C- and N-domains, respectively. The fluorescent Ca2+ 
indicator dye (0.2 μM) Oregon Green 488 BAPTA-5N (Oregon Green) was used to determine the 
free Ca2+ concentration at each titration point using equation as previously described. 
Where, F represents the fluorescence intensity of Oregon Green at each titration point, 
while Fmax and Fmin represent the fluorescence intensity of dye at Ca
2+-saturated and Ca2+- free 
states, respectively. Ca2+ titrations of CaM samples were repeated at least three times and fitted to 
a non-linear Hill equation.  
Where f is the fractional change in intrinsic fluorescence intensity,  Ca2+ nfree is the 
concentration of free ionized Ca2+ in solution, Kd represents Ca
2+ dissociation constant and n is the 
Hill coefficient. 
5.5.8 Mass spectroscopy  
The MALDI mass spectrometry analysis was performed by Dr. Chen Ma and Dr. Jingyou 
to analyze the purity of the sample with either contamination or degradation.  
5.5.9 Mammalian Cell Expression 
Frozen HeLa cells were recovered and allowed to grow in low glucose DMEM medium 
with 10% fetal bovine serum (FBS). They were split twice before they were prepared for 
transfection. For splitting cells, HBSS medium was used to rinse the excess DMEM (Dulbecco's 
Modified Eagle Medium), 1X trypsin was used to detach the cells and finally, DMEM was used 
to flush and homogenize the cells. These cells were transferred into smaller dishes with slides until 
the right confluency appeared. Lipofectamine 2000 (3X plasmid volume) was used to transfect the 
𝑓 =  
 Ca2+ nfree
𝐾𝑑 +  Ca2+ nfree
 Equation 5. 4 
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cells with hCx26-EGFP plasmid (2ug each for small dishes) in OPTI-MEM serum reduced 
medium. After 5-6 hours of transfection, the medium was changed to DMEM. 
5.5.10 Silver staining 
12.5% gel was first fixed with 50% methanol, 12% HAc, 0.005% formalin. It was followed 
by a wash with 35% EtOH and sensitized with 0.002% Na2S2O3. 0.25 silver nitrate, 0.0076% 
formalin was used to wash it. The gel was finally developed with 6% Na2CO3, 0.05% formalin. 
To stop the reaction, 50% methanol and 12% HAc was used.  
5.5.11 Bioluminescence Resonance Energy Transfer (BRET) 
The BRET assay was carried out on a TriStar LB941 multimode microplate reader. The 
HEK293 cells cotransfected with Venus-CaM and Cx26-Rluc were detached and suspended in 
sterilized BRET buffer (140 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 0.37 mM 
NaH2PO4, 24 mM NaHCO3, 25 mM HEPES, 0.1 % Glucose) and distributed into 96-well plates. 
Before measurement, coelenterazine was added to a final concentration of 5 μM and sequential 
measurements were performed at 460 ± 25 nm and 525 ± 25 nm. In some cases, cells were treated 
either with BAPTA-AM (50 μM) or CaCl2 (5 mM CaCl2 and 10 μM Ionomycin) or W7 (50 μM) 
for 20 min, 10 min, and 30 min, respectively, before BRET measurement. The average BRET 
signals from three experiments were plotted as a function of the ratio of acceptor over the donor. 
5.5.12 Cx26p1-21 peptide 
The peptide derived from the cytoplasmic loop of Cx26 (Cx26p1-21, Ac-
1MDWGTLQTILGGVNKHSTSI21-NH2) was obtained commercially from AnaSpec Inc. The 
peptide was > 90% pure on the basis of high-performance liquid chromatography and was used 
without further purification. Acylated N-termini and aminated C-termini were designed to mimic 
the protein environment and remove extra charges. 
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5.5.13 Circular Dichroism 
CD spectra were recorded on a Jasco-810 spectropolarimeter at ambient temperature using 
a 0.1-cm path length quartz cuvette, an integration time of 1s and a scan rate of 100 nm/s. The far 
UV CD spectra of Cx26 full-length protein at 8 μM was carried out and each spectrum shown is 
the ellipticity (mdeg) as a function of wavelength.  
Figure 5.8   Expression and purification analysed  
A. Expression Gel for WT CaM showing a distinct band for CaM at ~ 14 kDa. B. 
Purification Gel for WT CaM showing two distinct bands.  wtCaM was successfully 
expressed and purified with a yield of 37.1 mg/L. C. Growth Curve for WT CaM 
expression is shown. D. MALDI spectrum indicated pure wtCaM.  
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5.6 RESULTS 
5.6.1 Expression and purification of wtCaM  
 
The purified CaM was quantified using absorbance at 277 nm contributed due to the tyrosin 
residue. Two fractions F3 and F2 showed the presence of CaM. 27ml of CaM protein was 
concentrated to ~3.2ml and gel was run for the purified CaM (Figure 5.8). The concentration of 
purified CaM was found as 676 µM and yield was 37.1 mg/L. Two bands were observed that was 
close to 16kDa which were two forms of CaM bound with EGTA or Ca2+. MALDI was carried 
out and it showed two peaks, one for 16 kDa and other for 8 kDa (Figure 5.8D). The smaller 
indicates a degradation band.  
5.6.2 Expression of hCx26 using C43(DE3)pLysS 
The expression of hCx26 was optimized using varying temperatures, competent cells, 
IPTG concentrations and induction times. Similarly, purification was optimized using various 
detergents and methods. Table 1 is a summary of most of the optimization for expression. It was 











C43(DE3)pLysS M9 27 or 30 1.1 (11 h) 17 Good
C43(DE3)pLysS LB 37 1.4 (4.5 h) 18 Best
Rosetta gammi
(DE3) pLysS
LB/M9 28/37 ~1.0 16 None
Shuffle M9 16 or 30 1.1 (9 h) 18-19 None
Shuffle LB 16 or 30 1.1 (5.5 h) 21 OK (30 >16)oC
C43(DE3) LB 27 or 37 1.1 (11 h) 17 Moderate
C43(DE3) M9 27 or 37 1.4 (4.5 h) 18 Moderate
Table 5.2 Results of Various Expression Conditions   
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expression of 18 hr was the most optimal. DE3 lysogen contains T7 polymerase when induced by 
IPTG.  
 
Additionally, the pLysS plasmid produced T7 lysozyme to reduce basal level expression of the 
gene of interest. Therefore, all in all, this strain of C43(DE3)pLysS is effective in expressing toxic 
and membrane proteins. We also used shuffle because it expresses chromosomal copy of disulfide 
Figure 5.9  Choosing a competent cell.  
SDS gel for optimization 
with C43pLysS and Shuffle with 
varying media and temperatures, 
Western blot 
Vector/ Bacterial Strain Transformation/
Expression Conditions
Comments/ Western blot
A. pTrcHis2 A/ C43(DE3)pLysS 28˚C /28˚C, LB/M9 30sec, Good expression
B. pTrcHis2 A/ C43(DE3) 28˚C /28˚C, LB/M9 30sec
C. pTrcHis2 A/ C43(DE3) 28˚C /16˚C, LB/M9 30sec, Lowest expression
17
A                      B                C









A. SDS-gel. Optimization of expression 
of Cx26 with C43pLysS and Shuffle with 
varying media and temperatures, time of 
expression and ODs for induction. B. 
Western blot.  
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bond isomerase DsbC and promotes the correction of mis-oxidized protein into correct form, thus, 
correctly folds proteins with multiple disulfide bonds in the cytoplasm.  
5.6.3 Purification of hCx26 using C43(DE3)pLysS  
Various detergents and methods were applied to purify the hCx26.  
Empigen and DDM: According to the preliminary comparison of the western blots of 
eluted fractions, empigen worked best to yield higher result. Due to presence of imidazole in our 
fractions, we couldn’t quantify the fractions without the dialysis or anion exchange column, 
therefore, used western blot. 3.5% empigen was used to solubilize the membrane protein from the 
Figure 5.10   Optimization of expression of Cx26 in C43(DE3)pLyss. 
It was determined that induction at 1.4 OD at 4.5 hrs of transfer of the small-scale strains, 
IPTG of 1mM and growth for 18 hrs after induction is the most optimal for maximum 
expression. 
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supernatant and pellet separately after the cells were lysed and separated. Using 3.5% empigen on 
the cell pellets (condition I) produced prominent SDS bands for dimers (~52kDa) and anti-His tag 
Purification 
Buffers
Condition I Condition II
Lysis Buffer 75mM Tris HCl, 30mM NaCl, pH 7.7 75mM Tris HCl, 30mM NaCl, 
0.2mM EDTA, pH 7.7
Solubilization
buffer
10mM HEPES, 0.005% NaN3, 500mM 
NaCl, pH=7.5
Buffer I 40mM HEPES, 300mM NaCl, 
3%Empigen, 1mM TCEP, pH=7.5
Wash buffer I 10mM HEPES, 500mM NaCl, 10mM 
Imidazole, 3%Empigen, pH=8
40mM HEPES, 300mM NaCl, 
3%Empigen, 40mM Imidazole, 
1mM TCEP, pH=8
Wash buffer II 10mM HEPES, 500mM NaCl, 3% 
Empigen, 40mM Imidazole, pH=8
0.1% DDM, 25mM sodium
phosphate dibasic, 1mM TCEP, 
pH 7.2
Elution buffer 10mM HEPES, 150mM NaCl, 300mM 
Imidazole, pH 7.5
0.1% DDM, 1M imidazole, 1mM 
TCEP, pH 7.8
Dialysis buffer 1mM TCEP, 20mM Ammonium
bicarbonate, pH 7.4
Figure 5.11  Using empigen for Cx26 
purification 
Condition I and II were used for 
purification where empigen was 
first used to solubilize the 
membrane proteins followed by 
either empigen or DDM to finally 
used to sustain the membrane 
protein in elution. Empigen 
worked better but the yield was 
low in uM range.  
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western blot confirmed the presence of both dimers and monomers. Condition II where we used 
with 3.5% empigen and 2% DDM on supernatant and cell pellet respectively produced less 
promising bands than that the first condition. The SDS bands were not visible, although the western 
blot still showed the monomers. After dialysis and quantitating the yield, the concentration was 
low µM range.  
N-laurosarkosyl and octyl-glucoside: N-laurosarkosyl was used to lyse the total cell lysate 
and protein was eluted out in octyl-glucoside. 5L was purified again using the NLS-OG. The 
elution was concentrated to 0.5ml and gel filtration was carried out to separate the monomers. The 
elutions 8-10 and 20-23 were collected for gel analysis. Using UV280 the main fraction 14 was 
found to have 6.3 µM and yield of ~0.6mg/L. 
Even after gel filtration, a lot of contamination or degraded products was observed in our 
fractions as can be seen in the silver stained gel and western blot above. Western blot and 
absorption at 280 showed that fraction 14 and 15 contained most protein. Fraction 15 was sent for 
MALDI analysis which show poor result for any protein close to 26 or 52 kDa. The peaks at 26kDa 
show small peak indicating our protein and other peaks indicated contamination/degradation. 
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Gel Filtration Spectra for hCx26 Expressed in C43(DE3)pLysS
in 5L LB at 37oC Using OG
Gel-filtration of hCx26 Expressed in C43(DE3)pLysS








 Purification of hCx26 Expressed in C43(DE3)pLysS in 
5.0 L LB at 37oC Using NLS-OG System









Purification of hCx26 Expressed in C43(DE3)pLysS in 
5.0 L LB at 37oC Using NLS-OG System
12.5% SDS Page Gel
Figure 5.12   NGS/OG purification system.  
N-laurosarkosyl was used to lyse the total cell lysate and protein was eluted out in octyl-
glucoside. 5L was purified again using the NLS-OG. The elution was concentrated to 
0.5ml and gel filtration was carried out to separate the monomers. The elutions 8-10 
and 20-23 were collected for gel analysis. Using UV280 the main fraction 14 was found 
to have 6.3uM and yield of ~0.6mg/L.  
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5.6.4 Biophysical characterization of the hCx26 from bacteria 
5.6.4.1 MALDI Mass spectrometry 
MALDI showed a spectra at 37 and 35 kDa with low intensity instead of a 26 kDa monomer 
or an oligomer of 52, 78 or 156 kDa.  
5.6.4.2 Stability of secondary and tertiary structure of purified hCx26 from bacteria  
Circular dichroism displayed a typical α-helical structure with an inverse peak between -
208 and -222 nm for hCx26 purified. With Ca2+ and EGTA the structure changed but still retained 
the α-helical structure. In order to determine the proper folding of the protein, tryptophan emission 
of the purified Cx26 was compared with the free tryptophan. A blue shifted tryptophan emission 
spectrum was observed when the tryptophan emission at 340 was compared with free tryptophan 
which indicated that the tryptophan in our protein structure were in hydrophobic environment and 
therefore, well folded. The parameters used was: 
[hCx26]= 2uM in 10mM Tris, 30mM OG, 200mM NaCl and pH=6.8; 800uL 
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Figure 5.13 MALDI. Molecular weight of 37 kDa was observed. 
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The presence of detergent and NaCl in the buffer affected the CD spectra adding noise.  
 
5.6.4.3 Binding affinity using Tb3+/Ca2+ fluorescence measurement 
The purpose of this experiment is to obtain a binding affinity of Ca2+ to hCx26. Since, Ca2+ 
is not directly observed, Tb3+ is used in competition assay to get the Kd. 200mM of Tb was titrated 
into a 800 ul 6uM hCx26 in a 1cm pathlength cuvette. 500-600 nm spectrum was acquired with an 
excitation wavelength at 285nm. Energy transfer between two chromophores (namely, Trp and 
Tb3+) is measured. Trp is excited by wavelength of 285nm and this is transferred to the nearby 
Tb3+. The excited Tb3+ emits out the fluorescence between 500-600nm while returning to the 
Figure 5.14  Stability of secondary and tertiary structure of purified hCx26 from bacteria  
 
A. Typical α-helical structure was observed with an inverse peak between 210 and 220 nm 
for hCx26 purified. With Ca2+ and EGTA the structure changed but still retained the α-helical 
structure. B. The tertiary structure was observed comparing the tryptophan emission with 
free tryptophan.  
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ground state. The efficiency of this transfer is dependent on the distance between the two 
chromophores, shorter the higher. The parameters used were [hCx26]= 2µM or 4uM in 10mM 




1.1.1.1 Figure 5.15  Binding affinity 
using Tb3+/Ca2+ fluorescence 
measurement 
 
A. Tb3+ titration was carried out using 2uM 
hcx26 and carried out in triplicate. B. The 
Kd was found to be ~0.6 uM.  It was 
comparable to the Kd observed by previous 
lab members on full length Cx26 from SF9. 
After incubation of protein with Tb3+ for 0. 
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Kd for Tb
3+ for hCx26 from E. coli, was found to be in μM range similar to rCx26 from 
SF9 and E-1 grafted in CD2 from previous members (Figure 5.15). Kd for Ca
2+ for hCx26 from 
E. coli was found to be 37 mM (Figure 5.16). Tb3+/Ca2+ FRET assay indicated that Tb3+/Ca2+ binds 
to hCx26. In order to make sure that the fluorescence change was directly proportional to the 
protein concentration, the Tb3+ titration was performed with 2uM and 4uM hCx26. But 
interestingly, the enhancement of the peak was not doubled at expected. Additionally, to check if 
the integrity of the protein were preserved, the fluorescence was observed before and after ~30min 
of incubation of the hCx26 with Tb3+. The peak decreased drastically which must impact the 
calcium competition titration and Kd calculation. However, we still can observe the gradual 
decrease in the peak after calcium titration in hCx26 sample and not in the control buffer sample. 
This suggests that Tb3+ binding must change the protein conformation and therefore, the 
availability of tryptophan to Tb3+, or that the protein precipitated during this incubation. However, 
we still can observe the gradual decrease in the peak after calcium titration in hCx26 sample and 
not in the control buffer sample. 
Figure 5.16 Ca2+ competition titration. Kd for Ca
2+ for hCx26 from E. coli was found to be 
36 mM.  
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5.6.4.4 Effect of Cx26p1-21 on the domain specific Ca2+- binding affinity of CaM  
 
To examine Cx26p1-21 contribution to the calcium binding affinity of CaM, calcium binding 
affinity of both N- and C-domain of CaM was determined by monitoring the intrinsic fluorescence 
intensity change of Phe and Tyr respectively. Binding of Ca2+ to the N-domain (Site I and II) 
Ca2+ Equilibrium Titration - CaM (Tyr) 
CaM: 8 uM
Buffer: 50 mM HEPES, 100 mM KCl, 5 mM NTA, 0.05 mM EGTA, pH 7.4
Ex: 277 nm; Em: 290-350 nm 
Ca2+ stock: 15 mM Ca2+ in the same buffer
Slit: Ex=0.48; Em= 0.96
Ca2+ Equilibrium Titration - CaM (Tyr)+Cx26p1-21
CaM: 8 uM ; Cx26p1-21: 9.6 uM
Buffer: 50 mM HEPES, 100 mM KCl, 5 mM NTA, 0.05 mM EGTA, pH 7.4
Ex: 277 n ; Em: 290-350 nm 
Ca2+ stock: 15 mM Ca2+ in the same buffer
Slit: Ex=1.12; Em= 2.24
Ca2+ Equilibrium Titration - CaM (Phe) 
CaM: 8 uM
Buffer: 50 mM HEPES, 100 mM KCl, 5 mM NTA, 0.05 mM EGTA, pH 7.4
Ex: 253 nm; Em: 270-290 nm 
Ca2+ stock: 50 mM Ca2+ in the same buffer
Slit: Ex=0.4; Em= 0.8
 
Ca2+ Equilibrium Titration - CaM (Phe)+Cx26p1-21
CaM: 8 uM; Cx26p1-21: 9.6 uM
Buffer: 50 mM HEPES, 100 mM KCl, 5 mM NTA, 0.05 mM EGTA, pH 7.4
Ex: 253 nm; Em: 270-290 nm 
Ca2+ stock: 50 mM Ca2+ in the same buffer
Slit: Ex=1.12; Em= 2.24
Figure 5.17  Effect of Cx26p1-21 on the domain specific Ca
2+- binding affinity 
of CaM.  
In the presence of Cx26p1-21, the Kd of CaM to Ca
2+ increased from 1.35 to 4.10 µM 
(A and B) and 2.9 to 3.87 µM (C and D) for the N-domain and C-domain, respectively. 
This suggested greater conformational change of the N-terminal lobe by greater than 
2.5 folds than that of C-lobe of CaM upon Cx26p1-21 binding 
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induced the decrease of Phe fluorescence intensity in the absence of Cx26p1-21. The Phe 
fluorescence intensity upon addition of Ca2+ was plotted as a function of free calcium concentration 
determined by calcium indicator Oregon Green 488 BAPTA-5N and fitted by Hill equation. In the 
presence of Cx26p1-21 (molar ratio of CaM: Cx26p1-21 =1:1.2), the Kd increased from 1.35 to 4.10 
µM indicating that calcium binding affinity to N-domain of CaM was significantly decreased. 
Similarly, binding of Ca2+ to the C-domain (Site I and II) induced the increase of Tyr fluorescence 
intensity in the absence of Cx26p1-21. The Tyr fluorescence intensity upon addition of Ca
2+ was 
plotted as a function of free calcium concentration determined by calcium indicator Oregon Green 
 Kd (uM) Hill 
CaM (Tyr) 2.9±4.28E-02 2.19±0.07 
CaM-Cx26p1-21 (Tyr) 3.87±6.96E-02 1.7±0.05 
CaM (Phe) 1.35± 9.8E-02 1.54±0.09 
CaM-Cx26p1-21 (Phe) 4.10 ± 4.4E-1 0.58 ±0.03 
 Figure 5.18  Effect of Cx26p1-21 on the domain specific Ca2+- binding affinity of CaM fitted 
to Hill equation 
 
 
The titration from figure 18 was fitted to Hill equation. In the presence of Cx26p1-21, the 
Kd of CaM to Ca
2+ increased from 1.35 to 4.10 µM (A) and 2.9 to 3.87 µM (B) for the N-
domain and C-domain, respectively. This suggested greater conformational change of the 
N-terminal lobe by greater than 2.5 folds than that of C-lobe of CaM upon Cx26p1-21 
binding 
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488 BAPTA-5N and fitted by Hill equation. In the presence of Cx26p1-21 (molar ratio of CaM: 
Cx26p1-21 =1:1.2), the Kd increased from 2.9 to 3.87 µM indicating that calcium binding affinity to 
N-domain of CaM was significantly decreased.  
 
5.6.5 Bioluminescence Resonance Energy Transfer (BRET)  
Several combinations for the Cx26 and vectors Rluc and Venus were cloned. After 
sequencing results, it was confirmed that the Cx26-EYFPC1 and Cx26-RlucN1 were successfully 
cloned. To determine whether CaM associates directly with Cx26 full length in live cells, we used 
BRET. Here, in case of the association, the energy is transferred between the bioluminescent and 
fluorescent tags. Cx26 was tagged with bioluminescent Renilla reniformis luciferase (Rluc) at the 
C terminal and yellow fluorescent tag, Venus-C1, as cloned into CaM. The cells were co-
transfected with fixed amount of Cx26 and increasing amount of Venus-CaM. Signal was 
determined as the ratio of light emitted at 525 nm over the light emitted at 460 nm. The BRET 
result with and without Ca2+ for Cx26 shows that there is no interaction between CaM with yellow 
fluorescence fusion protein, Venus-C1 and Cx26 with the Renilla luciferase (Rluc-C1) fusion 
protein. However, Cx45-Rlu was used as a control where Venus-CaM was capable of producing a 
significant BRET. Elevating Ca2+i by pre-incubating cells with Ca
2+-ionomycin notably increased 
the BRET ratio one-fold. Taken together, these results suggest that there is. This implies that the 
interaction does not occur between the CaM and the C-terminus of Cx26.  
262 
5.6.6 Surface plasmon resonance   
Ideally for a kinetic analysis, the maximal RU signal should be ~ 100 RU for protein: 
protein interaction. We observe a robust immobilization of Cx26 peptide but no response was 
observed for the CaM titration. This suggest that Cx26p1-21 does not interact with CaM.  
 
5.7 Conclusion and Discussion 
To study the modulation of hemichannel activity through [Ca2+]o, we first aimed at 
optimizing the expression and purification of hCx26 in bacteria. There were many limitations 
while working with the Cx26 protein. (1) Stability was limited at 4oC for a narrow span of 12-24 
hours post-purification, (2) the gravity column was required along with manual purification due to 
high probability of the oligomerization and therefore, clogging the FPLC column and (3) limitation 
with final yield of the protein even after the exhaustive steps of expression and purification. Even 
with the challenges, the expression of hCx26 was improved drastically with the use of 
C43(DE3)pLysS expressed in LB at 37oC. The optimal OD for induction and expression period 
were 1.4 and 18hrs, respectively. Additionally, 1mM IPTG is optimum for maximal induction of 
Figure 5.19  Surface plasmon resonance measuring interaction between Cx26 peptide 
and CaM. 
 A. A robust immobilization of Cx26 peptide was observed but B. no response was 
observed for the CaM titration. This suggest that Cx26p1-21 does not interact with 
CaM. 
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expression. Addition of glucose or MgSo4 to the growth medium did not improve the expression 
level. 3.5% empigen was determined as the most suitable detergent for solubilization of intact and 
stable Cx26 membrane protein. However, the yield was limited to 0.6 mg/L and the purification 
was challenging due to the oligomerization and precipitation of the protein during the process.  
The secondary and tertiary structures of the intact proteins were studies using circular 
dichroism and Trp fluorescence. CD displayed a typical α-helical structure with an inverse peak 
between -208 and -222 nm. With Ca2+ and EGTA the structure changed but still retained the α-
helical structure. In order to determine the proper folding of the protein, tryptophan emission of 
the purified Cx26 was compared with the free tryptophan. A blue shifted tryptophan emission 
spectrum was observed when the tryptophan emission at 340 nm was compared with free 
tryptophan which indicated that the tryptophan in our protein structure were in hydrophobic 
environment and therefore, well folded.  
Next, after obtaining the protein, fluorometry was used to determine the binding affinity of 
the hemichannel Cx26 to Tb3+ which was 1.8 µM and indirect Ca2+ competition of bound Tb3+ 
exhibited a weak Kd of 37 mM. However, we found that the fluorescence change was non-linear 
to the protein concentration during the competition. Additionally, we observed the dependence of 
fluorescence of the protein on the time of pre-incubation with Tb3+. Both observations suggested 
protein conformation change or precipitation during these processes. Therefore, the result we 
obtained are not conclusive.  
In order to understand the interaction between Cx26 and CaM, wt-CaM was successfully 
purified at 37 mg/L. Effect of Cx26p1-21 on the domain-specific Ca
2+-binding affinity of CaM was 
examined by monitoring the intrinsic fluorescence intensity change of Phe and Tyr.  In the presence 
of Cx26p1-21, the Kd of CaM to Ca
2+ increased from 1.35 to 4.10 µM and 2.9 to 3.87 µM for the N-
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domain and C-domain, respectively. This suggested greater conformational change of the N-
terminal lobe by greater than 2.5 folds than that of C-lobe of CaM upon Cx26p1-21 binding. Further, 
the interaction between CaM and Cx26 in the living cell was examined using bioluminescence 
resonance energy transfer (BRET). Interaction between CaM with the yellow fluorescence fusion 
protein, Venus-C1 and Cx26 with the Renilla luciferase (Rluc-C1) fusion protein was found to be 
insignificant. This implies that the interaction does not occur between the CaM and the C-terminus 
of Cx26. This was further supported by surface plasmon resonance study where no significant 
binding was observed between CaM and Cx26p1-21. 
5.8 Major significance and future work 
The expression of hCx26 has been improved with the use of C43(DE3)pLysS competent 
cells. Purification with 3.5% empigen has been found optimal for the intact hCx26 from bacterial. 
However, further optimization needs to be sought to improve the yield as well as purity and longer 
stability of hCx26 for additional biophysical interrogation. Using Tb3+ titration and Tb3+/Ca2+ 
competition, it has been determined that Kd of hCx26 for Tb
3+ as 0.6 μM and Kd for Ca
2+ as 36 
mM. It has been established that the C-terminus of Cx26 does not interact with the CaM using 
BRET. Other constructs need to be cloned and various combinations between Cx26- /CaM- and 






6 CHAPTER VI: MAJOR FINDING AND FUTURE DIRECTIONS 
Ca2+ is a universal signaling ion that regulates life. In this study, we focus on understanding 
the integral role of extracellular Ca2+ on the regulation of two major proteins, the first being the 
CaSR that maintain systemic calcium homeostasis and the second being the Cx26 that maintains 
cellular homeostasis. Chapter II touches on the importance of knowledge of the mode of regulation 
and regulators of the CaSR is enormous as it is widely expressed throughout the body sustaining 
life by maintaining Ca2+ homeostasis. In order to achieve this, we employed and established 
protocols after many optimizations for immunoprecipitation of CaSR and tandem mass 
spectrometry. With our finding of 98 new putative CaSR interactors and the first protein-protein 
interaction network, we take the field of calcium signaling and CaSR signaling to a new height. 
The knowledge allows us to survey potential pathways and regulators of CaSR that could 
potentially allow us to develop drugs to modulate CaSR activity, its biosynthesis, trafficking or 
degradation. This could very well be a potential target for other cGPCRs. Chapter II also probes 
and validates the critical role of extracellular Ca2+ in regulating these CaSR interactions. The direct 
role of CaSR as a mediator of extra- and intra- cellular Ca2+ signaling and the novel role of Ca2+o 
in modulating the CaSR mediated proteostasis of CaSR interactors/regulators is colossal. The 
putative CaSR interactors are significantly enriched in the ER as shown by the gene ontology 
analysis related to protein folding in the presence of Ca2+o. The work also indicates the direct role 
of CaSR mediated Ca2+ signaling with ER Ca2+ signaling and ER proteostasis. The cellular state 
is largely dependent on the ER Ca2+ homeostasis and therefore, this inter-relationship between 
Ca2+, CaSR, and ER is large and allows us to take our research further into many avenues. Taken 
together, this study offers an insight into the interconnection of GPCR function, intracellular 
trafficking, and potential targets for Ca2+ homeostasis related pathogenesis of diseases.  
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CaSR-binding of some of the proteins such as Bip/GRP78 and CHIP has been validated 
through immunoassay and ICC. This chapter is a significant finding for the role of extracellular 
Ca2+ in CaSR biosynthesis and function, and it offers many potential future questions and projects: 
(1) Do most of the interacting proteins come from the ER compartment? If so, why? (2) Do proteins 
in the ER interact with functional plasma membrane CaSR through the process involved with 
bringing ER and plasma membrane to close proximity such as in the case of ORAI/STIM? (3) Is 
CaSR ubiquitination dependent on Ca2+? Why?  (4) Do the putative interactors directly or 
indirectly bind CaSR? (5) What is the mechanism for this alteration? (6) Do pathological cells 
such as cancer cells or tissues have similar interactors of CaSR as in HEK293 cells? (7) How does 
the ER Ca2+ signaling change during this process? (8) What are the interactors in normal cells in 
physiological conditions? Here, (1) and (2) can be explored using TIRF microscopy in live or fixed 
cells. (3) can be answered using ubiquitination assay. Ubiquitination of CaSR can be examined 
using co-IP in HEK293 cells and HEK293 cells with CHIP or RanBP2 shRNA knockdown. (4) 
and (5) need mechanistic studies with individual interactors. (6) and (8) can be achieved with the 
same experimental design with pathological tissues or cell or normal cells, respectively. To achieve 
(7), we can use ER sensors to measure and probe ER Ca2+ fluctuations in a live cell.  
Chapter III examines the differential CaSR mediated intracellular signaling mechanism in 
HEK293 cells and thyroid cancer cells. Understanding the intracellular Ca2+ response due to CaSR 
activation is an important and most direct way of studying CaSR mechanism. Response to stimuli 
from extracellular Ca2+, Mg2+, drugs, and regulators provide us invaluable information on how to 
modulate CaSR and its effects at the molecular level. Furthermore, information on the dysfunction 
of CaSR in pathological cells offers us with the clue on how to mend CaSR to allow for better 
treatment conditions. The intracellular calcium oscillation facilitated by wild type CaSR activation 
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via Ca2+o, Mg
2+ and tryptophan derivative (TNCA) is characterized in HEK293 cells. Ca2+ is more 
potent than Mg2+ to activate CaSR, and Ca2+ and Mg2+ cooperatively work together. This can be 
explained by the similar and shared residues both the ions coordinate to in their respective binding 
sites as shown in the crystal structure and the predicted binding site. Moreover, TNCA was able 
to act as a co-agonist and reduce the EC50 for both Ca
2+ and Mg2+, but more significantly for Mg2+ 
by 2.5 folds. Mutations at the Mg2+ binding sites, also ADH related mutations (E228I and E229I) 
resulted in impediment of the Ca2+/Mg2+ CaSR sensing as well as CaSR mediated Mg2+ evoked 
Ca2+i mobilization and calcium oscillation. This information allows us to have a better 
understanding of mechanistic functioning of wild type CaSR as well as provides us with insight 
into ADH related dysfunctions.  
Next, a thorough CaSR mediated mechanism in Ca2+ sensing mechanism was investigated 
in endogenous CaSR in thyroid carcinoma cells, human (TT) and rat thyroid medullary cancer 
cells (6-23), to understand the CaSR mediated Ca2+ sensing and were compared to the wild type 
hCaSR in HEK293 cells. A highly non-synchronous CaSR mediated oscillatory behavior was 
revealed in 6-23 cells. These cells contained a mixture of CaSR with variable activity, some with 
EC50 for Ca
2+ at 0.5 mM and a lower Hill number of 1.5 and some that did not respond to Ca2+ 
even at 10 or 20 mM. Interestingly, the responding CaSR were selective to Ca2+ and not to Mg2+ 
implying biased signaling or Ca2+ selective binding site. On the contrary, TT cells demonstrated 
exclusively CaSR mediated transient peaks. Using the CaSR calcimimetics, calcilytics and W7 
displayed significant changes to the CaSR mediated oscillatory patterns in both the cells. An 
overall change in oscillation distribution was determined with the use of CaSR allosteric agonist 
(cinacalcet) and antagonist (NPS-2143) as well as W7, an inhibitor of CaM, a CaSR regulating 
protein. Use of all three drugs displayed significant changes to the CaSR mediated oscillatory 
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patterns, start and end of oscillation, number of responding cells as well as oscillation frequency 
in the HEK293 cells. We showed for the first time that W7 is able to rescue partially the cinacalcet 
overactivation, or that cinacalcet can rescue the W7 inhibition.  These results (1) validated the 
oscillation and transient peaks in C cells were at least partially CaSR mediated, (2) provides direct 
evidence of tissue and species-specific CaSR mediated signaling and (3) provides a hint towards 
biased signaling in C cells. (4) Our findings also provide an important insight in the modulation of 
intracellular Ca2+ signaling through regulation of CaSR activation by using CaSR agonist in C 
cells. This (4) provides an exciting platform in changing intracellular Ca2+ in C cells and indirectly 
controlling its Ca2+ dependent molecular functions, possibly for therapeutic purposes.   
The investigation of the molecular cause of the above-mentioned differential signaling 
could be due to the presence of about six-fold lower expression in both 6-23 and TT cells as 
compared to stably wild type CaSR transfected HEK293 cells (5001) or transiently transfected 
HEK293 cells. We were able to show a variable pattern in the monomer and dimer forms of CaSR 
in C cells. Additionally, the effect in the trafficking of CaSR to the plasma membrane may affect 
the sensitivity of the CaSR. Further, RT-PCR method was used to characterize the CaSR in 6-23 
but due to low transcript, the sequencing was partial. However, we showed for the first time that 
6-23 contained CaSR with isoform I with 10 amino acid insertion in its 6th exon. The full 
sequencing by RNAseq may provide us with valuable information on CaSR in C cells.  
Similar to chapter III, chapter IV investigates the differential CaSR mediated Gαq 
associated Ca2+i response, such as the intracellular calcium oscillation and IP1 which were missing 
in PC3. Additionally, ERK1/2 was perturbed as compared to the wild type CaSR in HEK293 cells. 
Even using the agonists could not rescue the CaSR mediated intracellular Ca2+ response. 
Overexpression of wild type CaSR in these cells cannot rescue these signaling indicating that PC3 
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may lack the Gαq and other necessary regulators required for the oscillation signaling. In order to 
explain these differences, PC3 cells and CaSR in these cells were studied at molecular levels. We 
noted CaSR in PC3 occurs as a monomer in non-reducing condition and has a lower molecular 
weight with 110 kDa, indicating incapability to form a dimer and presence of a variant with a 
splice-variant or lower glycosylation. PC3, on the contrary, is able to generate a dimer when 
artificially transfected. Immunostaining showed that most CaSR occurs within the cell as 
compared to functional plasma membrane CaSR. Next, using RT-PCR we showed that a full CaSR 
with all seven exons are present. These results support that the CaSR in PC3 is present in the 
immature stage.  
To understand the PC3 cells better, we carried the global proteomics to understand shed 
light into the changes we observed. We note that global proteome is highly differential between 
the HEK293 cells and PC3 cells where the observation of CaSR through MS is null and general 
proteome increased in PC3 cells. The gene ontology of proteins in Ca2+ and EGTA conditions vary 
in PC3 where the citric acid cycle and trans-Golgi related proteins are upregulated in Ca2+. The 
proteomics is the integrative way to understand the biomarkers for prostate cancer but proper 
controls such as the normal prostate and prostate cancer at various states could be used for the 
comparison. Our results and methods will contribute to the future work to understand PC3 cells 
and CaSR in PC3 cells, as well as other pathological cells.  
The previous study in our laboratory has indicated the involvement of CaSR in PC3 
colonization in bones by preventing cell apoptosis of cancer cells, inhibiting invasion, and 
promoting mesenchymal-epithelial transition. My work in-vivo in collaboration with Dr. Wu 
showed a significant decrease in tumor growth when PC3 cells with CaSR knockdown and control 
knockdown are injected in mouse tibia in the presence of zoledronic acid. This result proves the 
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essential role of Ca2+ in prostate cancer proliferation in the bone. My work provides fundamental 
information of PC3 cell line as well as the role and molecular function of CaSR in PC3 cells. 
Further work is required to obtain decisive pathways and mechanisms in this context.  
In Chapter V we demonstrate that the expression of hCx26 has been improved with the use 
of C43(DE3)pLysS. Purification with 3.5% empigen has been found optimal for the intact hCx26 
from bacterial. However, further optimization needs to be sought to improve the yield as well as 
purity and longer stability of hCx26 for additional biophysical interrogation. This intensive 
optimization will allow the future investigator to obtain higher expression of hCx26 and to solely 
focus on purification and characterization. This method could be used for other full membrane 
expression as well. Using Tb3+ titration and Tb3+/Ca2+ competition, we have determined that Kd of 
hCx26 for Tb3+ as 0.6 μM and Kd for Ca
2+ as 36 mM. It has been established that the C-terminus 
of Cx26 does not interact with the CaM using BRET. Other constructs need to be cloned and 
various combinations between Cx26- /CaM- and Rluc/ Venus needs to be studied using BRET to 
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